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Abstract
Over recent decades, translational ovarian cancer research has been 
impeded by its underappreciated molecular heterogeneity and five-year 
survival has remained poor. One strategy for addressing this problem is 
to search for molecular biomarkers that can better inform the 
development and targeting of novel treatments. The aim of this thesis 
was to construct and validate a tissue microarray of ovarian cancer 
cases and to survey the expression and prognostic capabilities of 
immunological molecular markers: specifically HLA class I and the 
membrane bound complement regulatory proteins CD46, CD55 and 
CD59. These are central to the efficacy of certain immunotherapies and 
while they have been shown to have prognostic power in breast and 
colorectal cancer, they have been investigated less in ovarian cancer.   
Five copies of a tissue microarray representing 339 cases of ovarian 
cancer which presented to Derby City General Hospital between 1982 
and 1997 were made. The array was stained for CK7, CK20, CA125, 
CEA, p53 and Bcl-2 following a standard immunohistochemical 
protocol. A linked clinical database was adapted and assessed for data 
consistency and subsequently used to analyse the prognostic and 
clinicopathological associations of the expression data. The array was 
then stained for HLA class I, ȕ2microglobulin and CD59 using 
commercial antibodies and for CD55 and CD46 using in-house 
antibodies. Retained expression of HLA class I molecules 
independently predicted improved prognosis. High expression of CD55 
and CD59 were associated with worse prognosis, though not 
independently of other factors. CD55 expression was more widespread 
than previously appreciated. 
This thesis describes the discovery of a new independent marker of 
prognosis which suggests that immunoediting occurs in ovarian cancer, 
describes the distribution of markers known to have a negative impact 
on immunotherapy in ovarian cancer in a large series for the first time 
and documents the production of a valuable resource for future studies.
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Chapter 1: Introduction 

Ovarian cancer has a poor five-year survival which has improved little 
over the last 40 years despite our knowledge of the basic science 
underlying cancer increasing substantially during this period.  While 
such knowledge has led to palpable practical improvements at sites 
such as breast cancer, the same translation of basic science research 
has been less successful in ovarian cancer - mainly due to the relative 
complexity of its genetics and the heterogeneity of its key molecular 
pathways.  
Ovarian cancer is characterised by the development of resistance to 
first line platinum based chemotherapies and subsequently death. A 
major translational challenge therefore continues to be the development 
of effective molecular methods for the targeting of alternative treatment 
modalities. This is particularly pertinent to the large number of cases 
which progress rapidly on first line treatment and miss the opportunity 
to trial novel therapies. The informed search for biomarkers whose 
presence correlates with clinical outcome and response to treatment 
attempts to address this by translating research from the laboratory to 
the clinic and back again through the identification of subgroups 
particularly amenable to novel treatment modalities at an early stage. 
The components of a small number of molecular processes (such as 
angiogenesis, cell adhesion, growth signalling and so on) are likely to 
represent the most promising candidate biomarkers and this thesis 
concerns the search for those ones with possible roles within the 
immune based processes affecting ovarian cancer behaviour. This work 
therefore represents an attempt to add knowledge which could help in 
the development and targeting of immunotherapies such as cytokines, 
vaccines and monoclonal antibodies  which appear theoretically 
particularly suited to use in ovarian cancer. 
One important obstacle which has traditionally hampered such 
translational research in ovarian cancer has been its relatively low 
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frequency. This has frustrated the accrual of the large, homogenously 
processed cohorts of cases required for the study of a disease which 
displays divergent outcomes within seemingly identical groups of cases.  
Other barriers to the study of biomarkers in ovarian cancer using 
immunohistochemistry and whole sections have been its time 
consuming and expensive nature, a tendency towards under powering 
and the occurrence of intra- and inter- operator discrepancies when 
large numbers of cases are stained in batches. The aim of this work is 
to circumvent such traditional translational difficulties by taking 
advantage of a meticulously accrued clinicopathological cohort of 
several hundred cases of ovarian cancer and by the production and use 
of a tissue microarray  a validated technology allowing several 
hundred specimens to be simultaneously stained for a particular marker 
on a single slide. This was then stained  for immunologically relevant 
candidate biomarkers in order ultimately to help inform the more global 
translation of laboratory based immunotherapies into the clinic setting. 
This introduction aims to provide a relevant background to ovarian 
cancer in general, biomarker research and tumour immunology, 
including the use immunotherapy in ovarian cancer.
1.1. Ovarian Cancer  
1.1.1. Epidemiology 
Ovarian cancer is an uncommon disease which is commonly fatal. The 
lifetime risk of ovarian cancer is approximately 2% and it is the sixth 
and fourth most common cancer in women globally and in the UK 
respectively (Quinn 2001). In the UK, the direct age-standardised 
incidence rate has varied over the last 40 years (in part due to 
differences between birth cohorts) from 14.5/100 000 in 1971 to a peak 
of 19/100 000 in 1997, falling back to 16.7/100 000 in 2005 when this 
equated to 5456 new cases (Statistics 2008). The incidence of ovarian 
cancer varies widely between geographical regions and in 2002 the 
World Standard Rate (per 100 000) of ovarian cancer was 6.6 world-
wide, 11.3 in Western Europe, 10.6 in the US, 3.2 in China and 
13.4/100 000 in the UK (GLOBOCAN 2004). Though migrants generally 
Chapter 1: Introduction
2
adopt the background risk of their host nation, ethnic group and degree 
of social deprivation can remain linked to incidence through 
confounding, because racial, cultural and socioeconomic factors are 
often intertwined with the reproductive behaviour that determines the 
risk of developing ovarian cancer  those having higher numbers of 
children being relatively protected (Bartlett 2000). Indeed, the 
Surveillance, Epidemiology, and End Results (SEER) Programme 
registration data for cases diagnosed in the US between 1992 and 
1999 recorded an incidence (age-adjusted to the standard million 
population/100 000) of 17.24 for white women and 11.28 for non-white 
women (Quirk and Natarajan 2005).  
Ovarian cancer is largely a disease of postmenopausal women with 
only 10% of cases occurring in women under the age of 45. As age 
advances, the incidence of ovarian cancer increases sharply  
stabilising between the ages of 70 and 85 (at approximately 75/100 000 
population at risk) and falling thereafter (Quinn 2001). The majority of 
ovarian cancer cases present in the 50-59 or 60-69 age groups, with 
the median age of diagnosis being between 60-63 years (Yancik 1993; 
Heintz, Odicino et al. 2001; Quirk and Natarajan 2005). Advancing age 
is linked to worsening performance status and affects the clinical 
management, as weaker patients are unlikely to withstand maximal 
therapy and may also be excluded from clinical trials (Gospodarowicz 
2001). The effect of increasing age/decreasing performance status is 
therefore accepted to have a negative impact on prognosis (DiSilvestro, 
Peipert et al. 1997; Heintz, Odicino et al. 2001) and this prognostic 
power has occasionally been shown to be independent of other factors 
(Thigpen, Brady et al. 1993; Crijns, Boezen et al. 2003). In reporting 
age, the data have rarely been grouped in a standard way, having 
variously been analysed as a continuous variable, subdivided on the 
basis of the median into two groups, subdivided into two groups on the 
basis of arbitrary ages (such as 60, 55 or 50) or grouped into more 
complex categories (Heintz, Odicino et al. 2001; Crijns, Boezen et al. 
2003; Quirk and Natarajan 2005; Beral, Doll et al. 2008).  
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1.1.2. Aetiology 
1.1.2.1. Normal ovarian biology 
The ovaries are the primary sex organs in the female and are a pair of 
oval shaped organs approximately 3-5cm in length which lie in the 
pelvis between the utero-ovarian and infundibulo-pelvic ligaments 
within a so-called ovarian fossa. The purpose of the ovaries is the 
secretion of sex hormones and the ovulation of oocytes. Under the 
influence of Follicle Stimulating Hormone (FSH) and Lutenising 
Hormone (LH), a Graffian follicle develops from within a pool of 
primordial follicles. This dominant follicle contains the mature pre-
ovulatory oocyte and is the main source of cyclical oestrogens. Under 
the influence of a surge in LH, the oocyte is ejected and ruptures the 
ovarian capsule. Should fertilisation of the oocyte not occur, the 
redundant follicle undergoes fibro-hyaline degeneration to form the scar 
tissue of a corpus albicans. This cycle repeats itself until the pool of 
primordial follicles from which Graffian follicles develop falls to a 
critically low level, after which ovulation ceases and the menopause 
ensues. Ovulation may be suspended during pregnancy, lactation and 
the use of the combined oral contraceptive pill (McGee and Hsueh 
2000). 
1.1.2.2. Risk factors  
Familial 
Only a minority (5-10%) of ovarian cancer cases are associated with a 
familial tendency but for those individuals with cases in their immediate 
family this is their single most important risk factor. Where there is no 
specific genetic basis found the risk is approximately 9% but can vary 
depending on the number of first degree relatives affected and their age 
of onset of the disease (Holschneider and Berek 2000). Ovarian 
cancers with a known genetic basis often present at an earlier age than 
their sporadic equivalents and are associated with the development of 
cancer at other sites. Mutations within the BReast CAncer 1 and 2 
genes (BRCA1/2) are associated with a 30-40% and 27% risk of 
developing ovarian cancer respectively and account for most familial 
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cases of ovarian cancer, occurring in 40% and 25% of ovarian cancer 
families and 0.06% of the general population (Ford, Easton et al. 1994; 
Ford, Easton et al. 1995; Szabo and King 1997; Whittemore, Gong et 
al. 1997). These mutations have a variable penetrance which is 
influenced by factors such as ethnicity and most women will not go on 
to have ovarian cancer. However, the risk of breast cancer is higher 
and 87% and 84% of BRCA1 and BRCA2 mutation carriers develop it 
by the age of 70. This risk is reduced by 50% following prophylactic 
oophrectomy and, though this also reduces the risk of developing 
ovarian cancer, it is not completely prevented within embryological 
remnants (Ford, Easton et al. 1994; Miracle-McMahill, Calle et al. 1997; 
Kauff, Satagopan et al. 2002). Hereditary NonPolyposis Colorectal 
Cancer (HNPCC) predisposes to the development of right-sided colonic 
cancers in young adults and to the development of ovarian and 
endometrial cancer. The underlying genetic basis involves mutations in 
the DNA MisMatch Repair (MMR) genes and in such cases the risk of 
ovarian cancer is as high as 10% (Aarnio, Mecklin et al. 1995). 
Reproductive  
The lower risk of developing ovarian cancer with increasing parity has 
been well documented and is estimated to equate to a 16-22% 
reduction per birth (Risch, Marrett et al. 1994; Hankinson, Colditz et al. 
1995; Purdie, Green et al. 1995). There has been no convincing risk 
reduction shown for women who choose to breast feed (Rosenblatt and 
Thomas 1993). When correcting for nulliparity, women who do not get 
pregnant following pharmacological ovulation induction have a higher 
risk of ovarian cancer though a causal link has not been demonstrated 
(Bristow and Karlan 1996). Tubal ligation and hysterectomy have been 
shown to reduce the risk of developing ovarian cancer for at least the 
first two decades following the procedure (Purdie, Green et al. 1995; 
Miracle-McMahill, Calle et al. 1997; Hankey, Drachenberg et al. 2002). 
Late menopause is associated with a higher risk of ovarian cancer but 
early menarche is not (Franceschi, La Vecchia et al. 1991).  
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Hormonal 
Using the combined oral contraceptive pill (COCP) reduces the risk of 
ovarian cancer in both nulliparous and multiparous women. A recent 
re-analysis of 45 case-control studies concluded that lowest risk of 
ovarian cancer was in those that used the COCP for longer and that 
this benefit persisted for 30 years. After 10 years use the number of 
cases/100 users developing ovarian cancer by the age of 75 fell from 
1.2 to 0.8 with one death being prevented per 5000 women years 
(Beral, Doll et al. 2008). PolyCystic Ovarian Syndrome (PCOS) is linked 
to the development of endometrial cancer but a link with ovarian cancer 
is less certain, with some workers showing a marked increase in rates, 
especially for those cases where the COCP has not been used 
(Schildkraut, Schwingl et al. 1996), and others showing no association 
(Balen 2001). The Million Women study monitored 948 576 women 
between 1996 and 2001 and current HRT users were found to be at 
increased risk of ovarian cancer (RR 1.2) and death from ovarian 
cancer (RR 1.23) which persisted independently of known confounding 
factors such as parity and COCP use. Among a group of 3300 women 
taking HRT over a 5-year period one user will die from ovarian cancer 
solely as a result of its use (Beral, Bull et al. 2007). 
Environmental 
Eating eggs, lactose and cholesterol may be modestly associated with 
an increased risk of ovarian cancer while eating green vegetables may 
reduce risk (Kuchel, Tannenbaum et al. 2001), though a link between 
ovarian cancer and lactose consumption has not been found by all 
workers when parity and COCP use are corrected for (Risch, Jain et al. 
1994). Obesity (when defined as a Body Mass Index >30) is not only 
associated with breast and endometrial cancer but increased the risk of 
ovarian cancer by 30% in a recent meta-analysis (Olsen, Green et al. 
2007). Death from ovarian cancer was found to be related to cigarette 
smoking in the 6194 female doctors followed up from 1951 by Richard 
Doll and co-workers (Weiss, Lyon et al. 1982). On correcting for 
smoking, the consumption of coffee is linked to a modest increase in 
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the risk of developing ovarian cancer though a causal link has not been 
established (La Vecchia, Franceschi et al. 1984). Proving the precise 
mechanism remains obscure but the genital use of talcum powder has 
consistently been epidemiologically associated with the development of 
ovarian cancer (Weiss, Lyon et al. 1982; Purdie, Green et al. 1995). An 
increase in the number of ovarian malignancies expected was found in 
Swedish women who underwent radiotherapy for cervical carcinoma 
and survived to >10 years post-treatment (Weiss, Lyon et al. 1982). 
1.1.2.3. Theories of causation 
Four theories exist regarding the development of ovarian cancer which 
try to make sense of these risk factors. 
Incessant ovulation 
This theory suggests that physical trauma to the ovarian surface 
epithelium at ovulation and its subsequent exposure to viscous 
oestrogen are carcinogenic events (Fathalla 1971). It follows that the 
fewer ovulatory events that occur, the lower the chance of developing 
cancer. This explains why pregnancy and COCP use are protective and 
why hens are the only other animals to suffer from ovarian cancer in 
nature (Fredrickson 1987). A study supporting this estimated that each 
years worth of ovulation within the 20-29 year age group equated to an 
estimated 20% increase in the risk of ovarian cancer (Purdie, Bain et al. 
2003). Others regard this theory as an unlikely sole explanation of the 
epidemiology as it does not explain the protective effect of the 
progesterone only contraceptive pill (POP) which does not inhibit 
ovulation (Risch, Jain et al. 1994). 
Gonadotrophin hypothesis 
This theory postulates that exposure of the ovaries to high levels of 
gonadotrophins is carcinogenic (Cramer and Welch 1983). This 
explains why ovarian cancer is more common post-menopausally, the 
protective effect of pregnancy and the COCP and the effects of PCOS. 
However, others observe that it does not account for the high levels of 
oestrogen and HcG in seen in pregnancy and that gonadotrophins have 
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not been shown to be higher in post-menopausal women with ovarian 
cancer than their age matched controls (Helzlsouer, Alberg et al. 1995). 
Hormonal hypothesis 
This refinement of the last hypothesis attempts to bring all observations 
together by putting more emphasis on the roles of androgens and 
progesterone. The Graffian follicle contains a higher concentration of 
androgens than oestrogen, which could potentially be exposed to the 
surface epithelium during ovulation (Risch 1998). Androgens are 
present at higher levels in PCOS and are suppressed by the COCP and 
POP (Rosenburg 1994) (Gaspard 1983). Progesterone is anti-mitotic, 
present at large levels during pregnancy, is contained within the COCP 
and has been shown to increase wild type p53 tumour suppressor gene 
expression and induce apoptosis in human ovarian cancer cell lines 
(Bu 1997) (Riasch 1998). Finally, the rate of ovarian cancer in hens 
may be decreased by administering progesterone (Barnes, Berry et al. 
2002). 
Inflammation hypothesis 
During ovulation the walls of the follicle are broken down under the 
influence of inflammatory mediators and connective tissue dissolving 
enzymes (Bonello, McKie et al. 1996). This process is likely to involve 
leukocyte inclusion, nitric oxide release, cytokine release, 
vasodilatation, DNA repair and tissue repair which are all potentially 
carcinogenic (Zackrisson, Mikuni et al. 1996).  
As no single theory explains all epidemiological findings it is likely that 
each is in part correct, especially as ovarian cancer is a heterogeneous 
disease with a far from certain natural history (Fleming, Beaugie et al. 
2006). 
1.1.3. Pathology 
1.1.3.1. Histological type 
Primary neoplasia within the ovary can develop from a large variety of 
cell types and can behave in a benign, malignant or low malignant 
potential (borderline) manner. The degree of heterogeneity of disease 
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can be appreciated by examining the World Health Organisation (WHO) 
International Histological Classification of tumours which classifies 
neoplasia into at least 129 individual types with over 30 forms of frank 
cancer (Appendix 1) (Serov, Scully et al. 1973).  
Epithelial ovarian cancer 
Epithelial ovarian cancer accounts for over 90% of ovarian cancer and 
is thought to originate from invaginations of the ovarian surface 
epithelium.  
Borderline cancers 
Serous, mucinous, endometrioid or clear cell cancers of low malignant 
potential represent up to 15% of epithelial ovarian cancers but are 
histologically and biologically distinct from their frankly malignant 
counterparts (FIGO 1987). They exhibit the same proliferative features 
and cellular disorganisation but they do not generate a stromal reaction 
nor invade ovarian tissue, though they can spread, metastasise and 
invade distant organs (Scully 1977). They are staged in the same way 
as frank cancer but often present early (75% stage I) though, even 
correcting for this, they have a better overall 5-year survival of 89% 
compared to 51% for frank malignancy (Heintz, Odicino et al. 2001). 
Malignant serous adenocarcinoma 
Frankly malignant serous tumours are the most common form of 
ovarian cancer, accounting for 40-50% of cases (Heintz, Odicino et al. 
2001; Quirk and Natarajan 2005; Beral, Doll et al. 2008). They are often 
felt to be associated with a poor prognosis but they present late and, 
when stage correction is performed, their outcome is not significantly 
different to endometrioid types (Makar, Baekelandt et al. 1995). 
Malignant mucinous adenocarcinoma 
Mucinous cancers account for 9-15% of epithelial ovarian cancers, 
often presenting at an early stage (55%) when they have a good 
prognosis (91% at 5 years) (Heintz, Odicino et al. 2001; Quirk and 
Natarajan 2005; Beral, Doll et al. 2008). However, when they present at 
a late stage they have a poor prognosis when compared to serous or 
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endometrioid cancers, due to their relative insensitivity to platinum 
chemotherapy (Harrison, Jameson et al. 2008).  
Malignant endometrioid adenocarcinoma 
Endometrioid cancers are the second most common type after serous, 
accounting for approximately 12-18% of all ovarian cancers and in 
5-10% an origin within endometriosis may be demonstrated (Scully 
1977; Heintz, Odicino et al. 2001; Quirk and Natarajan 2005; Beral, Doll 
et al. 2008). Endometrioid cancers occur synchronously with 
endometrial cancer in up to 15% of cases and in this situation the most 
common presenting symptom is post menopausal bleeding, often 
leading to an early diagnosis with disease confined to the pelvis 
(Soliman, Slomovitz et al. 2004).  
Malignant clear cell adenocarcinoma 
Clear cell cancers are relatively uncommon and account for 4-6% of 
ovarian cancers (Scully 1977; Heintz, Odicino et al. 2001; Quirk and 
Natarajan 2005; Beral, Doll et al. 2008). They are unexplainably two to 
three times more common within Japanese populations but a relative 
scarcity means that less data are available concerning their biology, 
though they have consistently been found to be associated with pelvic 
endometriosis (Kennedy, Biscotti et al. 1989; Komiyama, Aoki et al. 
1999). Such circumstantial evidence may point to shared molecular 
aetiologies between the two conditions and, indeed, identical loss of 
heterozygositiy at 10q23 patterns and mutations in the phosphatase 
and tensin homolog (PTEN) tumour suppressor gene have been shown 
to exist (Sato, Tsunoda et al. 2000). Compared to serous ovarian 
cancer, clear cell cancers are more likely to present at an earlier stage 
but are more likely to recur and display platinum insensitivity, having a 
poorer prognosis on a sub-stage level as a result (Heintz, Odicino et al. 
2001; Takano, Kikuchi et al. 2006; Itamochi, Kigawa et al. 2008). 
Undifferentiated carcinomas 
Undifferentiated ovarian carcinomas occur with a variable frequency of 
5-25%, present at a late stage, advance rapidly and have the worst 
prognosis of all epithelial ovarian cancers with a 11-23% 5-year survival 
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(Scully 1977; Silva, Tornos et al. 1991; Heintz, Odicino et al. 2001; 
Quirk and Natarajan 2005). 
Ovarian cancer is a heterogeneous disease and its morphological 
subtypes exhibit different prognoses, probably because of underlying 
molecular variations (Bell 2005). Epithelial cancers may be ranked 
borderline, endometrioid, mucinous, serous, clear cell, mixed and 
undifferentiated in order of worsening prognosis. While histological type 
is an important prognostic factor it is not classified by the International 
Union Against Cancer (UICC  Union Internationale Contre le Cancer) 
as having prognostic power independent of other factors which have 
prognostic power independent of each other (stage, patient 
performance status/age, degree of cytoreducibility and chemotherapy 
use). This is probably because the varying biology of the different 
histological subtypes concurrently influences stage at diagnosis, thus 
interlinking its prognostic power with that of a genuinely independent 
prognostic factor.  
1.1.3.2. Histological grade 
The histological grade of a neoplasm refers to the microscopic 
appearances of its constituent cells and is an attempt to objectively 
assess their rate of proliferation and degree of abnormality. The 
importance of poorly differentiated disease in determining outcome in 
ovarian cancer is less clear than at other sites such as breast (Elston 
and Ellis 1991). Using the FIGO grading system, tumours are 
categorised as either well (G1), moderately (G2) or poorly (G3) 
differentiated with 24% G1, 30% G2 and 47% G3 (Benedet 2000). 
Undifferentiated, Brenner and clear cell subtypes are often all assumed 
to be G3 (Silva and Gershenson 1998). Though grading does not have 
independent prognostic power, it predicts prognosis on a sub-stage 
level independently and can be a useful adjunct in individual cases  
though it loses its predictive power in the most advanced cases 
(Gospodarowicz 2001; Heintz, Odicino et al. 2001). 
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1.1.3.3. Immunohistochemical profile 
7% of ovarian tumours are metastatic, from a variety of cancer sites 
such as endometrium, pancreas, stomach and bowel. (Ulbright, Roth et 
al. 1984). As ovarian cancers are often poorly differentiated and may 
contain confusing cell types, it can be impossible to tell whether a 
cancer is a primary or secondary on the basis of light microscopy alone. 
While collateral information from the clinical work up may make the 
diagnosis clear, a number of immunohistochemical markers have also 
been studied in the attempt to precisely define the differences between 
morphologically identical pelvic cancers from different sources on the 
basis of their molecular variations. 
Immunohistochemical expression of Cytokeratin 7 (CK7) 
Keratins are a multi-gene family of at least 20 epithelium specific 
cytosolic polypeptides which form intermediate filaments within the 
cytoskeleton. Different epithelia express different patterns of 
cytokeratins, which are preserved following malignant transformation 
(Moll, Franke et al. 1982). CK7 is expressed by many normal tissues 
including the epithelia of mammary gland ducts, trachea, bladder, lung, 
cervix, bile duct, outer ovarian surface and fallopian tube. In contrast, 
hepatocytes and Gastro-Intestinal (GI) tract epithelia do not express 
CK7 (Moll, Franke et al. 1982; Ramaekers, van Niekerk et al. 1990). 
The immunohistochemical expression of CK7 has most often been 
examined using the OV-TL 12/30 monoclonal antibody and (though 
there has been considerable methodological variation between studies) 
it has consistently been found to be expressed in between 94% and 
100% of ovarian cancers, with almost all serous and upwards of 80% of 
mucinous cancers expressing it (Ueda, Sawada et al. 1993; 
Berezowski, Stastny et al. 1996; Lagendijk, Mullink et al. 1998; 
Torenbeek, Lagendijk et al. 1998; Multhaupt, Arenas-Elliott et al. 1999; 
Chu, Wu et al. 2000; Cathro and Stoler 2002; Nishizuka, Chen et al. 
2003; Dennis, Hvidsten et al. 2005; Heatley 2008). CK7 expression is 
commonly expressed in lung, breast, pancreatic and, to a lesser 
degree, gastric carcinoma. However, CK7 is rarely expressed in colonic 
or renal cancers. In addition, there is usually good correlation between 
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the expression of CK7 in the primary and metastatic sites (Tot 2002). 
There is no evidence that CK7 has any prognostic power in ovarian 
cancer. 
Immunohistochemical expression of CytoKeratin 20 (CK20) 
CK20 was discovered by Moll and co-workers in 1990 (Moll, Schiller et 
al. 1990). Initial data indicated that CK20 was widely expressed in the 
epithelia of normal small bowel and colon but not expressed in lung, 
breast, female genital tract, pancreatic or breast epithelia. CK20 
expression pattern in tumours followed that seen in normal tissue and 
no non-mucinous ovarian cancers were found to express it, whereas 
most colonic cancers did. Accounting for methodological differences, 
subsequent surveys show the expression of CK20 in the general 
population of primary ovarian cancers to be approximately 0-36%, with 
serous cancers being almost exclusively negative and most CK20 
positive cancers being of a mucinous subtype (Ueda, Sawada et al. 
1993; Berezowski, Stastny et al. 1996; Lagendijk, Mullink et al. 1998; 
Torenbeek, Lagendijk et al. 1998; Lagendijk, Mullink et al. 1999; 
Multhaupt, Arenas-Elliott et al. 1999; Chu, Wu et al. 2000; Cathro and 
Stoler 2002; Nishizuka, Chen et al. 2003; Dennis, Hvidsten et al. 2005; 
Heatley 2008).  
Immunohistochemical expression of Carcino Embryonic Antigen (CEA) 
CEA is a highly glycosolated protein first described by Gold and co-
workers in the human digestive tract (Gold and Freedman 1965). CEA 
is expressed in the normal squamous epithelial cells of the cervix, 
tongue and oesophagus and in mucous secreting upper and lower GI 
cells. Its expression is retained in colorectal, lung, pancreatic and 
endometrial tumours (Hammarstrom 1999). CEA is more variably 
expressed in ovarian cancers with 21-41% of all cases being reported 
as positive for CEA, though occasional studies on small numbers of 
selected cases have put this figure as high as 100% with the mucinous 
subtype most likely to express it (Macdonald, Bird et al. 1988; 
Breitenecker, Neunteufel et al. 1989; Neunteufel and Breitenecker 
1989; Berezowski, Stastny et al. 1996; Torenbeek, Lagendijk et al. 
1998; Keen, Szakacs et al. 1999; Lagendijk, Mullink et al. 1999). Serum 
Chapter 1: Introduction
13
CEA may act as a tumour marker in colorectal cancer but there is no 
evidence that its immunohistochemical expression in ovarian cancer 
tissue has prognostic value. 
Immunohistochemical expression of Cancer Antigen 125 (CA125) 
CA125 was indirectly discovered in 1981 by Bast and co-workers. They 
developed a murine IgG1 monoclonal antibody to ovarian cancer cell 
lines that was found to stain ovarian cancer tissues and which they 
named OC125. The initial study indicated that OC125 was 100% 
sensitive and specific for ovarian cancer though subsequent work has 
found it to be present in less than 80% of ovarian cancers and more 
widely distributed in the normal and cancerous derivatives of the 
embryological coelomic epithelium (pleural, pericardial and peritoneal 
tissues) (Kabawat, Bast et al. 1983). Though the CA125 antigen proved 
difficult to investigate, its gene was finally cloned in 2001 by Yin and co-
workers. They surmised that it was a new mucin species, the product of 
the MUC 16 gene (Yin and Lloyd 2001). Between 54% and 78% of the 
general population of ovarian cancers express CA125, with the 
proportion being higher for serous cancers (68-93%) compared to 
mucinous ones (25-43%) (Kabawat, Bast et al. 1983; Macdonald, Bird 
et al. 1988; Breitenecker, Neunteufel et al. 1989; Neunteufel and 
Breitenecker 1989; Loy, Quesenberry et al. 1992; Torenbeek, Lagendijk 
et al. 1998; Keen, Szakacs et al. 1999; Multhaupt, Arenas-Elliott et al. 
1999; Dennis, Hvidsten et al. 2005). In specific circumstances, CA125 
negative tumours may be associated with poorer outcome in late stage 
disease (Hogdall, Christensen et al. 2007) but there is little supportive 
evidence for CA125 tissue antigen expression being independently 
prognostic. 
Immunohistochemical marker panels 
While the expression of these four markers has been well 
characterised, used singly they are of limited use in determining the 
origin of an undifferentiated ovarian tumour. Using them together, as a 
panel, a tumour which is CK7(+)CK20(-) CEA(-)CA125(+) will most 
likely be of ovarian origin and not colonic origin (Tot 2002; Nishizuka, 
Chen et al. 2003; McCluggage and Young 2005) (Heatley 2008). 
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However, this panel is imperfect and the utility of a host of other 
supplementary markers has been assessed including CDX-2 (caudal 
related homeobox transcription factor 2), ȕ-catenin, ER (oestrogen 
receptor), PR (progesterone receptor), WT1 (Wilms Tumour 1), P504s 
(alpha-Methylacyl-COA-racemase), p16 (cyclin dependent kinase 
inhibitor 2A) and DPC4 (Deleted in Pancreatic Cancer 4). Despite this, 
even extensive, complex panels do not approach 100% accuracy, with 
various combinations of markers from three (CEA, CK7, Vimentin) 
(Lagendijk, Mullink et al. 1998) to 10 (CA125, CDX2, CK7, CK20, ER, 
GCDFP-15 [Gross Cystic Disease Fluid Protein 15], lysozyme, 
mesothelin, PSA [Prostate Specific Antigen], TTF1 [Thyroid 
Transcription Factor 1]) (Dennis, Hvidsten et al. 2005) yielding 
accuracies of between 66% (Brown, Campagna et al. 1997) and 88% 
(Dennis, Hvidsten et al. 2005) in predicting the primary source of a 
tumour. The most recent review places emphasis on a panel including 
CK7, CK20, WT1, ER, PR, GCDFP-15, CDX2, DPC4, p16 and ȕ-
catenin in assessing the origin of cancers clearly metastatic to the ovary 
with CA125 and CK20 having a role in excluding possible colonic 
cancer metastases from probable primary ovarian cancer and CEA 
having no clear role (Mittal, Soslow et al. 2008). 
1.1.3.4. Staging  
The stage of the disease describes the extent to which it has advanced 
at the time of diagnosis and is assessed clinically, surgically, 
pathologically and, increasingly, radiologically. Ovarian cancer spreads 
by its direct extension, by the exfoliation and migration of cancer cells 
throughout the peritoneal cavities and through the movement of tumour 
emboli throughout the lymphatic system (Bartlett 2000). In 1973 FIGO 
published data to validate an ovarian cancer staging system which 
identified four distinct stages: confined locally (stage I), extending to 
neighbouring structures (stage II), more distant regional spread (stage 
III) and distant metastasis (stage IV) (Appendix 2). This was adopted by 
the American Joint Committee on Cancer (AJCC) in preference to an 
alternative system developed by UICC which describes the stage of all 
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cancers in the same terms of tumour characteristics (T), lymph node 
involvement (N) and metastasis (M). The FIGO system remains the 
internationally recognised standard for staging ovarian cancer but, as 
all three bodies collaborate closely, the two systems have converged to 
the point where they are now almost identical (Benedet 2000; Odicino, 
Pecorelli et al. 2008). Having a reproducible, validated and practical 
staging system is useful prognostically and facilitates meaningful 
scientific discussion with disease also potentially being more precisely 
described on a sub-stage level (Appendix 2). Reviewing cohorts of 
ovarian cancers that included cases presenting between 1982 and 
1997 which were subsequently reported in the literature, the majority of 
series had a distribution of cases amongst the stages of 21-33% 
stage I, 4-11% stage II, 24-52% stage III and 12-37% stage IV (Table 
1.1) (Hand, Fremgen et al. 1993; Yancik 1993; Brun, Feyler et al. 2000; 
Holschneider and Berek 2000; Heintz, Odicino et al. 2001; Quirk and 
Natarajan 2005).  
1.1.4. Diagnosis 
Screening 
Diagnosing a disease in the population at risk through the widespread 
application of a test to asymptomatic individuals is the process of 
screening. The aim is to detect the disease at an earlier stage than it 
would otherwise be detected clinically, at a point in its natural history 
where intervention may be more successful and an improvement in 
mortality seen. This has been achieved by the national UK cervical 
screening programme but no national equivalent for ovarian cancer yet 
exists (Quinn, Babb et al. 1999). For the intended benefits of a 
screening programme to be achieved, most of its targeted population 
needs to participate and so the test employed must be simple and 
acceptable. As accurate diagnostic tests are often unpleasant, 
acceptable screening tests often have to compromise on accuracy, 
producing false negative results (leading to individuals being falsely 
reassured) and false positive results (leading to individuals undergoing 
unnecessary diagnostic testing or treatment). A good screening test 
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Table 1.1 FIGO stage and related 5-year survival  
Data derived from cohorts recruited within the time period covered by 
this study (1982 – 1997) which were reported in the literature.  
  
Series 
 
 
Wolfe 
 
 
(1997) 
Granai
 
 
(1997) 
Berek
 
 
(2000) 
Yancik
 
 
(1992) 
Quirk
 
 
(2001) 
Hand 
 
 
(1993) 
Brun 
 
 
(2000) 
Heintz
 
 
(2001) 
 
 
Number 
of cases 
 
118 137 12316 21000 23484 2977 323 3758 
Location U.K U.S U.S U.S U.S U.S E.U Global 
 
Time 
period 
 
1991 
 
1987 
1992 
 
1983 
1988 
 
1973  
1987 
 
1992 
1999 
 
1983 
1988 
 
1975 
1995 
 
1993  
1995 
 
% cases 
by stage 
        
I 13 47 32 26 26 29 21 33 
II 66 14 11 4 11 11 7 9 
III 53 27 32 70 59 24 52 46 IV 12 25 37 20 12 
 
5-year 
survival 
by stage 
       
I 89 93 76-80 76 80-89 
II 66 70 61 42 64 -70 
III 39 37 21-28 21 29-59 
IV 6 25 15-1 6 17 
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seeks to balance the benefits of acceptability with the risks of 
inaccuracy. Two tests for ovarian cancer have been most investigated, 
serum CA125 and Trans Vaginal ultrasound Scanning (TVS). Serum 
CA125 levels above the upper limit of normal are found in 80-90% of 
patients with epithelial ovarian cancer (Hogdall, Christensen et al. 
2007). Though lacking in formal consensus, a level of 35 U/ml has 
become the widely accepted value for delimiting normality with a level 
of >50 U/ml being associated with malignancy in 94% of instances 
(Jacobs, Oram et al. 1990; Einhorn, Sjovall et al. 1992; Hogdall, 
Christensen et al. 2007). However, raised levels (of up to 5000 U/ml) 
may also be seen in benign situations such as menstruation, 
pregnancy, endometriosis, pelvic inflammatory disease, peritonitis and 
in association with any cause of ascites or pleural effusion (Daoud and 
Bodor 1991). In addition, many mucinous epithelial ovarian cancers and 
up to 50% of stage I epithelial ovarian cancers have a normal serum 
CA125 (Jacobs and Bast 1989; Einhorn, Sjovall et al. 1992). For this 
reason a single abnormal measurement of CA125 on its own has an 
unacceptable sensitivity (81%) and specificity (75%) for screening. With 
a relatively low prevalence of ovarian cancer in the general population 
at risk, using such a test would be associated with a large number of 
false positive results and consequently unacceptable expense and 
morbidity (Jacobs, Oram et al. 1990). The use of serial measurements 
and a risk score improves accuracy slightly to a sensitivity of 86% and 
specificity of 98% (Skates, Menon et al. 2003). A series of over 25 000 
women received annual TVS screening by a group at the University of 
Kentucky with a sensitivity of 85%, specificity of 98.7%, Positive 
Predictive Value (PPV) of 0.14 and a Negative Predictive Value (NPV) 
of 0.99 being reported. There was evidence of a downward shift of 
stage at diagnosis with 82% being diagnosed at stage I/II. Additionally, 
5-year Overall Survival (OS) was higher in this group (77%) than in the 
local registry population (49%). However, the low sensitivity and PPV of 
TVS means that it may not be accurate enough to act as a lone tool in 
national screening (van Nagell, DePriest et al. 2007). The large scale 
feasibility of first line TVS alone or following abnormal CA125 
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measurements is therefore being assessed in a randomised multi-
centred trial that benefits from an unscreened control group, a cohort of 
200 000 initially asymptomatic women having been recruited. It will 
report in 2012 (United Kingdom Collaborative Trial of Ovarian Cancer 
Screening  UKCTOCS) (Menon, Skates et al. 2005).  
Symptoms  
The clichéd description of ovarian cancer as the silent killer is 
inaccurate as it implies that it is asymptomatic. In fact, patients 
retrospectively recall a variety of symptoms including increasing 
abdominal size (63%), abdominal bloating (68%), abdominal pain 
(50-58%), pelvic pain (26-41%), fatigue (50%) urinary symptoms (34%), 
along with upper gastrointestinal symptoms such as indigestion, feeling 
full quickly and reduced appetite which precede the diagnosis by many 
months (Bankhead, Kehoe et al. 2005). A more accurate summation 
might be that ovarian cancer is associated with a variety of commonly 
seen non-specific symptoms, the significance of which is usually only 
appreciated retrospectively by the majority of patients (Smith and 
Anderson 1985). One group that reported data collected prospectively 
from cases and controls concluded that the onset, duration and 
frequency of symptoms discriminated between ovarian cancer and non-
specific conditions. New onset symptoms of <12 months duration 
(abdominal pain, increasing abdominal size, urinary symptoms and 
feeling full) occurring >12 times per month had a sensitivity of 87% and 
specificity of 87% in the >50 year age group for detecting ovarian 
cancer (Goff, Mandel et al. 2007).  
Investigation 
Surgery for ovarian cancer is usually undertaken before a definitive 
tissue diagnosis has been made and, for that reason, supplementary 
tests are performed in order to reduce the likelihood of false positives. 
Incidentally discovered masses 
Such adnexal massed are investigated by TVS and the measurement 
of the serum CA125. These data are used to compute the risk of 
malignancy index (RMI), a validated scoring system originally 
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developed by Jacobs and co-workers which assesses the malignant 
potential of the mass (Jacobs, Oram et al. 1990; Scottish Intercollegiate 
Guidelines Network. 2003) (Figure 1.1). Some radiologists advise that a 
single high resolution 3 Teslar Magnetic Resonance (MR) scan can 
now adequately define the nature of masses accurately enough to 
remove the need for this approach (Spencer 2008). 
Clinical Ovarian cancer 
Where ovarian cancer has been diagnosed clinically, baseline tumour 
markers are sent which include CA125 and markers which help exclude 
alternate primaries including CA153 (breast) (Duffy 2006), CA19-9 
(pancreatic) (Goonetilleke and Siriwardena 2007) and CEA (colorectal) 
(Moreno Carretero, Cerdan Miguel et al. 1998). To assess the extent of 
the disease, radiological imaging of the chest, upper abdomen and 
pelvis is required. Ultrasound (USS), CT and MR have similar 
accuracies in determining whether disease has spread beyond the 
pelvis (Kurtz, Tsimikas et al. 1999) but CT scanning has been shown to 
be superior to USS and equivalent to 1.5 Teslar MR scanning in 
approximating the stage of advanced disease. Cytological samples may 
be taken from ascites or from effusions prior to surgery to delineate 
spread and these imaging modalities can be used to guide the taking of 
these samples and the removal of biopsy tissue where necessary.  
1.1.5. Treatment of epithelial ovarian cancer 
The successful treatment or longer term palliation of ovarian cancer 
combines surgical and medical approaches. 
1.1.5.1. Surgical treatment 
Surgery combines the expert assessment of the extent of the disease 
(staging) with its removal (debulking).  
Surgical staging 
An adequate staging operation demands a vertical mid-line abdominal 
incision, the collection of samples for cytology, the complete inspection 
and palpation of all of the abdominal contents, the taking of biopsies 
from suspicious sites and random ones from all other peritoneal 
surfaces, the inspection of the ovaries for signs of capsular rupture, the 
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Figure 1.1 The Risk of Malignancy Index (RMI)  
Developed by Jacobs et al for assessing the likelihood of ovarian 
pathology detected at ultrasound being cancerous (Jacobs, Oram et al. 
1990. 
 
Parameter Score 
 
Ultrasound appearances  
no abnormality = 0 
 
 
1 abnormality = 1 
 
 
2 or more abnormalities = 4 
Multilocular cyst
Solid areas
Bilateral lesions
Ascites
Intra-abdominal metastases
Menopausal status  
Post-menopausal 4 
 
 
1 
Pre-menopausal
 
CA125 level U/ml 
 
RMI = ultrasound score x menopausal score x CA125 
 
 
Using a cut-off of 200; Positive predictive value = 80%; Sensitivity 74-80%; Specificity 
89-92% (Scottish Intercollegiate Guidelines Network. 2003) 
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removal of all visible tumour, the removal of the omentum and the 
removal of the regional lymph nodes to the level of the renal hilar. By 
the end of the operation a total hysterectomy and bilateral salpingo-
oophrectomy should have been completed (Benedet 2000; Te Linde, 
Rock et al. 2003). Despite these recommendations, concerns about 
surgical morbidity mean that most patients have historically been 
incompletely staged, with the lymphadenectomy and random biopsies 
being the most frequently omitted steps (Trimbos, Schueler et al. 1990; 
Murakami, Nagashima et al. 2002). As lymph node infiltration (Stage III) 
occurs in up to 38% of apparently otherwise stage I cases, such 
incomplete staging can lead to under treatment and unexpectedly poor 
outcomes in this group (Knapp and Friedman 1974; Morice, Joulie et al. 
2003). The risks of operative complications have therefore to be set in 
context and most authorities recommend that a full staging operation 
which includes loco-regional lymphadenectomy is undertaken in 
apparent stage I cases (di Re, Baiocchi et al. 1996; Benedet 2000; 
Angioli, Plotti et al. 2008). 
Surgical debulking 
Solid tumours are conventionally treated surgically if it can be 
reasonably certain that all the disease will be removed, the potential for 
cure offsetting the risks of complex surgery. In ovarian cancer this 
principle is distorted due to the massive tumour volumes involved. 
Attempting to remove all of the tumour may be impossible in advanced 
disease but aiming to remove as much of the tumour as possible 
(debulking) will improve a patients performance status, quality of life 
and the subsequent effectiveness of chemotherapy (Blythe and Wahl 
1982; Hoskins and Rubin 1991). Minimal residual disease (tumour 
remaining at the end of debulking surgery) is an end-point which has 
been variously defined as the presence of cancer deposits with a 
diameter of <2cm, <1cm, <0.5cm or the absence of any visible disease 
(maximal macroscopic cytoreduction). The lower the amount of residual 
disease the better the OS and the absence of any visible disease is an 
important independent prognostic factor, with the persistence of 
residual deposits 2cm following surgery conferring no improvement in 
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OS above that of a simple diagnostic surgical procedure 
(Gospodarowicz 2001) (Makar, Baekelandt et al. 1995). If a strategy of 
debulking surgery is to be aggressively pursued, it must thus aim to 
attain a level of cytoreduction below this and preferably to the level of 
maximal cytoreduction. If this is achieved, the morbidity of even 
complex procedures (extensive bowel resection, splenectomy, 
cystectomy, nephrectomy, hepatic lobectomy) can be offset in even the 
most advanced cases by improvements in survival and quality of life 
(Curtin, Malik et al. 1997; Liu, Benjamin et al. 1997; Bristow, Montz et 
al. 1999; Benedet 2000). Though maximal cytoreduction is associated 
with the best outcomes, debulking the disease to a maximal point 
possible below 2cm is the accepted surgical standard (Omura, Brady et 
al. 1991; Hoskins, McGuire et al. 1994). It has not been discerned 
whether achieving maximal cytoreduction is made possible by 
biologically indolent cancer, or if the surgery itself alters the biology of 
the disease. However, the prognostic power in multivariate models of 
residual disease has diminished following the adoption of platinum 
based chemotherapy, demonstrating some interdependence between 
the two (Hoskins and Rubin 1991; Hunter, Alexander et al. 1992; 
Venesmaa 1994; Kehoe 1996; Brun, Feyler et al. 2000). Alterations in 
chemo-sensitivity may explain an interdependency as poor blood 
supply and the presence of quiescent or resistant clones are features of 
both high volume disease and chemo-resistance that should 
theoretically respond to its surgical reduction (Bartlett 2000). 
Surgical sub-specialisation 
Several studies have shown that cases managed by general surgeons 
have a poorer OS than those managed by gynaecologists, though 
improvements when a sub-specialist gynae-oncologist performs the 
surgery have been less clearly demonstrated (Nguyen, Averette et al. 
1993; Kehoe, Powell et al. 1994; Junor, Hole et al. 1999). This variation 
in survival may be explained by surgical differences (gynaecologists 
performing more accurate staging, more hysterectomies and more 
lymphadenectomies) or through the improved coordination of care seen 
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when gynaecological cancers are treated within a gynaecological 
department (Earle, Schrag et al. 2006).  
1.1.5.2. Medical treatment  
The specific medical therapy employed depends on the origin (non-
epithelial/epithelial) and stage (early/advanced) of the disease and has 
evolved over time with the retirement of certain modalities 
(radiotherapy) and the ever more imaginative delivery of successive 
novel chemotherapeutic agents. Monitoring response to treatment is 
the key to detecting resistance and newer strategies and agents 
continue to be developed to deal with cases which fail to respond to the 
best first line treatments.  
Early stage 
Assuming that the disease has been correctly staged, well 
differentiated stage Ia and Ib tumours have a >90% chance of cure 
through surgery alone with the remainder of early stage cancers having 
a high risk of recurrence (40-50%). Trials which have investigated the 
use of single agent platinum chemotherapy in early stage ovarian 
cancer concluded that it confers significant benefit in all Ic cases and 
those Ia and Ib cases showing certain high risk features on histological 
assessment. However, most patients in the high risk group would 
survive without chemotherapy and as 18% will have recurrent disease 
despite receiving it the current system is imperfect (Trimbos, Parmar et 
al. 2003; Ozols 2005). 
Advanced stage 
First line medical treatment of advanced epithelial ovarian cancer is 
usually commenced following surgical debulking and the most accepted 
practice is to administer 6 cycles of carboplatin combined with paclitaxel 
at three-weekly intervals. Ovarian cancer is sensitive to chemotherapy 
and the majority (75%) of cases will initially respond, though the 
disease is characterised by high levels of recurrence (75%) and 
eventual death following the development of resistance to platinum 
based chemotherapies (Lister-Sharp, McDonagh et al. 2000; Ozols, 
Bundy et al. 2003). 
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Evolution of chemotherapeutic regimens  
The practice of using single alkylating agents was abandoned from the 
late 1970s onwards as evidence that the use of platinum was superior 
accumulated (Lambert and Berry 1985). Platinum based drugs interact 
with DNA forming inter-strand cross-links and DNA-Platinum-Protein 
Complexes (DPCLs) which trigger cell death through as yet imperfectly 
defined mechanisms, though the final common pathway is likely to be 
apoptosis (Bartlett 2000; Chvalova, Brabec et al. 2007). A regimen 
combining cisplatin and cyclophosphamide found favour following the 
accumulation of evidence, eventually distilled in a Cochrane meta-
analysis (2000), that this regimen improved survival above the single 
agent regimen. A meta-analysis in 1995 looking at the effect of the 
anthrocyclin doxyrubicin supported using this drug in combination with 
platinum, the standard treatment having become Cyclophosphamide-
Anthracyclin-Platinum (CAP) (A'Hern and Gore 1995). Carboplatin was 
then found to be equivalent to CAP and to cause less toxicity (1998). 
Paclitaxel is a member of a family of drugs derived from the bark of the 
Pacific Yew tree (taxanes) that achieve cell killing by promoting the 
assembly and persistence of microtubules within the cell, leading on to 
mitotic arrest and apoptosis (Blagosklonny and Fojo 1999). Paclitaxel 
was shown to have activity in non-responding cases (McGuire, 
Rowinsky et al. 1989) and to improve tolerability and response rates 
when used in combination with cisplatin (Muggia, Braly et al. 2000). The 
use of combined paclitaxel and platinum regimens was extensively 
assessed, with many workers discovering improved outcomes 
(McGuire, Hoskins et al. 1996; Piccart, Bertelsen et al. 2000) (du Bois, 
Luck et al. 2003; Ozols, Bundy et al. 2003). However, this was not a 
universal finding and the large International Collaborative Ovarian 
Neoplasia (ICON) 3 trial found no clear benefit from adding paclitaxel to 
carboplatin and some evidence of worse toxicity (2002). Despite this, 
the consensus statement on the management of ovarian cancer issued 
by the Gynaecologic Cancer Inter Group (GCIG) concluded that best 
practice regimen to which new therapies should be compared should 
be carboplatin (AUC 5-7.5) and paclitaxel 175mg/m2/3h given every 
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three weeks for 6 courses for FIGO stages IIb-IV (du Bois, Quinn et al. 
2005). Guidance in the UK currently falls short of recommending this 
unless the clinician and patient feel that the benefits outweigh the risks 
(NICE 2003).  
Novel chemotherapy delivery and scheduling 
Investigating ways of delivering established agents more effectively can 
be an economical way of improving efficacy. 
Intra-peritoneal administration 
There is evidence that administering chemotherapy directly into the 
peritoneal cavity (IP) improves OS in optimally debulked patients and 
since 2006 the National Cancer Institute (NCI) has recommended that it 
be considered in such circumstances. Disadvantages include increased 
toxicity, unfamiliarity with the technology, catheter related problems and 
a perception of IP administration of chemotherapy as old fashioned 
(Trimble and Christian 2008). However, a meta-analysis of 8 phase III 
trials estimated an increase in survival of up to 17 months through 
administering the platinum component of standard therapy IP (Jaaback 
and Johnson 2006) and it is likely to become more widely used. 
Delaying primary surgery 
In cases where optimal debulking of the disease is considered unlikely 
(due to radiological or clinical findings or patient factors) the option 
exists to initiate primary chemotherapy and to reassess the case for 
surgery thereafter, the argument being that surgical debulking might 
become possible and be more complete in such cases if neo-adjuvant 
chemotherapy is used (Jacob, Gershenson et al. 1991). The data 
suggest that neo-adjuvant chemotherapy followed by surgery is no 
worse than a conventional approach, although survival is worse if 
surgery is still not attempted following it (Schwartz, Rutherford et al. 
1999; Morrison, Swanton et al. 2007). An ongoing randomised, 
controlled Medical Research Council (MRC) trial  CHemotherapy OR 
Upfront Surgery in ovarian cancer patients (CHORUS) should 
determine which philosophy is superior.  
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Maintenance schedules 
Extended courses of single agent cisplatin of up to 12 cycles have not 
been shown to improve OS or Progression Free Survival (PFS) but do 
increase toxic side effects (Jaaback and Johnson 2006). However, one 
randomised phase III trial has looked at continuing paclitaxel over a 12-
month period following standard chemotherapy in patients with a 
complete response to primary therapy and has shown an improvement 
in PFS. Paclitaxel may work well as a long term drug circumventing 
platinum resistance though a definite role for using it in this manner is 
yet to be defined (Markman 2008). 
Response to treatment, detection of recurrence and long-term follow-up 
Detecting refractory or recurrent disease allows salvage chemotherapy 
to be initiated at the earliest opportunity. Response to treatment and the 
detection of recurrence is measured clinically, radiologically and 
biochemically with guidelines for objectively measuring these 
parameters having been developed. The first guidelines were 
developed by the WHO (Miller, Hoogstraten et al. 1981) but updated as 
technology improved into the Response Evaluation Criteria In Solid 
Tumours (RECIST) criteria which place emphasis on measuring the 
tumour volume radiologically in reproducible sites over time (no less 
than 4 weeks, usually 6-8 weeks). This allows treatment effects to be 
objectified as either complete response (CR) to treatment (no tumour 
detected at >4 week intervals), partial response (PR) (>50% decrease 
in tumour burden), stable disease (SD) (>25% but 50% decrease in 
tumour burden) or progressive disease (PD) (new lesions or >25% 
increase in existing lesions) (Therasse, Arbuck et al. 2000). 
As the miliary nature of ovarian cancer may not be appreciated 
radiologically, the response to treatment may be assessed by a 
second-look operation. The findings at such procedures correlate with 
survival though undertaking them does not confer a survival benefit 
(Nicoletto, Tumolo et al. 1997; Benedet 2000). 
A 50% fall in the serum CA125 level from its pre-treatment value in the 
initial treatment phase which is maintained for at least 28 days indicates 
a PR to treatment (providing that the initial level was at least twice the 
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upper limit of normal) while rising post-treatment levels approach 100% 
specificity for PD. In the context of longer term follow-up, rising serial 
CA125 levels have been validated, predicting relapse before clinical 
signs become apparent and having a specificity approaching 98% when 
there is also a clinical suspicion of recurrence (Rustin, Nelstrop et al. 
1992; Rustin, Nelstrop et al. 1996). Some clinicians commence the 
treatment of recurrent/progressive disease solely on the basis of CA125 
levels, arguing that few unnecessary treatments occur (Markman, 
Rothman et al. 1991; Guppy and Rustin 2002) and an MRC trial (OV05) 
is under way to assess this management strategy. 
The follow-up schedule after the successful treatment of advanced 
ovarian cancer needs to balance the presumed need to detect 
recurrence early with the creation of unnecessary patient anxiety. FIGO 
recommends that follow-up should occur at 4-6 month intervals, after an 
initial year of three-monthly assessments, followed by annual reviews 
after 5 years of survival (Benedet 2000). The routine use of radiological 
tests is eschewed, with their role remaining confined to the investigation 
of clinically or biochemically suspected recurrence. There remains, 
however, variation and individualisation of follow-up arrangements as a 
robust evidence base for a prescriptive schedule is lacking (Vaidya and 
Curtin 2003).  
Treatment of recurrent and unresponsive disease 
Though recurrent or refractory disease is incurable, salvage therapies 
have been developed which prolong survival. 
Platinum sensitive recurrent disease 
Where an initial response to platinum has been demonstrated and a 
platinum free interval of >6 months has been observed, recurrent 
disease may still respond to platinum (Sabbatini and Spriggs 1998). 
Further courses of platinum based chemotherapy are therefore offered 
to patients with suspected platinum sensitive disease until it develops 
resistance or until quality of life issues predominate (Markman 1998). In 
this scenario standard first line combination chemotherapy has been 
shown to improve median OS by 5 months and median PFS by three 
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months when compared to single agent platinum chemotherapy 
(Thigpen, Blessing et al. 1994; Parmar, Ledermann et al. 2003).  
Conventional second line treatment 
Disease which progresses during initial therapy or on supplementary 
courses of first line chemotherapy is termed platinum refractory and 
platinum resistant respectively. Such cases have the salvage option of 
using a variety of established second line agents such as paclitaxel, 
topotecan, etoposide and Pegylated Liposomal Doxorubicin (PLD). 
However, as no second line regimen has been shown to be superior, 
the goals of second line therapy seek to balance modest survival gains 
with quality of life and the need to assess the effect of new treatments 
in clinical trials (Vermorken 2008).  
Novel treatments directed against platinum resistance 
mechanisms  
When intrinsic cellular resistance to platinum occurs, this may only be 
overcome by developing novel drugs which either circumvent or 
antagonise the mechanisms involved. 
Valspodar abrogates the effect of P-glycoprotein (PgP), which mediates 
multi-drug resistance (MDR) by encouraging trans-membrane efflux of 
drug but, so far, only a modest clinical impact has been observed in 
phase II trials (Fracasso, Brady et al. 2001). Gemcitabine is a false 
nucleotide which inhibits Excision Repair Cross-Complementation 
group 1 (ERCC1) mediated DNA repair and acts synergistically with 
platinum therapies; it has been shown to have some effect in phase II 
studies and is being evaluated in the phase III ICON5 trial (Lorusso, Di 
Stefano et al. 2006). Decitabine reverses the epigenetic hyper-
methylation of DNA about the Mut-L -Homolog 1 gene (MLH1) that can 
lead to its silencing, the incorrect functioning of the DNA MisMatch 
Repair (MMR) family of genes and then platinum resistance. Similarly, 
DNA polymerase alpha inhibitors disrupt the function of the NER 
(Nucloetide Excision Repair) pathway that confers platinum resistance 
through the repair of the platinum DNA adducts that trigger apoptosis. 
However, both of these drug types have currently only been completely 
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assessed in phase I trials (Sessa, Zucchetti et al. 1991; Sargent, Elgie 
et al. 1996; Appleton, Mackay et al. 2007). Over-expression of the 
ErbB2 and ErbB1 tyrosine kinase members of the Epidermal Growth 
Factor Receptor (EGFR) signalling family are implicated in the 
progression of cancer and have been shown by some groups to be 
associated with poorer outcome in ovarian cancer (Lassus, Leminen et 
al. 2004; Psyrri, Kassar et al. 2005). Small molecules targeting this 
pathway such as Erlotininb have shown only marginal effects in ovarian 
cancer so far (Gordon, Finkler et al. 2005). Many chemoresistant 
tumours exhibit resistance to a range of agents with the final common 
pathway of apoptosis with one of its most important regulators, p53, 
being associated with chemoresistance in ovarian cancer when the 
non-functional mutant form is expressed (Righetti, Della Torre et al. 
1996). Therapies specific to cells lacking functional p53 (Onyx-015 
oncolytic adenovirus) or directed at reviving functional p53 expression 
in mutant p53 expressing cells (Adenoviral vector p53  Ad-p53) have 
been shown to be safe and to exert a modest effect (Buller, Shahin et 
al. 2002; Vasey, Shulman et al. 2002).  
The development of drug resistance depends upon the production of a 
population of resistant cells. This may occur due to the selection and 
then proliferation of intrinsically resistant clones by therapy but, as 
cytotoxic chemotherapy is targeted against rapidly dividing cells, 
potentially sensitive cells outside the cell cycle will also show a degree 
of chemo-resistance. This may help explain the often poor translation of 
laboratory findings into the clinic. Developing therapies designed to 
target quiescent cells is an important field of research, as is the 
development of predictive markers that might inform first line therapies 
for individual patients (Agarwal and Kaye 2003; Agarwal, Linch et al. 
2006).  
1.1.6. Survival 
Reporting survival data 
Various forms of survival data exist against which the prognostic effect 
of age, histological cell type, histological grading, stage of disease, the 
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use of adjuvant treatment and the expression of established and novel 
biomarkers can be assessed. 
The simplest data are whether the patient is alive or dead. This is 
crucial and easily confirmed but on its own does not discriminate 
between those who die as a result of cancer and those who die of other 
causes such as peri-operative events, accidents, co-morbidities and 
old age". While accurate peri-operative mortality data are objectively 
generated (percentage of patients who die within 28 or 30 days of 
surgery), objective data regarding specific cause of death are more 
difficult to compile, given that the disease specific causes of death are 
many and subjective (malignant bowel obstruction, inadequate nutrition 
and electrolyte imbalances, obstructed urinary system, thromboembolic 
disorders, respiratory complications, etc) and the accuracy of data 
collected from registries and death certificates is inconsistent (Gagliardi, 
Fung et al. 2005). Despite such issues, cause specific survival data are 
key in calculating standard comparable measures of disease specific 
deaths such as fatality and mortality rates. The fatality rate is the 
percentage of cases dying from the disease and the mortality rate is the 
annual number of deaths from a disease per year/100 000 population at 
risk. European Standard Rate (ESR) mortality is the same measure 
age-adjusted to reflect the average European population, allowing 
meaningful direct comparison between regions. A measure of survival 
which accounts for deaths from other causes without a need to 
measure cause specific deaths is the relative age-adjusted survival 
rate. This compares the percentage of deaths within a cohort of 
patients with the percentage of deaths in the aged matched unaffected 
population at a fixed time point following treatment. This returns a ratio 
of two percentages, itself expressed as a percentage  the relative age-
adjusted 1-, 3- or 5-year survival.  
The length of time between treatment and death from any cause is 
termed the Overall Survival (OS), with the median or mean value being 
quoted for cohorts of patients. Using a fixed time point, 1-, 3- or 5-year 
OS can be expressed as a percentage of the total cohort in a crude 
non-adjusted manner. Large epidemiological studies most commonly 
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use relative, age-adjusted, standardised data, whereas studies 
comparing molecular marker expression with prognosis within a series 
most commonly use crude OS data (Quinn 2001). Crude OS data have 
the advantage of being easily acquired and objective and are clinically 
useful for patients, as they are interested in their chances of being alive 
at a future point rather than their chances of dying from a specific 
cause. 
Trends in survival 
Ovarian cancer represents 4% of cancers in women but accounts for 
6% of all cancer deaths and this disproportion is due to its high fatality. 
Overall ESR mortality in 1997 was 11.6/100 000 in the UK and this has 
altered little over the last 50 years. Though mortality increases with age 
(as for all cancers), when this is corrected for ovarian cancer mortality 
also varies by decade of birth, with cohorts up to the 1930s having a 
higher mortality than the after coming ones (Quinn 2001). Peri-
operative mortality has not been systematically reported for individual 
ovarian cancer cases but retrospective figures in the literature suggest 
a range of 0-5% depending on the size and co-morbidity of the 
population (Jalêuvka 1980; Elit, Bondy et al. 2002; Ben-Ami, Vaknin et 
al. 2006).  
The observed country-weighted 1- and 5-year survival for ovarian 
cancer in Europe for patients diagnosed from 1990-1994 (Eurocare3) 
were 65% and 34% respectively with relative survival equivalents of 
66% and 38%. The low proportions surviving to 5 years and the small 
size difference between observed and relative data illustrate the high 
fatality of the disease. For the UK the relative age-adjusted 1- and 
5-year survival data were 59% and 32% compared to Austria (best 
outcomes)  81.9% and 49.3%  and Estonia (worst outcomes)  
53.3% and 25.6%. These marked differences in survival data across 
Europe (which persist in Eurocare4) are thought to be due to variations 
in the stage at diagnosis, the inclusion or exclusion of borderline cases, 
the quality of registry data and the quality of cancer care (Sant, Aareleid 
et al. 2003; Berrino, De Angelis et al. 2007). There is some evidence 
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from Eurocare4 that relative 5-year survival data for the UK may be 
improving slightly though its survival figures still compare unfavourably 
to the rest of Europe when the former Soviet and Eastern Bloc 
countries are discounted (Berrino, De Angelis et al. 2007).  
These survival data are adjusted for age and background mortality but 
are not corrected for the influence of independent prognostic factors 
such as FIGO stage (Gospodarowicz 2001). This is important, as 
survival between stages and the distribution of stage of disease 
geographically varies considerably. Reviewing international series of 
ovarian cancers that included patients presenting within the period 
1982-1997 reveals relative 5-year survival figures of 76-93% for stage I, 
42-70% for stage II, 21-59% for stage III and 6-25% for stage IV (Table 
1.1) (Hand, Fremgen et al. 1993; Yancik 1993; Ilekis, Gariti et al. 1997; 
Wolfe, Tilling et al. 1997; Brun, Feyler et al. 2000; Holschneider and 
Berek 2000; Heintz, Odicino et al. 2001; Quirk and Natarajan 2005). 
However, on an individual level, even when age, stage, the use of 
chemotherapy and the degree of residual disease are corrected for, 
seemingly identical cases continue to have divergent outcomes and this 
points to the existence of other as yet undiscovered independent 
prognostic (probably molecular) factors which may also help explain the 
regional variations seen in outcome. 
Overall, a review of the evidence compiled by FIGO indicates that 
5-year survival improved internationally from 27% (1958-1962) to 35% 
(1982-1986) and then dramatically to 48% (1993-1995) following the 
introduction of platinum based regimens, this improvement occurring for 
all stages (Heintz, Odicino et al. 2001).  
1.2. Immunological biomarkers 
The purpose of this section is to outline why biomarkers are 
researched, the logic behind selecting particular biomarkers for 
investigation, why tissue microarrays may be employed, the importance 
of the immune system in human cancers and the rationale behind 
investigating biomarkers of an immunological nature in ovarian cancer. 
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1.2.1. Biomarkers in general 
1.2.1.1. The importance of prognosis and prognostic factors 
Making a prognosis necessitates reasonably forecasting the course, 
pattern, progression, duration and termination of a disease for an 
individual patient (Gospodarowicz 2001).  
Cancer is a heterogeneous disease and prognostic factors are the 
variables which account for differences in the expected course of the 
disease that this produces. Commonly used prognostic factors in 
oncology can be split into tumour, host and environmental factors. In 
ovarian cancer they include stage and degree of cytoreduction 
(tumour), performance status/age (host) and the delivery of optimal 
treatment (environmental/geographic). Though factors associated with 
variation in response to treatment are termed predictive rather than 
prognostic, the predicted response to treatment remains the de facto 
prognostic factor upon which patients rely in making a decision whether 
to undergo or decline treatment. (Henderson and Patek 1998). The 
foremost role for prognostic factors is in counselling patients. However, 
a knowledge of them also aids learning from experience, informs the 
allocation of public health resources and allows outcome end points 
(PFS/OS) to be meaningfully compared between centres whilst 
additionally identifying patients who may benefit from novel therapies 
most. Furthermore, applying equal stratification for known prognostic 
factors within all experimental arms in clinical trials allows for the effect 
of the intervention to be more independently assessed (Gospodarowicz 
2001). New independent prognostic factors are those which predict 
prognosis in a way which does not depend upon an association with a 
currently clinically employed independent prognostic factor. As these 
factors add prognostic information and are not surrogates for known 
factors, they also imply causation. Discovering a molecular marker with 
independent prognostic power may therefore reveal the importance of a 
particular intracellular process and identify a target to which novel 
therapy can be developed and directed. However, for a molecular 
marker to make the transition to the clinic it must be externally 
Chapter 1: Introduction
34
validated, employ reproducible assays, have substantial predictive or 
prognostic power and have therapeutic implications. Therefore, the 
systematic study of molecular markers demands a logical approach 
rooted in the biology of cancer (Gospodarowicz 2001).  
1.2.1.2. The hallmarks of cancer 
The American Cancer Society (ACS) defines cancer as a group of 
diseases characterised by uncontrolled growth and the spread of 
abnormal cells which, if not controlled, can result in death. The 
essential properties or hallmarks of cancer which lead to this type of 
behaviour comprise self sufficiency regarding growth signalling, 
insensitivity to inhibitory growth signals, evasion of apoptosis, limitless 
replication potential, sustained angiogenesis, tissue invasion and 
metastasis (Hanahan and Weinberg 2000). The drivers of this 
behaviour are molecular. 
1.2.1.3. Examples of molecular processes involved in 
carcinogenesis 
A cancer cell may take control of its own growth by upregulating its 
secretion of growth signals, instructing nearby cells to secrete growth 
factors in a paracrine fashion and by upregulating its expression of 
growth factor receptors such as Erythroblastic leukemia viral oncogene 
homolog 2 (ErbB2) (Skobe and Fusenig 1998; Yarden and Sliwkowski 
2001). A major effector mechanism of anti-proliferative signals is the 
Retinoblastoma protein (pRb) which blocks cell cycle progression whilst 
unphosphorylated. As phosphorylation of this protein is controlled by 
Transforming Growth Factor ȕ (TGFȕ), disruption of its receptor, loss of 
pRb itself or loss of intermediate signalling molecules can all lead to 
loss of responsiveness to anti-proliferative signals (Fynan and Reiss 
1993). Apoptosis balances cell proliferation by causing cells to 
dismantle themselves in response to effector stimuli such as the binding 
of fasLigand (fasL) to its receptor. Apoptosis is under the control of 
numerous intracellular mediators, of which two of the most important 
are the p53 tumour suppressor gene and Bcl-2. The disruption of these 
can lead to an acquired resistance to this process (Wyllie, Kerr et al. 
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1980). The majority of cell populations have a finite ability to divide 
mediated partly by a shorting of telomeres which occurs at each 
division (Hayflick 1997). Most cancers (91% of ovarian) exhibit 
telomerase activity, an enzyme which maintains telomere length 
through telomeric DNA synthesis. It is thought that this contributes to 
the development of immortality (Shay and Bacchetti 1997). Tumour 
growth is disordered and with cells often lying >100µm from capillary 
vessels, hypoxia is common. Tumours attempt to correct this using 
angiogenic factors (Hanahan and Weinberg 2000). Vascular 
Endothelial Growth Factor (VEGF) is a cytokine which is a stimulus for 
angiogenesis and which is commonly secreted by neoplastic cells. It 
stimulates neovascularisation through binding to VEGF receptors 
(VEGFR) on endothelial cells, relieving hypoxia (Neufeld, Tessler et al. 
1994; Bamberger and Perrett 2002). Successful proliferation, 
immortality and angiogenesis leads on naturally to invasion and 
metastasis, the cause of the majority of cancer deaths (Sporn 1996). 
Disruption of cell adhesion molecules such as E-Cadherin and the 
upregulation of protease producing genes are key processes by which 
the cancer cell may manipulate its immediate environment to achieve 
its invasive and metastatic potential (Werb 1997; Semb and Christofori 
1998). 
These molecular processes are examples of the many routes through 
which cancer cells can develop these 6 key abilities, a situation 
favoured by their genetic instability. This predisposes their genome to 
mutational events which otherwise occur only rarely and is engendered 
by the disruption of DNA repair mechanisms (Lengauer, Kinzler et al. 
1998). 
1.2.1.4. Biomarker research strategy 
The NIH defines a biomarker as a characteristic that is objectively 
measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a therapeutic 
intervention. With respect to cancer, studying the molecular changes 
associated with the development of its hallmarks is the logical way of 
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searching for molecular biomarkers which may have independent 
prognostic power that may thereafter direct clinical and research efforts.  
Molecular markers may be found in bodily fluids (urine, saliva, serum, 
etc), cancer cell lines or cancer tissue (fresh, frozen, Formaldehyde 
Fixed Paraffin Embedded [FFPE]). When researching post-surgical 
prognostication, the search for biomarkers expressed in tissue is a 
common strategy. Molecular alterations associated with cancer may be 
studied along any point of the axis leading from gene (genomics/ 
epigenomics), through its transcription (transcriptomics) to the final 
protein responsible for cell function (proteomics) (He and Chiu 2003). 
The traditional starting point is the screening of the genome for 
alterations which can be followed through to the protein level. The 
disadvantage of this strategy is that many aberrations in the genome 
are not represented at the protein level, with single genetic aberrations 
in sporadic cancers usually requiring a second genomic hit before a 
cellular impact becomes evident (Knudson 1971). Variation in post-
translational modification of peptides also means that single genomic 
changes map to a wide number of potential proteomic alterations (Cho 
2007). Working backwards from the discovery of abnormal protein 
expression is the pragmatic alternative and several experimental 
platforms exist with which to investigate protein expression in cancer 
samples, including 2D-Gel Electrophoresis (Western blot), Enzyme 
Linked Immunosorbant Assay (ELISA), Mass Spectrometry (MS), 
protein microarrays and IHC, the uses of which are often 
complementary (Petricoin and Liotta 2002; Park, Kerbel et al. 2004). 
Regarding IHC, the high-throughput platform developed over recent 
years to survey large populations for prognostic biomarkers is the 
Tissue MicroArray (TMA) (Chung, Braunschweig et al. 2007). 
1.2.1.5. The TMA platform 
The development of TMAs (Figure 1.2) 
Traditional experimental immunohistochemistry involves the staining of 
whole sections of tumour tissue. As only 20-40 slides can be stained by 
an average worker per day, in the past it was only possible to 
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Figure 1.2 The evolution of multi tumour tissue blocks (MTTB) 
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accumulate data for large cohorts over a number of experimental runs 
and so, historically, many studies were often either small and 
underpowered or subject to considerable intra- and inter-observer 
variability due to variation in experimental conditions. As the use of 
whole sections quickly renders a tissue block either unusable or non-
diagnostic (many sections are discarded before one high quality section 
is acquired), work has to be performed in a very coordinated manner 
between groups in order to preserve tissue. A further disadvantage of 
the whole section approach is that each slide requires a full set of 
expensive reagents. 
To address these points the principle of transferring small samples from 
many archived tumour blocks into a single Multi Tumour Tissue Block 
(MTTB) block was explored and first described in 1986 (Battifora 1986). 
This method involved deparaffinising archived tissue, cutting 1mm wide 
slivers from multiple specimens and then tying them together in a 
bundle before re-embedding them in wax. The result was termed a 
sausage block, due to its cross sectional appearance. This proved 
effective at reducing the amount of monoclonal antibody required but 
was only useful for quality control as individual tumours could not be 
identified. This technique was refined to the chequerboard block 
where the location of tumours was known (Battifora and Mehta 1990) 
but was ultimately superseded by a different method of producing a 
MTTB, developed by Wan and co-workers (Wan, Fortuna et al. 1987). 
This involved boring tissue cores from archived blocks using a 16-
gauge needle, without deparaffinisation. More tumours could be re-
embedded but tumour identification was still not possible. The following 
year Kraaz and colleagues described a technique of removing cores 
using a skin punch biopsy tool and then pushing them into known 
locations in a warm paraffin block though, due to tissue size, only 20 
samples could be transferred (Kraaz, Risberg et al. 1988). The major 
advance came when Kononen and co-workers described the use of a 
custom built instrument (Tissue Microarrayer  Beecher instruments, 
Sun Prairie, WI, US) which allowed 0.6mm wide cylindrical tissue cores 
to be punched out from archived blocks and transferred immediately to 
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holes precisely punched out at known coordinates in a recipient paraffin 
block (Kononen, Bubendorf et al. 1998).  
TMAs are now usually constructed using this method with up to 1000 
cores being transferred into known locations without the need for 
deparaffinisation. As 3-4mm long cores are transferred and 4-8µm thick 
sections are cut, 200 slides can theoretically be obtained from each 
TMA block with each stained section providing data about many 
hundreds of cases for a given marker (Kononen, Bubendorf et al. 
1998).  
Validation of TMAs  
Studies validating the use of TMAs aimed to show that the biochemical 
characteristics of a population of tumours as predicted by staining a 
TMA of small tumour biopsies would be the same as that predicted by 
whole sections. 
Konnen and colleagues originally validated TMA use in breast cancer. 
Three hundred and seventy-two cancer tissue samples were 
assembled into a TMA and amplifications in three breast cancer 
oncogenes, ErbB2, MYC and Cyclin D1 (CCND1), were detected which 
concurred with published data. They also observed corresponding 
upregulations of mRNA and protein expression upstream. On 
examining ER, an 84% concordance was seen between the 
immunohistochemically and biochemically determined ER content  as 
would have been expected if whole sections had been used. The 
authors concluded that, despite the theoretical problem of using small 
samples of tissue to examine tumours which might express a marker 
heterogeneously, this technique could be used to produce scientifically 
valid results in place of whole sections as long as representative 
samples were selected. TMAs have subsequently been validated for 
use in prostate cancer (Mucci, Akdas et al. 2000), lymphoma (Hedvat, 
Hegde et al. 2002), gastric cancer (Gulmann, Butler et al. 2003), 
bladder cancer (Nocito, Bubendorf et al. 2001) and colorectal cancer 
(Fernebro, Dictor et al. 2002). The use of TMAs in ovarian cancer was 
validated by Rosen and co-workers. They stained 6 copies of a TMA 
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containing 45 ovarian cancers for Ki-67, mutant p53 and ER. A 
concordance of 98% was seen between the results from the whole 
sections and the TMA on analysing three cores, which did not increase 
on examining more copies. Overall agreement of expression data with 
that in published studies was also observed (Rosen, Huang et al. 
2004).  
1.2.1.6. Trastuzumab in breast cancer (Herceptin) 
The development of Herceptin highlights the importance of biomarker 
discovery and how this can be translated into measurable clinical 
improvements (Shepard, Jin et al. 2008). ErbB2 (Her2/Neu) is a gene 
which encodes for a tyrosine kinase receptor implicated in cell 
proliferation, cell survival, angiogenesis and cell adhesion (Shepard, Jin 
et al. 2008). Its upregulation was found to be present in 20-30% of 
breast cancers and to be an independent prognostic and predictive 
factor (Slamon, Clark et al. 1987). Over-expression was subsequently 
found to be associated with the transformation of cells into a Tumour 
Necrosis Factor (TNF) Į/macrophage resistant phenotype. However, 
this could be reversed using a murine monoclonal antibody (mAb) 
directed at the extracellular domain of ErbB2 (Hudziak, Lewis et al. 
1989). Subsequently, Herceptin, a humanised version of this murine 
anti-p185HER2 mAb, was developed. Herceptin mediates an anti-
proliferative effect through its target receptor and the initiation of 
Antibody Dependent Cellular Cytotoxicity (ADCC) (Carter, Presta et al. 
1992). Clinical trials subsequently established the clinical role of 
Herceptin as a first line agent in node positive, immunohistochemically 
strongly ErbB2 expressing breast cancers (Vogel, Cobleigh et al. 2002; 
Romond, Perez et al. 2005).  
1.2.1.7. Tissue expressed proteomic biomarkers in ovarian cancer 
Candidate markers 
A large number of tissue proteomic biomarker studies continue to be 
performed and promising candidates, including Mucin4 (MUC4), 
MatrixMetalloProteinase4 (MMP4), EPithelial Cell adhesion molecule 
(EpCam), CD24 and ErbB3, have been recently identified (Gagnon and 
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Ye 2008). Four of the most commonly studied molecular markers 
historically have been Epidermal Growth Factor Receptor (EGFR), 
ErbB2, Glutathione S-Transferase-pi (GSTpi) and mutant p53, which 
were reviewed by Crijns and co-workers in 2003 (Crijns, Boezen et al. 
2003).  
Of 11 studies reviewed concerning Epidermal Growth Factor Receptor 
(EGFR), in univariate analysis one showed a correlation with improved 
prognosis, four a correlation with worse survival and one a correlation 
with reduced response to chemotherapy; in multivariate analysis three 
studies showed EGFR to be an independently negative prognostic 
factor. Of 16 studies reviewed concerning ErbB2, in univariate analysis 
8 showed a correlation with worse survival and three with a poorer 
response to chemotherapy; in multivariate analysis three showed ErbB2 
to be an independently negative prognostic factor. Of 14 studies 
reviewed concerning GSTpi, in univariate analysis 5 showed a 
correlation with worse survival and worse response to chemotherapy. 
No study found it to be an independent prognostic factor. Of the 42 
studies reviewed concerning mutant p53, in univariate analysis 24 
showed a correlation with worse survival, 7 a correlation with shorter 
PFS, one an association with improved response to chemotherapy and 
7 with worse response to chemotherapy; in multivariate analysis 12 
studies showed mutant p53 expression to be a negative independent 
prognostic factor, with two showing it to have independent predictive 
power  one for a good response to chemotherapy and one for a poor 
response. 
Translational difficulties 
An ideal biomarker is linked to a biological phenomenon associated 
with the development of cancer, is easily detectable, is reproducible, 
has independent prognostic power, predicts outcome and response to 
treatment, has clinical relevance and is validated by several groups 
independently of each other (Gasparini, Pozza et al. 1993). However, 
as shown, the literature for biomarker studies is often inconsistent, with 
conflicting associations being the norm and the difficulty meeting these 
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criteria with the available evidence means that the only biomarker used 
clinically in ovarian cancer remains post-treatment serum CA125 
(Agarwal and Kaye 2006). Efforts to standardise the reporting of 
biomarker studies may improve this, as the lack of a common 
systematic approach to biomarker studies has been cited as the most 
likely cause of the many unrepeatable, small, positive studies which 
confound the literature (McShane, Altman et al. 2006). However, as 
standard treatment is given to virtually all cases of ovarian cancer, and 
as few rational first line alternatives are currently available, part of the 
reason that the aggressive translation of markers into the clinic has not 
been pursued may be a perception that they will not influence the 
clinical decision making (Agarwal and Kaye 2005). 
Despite this, the search for independent prognostic markers of 
prognosis remains important, though the logical selection of research 
markers is essential. Candidates should be biologically and clinically 
relevant and expected to have prognostic and therapeutic implications. 
Immunological molecular markers fulfil this brief. 
1.2.2. The immune system in general 
1.2.2.1. The innate immune system 
Innate immunity non-specifically targets harmful agents which have not 
been encountered before. It results in a rapid, intense, generic 
response which is mediated by both cellular and humoural elements. 
1.2.2.1.1. Cellular elements 
Phagocytes 
Macrophages and neutrophils are the main cells tasked with engulfing 
and destroying foreign material. They recognise the Pathogen 
Associated Molecular Patterns (PAMPs) expressed by foreign material 
through their expression of Pattern Recognition Receptors (PRR). 
PAMPs are molecular signatures characteristic of particular invaders 
such as the flagellin in bacteria and the double stranded DNA in virally 
infected cells. PRRs recognise particular PAMPs and comprise three 
main groups: Toll-Like Receptors (TLRs), C-type lectins and the 
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LipoPolySaccharide (LPS) binding CD14 scavenger molecule. The 
interaction between PRR and PAMP initiates phagocytosis, the release 
of cytokines and the acute inflammatory response, which attracts cells 
of the adaptive immune system to the site. The phagocyte employs a 
variety of mechanisms to effect actual cell killing, including the 
superoxide anion, nitric oxide, defensins, lysozyme and proteolytic 
enzymes (Roitt and Delves 2006). 
Natural Killer (NK) cells 
NK cells are lymphocytes defined by the expression of CD56 and the 
absence of expression of CD3 and are crucial effectors of innate 
immunity. NK cells kill and release cytokines without specific 
sensitisation and to prevent normal tissue from initiating this process 
they are tightly regulated through the expression of surface NK 
Receptors (NKRs). Several types of receptor exist, including Killer 
Immunoglobulin (Ig)-like Receptors (KIRs), the C-type lecthin family 
(including NKG2 and CD94), Ig-Like Transcripts (ILTs) and Natural 
Cytotoxicity Receptors (NCRs). NKRs may be inhibitory or activatory on 
binding, with the balance between the two determining the overall 
response. Generally, KIRs favour a state of inhibition unless the Human 
Leukocyte Antigen (HLA) class I allele that they bind to is absent or lost 
on a given cell (Vales-Gomez, Reyburn et al. 2000). 
An activated NK cell kills by triggering apoptosis through the initiation of 
the capsase cascade. This is in part mediated by the release of 
perforin, which creates pores in the target cells membrane through 
which pro-apoptotic factors such as granzyme B may pass (Hudig, 
Ewoldt et al. 1993). Apoptotic stimuli may also be transduced through 
the binding of fasL and TNF (Tumour Necrosis Factor) Related 
Apoptosis Inducing Ligand (TRAIL) to the corresponding death 
receptors on the target cell (Screpanti, Wallin et al. 2005). NK cells are 
also a rich source of tumouricidal cytokines such as interferon (IFN) ܵ, 
TNFȕ, IL (Interleukin)-10, IL-13 and Granulocyte Macrophage-Colony 
Stimulating Factor (GM-CSF). NK cells may be either predominantly 
cytotoxic or cytokine producing dependent upon on their relative 
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expression of CD56 and CD16 (Cooper, Fehniger et al. 2001; Cooper, 
Fehniger et al. 2001; Roitt and Delves 2006). 
Gammadelta (Ѭį) T cells 
ܶį T cells are distinct from Įȕ T cells as they respond to antigen 
without a need for its presentation with HLA molecules. The TCR in this 
subclass exhibits increased diversity and these cells each recognise a 
range of epitopes, lessening the need for clonal expansion when 
abnormal tissue is encountered. These cells are thought to play a role 
in the removal of stressed or damaged cells. It has been noted that 
mice deficient in this cell type are predisposed to the development of 
tumours (Girardi, Oppenheim et al. 2001; Hayday and Tigelaar 2003; 
Raspollini, Castiglione et al. 2005; Roitt and Delves 2006). 
1.2.2.1.2. Humoural elements 
Cytokines, chemokines and acute phase proteins 
Cytokines are low molecular weight proteins which are secreted by T 
helper (Th) cells, NK cells, mast cells, stromal cells and monocytes. 
They consist of several families, including interleukins (IL1-33), Colony 
Stimulating Factors (CSFs), TNFs and IFNs, and they modulate the 
immune response on a local level. Typical actions include the control of 
cellular differentiation, the upregulation of receptors, the initiation of an 
inflammatory response, anti-tumour and anti-viral activity, direct 
cytotoxicity and the priming of the adaptive immune response. 
Chemotactic cytokines attract cells to areas of need, while IL-1 and IL-6 
cause the release of acute phase proteins. Acute phase proteins such 
as C- Reactive Protein (CRP) and Mannose Binding Lectin (MBL) coat 
non-self material, opsonising them and fixing complement. 
Complement (C) 
Complement refers to a triggered enzyme system of more than 30 
plasma proteins which mediate opsonisation, chemotaxis, activation of 
leukocytes, lysis of foreign cells, augmentation of antibody responses, 
enhancement of immunological memory, the disposal of immune 
complexes and the clearance of apoptosed cells. 
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Complement cascade 
The key step in the activation of complement is the production of C3 
convertase which formally cleaves the abundant component C3 into two 
pieces, C3a (small fragment) and C3b (large fragment). C3b then 
complexes with other complement components to form C5 convertase. 
This cleaves C5 into C5a and C5b with C5b then sequentially binding 
C6, C7 and C8 to form C5b-8 on the target cell membrane. This in turn 
facilitates the deposition and polymerisation of C9 to form a 
transmembrane channel termed the Membrane Attack Complex (MAC), 
which lyses the cell (Figure 1.3) (Muller-Eberhard 1986; Walport 2001). 
The formation of MAC is the final common pathway of the complement 
cascade but the production of the convertases is driven by three distinct 
pathways, each activated in a different way. 
The classical pathway 
The classical pathway is initiated by antibody-antigen complexes (IgG 
and IgM), the presence of apoptotic cells, gram negative bacteria and 
the presence of CRP binding. C1 is activated by these stimuli, cleaving 
C2 and C4 into C2a, C2b, C4a and C4b. C4b and C2a then complex to 
form C3 convertase which complexes to the product of its action, C3b, 
to form C5 convertase (Figure 1.3).  
The alternative pathway 
C3b is continually produced by spontaneous hydrolysis in plasma but is 
normally converted into its inactive iC3b form by the presence of factors 
I and H. In the alternative pathway, factor b expressed on the surface of 
bacteria and fungi binds this C3b and forms C3 convertase under the 
influence of factor D. C3b production then enters a positive feedback 
loop amplifying the production of C3 convertase and C3b. These 
combine to form C5 convertase, leading to the formation of MAC 
(Figure 1.3). 
The MBL pathway 
The MBL pathway mediates the cleavage of C2 and C4 in a similar 
manner to the classical pathway and is initiated by the binding of the 
acute phase protein MBL to the terminal mannose groups present on 
the surface of bacteria. This forms complexes with MBL Associated 
Chapter 1: Introduction
46
Figure 1.3 The complement cascade 
A schematic illustrating how the classical, MBL and alternative 
pathways initiate and amplify the complement cascade and the final 
common pathway of MAC assembly which ultimately leads to cell lysis. 
The classical pathway is initiated by the presence of antigen-antibody 
complexes and the alternative pathway by the presence of factor B on 
the surface of pathogenic material. 
 
 
 
Please refer to Figure 1; Walport, M. J. (2001). "Complement. First 
of two parts." N Engl J Med 344(14): 1058-66. 
 

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Serine Protease (MASP) 1 and 2; MASP2 then cleaves C2 and C4 with 
MASP1 cleaving C3 directly. The convertases are then produced in an 
analogous manner to the classical pathway (Figure 1.3) (Makrides 
1998). 
Anaphalaxtoxins 
The small fragments C3a, C4a and C5a are called anaphalatoxins and 
mediate the acute inflammatory response to complement activation by 
causing mast cells to release histamine, chemokines, interleukins, 
leukotrienes, prostaglandins and thromboxanes. These mediators result 
in smooth muscle relaxation, increased vascular permeability and the 
recruitment of appropriate cells to the site of complement activation. 
C5a is the most potent of the three (Roitt and Delves 2006) (Gerard and 
Gerard 1994; Liszewski, Farries et al. 1996; Hartmann, Henz et al. 
1997). 
Complement regulation 
Complement is a powerful humoural element of the innate immune 
system and, as its action is self perpetuating once triggered, a number 
of mechanisms exist to prevent damage to healthy normal tissue. 
There are numerous soluble factors involved in regulating the activation 
and deposition of complement and MAC, such as C1 inhibitor, factor I, 
factor H, C4 binding protein, properdin, S protein, and clusterin 
(Liszewski, Farries et al. 1996). Cells may also express four membrane-
bound complement regulatory proteins (mCRPs), CR1, CD46, CD55 
and CD59. These are encoded for by genes lying within the Regulators 
of Complement Activation (RCA) cluster at 1q3.2 (Liszewski, Farries et 
al. 1996). 
CD35 
CR1 is a large 160-260 KDa glycoprotein which binds to C3b and C4b 
acting as a co-factor for their factor I mediated breakdown. The 
distribution of CR1 is restricted to erythrocytes and leukocytes with 
some expression on peripheral nerve cells and glomerular podocytes. 
Having a higher affinity for C3b than for C4b, it has a greater effect on 
the alternative pathway (Fearon 1979; Morgan and Meri 1994). 
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CD46 
Also known as Membrane Co-factor Protein (MCP), this is a 4868 KDa 
glycoprotein comprising four Short Consensus Repeats (SCRs), a 
Serine Threonine Proline (STP) rich region, a transmembrane domain 
and a cytoplasmic tail (Figure 1.4). It is expressed on the majority of 
cells, with the exception of erythrocytes, and it controls the availability 
of C3b through its action as a co-factor for its factor I mediated 
inactivation to iC3b. By controlling this precursor, it controls the levels of 
the C3 and C5 convertases produced by the alternative pathway 
(Figure 1.5) (Cole, Housley et al. 1985; Liszewski and Atkinson 1992; 
Morgan and Meri 1994). Additional roles of CD46 in intracellular 
signalling, the differentiation of naïve T cells into regulatory cells and in 
reproduction have also been suggested and the deficiency state is 
linked with the inherited predisposition to the development of 
Haemolytic Uraemic Syndrome (HUS) (Riley-Vargas, Gill et al. 2004). 
CD55 
Also known as Decay Accelerating Factor (DAF), CD55 is a 70-80 KDa 
glycoprotein featuring four SCRs, an STP rich region and a Glycosyl 
Phosphatidyl Inositol (GPI) anchor with which it attaches to the cell 
membrane (Figure 1.4). CD55 is widely distributed and present on all 
haemopoetic cells, vascular endothelium and epithelia of the 
gastrointestinal and genitourinary tracts. It accelerates the 
decomposition of C3 convertase in both the classical and alternative 
pathways by causing C2a and Bb to dissociate respectively (Figure 1.5) 
(Hoffman 1969; Medof, Walter et al. 1987; Morgan and Meri 1994; 
Nicholson-Weller and Wang 1994; Liszewski, Farries et al. 1996). 
There is evidence that CD55 may also inhibit NK cell lysis and 
apoptosis while its action as a ligand for CD97 may promote 
invasiveness, metastasis and angiogenesis in the tumour environment 
(Mikesch, Buerger et al. 2006). A lack of membrane bound CD55 is 
associated with the disease Paroxysmal Nocturnal Haemoglobinuria 
(PNH) (Jarva and Meri 1999). 
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Figure 1.4 The structure of the membrane bound complement regulatory 
proteins 
Short Consensus Repeats (SRCs) are represented by square blocks. 
The Glycosyl Phosphatidyl Inositol (GPI) anchors of CD59 and CD55 
are illustrated along with the transmembrane spanning domain of CD46 
inserting into the cytosol (CY) and the Serine Threonine Proline rich 
areas of CD46 and CD55 (ST).  
 
Please refer to Figure 2; Makrides, S. C. (1998). "Therapeutic 
inhibition of the complement system." Pharmacol Rev 50(1): 59-87. 
 
 
Figure 1.5 The site of action of the mCRPs 
CD55 (DAF) accelerates the decay of the C3 convertases, CD46 (MCP) 
acts as a co-factor for the factor I mediated conversion of C3b to iC3b 
and CD59 binds to the C5b-9 complex, preventing the polymerisation of 
C9 and the assembly of the MAC. 
 
 
Please refer to Figure 2; Gasque, P. (2004). "Complement: a unique 
innate immune sensor for danger signals." Mol Immunol 41(11): 
1089-98. 
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CD59 
Otherwise known as protectin, CD59 is an 18-20 KDa single chain 
glycoprotein which links to the cell surface via a GPI anchor (Figure 
1.4). CD59 is widely expressed on the majority of cells, including 
circulating cells, epithelia and endothelium, and it prevents the 
assembly of the MAC by binding the C5b-8+9 complex and preventing 
the polymerisation of C9 (Figure 1.5-6). The global deficiency of GPI in 
PNH means that membrane bound CD59 deficiency is also seen in this 
disease (Sugita, Nakano et al. 1988; Meri, Morgan et al. 1990; Meri, 
Morgan et al. 1990; Morgan and Meri 1994; Liszewski, Farries et al. 
1996). Possible complement independent roles may include tyrosine 
kinase and LPS signalling and the regulation of NK-, T- and B-cells 
(Kimberley, Sivasankar et al. 2007). Nucleated cells may also resist the 
MAC mediated cell lysis through CD59 independent ways including 
membrane repair systems, mechanisms which physically remove MAC 
and intracellular metabolic processes (Morgan 1989). 
1.2.2.2. The adaptive system 
The adaptive immune system deals with pathogens which evade innate 
responses and produce a more specific response to foreign invasion. 
As with the innate immune system, both humoural and cell-mediated 
elements contribute. 
1.2.2.2.1. Humoural elements 
Antibodies 
Antibodies, or immunoglobulins, bind the unique antigenic determinants 
of particular foreign organisms and initiate immune responses 
specifically directed against them. The antibody consists of two identical 
protein light chains and two identical protein heavy chains, often 
represented pictorially as a Y shaped molecule, the stem of which is 
called the Fragment crystalline (Fc) unit and each arm of which is 
termed a Fragment antigen binding (Fab) unit. The Fc unit binds 
effector molecules while the Fab units have regions which vary highly 
between antibodies and which each bind antigenic determinants unique 
to each antibody (Figure 1.7). Immunoglobulins come in 5 classes, IgG, 
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Figure 1.6 The function of CD59 
A more detailed schematic illustrating how CD59 obstructs the 
unfolding and polymerisation of C9, thus preventing MAC assembly 
and cell lysis. 
 
Please refer to Figure 2; Gorter, A. and S. Meri (1999). "Immune 
evasion of tumor cells using membrane-bound complement 
regulatory proteins." Immunol Today 20(12): 576-82. 
 

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Figure 1.7 
 
 
 
The antibody structure 
The immunoglobulin is made up of two identical heavy (H) and light (L) 
peptide chains which have both constant (C) and variable regions (V). 
The fragment crystalline (Fc) bears carbohydrate regions and is 
responsible for mediating the effector response whereas the Fragment 
antigen binding (Fab) recognises and binds antigen. 
 
 
 
Please refer to Figure 2; Boenisch, T., A. J. Farmilo, et al., Eds. 
(2001). Handbook: Immunohistochemical Staining Methods. 
Gostrup, Denmark, Dako. 
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IgM, IgE, IgA and IgD. Each differs regarding its Fc unit with each 
triggering different effector mechanisms. The principal serum form of 
antibody is IgG, a monomer which comes in four subclasses, IgG1, 2, 3 
and 4. Each fixes complement when complexed to antigen, with IgG3 
performing this more potently than IgG1 and both performing this more 
potently than the other subclasses. Effector cells express Fc receptors 
for particular classes of immunoglobulin and antibodies therefore trigger 
specific immune responses through both cell mediated and humoural 
means. Each specific antibody originates from a single B-cell 
genetically predetermined to recognise a specific antigen (Roitt and 
Delves 2006). 
1.2.2.2.2. Cellular elements 
B-cells 
B-cells develop in bone marrow and undergo a series of steps during 
their maturation which are associated with rearrangements within the 
genes encoding the variable regions of their surface immunoglobulin  
the B-cell receptor (BCR). On encountering its corresponding antigen, 
BCR binding signals the B-cell to internalise the antigen, process it and 
express it complexed to HLA class II. B-cells may subsequently develop 
further into plasma cells, which can clonally expand to become many 
cells producing identical immunoglobulin in large quantities (Defrance, 
Casamayor-Palleja et al. 2002; Gold 2002; Roitt and Delves 2006). 
Human Leukocyte Antigen 
HLA is the human form of Major Histocompatability Complex (MHC) 
and its gene group on chromosome 7 encodes for three classes of 
molecules. 
HLA Class I region 
HLA class I itself is a heavy chain 44KDa polypeptide molecule 
consisting of three globular helical domains (Į1, Į2, and Į3) which are 
expressed on the cell surface and which inserts into the cytosol through 
the cell membrane. Its heavy chain is always associated with a lighter 
ȕ2microglobulin (ȕ2m) chain and three different class I antigens (-A, -B 
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and -C) are expressed, each of which displays marked allelic variation 
between individuals (Figure 1.8a).  
HLA class I is expressed on virtually all cells and is responsible for the 
presentation of intracellular peptides associated with abnormal cellular 
conditions. Peptide undergoes processing by the proteosome and is 
transported by Transporters associated with Antigen Processing (TAP) 
1 and 2 through the endoplasmic reticulum and Golgi apparatus to the 
cell surface. During this process it is complexed to ȕ2m, arriving at the 
cell surface as an HLA class I antigen. This peptide-HLA complex then 
becomes a target for cytotoxic T-cells. Other non-classical HLA and 
HLA related molecules are encoded for in the HLA class I region 
including HLA- E, G, F and MHC Class I polypeptide-related sequence 
(MIC) A and B (Roitt and Delves 2006). 
HLA class II region 
HLA class II molecules themselves consist of two helical domains, 
(Į1+Į2) and two beta sheets (ȕ1+ȕ2) (Figure 1.8b). Its distribution is 
restricted to B-cells, Dendritic Cells (DCs), macrophages and thymic 
epithelium under normal circumstances with DP, DQ and DR 
subclasses in existence. Its role in Antigen Presenting Cells (APCs) is 
to present processed foreign antigen to Th cells (Roitt and Delves 
2006). 
HLA class III region 
Non-classical molecules encoded within the class III region of the HLA 
gene group include C4, C2, factor B, Heat Shock Proteins (HSPs) (Roitt 
and Delves 2006). 
Dendritic Cells 
Cells which can present antigen in the context of HLA class II to 
Th cells are termed professional APCs and include the macrophages, 
B-cells and DCs. DCs originate in bone marrow and may be divided into 
two major subsets, myeloid (mDC) and plasmacytoid (pDC), on the 
basis of their differential expression of surface markers such as TLRs, 
CD8a, CD11b and CD11c. pDCs are found in blood and secondary 
lymphoid tissue and secrete large amounts of IFNܵ in response to virus. 
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Figure 1.8a Structure of the HLA class I molecule 
The association of three globular helical domains with ȕ2m is shown 
along with the groove for peptide presentation. HLA class I is 
expressed on virtually all cells. 
 
 
 
 
 
Figure 1.8b Structure of the HLA class II molecule 
The two pleated sheets and two helical domains are shown. HLA class 
II expression is mainly restricted to APCs. 
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mDCs reside in skin and areas where they are likely to come in contact 
with foreign antigen. Here, stimuli such as PAMPs, apoptosis, necrosis, 
inflammation and the presence of other immune system cells can 
activate mDCs, causing them to begin a process of maturation and 
migration to the lymph nodes. When mDCs arrive at lymph nodes, 
those presenting self antigens are deleted, suppressed or rendered 
anergic (due to a lack of co-stimulation), which allows the peripheral 
tolerance of self. However, when foreign antigen is being presented, 
the co-stimulatory molecules expressed on mature DCs cause naïve 
T cells to become activated, facilitating a primary immune response 
which subsequently also directs the maturation of these T cells through 
the release of cytokines (Blanco, Palucka et al. 2008). 
T cells 
The two main types of T cell are the CD8+ (Tc, Cytotoxic 
T-Lymphocytes, CTLs) and the CD4+ (Th). Both originally derive from 
bone marrow but undergo most of their development in thymus where 
they differentiate from CD8+ CD4+ double positive cells into singly 
CD8+ or CD4+ cells. This process is driven by an individual cells 
strength of reaction when presented to HLA class I or class II 
complexed to self antigen in the thymus. Those cells which do not react 
with HLA of either class are deleted (positive selection) and those which 
overreact to HLA are either deleted or become regulatory T cells 
(Tregs), in order to prevent autoimmunity (negative selection). The 
surviving naïve CD8+ and CD4+ cells are therefore those which 
recognise HLA class I or HLA class II respectively and which do not 
express a TCR for self antigen (Roitt and Delves 2006).  
 
CD8+ cells 
These recognise antigen presented in conjunction with HLA class I and 
so recognise and deal with the abnormal intracellular processes 
responsible for such peptide presentation within all cells. Its cytotoxic 
mechanism is the same as that of NK cells (Roitt and Delves 2006).  
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CD4+ cells 
Naïve T cells are thought to require two signals for their activation, with 
a lack of the second signal leading to a state of anergy. The first 
normally comes in the form of TCR binding to an HLA-peptide complex 
on the surface of a DC in the periphery. In the case of CD4+ cells, the 
second comes in the form of its CD28 molecule binding to the 
co-stimulatory molecules B7.1 and B7.2 on the surface of APCs. 
Depending on the nature of the pathogen, the resulting clonal 
expansion of CD4+ cells produced from the naïve cell may produce a 
pool of either Th1 or Th2 cells. Th1 cells produce cytokines which aid 
cellular immunity such as IFNܵ and IL-2 while the Th2 subset produces 
cytokines which aid humoural immunity such as IL-4, 5, 6,10 and IL-13. 
The resultant response to pathogen depends upon the relative sizes of 
each pool as the cytokine responses antagonise each other (Roitt and 
Delves 2006). 
Regulatory T cells 
CD4+ CD8+ naïve T cell progenitors which are neither apoptosed nor 
positively selected in the thymus are thought to undergo differentiation 
into Tregs. These are mainly CD4+ cells and are characterised 
phenotypically by the expression of the transcription factor Forkhead 
box p3 (Foxp3). Their role involves the suppression of excessive or 
inappropriate immune responses (hypersensitivity/autoimmunity) and 
the curtailing of the immune response once the original stimulus has 
been dealt with (Maloy and Powrie 2001; Roitt and Delves 2006).  
1.2.3. The immune system and cancer 
1.2.3.1. Immunosurveillance 
The concept of the immune system influencing the growth of cancer 
crystallised into the theory of immunosurveillance first forwarded by 
Burnet and colleagues. This concept described a situation where 
cancer cells were constantly being produced and concurrently being 
continually removed by the immune system at the subclinical level 
(Burnet 1970).  
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Immunosurveillance in mice 
This theory was tested by comparing the frequency of spontaneous 
cancers in over 10 000 inbred mice presumed to be immunocompetent 
with that found in their wild type counterpart. As no difference in 
frequency was found, this theory initially fell out of favour (Rygaard and 
Povlsen 1974). However, following the characterisation of the innate 
immune system it became clear that conclusions had been drawn using 
an imperfect model of immunocomprimise. The use of more genetically 
tailored murine models revealed that mice lacking NKT, T and B-cells 
developed spontaneous and induced cancers more readily (Strehlow 
2000). Subsequently, it was found that an individual lack of these cells, 
perforin or IFNܵ was independently linked to increased tumour activity 
indicating important roles for them in a revived theory of 
immunosurveillance (Dunn, Bruce et al. 2002). 
Immunosurveillance in humans 
In humans the study of immunosurveillance in states of 
immunocomprimise is opportunistic. Evidence for the presence of 
immunosurveillance in humans has been gathered from observations in 
transplant patients, the comparison of clinical outcome data with the 
presence of immune cells within the tumours and the study of tumour 
reactive immunoglobulins in serum and their Tumour Associated 
Antigens (TAAs) (Dunn, Bruce et al. 2002). 
Transplant data 
A review of Scandinavian patients receiving renal transplants showed a 
3- to 4-fold increase in non-viral cancers at sites such as colon and lung 
(Birkeland, Storm et al. 1995). A two-fold increase in the risk of 
malignant melanoma was also found in transplant patients in a US 
study (Penn 1996).  
Tumour Infiltrating Lymphocytes 
Cells of the adaptive immune system specific for antigens found to be 
restricted to particular cancers have been discovered, illustrating the 
inherent immunogenicity of tumours. The Cancer Testis (CT) antigen 
NY-ESO-1, which is restricted to a limited variety of normal tissues, has 
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been found in cancers at sites where it would not be expressed and has 
been investigated from its inappropriate genetic upregulation to the 
production of specific CD4+ and CD8+ cells. This is supporting 
evidence for the process of immunosurveillance in humans (Gnjatic, 
Nishikawa et al. 2006). MICA/B are ligands for NK, CD8+ and ܵį T cells 
and are important in initiating target cell killing by these effectors in 
innate immunity (Pende, Cantoni et al. 2001). Their expression is 
mainly restricted to gastrointestinal epithelia but they can be 
upregulated by intracellular stress under the influence of HSPs and are 
more widely distributed in cancer (Groh, Bahram et al. 1996; Groh, 
Rhinehart et al. 1999). MICA/B expression on tumours has been shown 
to be associated with cell killing by ܵį T cells, supporting the theory of 
immunosurveillance. As the expression of NKG2D on Tumour 
Infiltrating Lymphocytes (TILs) has been shown to be lower in MICA/B 
expressing tumours, this supports the existence not only of 
immunosurveillance but also the possibility of the development of 
mechanisms whereby tumours may avoid the attentions of the immune 
system (Dunn, Old et al. 2004). The infiltration of tumours by TILs has 
been seen in a variety of cancers and has been shown to be associated 
independently with improved prognosis in ovarian cancer (Zhang, 
Conejo-Garcia et al. 2003), while the presence of CD8+ cells has been 
independently associated with improved prognosis in colorectal and 
oesophageal cancer (Naito, Saito et al. 1998; Schumacher, Haensch et 
al. 2001). Similar findings have been shown for other cell types such as 
NK cells (Balch, Riley et al. 1990). The presence of TILs in tumours 
which is associated with outcome is further supporting evidence for the 
process of immunosurveillance in humans. 
1.2.3.2. Immunoediting 
The concept of immunosurveillance has, however, increasingly been 
superseded by a broader model of immunoediting, a refinement of its 
predecessor aimed at explaining observations such as the failure of 
immunosurveillance in clinically apparent tumours (Dunn, Bruce et al. 
2002). Immunoediting maintains that the immune system interacts with 
Chapter 1: Introduction
60
the tumour mass in complex ways in order to sculpt or edit it rather than 
simply to destroy it, the immune system providing a Darwinian selection 
pressure favouring the propagation of cells with less immunogenic 
phenotypes. In this way tumours may be produced which ultimately 
grow successfully in spite of a functioning immune system. Evidence for 
this in the murine model comes from the observation that tumours in 
mice with a deficiency in perforin rapidly grow but remain immunogenic 
enough to be rejected when transferred to wild type mice; conversely, 
when perforin functions normally the more immunogenic types are 
destroyed and these tumours are then not rejected following transfer to 
mice with an competent immune system (Street, Trapani et al. 2002).  
The theoretical model of immunoediting envisages three states in which 
tumours may reside; elimination, equilibrium and escape (Dunn, Old et 
al. 2004). 
Elimination 
The elimination state equates to immunosurveillance inasmuch as the 
end result is the death of the tumour cell. The theoretical process 
begins with the development of a tumour cell which interacts 
abnormally with its environment due to its underlying deviant physiology 
(the 6 hallmarks of cancer). This would attract the attention of elements 
of the innate and adaptive immune system resulting in IFNܵ release. NK 
cells and macrophages would then synergistically release IL-12 and 
further IFNܵ, leading to a slowdown in proliferation, apoptosis and 
angiogenesis. Following tumour cell destruction by these cells, antigen 
would become available for presentation to the adaptive immune 
system via DCs which would migrate to the lymph nodes and stimulate 
the production of tumour specific CD4+ and CD8+ cells, leading to 
tumour cell killing and the release of more anti-tumour IFNܵ. This 
process would occur every time a microscopic tumour nest arose and 
become less efficient with senescence (Dunn, Old et al. 2004).  
Equilibrium 
The equilibrium phase equates to a stage of tumour development 
where the tumour population has been incompletely eliminated. During 
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this stage, the inherent genetic instability of cancer would mean that 
certain cells within the population would be immunogenic and be 
removed, whereas other less immunogenic cells would be more 
successful and propagate. It is envisaged that this phase would be the 
longest, the clinical exemplar perhaps being the long lead time 
observed between the development of genetically unstable Cervical 
Intraepithelial Neoplasia (CIN) and the occurrence of invasive cervical 
cancer. If this undetectable process were actively under way in 
transplant donors, it might explain the relatively rapid development of 
non-viral cancers in their immunosuppressed recipients (Dunn, Old et 
al. 2004). 
Escape 
The final state in immunoediting would be an escape phase, where the 
tumour mass would evolve to the point where it could continue to grow 
despite the presence of a functional immune system. A number of 
mechanisms known to occur in human cancers might underlie 
immunological escape such as loss of HLA class I expression, 
downregulation of tumour antigen, defects in death receptor pathways 
(fasL and TRAIL), a lack of co-stimulation, the presence of 
immunosuppressive cytokines, apoptosis of T cells, the effects of 
Tregs, the shedding of NKG2D ligand and IFNܵ insensitivity (Khong 
and Restifo 2002). It is likely that tumours develop strategies to escape 
both the innate and adaptive arms of the immune system. 
1.2.3.3. Evidence for immunoediting in ovarian cancer 
The concept of immunoediting remains largely theoretical in humans. 
However, altered expression of mCRPs and HLA class I, which both 
represent possible mechanisms of immunological escape, have been 
found to correlate independently with survival in breast cancer, which 
supports the model (Madjd, Pinder et al. 2003; Madjd, Durrant et al. 
2004; Madjd, Spendlove et al. 2005). Evidence is also accumulating 
which suggests that immunoediting also occurs in human ovarian 
cancers. 
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Adaptive humoural reaction 
Immunoglobulins to TAAs are found in serum such as mesothelin and 
cathepsin D (Taylor and Gercel-Taylor 1998; Ho, Hassan et al. 2005).  
Innate cellular reaction 
NK cells infiltrate ovarian tumours relatively sparsely and have been 
found to have a lower level of activity than normal in ovarian cancer 
patients. This activity becomes progressively less when observing the 
peripheral blood, ascitic and then TIL pools (Kabawat, Bast et al. 1983; 
Lotzova, Savary et al. 1984; Garzetti, Cignitti et al. 1993; Lutgendorf, 
Sood et al. 2005). A reduction in NK Cell Cytotoxicity (NKCC) has been 
shown to be associated with disease progression by one group 
(Garzetti, Cignitti et al. 1993), with an observed resistance of NK cells 
to IL-2 and their reduced secretion of IFNܵ possible underlying 
mechanisms (Lai, Rabinowich et al. 1996). Intriguingly, increased levels 
of psychological distress amongst ovarian cancer patients and poor 
social support appear to correlate with reduced NKCC in TIL. Though a 
link is biologically plausible, through neuroendocrinological 
mechanisms, causation has not, however, been established 
(Lutgendorf, Sood et al. 2005). This group also investigated the 
influence of psychological factors on the presence of NKT cells (which 
have been show to display potent cytotoxicity to ovarian cancer cell 
lines in vitro), finding that tumours accumulated NKT cells compared to 
their surroundings and that this was positively influenced by better 
psychological indicators (Gritzapis, Dimitroulopoulos et al. 2002; 
Lamkin, Lutgendorf et al. 2008). Tumour Associated Macrophages 
(TAMs) are generally abundant within the cancer microenvironment and 
interaction between the two is thought to foster a cytokine environment 
which actually promotes tumour growth in many cancers, including 
ovarian (Hagemann, Wilson et al. 2006; Allavena, Sica et al. 2008). In 
ovarian cancer up to 70% of cases are infiltrated by TAMs though this 
not been shown to predict outcome (Shah, Allison et al. 2008). 
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Innate humoural reaction 
Complement deposition and associated cell lysis has been shown to 
occur by several groups on various tumours and has been shown to be 
inhibited by mCRPs (Niculescu, Rus et al. 1992; Yamakawa, Yamada 
et al. 1994; Donin, Jurianz et al. 2003). However, this has not invariably 
been the case with Niehans and colleagues finding that C5-9 deposition 
occurred in small cell lung cancers which were completely devoid of 
mCRPs. This group hypothesised that other MAC resistance strategies 
could be at work in tumour cells which had lost the expression of 
mCRPs. They also found that a change in expression pattern of 
mCRPs was common in cancer systems which varied by cancer site 
and could be an up- or downregulation of one or more mCRP (Niehans, 
Cherwitz et al. 1996). Examining 12 ovarian cancers in addition to 
ovarian cancer cell-lines, Børge and co-workers found that CD59 and 
CD46 were ubiquitously expressed whilst CD55 expression was more 
variably seen. By using an effector monoclonal antibody whilst variably 
blocking mCRP activity they were able to show that these molecules 
impede the Complement Dependent Cytotoxicity (CDC) of the innate 
immune system in vitro (Figure 1.9) (Bjorge, Hakulinen et al. 1997). 
Adapative cell mediated reaction 
Zhang et al examined 186 cases of advanced ovarian cancer and 
discovered that 55% were associated with a significant presence of 
CD3+ TILs, the presence of which was associated with a higher level of 
IFNܵ and IL-2. This suggested a functionally active infiltration and its 
presence was independently associated with improved 5-year OS and 
PFS (Zhang, Conejo-Garcia et al. 2003). This finding has been 
corroborated by a recent study showing the same prognostic 
association (Tomsova, Melichar et al. 2008) and replicated in a series 
of 95 advanced serous ovarian cancers where it was additionally 
discovered that an environment particularly enriched with ܵį TCRs 
correlated with worse OS in a univariate analysis (Raspollini, 
Castiglione et al. 2005). Woo and co-workers found that CD8+ 
infiltrated ovarian cancers exhibited low levels of IL-2, IFNܵ and TNFȕ 
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Figure 1.9 Effector mechanisms of the innate immune system provoked by 
mAb binding to antigen 
Depending on class of IgG, a mAb may harness the innate immune 
system to effect cell killing by mediating Antibody Dependent Cellular 
Cytotoxicity (ADCC) or Complement Dependent Cytotoxicity (CDC) 
directly and by the indirect initiation of Complement Dependent Cellular 
Cytotoxicity (CDCC) via the rising C5a levels which follow the 
complement fixing effect of antibody-antigen binding.  IgG3 and IgG1 fix 
complement most effectively and with much greater potency than IgG2 
and IgG4. 
 
 
Please refer to Figure 1; Gorter, A. and S. Meri (1999). "Immune 
evasion of tumor cells using membrane-bound complement 
regulatory proteins." Immunol Today 20(12): 576-82. 





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when TGFȕ secreting Tregs were present, illustrating a potential 
immunological escape mechanism (Woo, Chu et al. 2001). This finding 
was supported by the work of Curiel et al which demonstrated that the 
presence of Foxp3 positive Tregs in the TIL was correlated with 
reduced OS. In addition, it was discovered that TAA directed T cell 
specific immunity was inhibited by the presence of Tregs (Curiel, 
Coukos et al. 2004). In contrast to Zhang and co-workers, Sato et al, on 
studying a series of 117 ovarian cancers, found that the presence of 
CD3+ cells within the TIL mass had no prognostic effect. However, this 
group did find that a high ratio of CD8+/Tregs was correlated with 
improved OS, supporting the notion that the adaptive response to 
tumour is regulated and that tumours become tolerated in the periphery 
(Sato, Olson et al. 2005). High expression of IFNܵ within TILs has been 
found to correlate with improved prognosis independently of other 
factors (Marth, Fiegl et al. 2004) and HLA class I expression has been 
shown to be downregulated in approximately 40% of ovarian cancers 
and non-independently associated with reduced OS in a series of 51 
ovarian cancers (Vitale, Pelusi et al. 2005). A slightly smaller study of 
29 patients where more allelic versions of HLA class I were investigated 
did not support this, however, with no cancers being found to have HLA 
class I downregulation and few showing any evidence of class II 
downregulation (Nijman, van Diest et al. 2001). Despite this, within TIL, 
reduced HLA class II expression and increased CD4+ presence has 
been associated with ovarian cancer progression (Tamiolakis, Kotini et 
al. 2003) and increased HLA Class II expression and CD8+ infiltration is 
associated with improved outcome (Matsushita, Ghazizadeh et al. 
2003). Scant evidence has been accumulated concerning the 
expression of MICA/B in ovarian cancer, though a recent study found it 
to be expressed in one of 6 tumours (Carlsten, Bjorkstrom et al. 2007). 
Summary of immunoediting in ovarian cancer 
Ovarian cancer is immunogenic and elicits both humoural and cell-
mediated reactions whilst mobilising both innate and adaptive arms. 
Immunoglobulins are produced against it and immunological cells of all 
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kinds infiltrate it. Cell killing may occur through complement dependent 
or purely cell mediated means and there is evidence that ovarian 
cancers interact with the immune system differently to normal tissue, 
lending support to the theory that immunoediting is active in this 
disease. The attenuation of NKCC, IFNܵ secretion and HLA class I 
expression are a few of the apparently active mechanisms of 
immunological escape, along with the infiltration of tumour by Tregs, 
TAMs and the ubiquitous expression of mCRPs. Direct prognostic 
evidence that some of these mechanisms have a clinical impact is 
slowly accruing though the prognostic effect of HLA class I expression 
and of the mCRPs in ovarian cancer has yet to be fully examined in the 
same way that it has at other sites such as breast cancer (Madjd, 
Pinder et al. 2003; Madjd, Durrant et al. 2004; Madjd, Spendlove et al. 
2005) (Nelson 2008). 
1.2.4. Immunotherapy in ovarian cancer 
The aim of immunotherapy is to employ the hosts immune system in 
order to achieve tumour cell killing, with two broad strategies existing. 
Active immunotherapy aims to produce long term antigen-antibody 
specific reactions to TAAs through vaccination, whereas passive 
immunotherapy seeks to produce a response through the transference 
of ready functional effector elements such as cytokines, CD8+ cells or 
immunoglobulins. Up to 20% of optimally debulked ovarian cancer 
cases are associated with micrometastatic disease in bone marrow 
and, as these cells are often in the G0 phase, they may represent a 
pool of chemoinsensitive cells and a source of recurrent disease 
(Barnhill, Piepkorn et al. 1998; Braun, Schindlbeck et al. 2001). As 
immunotherapy can also target non-dividing cells, this makes it an 
attractive adjuvant to standard therapy in ovarian cancer (Rubin 1993; 
Bjorge, Stoiber et al. 2006) though immunoediting processes which 
may have reduced tumour cell susceptibility must be taken into account 
(Schuster, Nechansky et al. 2006). 
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1.2.4.1. Vaccination 
The principle behind active vaccination strategies is to challenge the 
immune system with TAA processed by APCs. This is then presented 
to CD8+/CD4+ TCRs in conjunction with HLA class I/II and 
co-stimulation to mediate CD8+ lysis and to recruit further innate and 
humoural responses. An example of a vaccination strategy under 
investigation in ovarian cancer is Oregovomab. This is a murine anti-
CA125 antibody which when administered to humans in small doses 
stimulates the immune system to produce Human Anti-Mouse 
Antibodies (HAMA), anti-idiotypical antibodies and anti-CA125 
antibodies  an antibody as antigen strategy. This approach 
stimulates both innate and specific arms of the immune system and is 
well tolerated. However, the results of phase II studies in recurrent 
disease are yet to show a clinical impact (Ehlen, Hoskins et al. 2005). 
As there are many ways in which vaccine strategies may fail in tumours 
that are immunoedited (including HLA Class I antigen loss and the 
infiltration of the tumour by Tregs), it is likely that co-administration of 
Oregovomab with cytokines and co-stimulatory molecules may prove 
more successful (Berek, Dorigo et al. 2003) (Sabbatini and Odunsi 
2007).  
1.2.4.2. Cytokines 
IFNܵ has anti-tumour and anti-proliferative effects in vitro and has been 
shown to be safe to administer in combination with cisplatin and 
cyclophosphamide in ovarian cancer patients, with an improvement in 
PFS observed (Barton, Davies et al. 2005) (Windbichler, Hausmaninger 
et al. 2000). However, when this trial was repeated to facilitate 
comparison with current best practice chemotherapeutic regimens, 
though the safety profile remained the same OS was reduced in the 
IFNܵ group and the trial was abandoned early (Marth, Windbichler et al. 
2006; Alberts, Marth et al. 2008). Potential explanations include a 
reduction in the dosage of standard chemotherapeutic agents in the 
IFNܵ arm due to tolerance issues or potentially the role of longer term 
IFNܵ administration in the proliferation of Tregs (Wood, Feng et al. 
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2007). However, the presence of IFNܵ remains clinically associated 
with improved outcome and it may have a role in improving the efficacy 
of HLA class I dependent immunotherapies, as it has been shown to 
upregulate the expression of HLA class I in ovarian cancer cell lines 
(Mobus, Asphal et al. 1993; Wood, Feng et al. 2007). 
1.2.4.3. Adoptive T cell transfer 
A passive method of initiating a cell mediated response involves the 
transfer of modified T cells. Kershaw and colleagues genetically re-
engineered ex vivo autologous CD4+ and CD8+ cells to express anti- 
alpha folate receptor immunoglobulin, a TAA in ovarian cancer. 
However, there was little persistence of the T cells within the circulation 
as detected by Polymerase Chain Reaction (PCR) or localisation of the 
T cells within tumour as assessed by the activity of 111In labelling. The 
failure of this approach was ascribed to the development of an 
inhibitory factor (Kershaw, Westwood et al. 2006). 
1.2.4.4. Monoclonal antibodies 
Passively initiating a primary immune response via the humoural arm of 
the immune system may be achieved through the use of monoclonal 
antibodies (mAbs). mAbs are intended to specifically target antigens 
associated with cancer or its progression. They can act through 
blocking pathways integral to the development of the hallmarks of 
cancer such as VEGF (Bevacizumab) and EGFR (Certuximab) or 
through binding TAAs to provoke an immune response via the 
complement cascade and NK cells. In reality, these mechanisms 
probably work synergistically (Figure 1.9) (Gorter and Meri 1999; Macor 
and Tedesco 2007). The use of mAbs in haematological malignancies 
is routine but their efficacy in ovarian cancers is disappointing. Oei et al 
recently reviewed 44 papers which included: 42 phase I/II trials and two 
phase III trials; 5 different TAAs (and VEGF); 15 different antibodies; 23 
trials of unconjugated antibodies; 5 antibodies as antigens vaccination 
studies; and 16 studies concerning radioimmunotherapy. The TAAs 
studied were CA125, Human Milk Fat Globule (HMFG), ErbB2, MUC1 
and Tumour Associated Glycoprotein72 (TAG72). The antibodies used 
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would be expected to effect responses through a combination of 
complement activation, innate and adaptive responses and possibly 
HAMA development (Oei, Sweep et al. 2008). The two most promising 
mAb clinically appear to be Bevacizumab and Oregovomab, each of 
which has a definite mode of action independent of fixation of 
complement. Any clinical effect of response to Herceptin (Trastuzumab) 
was abrogated by the infrequency of its over-expression in ovarian 
cancer (10% of cases) with the remaining unconjugated antibodies 
having no significant effect on OS (Bookman, Darcy et al. 2003) (Oei, 
Sweep et al. 2008). The lack of clinical responsiveness to simple 
unconjugated mAbs to TAAs, which is often at dissonance to animal 
work, may in part be due to an abrogation of complement fixation and 
deposition by the expression of mCRPs on human target tumour cells 
which do not exist in a murine model (Shin, Hansch et al. 1986). This 
theory is supported by in vitro work by several groups showing 
increased cell lysis in response to mAbs when mCRP function is 
experimentally disabled (Brasoveanu, Altomonte et al. 1996; Jurianz, 
Maslak et al. 1999; Bjorge, Stoiber et al. 2006). 
1.2.4.5. Circumventing immunoediting escape mechanisms 
Complement fixing mAbs theoretically have the advantage of being 
able to harness a powerful and ubiquitous soluble effector mechanism 
which can penetrate the disease well. However, for this strategy to be 
fully exploited, it is important for mechanisms of combining mAb therapy 
with the disabling of mCRP function in the clinical setting to be 
developed. As mCRPs are ubiquitously expressed, in order to prevent 
indiscriminate damage to normal tissues any such strategy needs to be 
more targeted than that used experimentally (Gorter and Meri 1999). 
One mechanism of achieving this may be through the use of antibodies 
bispecific for both TAAs and mCRPs, where the TAA Fab moiety is of 
sufficiently high affinity to restrict its deposition outside of tumour sites. 
There is preliminary in vitro evidence that this may prove effective 
(Gelderman, Blok et al. 2002; Gelderman, Kuppen et al. 2002). An 
alternative strategy might be through the use of anti-idiotypic antibodies 
Chapter 1: Introduction
70
as antigens which not only bind TAA but also resemble mCRP, leading 
to the generation of antibodies which locate tumour and block mCRP 
simultaneously (Spendlove, Li et al. 2000) (Fishelson, Donin et al. 
2003). mCRPs represent an obvious obstacle to the efficacy of 
unconjugated mAb to non-signalling TAA which rely on complement 
fixation for their effect. This perhaps explains why most ongoing mAb 
trials in ovarian cancer focus on mAb with a more discrete action. Of 
the 234 trials currently active as recorded by National Cancer Institute 
(accessed 23 June 2008 search: Epithelial Ovarian Cancer; All types; 
All stages; Treatment) there were several phase III trials of 
Bevacizumab (anti-VEGF), a phase I/II trial of Volociximab (anti-
angiogenesis factor), a phase II trial of Catumaxomab (anti-EpCAM), a 
phase I trial of Almetuzamab (Anti-Vascular Leucocytes) and a phase I 
trial assessing the T Cell response to Trastuzumab (2008).  
1.2.5. Immunological markers in ovarian cancer 
Ovarian cancer is an immunogenic cancer but there is evidence that it 
presents clinically in an immunoedited form. An increased expression of 
mCRP and a decrease in the expression of HLA class I are two 
potential mechanisms by which escape from immune control might 
occur and the expression of these molecules in clinical cancers is 
therefore important. Immunotherapy is an emerging treatment strategy 
which would appear particularly suited to ovarian cancer, given its 
propensity to relapse late and the common presence of micrometastatic 
deposits which are likely to reside outside of the cell cycle. The high 
expression of mCRPs and the low expression of HLA class I also 
represent two potential barriers to the effective use of this emerging 
modality. 
1.3. Study outline 
The aims of this project were dual. The first aim was to produce a TMA 
representative of the ovarian cancer cases which had presented at 
Derby City General Hospital (DCGH) between 1982 and 1997 and 
which had been followed until the present day. The objectives were to 
identify and review each case pathologically, physically construct the 
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TMA, determine the optimal number of cores required to return valid 
expression data, confirm the consistency of the data in an associated 
clinical database and, having then adapted it appropriately, assess the 
validity of using the TMA and database in an integrated manner to 
assess not only marker expression but also its prognostic and 
clinicopathological associations. This would allow previously studied 
markers to be assessed using a new technique, allow the expression of 
novel markers to be rapidly surveyed in a large series and would 
facilitate future work by other researchers in the department. The 
second aim was to use the TMA to study immunological markers. The 
first objective was to stain the TMA for HLA class I and ȕ2m to 
determine the prognostic effect of their co-expression. The second 
objective was to immunohistochemically stain the TMA for CD59 using 
a commercial antibody and then for CD55 and CD46 using specially 
developed in-house antibodies, allowing the co-expression of these 
markers to be surveyed in a large series for the first time.  
 
Chapter 1: Introduction
72
Chapter 2: Materials and Methods 
 
This study aimed to construct a TMA to complement a clinical 
database. This would then be tested for its ability to produce data likely 
to be generally applicable to ovarian cancer before finally being used to 
investigate immunological markers for their prognostic value. 
The following chapter describes the administrative tasks, generic 
techniques and the majority of the specific experimental and analytical 
methodologies used in achieving these aims. It details the importance 
of research governance in this project, examines the method behind the 
immunohistochemical examination of molecular marker expression and 
covers the statistical tests employed for analysis of data. 
Further chapters will explain in more detail how the TMA and database 
were constructed and tested as well as reporting the findings of the 
experimental work.  
2.1. Research governance 
In order to perform this study, stored patient tissue in the form of 
paraffin embedded blocks had to be first identified and then removed 
from the pathology department archives at Derby City General Hospital 
(DCGH), from where they would be transferred to Nottinghams 
Queens Medical Centre (QMC) and Nottingham City Hospital (NCH) for 
subsequent review and use. This necessitated that the prospective 
confidential database of patients clinicopathological information be 
used in a linked manner in order that the correct samples be accurately 
identified, removed, processed and returned to storage.  
The study would involve several key individuals and institutions: Ian 
Scott (I.Sc)  Consultant Obstetrician and Gynaecologist and local 
researcher, Derby City General Hospital; Philip Rolland (P.R)  DM 
student, University of Nottingham (UoN) and clinical research fellow 
NCH; Ian Spendlove (I.S)  Chief Investigator, Academic and Clinical 
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Department of Oncology (UoN) on the NCH campus and Suha Deen 
(S.D)  Gynaecological Pathologist, QMC, all of whom would require 
access to patient data and material. 
The use of this type of material by multiple individuals at multiple 
separate institutions meant that managing the governance side of the 
project was labour intensive but important in complying with the 
Department of Health Research Governance Framework (RGF) (Davies 
2005). 
This meant embracing the overlapping requirements of two main areas: 
research ethics and research and development (R&D). 
2.1.1. Ethics 
This refers to the legal and moral responsibility of a researcher to 
protect the patients involved in the study. 
2.1.1.1. Ethics and medical research  
Following Nazi human experimentation during the Second World War, 
the need for a set of ethical standards by which to judge the accused 
led to the creation of the Nuremberg code of 1947. A need for more 
sophisticated ethical standards to guide medical research led to the 
development of this pragmatic tool and the Declaration of Helsinki at 
the assembly of the World Medical Association in 1964 (Markman and 
Markman 2007). Although this holds no legal authority itself, its 
principles, last updated in 2000 (2000), are embedded into national 
laws. Subsequently, the Belmont report helped to define key ethical 
principles underlying the involvement of patients in research and 
developed the idea of autonomy (respect for patients), beneficence 
(doing the most good and the least harm for patients) and justice (the 
even distribution of the burdens and benefits of research)(1979). These 
key documents led to specific practical consequences.  
Research using human material should be performed with the informed 
consent of the individuals involved (which may be withdrawn at any 
time without prejudicing their care), provide information unobtainable by 
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other methods, be scientifically appropriately designed to achieve its 
aims and have objectives the benefits of which exceed the risks  its 
benefits being subsequently appropriately dissipated. There is also a 
requirement for independent ethical review bodies to provide approval 
for and oversight of research projects.  
2.1.1.2. Review bodies 
The first ethics committees were set up in the UK in 1966 and formal 
guidance for the establishment and operation of local research ethics 
committees (LRECs) by the district health authority followed in 1991 
(1991). As research became more complex and collaborative, new 
multi-centred research ethics committees (MRECs) were established to 
deal with projects involving more than 5 sites. In addition, new 
authorities overseeing particular branches of research joined those 
wishing to approve research proposals (e.g. Gene Therapy Advisory 
Committee). Until recently, moderately sized pan-regional studies 
involving fewer than 5 sites have in practice needed to submit similar 
hard copy information in slightly different formats to multiple review 
bodies  the bureaucracy of which proved prohibitive. The submission 
of proposals has therefore been streamlined and computerised by the 
Central Office for Research Ethics Committees (COREC) followed by 
the National Research Ethics Service (NRES). Soon researchers will 
input information into the Integrated Research Application System 
(IRAS), which is designed to allow relevant information to be sent on to 
all necessary review bodies in the request through the filling of a single 
form. 
2.1.1.3. Ethical committee approval 
The application for ethical approval for this study pre-dated COREC 
and therefore a proposal entitled The Significance of Complement 
Regulators in the Prognosis of Ovarian Cancer was submitted to the 
Southern Derbyshire LREC on 5 June 2002, whereupon it was given 
the reference SDLREC:0205/495 and the R&D reference 
SDAH/2002/047.  
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Figure 2.1   The MRC established collections algorithm 
Showing how the decision to approve the study was arrived at and 
why specific conditions concerning anonymisation were required. 
 

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The committee reviewed protocol version 1. In brief the unanonymised 
database of cases of ovarian cancer presenting to DCGH between 
1982 and 1997 would be used to identify patients, the tissue would be 
removed from the archive and transferred to NCH for processing and 
the database at DCGH would be used on that site to analyse results. 
Subsequently, the ethics committee gave the initial approval for the 
study to proceed in September 2003 (protocol version 2). Plans were 
made to review the projects progress on a yearly basis and the 
importance of amending the protocol prospectively if it needed to 
change was emphasised.  
2.1.1.4. Ethical considerations and amendments  
There were a number of ethical considerations which required protocol 
amendments before final approval could be given. 
Consent 
Before using a patients biological data and/or tissue in research, that 
patient has to be given sufficient information in an appropriate form 
concerning the implications for themselves and/or others of participating 
in the study and be given the opportunity to ask questions. This 
respects a patients autonomy and allows them to consent to 
involvement in an informed way. In this study, the majority of the 
patients had been prospectively consented for their cases to be used in 
research. However, as many cases dated back almost 20 years, it was 
felt that what was documented in the patients notes did not represent 
adequate or valid consent in the context of modern standards and 
technologies. The options were to proceed without informed consent or 
to gain informed consent. The practicalities of gaining informed consent 
meant that it could not be considered as many of the patients were 
dead, there were over 400 cases and the risk of upsetting patients or 
their bereaved relatives by asking for retrospective consent many years 
after their treatment was real. Taking this into account, and using the 
MRC decision tree (Figure 2.1) (Johnstone 2001), approval was given 
to continue without consent. The main risk of causing harm by 
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proceeding without consent concerned the scenario of patients being 
made aware of potentially important information concerning their 
disease which could lead to difficult decisions either for themselves or 
their families, when they had never expected such information to come 
to light. The risks of their not being informed of new information about 
their case could also be damaging. 
Anonymisation 
To minimise the risk of harm to individual patients, while not losing the 
good that could come from using this prospectively gathered database, 
the LREC required that a new database be constructed that was 
anonymised and unlinked from the original by the removal of any field 
that could be used to reliably re-link them using reasonable methods 
(name, date of birth, address, local patient numbers, etc).  
The unanonymised database was transferred to the trust server (DCGH 
NHS Trust) and access restricted to a small number of individuals 
based on site. A single worker was to identify a case from the database, 
acquire a pathology report for that case, update any missing fields in 
the database, acquire the appropriate tissue block and assign a unique 
study number to the tissue block and to the case on a copy of the 
unanonymised database. When the TMA had been constructed, the 
pathology reports would then be anonymised (photocopying the report 
with the unique fields covered, adding the TMA coordinates of the case 
to the copy and destroying the original). The copy of the unanonymised 
database would then be anonymised and unlinked by removing all 
unique fields including the study number. Linkage to the now 
anonymised pathology reports via the unique TMA coordinates would 
be maintained.  
There would be no way that expression data generated off site could be 
re-linked to a specific patient. This had the advantage of eschewing a 
situation of generating data that should be made available to particular 
individuals. However, the disadvantages included the intensity of labour 
involved, the inability to update clinical data at a later date and the 
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potential for errors to occur when numbers and not names were being 
used. 
No carte blanche 
Ethical approval was given to study a small number of named 
molecules which needed to be amended if other ones were to be 
studied. Ethics committees are discouraged from giving researchers 
approval to study any marker they wish. They prefer that the scientific 
case for studying a new tranche of markers is made at intervals. 
Human Tissue Act 2004 
The Human Tissue Act (HT) was enacted in 2004 and came into force 
fully on 1 September 2006. The act replaced the Human Tissue Act 
1962, the Anatomy Act 1984 and the Human Organs Transplants Act 
1989. Its implementation is overseen by the Human Tissue Authority 
(HTA). When it was revealed that the storage and use of human tissue 
without consent was commonplace (Kennedy 2001; Redfern, Keeling et 
al. 2001) the existing law was deemed inadequate and, hence, the 
need for a new act apparent.  
The HT covers all aspects of research on archived human tissue but 
does not apply to the tissue used in this study because it was already 
being used for a scheduled purpose before the HT was implemented. 
However, as the HT simply makes sound ethical standards a legal 
requirement, this study would easily meet the current legal 
requirements if an application for approval was made today (2004).  
2.1.1.5. Subsequent amendments  
Substantial 
During the initial phase of the study a number of issues arose which 
necessitated the amendment of the terms of our ethical approval. 
Following the submission of an updated protocol (protocol version 3) a 
substantial amendment was granted by the LREC in June 2005 which 
covered three areas. 
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Access to the original unanonymised database was required continually 
by off-site researcher P.R in order to speed up the accurate extraction 
of relevant tissue and then to transform the database into its statistically 
useable form. In order to achieve this, permission was granted for P.R 
to have access to the original database on the DGCH trust server and a 
copy to use at NCH. The data were kept at the Department of 
Academic and Clinical Oncology and were password protected. 
The database included patients up until 2002 but permission had only 
been requested to use cases up until 1997 (cases with 5 year survival 
data). As the study proceeded, 5 year survival data were becoming 
available for later cases and permission was granted to use the full 
database worth of cases to increase the power of the study further. 
The study was renamed The Significance of Biomarkers in Ovarian 
Cancer and permission was given to continue research into other non-
immune markers as long as a list of what was studied was periodically 
sent to the committee for review. 
Non-substantial 
The following procedural revisions did not require substantial 
amendments to the protocol but required the ethics committee to be 
informed by letter, which it was.  
Identifying representative tissue blocks from archived cases could only 
be reliably done by making new slides and having them reviewed 
contemporaneously by S.D at QMC. We were given permission to use 
the tissue in this way. September 2004. 
Coordinating the extraction of the correct tissue blocks was more 
complex than anticipated and required more man hours. It was agreed 
that P.R could extract the blocks from the archive. September 2004. 
The database had missing fields which could be populated 
appropriately from the patient notes. Permission was granted for P.R to 
do this. September 2004. 
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Whole sections of ovarian tissue were needed to act as controls and for 
titrational experiments. Permission was granted to use the tissue blocks 
in this different manner. June 2005. 
We had erroneously made 5 and not 4 copies of the array. The ethics 
committee granted us permission to use all 5. June 2005. 
Having studied a breast cancer array for multiple markers and then 
analysed the results using an Artificial Neural Network (ANN) to good 
effect, we were granted permission to apply this technique to our 
results. June 2005. 
2.1.2. Research and development 
The Department of Health requires organisations providing care in 
England to be aware of any ongoing research within their body 
involving patients, tissue or data for which they are responsible. They 
must oversee the implementation of the RGF for each project and this 
has led to the establishment of R&D departments within each individual 
NHS organisation. Before a study can be conducted, permission from 
the appropriate R&D department is mandatory. As all the cases 
originated from DCGH, an application for approval was filed with the 
Southern Derbyshire Acute Hospitals (SDAH) NHS trust R&D 
department in June 2002. Final approval to commence the research 
was given on 16 September 2004. The time taken to get final approval 
reflects the time taken to assemble written evidence of the studys 
compliance with all the elements of the RGF for which the R&D 
department was providing oversight. 
Ethical approval 
The R&D department has a key responsibility to ensure that ethical 
approval has been granted by a body with the authority to grant it. 
Delays in obtaining ethical approval due to concerns over the use of 
human tissue without consent lead to delays with R&D approval. 
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Honorary contracts 
Non-NHS employed researchers who perform research which 
potentially impacts on individuals cared for by NHS organisations 
normally have to hold an honorary NHS contract. The R&D department 
was more exacting and wanted all non-locally based researchers to 
hold a local NHS honorary contract. These were subsequently obtained 
for P.R and I.S, creating a minor delay. 
Legal requirements 
At the time of application, the development and enactment of the HT 
was in progress. In retrospect, this legislation does not affect the study 
but there was confusion about and unfamiliarity with the likely impact 
that this new law would have at the time. As the R&D department had a 
responsibility to ensure that the law would not be broken, a cautious 
approach to granting approval was taken. 
Sponsorship 
The R&D department required written proof that the study had a named 
sponsor. The sponsor is the individual or organisation responsible for 
ensuring that researchers have the necessary capabilities and 
resources to deliver the research, that the research is managed and 
monitored effectively, that external peer review has taken place and 
that a system is in place for the protection and division of intellectual 
property rights and the appropriate dissemination of findings. The 
sponsor is normally the employer of the chief investigator and therefore 
the University of Nottingham became the sponsor for this project. 
External peer review 
The ethics committee has a responsibility to ensure that the study is 
scientifically worthwhile and well designed but this is underwritten by 
the sponsor who, in turn, requires that the study is externally peer 
reviewed in addition to its own internal peer review system. The 
interrelations of these requirements lead to delays. The project was 
favourably externally peer reviewed by Dr M Illyas (senior lecturer in 
Chapter 2: Materials and Methods
82
pathology, Academic Unit of Pathology, Leeds General Infirmary) by 
June 2005. 
Financial considerations 
The involvement of a gynaepathologist at a separate NHS institution to 
review the projects slides during her special programmed activity 
sessions had cost implications. This £18 037 had to be signed off by 
the QMC NHS trust R&D. This required a separate application for R&D 
approval at this site, which caused a delay. The small costs incurred in 
the experimental arm of the project were met internally through a 
combination of the University of Nottingham, the three NHS trusts 
employing the co-researchers and a small donation of £4000 from the 
Derby City General Hospital Charitable Fund. 
2.2. Immunohistochemistry 
 
The main investigative method used in this work was 
ImmunoHistoChemistry (IHC), a technique which exploits the specific 
interaction between antigens and specially designed antibodies to 
estimate protein expression in tissue. It can be performed on freshly 
frozen tissue or Formalin Fixed Paraffin Embedded (FFPE) tissue which 
may have been archived for many years. It is quick, easily learned and 
reliable but subjective, and experience is required to know when 
staining is non-specific. The method used in this work comprised the 
following elements. 
2.2.1. Tissue preparation
Following surgical removal, the tissue was fixed for 24 hours 
(exceptionally, up to a maximum of 72 hours for large specimens) in 
10% w/v neutral buffered formalin (40% w/v formaldehyde) (NBF). The 
samples were then archived in an ambient environment for between 6 
and 23 years.  
Formaldehyde fixation preserves tissue morphology well but alters 
RNA, DNA and protein structure through cross linking functional groups 
such as amines (eg, lysine) and thiols (eg, cystein) (Fox, Johnson et al. 
1985). These methylene bridges can only be broken down by drastic 
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hydrolysis (Puchtler and Meloan 1985). Therefore, when an antigen 
becomes changed by this process it becomes very stable, with little 
chance it will degrade even after long term storage. However, these 
conformational alterations often change immunoreactive epitopes to 
inert ones, complicating IHC techniques (Werner, Von Wasielewski et 
al. 1996).  
There is evidence that the antigenicity of sectioned tissue decreases 
over time. This is worse in certain cancers, such as colorectal where it 
becomes obvious after 6 months. Degradation is influenced by the 
method used to fix the tissue but 10% NBF performs comparatively well 
(Atkins, Reiffen et al. 2004). Under-fixation (but not over-fixation) of 
tissues also leads to loss of antigenicity, (von Wasielewski, Mengel et 
al. 2002).Therefore, tissue should be fixed for at least 24 hours (at room 
temperature) and the case for using cut sections with minimal delay has 
been reinforced by work on breast cancer (Fergenbaum, Garcia-Closas 
et al. 2004). Therefore, 4 µm thick sections of TMA, whole sections of 
ovarian cancer and positive control tissue were cut as close to the date 
of staining as practical with all sections being utilised within 14 days. 
The sections were mounted onto positively charged slides to improve 
tissue adherence (Superfrost Plus  Surgipath Europe, Peterborough, 
UK). The control tissues were as recommended by the manufacturers 
of the primary antibodies or occasionally tumour known to express the 
marker well. Two copies of the array (8 sections) were prepared for 
each experiment in order to benefit from the advantages of the 
technique (minimising tissue usage, lowering reagent usage and 
staining all the tissue samples in a single run) while still aiming to 
achieve a high concordance with what would be expected in whole 
tissue sections. While some studies recommend staining 5 copies of 
the array (Fergenbaum, Garcia-Closas et al. 2004; Goethals, Perneel et 
al. 2006), most have used a single core, which is known to give a 91% 
concordance with whole sections. This increases to 96% with two 
copies and 98% with three copies, after which little improvement in 
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concordance occurs (Camp, Charette et al. 2000; Rosen, Huang et al. 
2004). 
To remove the paraffin-wax from the slides, they were heated in a dry 
oven at the melting point of wax (60ºC) for 10 minutes and then placed 
in xylene (BDH, Poole, UK) to dissolve the paraffin for a total of 20 
minutes. The tissue was rehydrated by sequential bathing for 10 
seconds in graded alcohol baths of 100%, 95% and 75% ethanol 
(Sigma-Aldrich, Gillingham, UK). The reagent baths were in a fume 
cupboard. 
2.2.2. Antigen retrieval 
 
Though chemically fixing tissue and heating it to 60º for embedding 
leads to the denaturement of the antigenic epitopes, treating tissue 
using antigen retrieval solutions and heat before the application of the 
primary antibody has been shown to help antigens regain 
immunogenicity (Shi, Key et al. 1991; Leong 1996), though precisely 
why this works still remains unclear (Leong and Leong 2007). In this 
work, the retrieval solutions used were either Ethylene Diamine 
Tetracetic Acid (EDTA) at pH 8.0-9.0 or Citrate buffer at pH 6.0 (Table 
2.1). An 800w microwave was used as a source of heat radiation to 
bring the buffer to the boil.  
2.2.3. Preventing non-specific antibody binding
A primary antibody is designed to bind a specific epitope in order to 
precisely locate a molecular marker. If there is no marker to bind, then 
there should be no staining. However, the antibody can undergo non-
specific hydrophobic interactions with tissue in the absence of a specific 
epitope, leading to non-specific staining. To prevent this, normal swine 
serum (NSS) (X0901, Dako, Ely, UK) was applied to the sections and 
also used in diluting the primary antibody. NSS contains proteins which 
interact with and mask non-specific hydrophobic sites while not 
interacting with the experimental antibodies itself. 
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2.2.4. Application of the primary antibody 
Selection 
Primary antibodies for IHC on FFPE tissue should be designed to 
detect antigenic epitopes which can be effectively retrieved after the 
fixing and embedding process. In addition, they should have proven 
specificity, be available in sufficient quantities and ideally have been 
used in previous published work. Commercially available antibodies are 
preferred and usually meet these requirements but when none is 
available for a particular marker for use on FFPE tissue then the 
development and testing of an in-house antibody is possible. 
Titration 
The optimal working dilution for an antibody is defined as the dilution of 
antibody that gives the most intense specific staining with the least 
amount of background staining. It is affected by many factors, including 
how the tissues were originally fixed; the concentration, age and 
method of storing the antibody, the time between cutting the sections 
and the staining, the type of antigen retrieval method that is used and 
whether an avidin-biotin blocking step is performed  (Boenisch, Farmilo 
et al. 2001). For this reason it varies between laboratories and was 
determined by performing titrational experiments: multiple sections of 
tissue found to stain with an antibody were stained at various dilutions. 
This titration preceded the full experiment, which could then be 
performed at optimal dilution for all slides. The primary antibody was 
titrated to a fixed application time of 60 minutes.  
Negative control 
The negative control had all the reagents applied to it apart from the 
primary antibody, confirming that all staining of experimental tissue was 
due to the primary antibody interacting with its specific epitope. In place 
of the primary antibody, non-immune immunoglobulin of the same 
subclass and from the same species was substituted. For commercial 
antibodies this was as recommended by the manufacturer. 
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2.2.5. Washing 
 
The slides were mounted onto Shandon cover plates and placed into 
Shandon Sequenza slide racks. (Thermo Fischer Scientific Inc, 
Massachusetts, US). This system exploits a capillary gap method: 
holding slide and cover plate upright and apart by a fixed distance with 
reagents applied from a funnel arrangement above. This way, all 
sections are incubated in the same volume of reagent (Figure 2.2). 
Thorough washing of the sections between steps with Tris Buffered 
Saline (TBS) was essential to prevent them drying out. This also limited 
artifactual staining by ensuring that each reagents excess was washed 
off before the application of the next. See Table 2.1 for details of the 
preparation of the in-house reagents. 
2.2.6. ABC method  amplification of the signal
The two basic principles behind IHC involve the specific recognition of a 
human antigen by an antibody raised in another species and the 
reaction between an oxidising enzyme such as Horse Radish 
Peroxidase (HRP) and a chromogen such as 3, 3-DiAminoBenzidine 
(DAB).  
If the primary antibody is labelled with HRP, it can be directly linked to 
the chromogen but this leads to only a small amount of staining at each 
site of interaction (Figure 2.3a). An increased amplitude of staining can 
be achieved by indirect linking of chromogen to the primary antibody via 
an intermediate, as in the ABC method this work employs (Hsu, Raine 
et al. 1981). 
This method exploits a phenomenon whereby one molecule of avidin 
can bind four molecules of biotin (vitamin B7). After the incubation of 
the primary antibody, a secondary antibody C is applied which binds it 
and, indeed, all antibodies of that species (Figure 2.3b). This antibody 
is biotinylated; it is engineered to express multiple molecules of biotin, 
each able to bind avidin once. The next two reagents are mixed and 
given at least 30 minutes to associate; they are A streptavidin (a form 
of avidin better for IHC) and B  biotin complexed with HRP. When 
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
Figure 2.2  The Shandon cover plate Sequenza™ system 


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Table 2.1 The ‘in-house’ preparation of solutions most commonly used in 
immunohistochemistry 
 
Solution Materials Company Quantity Method 
 
Citrate 
buffer 
concentrate 
Citric acid. 
H2O 
Sigma-
Aldrich, 
Gillingham, 
UK 
21g Working dilution: Take 50mls 
of the citric acid concentrate 
and make up to 500mls with 
dH2O. Adjust the pH to 6.0 
using 5-10 mmol HCl. NaOH 
pellets  
Sigma-
Aldrich, 
Gillingham, 
UK 
10g 
dH2O  In-house 1000mls 
 
EDTA 
concentrate 
TRIS Sigma-
Aldrich, 
Gillingham, 
UK 
12.1g  Working dilution: Take 50ml of 
EDTA concentrate made up to 
500mls with dH2O. Adjust the 
pH to 8 – 9 using 5 -10 mmol 
NaOH / 5 – 10 mmol HCl. 
 
EDTA Sigma-
Aldrich, 
Gillingham, 
UK 
374.24g 
dH2O  In-house 1000mls 
 
TBS Tris Base Sigma-
Aldrich, 
Gillingham, 
UK 
6.06g To make 1l of 0.05m Tris 
0.15m NaCl TBS: Dissolve the 
Tris base in 90ml of dH2O. 
Adjust the pH with 10 mmol 
HCl to 7.6 and bring the whole 
up to 100mls with dH2O. 
Dissolve the NaCl in 100ml of 
dH2O. Add both solutions to 
the remaining 800mls of dH2O. 
Add 2ml of Brij 35 to decrease 
the surface tension. 
NaCl Sigma-
Aldrich, 
Gillingham, 
UK 
8.76g 
dH2O  In-house 1000mls 
 Brij 35 Sigma-
Aldrich, 
Gillingham, 
UK 
2mls 
     
0.5 % 
Copper 
Sulphate 
solution 
CuSO4 Sigma-
Aldrich, 
Gillingham, 
UK 
2.5g To make 500mls of 0.5% 
CuSO4 solution, 0.8% NaCl: 
Add 2.5g of CuSO4 to 500mls 
dH2O and add the 4.0g NaCl. 
 NaCl Sigma-
Aldrich, 
Gillingham, 
UK 
4.0g 
 dH2O In-house 500mls 
dH2O: deionised water   NaOH: Sodium hydroxide 
TBS: TRIS Buffered Saline    NaCl: Sodium Chloride 
Tris: TRIShydroxymethylaminomethane CuSO4: Copper Sulphate  
EDTA:  Ethylene Diamine        
 Tetracetic Acid 
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 Figure 2.3 The molecular arrangement of reagents in immunohistochemistry 
 
 
  
 
Figure 2.3a 
 
The molecular arrangement of reagents in direct IHC and the presence of an 
HRP labelled primary antibody 
 
 
Please refer to Figure 1; Boenisch, T., A. J. Farmilo, et al., Eds. (2001). 
Handbook: Immunohistochemical Staining Methods. Gostrup, Denmark, 
Dako. 
 
 
 
 
 
Figure 2.3b 
 
The molecular arrangement of reagents indirect IHC and the presence of a 
secondary antibody 
 
 
Please refer to Figure 7; Boenisch, T., A. J. Farmilo, et al., Eds. (2001). 
Handbook: Immunohistochemical Staining Methods. Gostrup, Denmark, 
Dako. 
 
 
 
 
 
 
Figure 2.3c 
 
The molecular arrangement of reagents in the ‘ABC’ method 
The streptavidin-biotin-HRP complexes are seen attached to a biotinylated secondary 
antibody. 
 
 
Please refer to Figure 10; Boenisch, T., A. J. Farmilo, et al., Eds. (2001). 
Handbook: Immunohistochemical Staining Methods. Gostrup, Denmark, 
Dako. 
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associated into AB, each streptavidin molecule binds several biotin-
HRP complexes. When this is added to the tissue each multi-HRP 
expressing complex can bind to each biotin site on the secondary 
antibody, multiplying the sites available for chromogen binding many 
times when compared to a direct method (Figure 2.3c). A commercially 
available kit was used for this work: 
(StreptABCComplex/HRP Duet, Mouse/Rabbit - K0492; Dako, Ely, UK). 
A = streptavidin in 0.01 mol/L phosphate buffered saline, 15mmol/L 
NaN3; pH 7.2 diluted to 1:100 
B = biotinylated horseradish peroxidase in 0.01 phosphate buffered 
saline, 15mmol NaN3; pH 7.2 diluted to 1:100 
C = biotinylated goat anti-mouse/rabbit secondary antibody diluted to 
1:100. 
Many normal tissues exhibit Endogenous Avidin Binding Activity 
(EABA) which can lead to non-specific binding of AB. Therefore, to 
prevent non-specific staining, before the primary antibody was applied 
the tissue was incubated with avidin which saturates its binding 
capacity, producing a layer that will bind biotin. By then incubating the 
tissue in excess biotin, all biotin binding sites are filled, preventing non-
specific binding of AB as biotin can only bind avidin once (Wood and 
Warnke 1981) (Figure 2.4). A commercial blocking kit was used to 
perform this (Avidin-Biotin blocking kit  SP-2001, Vector Laboratories, 
Burlingame, US).  
2.2.7. Visualisation of the primary antibody 
In order to visualise the location of the primary antibody-secondary 
antibody-streptavidin-biotin-HRP complex and thereby determine the 
antigen expression, the chromogen 3, 3-diaminobenzidine (DAB) 
(K3465, Dako, Ely, UK) was used. On oxidisation by HRP, DAB 
produces a brown substrate which is clearly seen on microscopy.  
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Figure 2.4 The suppression of Endogenous Avidin Binding Activity (EABA) 


Please refer to Figure 1e-f; Wood, G. S. and R. Warnke (1981). 
"Suppression of endogenous avidin-binding activity in tissues and 
its relevance to biotin-avidin detection systems." J Histochem 
Cytochem 29(10): 1196-204. 

  


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Endogenous peroxidase in tissues not labelled by primary antibody can 
non-specifically oxidise DAB. In order to prevent non-specific staining, 
the endogenous peroxidase activity was blocked before the antigen 
retrieval step using 0.3% hydrogen peroxide in methanol; 4mls of 30% 
hydrogen peroxide (Sigma-Aldrich, Gillingham, UK) was added to 
400mls of methanol (Sigma-Aldrich, Gillingham, UK). A stronger 3% 
solution of hydrogen peroxide was not used in an attempt to preserve 
the integrity of cell surface antigens. 
After the application of the DAB, the staining was darkened by the 
application of 0.5% copper sulphate in 0.8% sodium chloride (Table 
2.1) and haematoxylin (Vector Laboratories Inc, California, US) used to 
counter stain the background blue.  
To view the sections under the microscope, they were dehydrated in 
the graded alcohols (by reversing the order they proceeded through 
them), cleared of ethanol in xylene and Distyrene, Plasticiser and 
Xylene (DPX) (BDH, Poole, UK) was applied, followed by cover slips. 
This was performed in a fume cupboard and the slides were left to dry 
overnight. 
2.2.8. IHC protocol 
The principles described above are condensed into the following 
protocol. 
1. Place the sections into a slide basket and then into a dry oven at 60º 
for 10 minutes. 
2. Place the slide basket into a xylene bath (kept in a fume cupboard) 
for 10 minutes. Repeat this step using a different xylene bath. 
3. Transfer the slide basket sequentially into three baths containing 
graded alcohols (kept in a fume cupboard) spending 10 seconds in 
each. 
4. Place the slide basket into a bath of 0.3% hydrogen peroxide 
solution in methanol for 15 minutes (still within the fume cupboard). 
5. Wash the slides in a container of tap water through which water is 
running. 
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6. Place the slide basket into a closed microwavable plastic container 
holding 500mls of the appropriate antigen retrieval fluid made up to 
the required dilution and pH. Microwave the container for 10 minutes 
on high power and then 10 minutes on low power. 
7. Transfer the slide basket to a container of tap water through which 
water is running. Mount the slides onto cover plates and place them 
in a Sequenza, taking care not to allow the sections to dry out. 
8. Wash the sections with TBS. 
9. Apply 100 µl of NSS diluted 1:5 in TBS to each slide for 15 minutes. 
10. Apply 100 µl of avidin D solution to each section for 15 minutes and 
then rinse with TBS. Apply 100 µl of biotin solution for a further 15 
minutes. 
11. Rinse the sections three times, for 5 minutes each time, with TBS. 
12. Apply 100 µl of optimally diluted antibody to each section, except 
the negative control, for 60 minutes. 
13. Apply 100 µl of appropriately selected and diluted negative control 
immunoglobulin to the negative control sections for 60 minutes. 
14. Wash the sections three times, for 5 minutes each time, with TBS. 
15. Apply 100 µl of reagent C, diluted to 1:100 in TBS, to each slide for 
30 minutes.  
16. Wash the sections three times, for 5 minutes each time, with TBS. 
17. Combine and dilute reagent A and reagent B to 1:100, by adding 
equal quantities to the appropriate volume of TBS. This must be at 
done at least 30 minutes before the AB can be used. 
18. Apply 100 µl of the AB complex to each section for 60 minutes. 
19. Wash the sections three times, for 5 minutes, with TBS. 
20. Apply 100 µl of DAB, diluted 1:50 in its substrate buffer, to each 
section for 5 minutes. Repeat this step once. 
21. Wash the sections three times, for 5 minutes each time, with TBS. 
22. Apply 100 µl of 0.5% copper sulphate solution to each slide for 5 
minutes. Repeat this step once. 
23. Wash the sections three times, for 5 minutes each time, with TBS. 
24. Apply 100 µl of haematoxylin to each slide for 5 minutes. Repeat 
this step once. 
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25. Remove the sections from the Sequenza and cover plates and 
wash in them in a container of tap water through which water is 
running. 
26. Return the sections to a slide basket and dehydrate them by rotating 
them through the three sequential alcohol baths in reverse order, 
spending 10 seconds in each. 
27. Place the sections into a xylene bath for 10 seconds and repeat this 
step in a different xylene bath. 
28. Mount slide covers onto the slides using DPX and leave the slides in 
the fume cupboard to dry overnight. 
2.2.9. Evaluation of the staining 
The scoring of the tissue was performed concurrently by two 
experienced investigators, blinded to the clinical information (P.R and 
S.D), using a double-headed microscope. Whole sections and controls 
were initially reviewed to check that the location of the staining was 
correct. The TMA cores were then reviewed and scored using semi-
quantitative systems. 
Semi-quantitative systems 
Within each core, only tumour cells were considered and if this 
represented <10% of the core, then the core was not scored.  
The percentage number of cells staining was scored to the nearest 5%. 
This approach is supported by data showing that human observers can 
score the overall percentage of pink areas, that have been randomly 
superimposed onto a blue square in known quantities by a computer, 
with this level of accuracy (Cross 2001). 
The intensity of the staining was scored if it appeared to vary between 
cases. The scoring system was 0 = 0; mild = 1; moderate = 2; strong = 
3. Reference images of typical intensities were made to aid scoring.  
Where the intensity and percentage of cells staining varied highly 
between cases, composite Intensity Scores (IS) were generated. IS = 
percentage cells stained x intensity (range = 0-300). 
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Concordance 
The TMA matrices were scored by systematically following the array 
grids (Figure 3.6 a-d). Random cases were selected, scored and 
discussed, acting as a learning set. The arrays were then scored fully 
and independently, with consensus being reached if difficult cases were 
encountered. At the end of scoring each array grid, concordance was 
checked and was invariably >90%.  
Post hoc data processing 
Following scoring, all expression data (apart from intensity) needed 
appropriate grouping to facilitate statistical analysis. This was most 
commonly grouped into binary categories using justifiable cut-offs (high-
low/positive-negative/either side of the median) or quartiles. Though 
initial allocation into discrete categories (positive/negative) is more 
reproducible when performing a semi-quantitative analysis than using 
more complex systems (eg, to the nearest 5%, H-score, etc) (Cross 
1998), the opportunity was most often taken to collect more detailed 
data as there were no concerns regarding lack of concordance in this 
work. Cut-offs were informed by the median values, previous work and 
initial statistical analyses.  
Quantitative scoring 
Lack of standardisation in IHC is one reason why findings can be 
difficult to reproduce between centres. Semi-quantitative scoring is 
subjective and moves to objectify this and thereby improve 
standardisation have been made through introducing automated image 
analysis.  
These systems produce a detailed digital image of the slide and are 
then be calibrated to analyse tumour areas within the cores, returning 
detailed quantitative data regarding intensity and the percentage of 
area stained. These systems have been used successfully by different 
groups studying ovarian cancer, both on whole sections and TMAs 
(Geisler, Geisler et al. 1997; Rosen, Huang et al. 2004). However, there 
are disadvantages. The set up of the system introduces variation 
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between operators which has been shown to reduce reproducibility. In 
addition, they are expensive, relatively slow and not widely available. 
As it can also be shown that semi quantitative scoring by a human 
observer is as accurate, quantitative scoring was not pursued in this 
work (Cross 2001; Goethals, Perneel et al. 2006). Some workers have 
argued that until standardisation of antigen retrieval and fixation is 
achieved, quantitative scoring will add relatively little to improving inter-
laboratory variation (von Wasielewski, Mengel et al. 2002). 
2.2.10. Pilot staining study at DCGH pathology laboratory 
A pilot staining study was performed in order to acquire preliminary data 
about the staining characteristics of the array. Single copies of the array 
(copy 1) were stained for the markers which are routinely used to 
differentiate ovarian cancers from secondary ovarian deposits 
(colorectal, breast, etc). These comprised CK7, CK20, CEA and CA 
125 (Lagendijk, Mullink et al. 1998). 
The method used differed slightly from that detailed previously because 
the slides were included in a routine run of work performed at DCGH by 
Miss Andrea Gooding using an Optimax automated staining system 
(Biogenex, California, US). In brief, sections were mounted on 
3-aminoPropyltriEthoxySilane (APES) treated slides and dewaxed in 
the normal way. Endogenous peroxidase activity was blocked using 3% 
hydrogen peroxide in methanol. The antigen retrieval was as detailed 
previously with citrate buffer being used. The details of the primary 
antibodies are shown in Table 2.2. The negative control was by the 
omission of the primary antibody and its substitution with NSS. The 
amplification step was performed using Super Sensitive Polymer-
HRP IHC Detection (Biogenex, California, US) and visualisation was by 
DAB. The cores were scored in the manner in which pathologists would 
normally score them  positive or negative, in binary fashion. Positive 
cases were effectively identified when >5% of cells stained within a 
core. 
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Following the results of the pilot study, four copies of the array were 
stained manually for CK7 and CEA to allow more detailed evaluation. 
2.2.11. Manual staining details for individual markers 
All manual staining was performed at NCH using the IHC protocol 
(2.2.8) with the following modifications for the individual markers (Table 
2.3) 
2.2.12. Staining the TMA for CD46 
CD46 represented a special case, as no suitable antibody that had 
previously been used in published work to study CD46 expression in 
FFPE tissue could be found in sufficient quantities. Fortunately, prior 
work within the department performed by Dr Z Madjd had resulted in 
the successful production and validation of a suitable anti-CD46 
antibody. This is detailed in her PhD thesis (Madjd 2004). As this 
antibody was used in this study, a brief summary of the steps involved 
in its creation and validation is provided below.  
Generation of anti-CD46 monoclonal antibody 
Monoclonal antibodies to CD46 were generated as previously 
described (Madjd, Durrant et al. 2004). Briefly, the peptide 
(CLKVSTSSTTKSPA), located on serine-threonine-proline rich (STP) 
regions of CD46 and was synthesised (Alta Bioscience, Birmingham) 
and conjugated to the carriers Keyhole Limpet Haemocyanin (KLH) and 
Bovine Serum Albumin (BSA) using sulpho-Maleimidobenzoyl-N-
hydroxysulfosuccinimide (MBS) (Perbio Science, Cheshire, UK). The 
purified peptide-KLH conjugates were used to immunise Balb/c mice. 
Immune serum was tested by Enzyme Linked Immunosorbant Assay 
(ELISA) against peptide-BSA conjugates. Peak titre anti-sera was used 
in ELISA against peptide-BSA conjugate and compared against pre-
immune sera (Figure 2.5). Splenocytes from the mouse showing 
greatest response were fused with NS0 (myeloma) 5 days after the final 
injection, seeded onto microtitre culture plates and suspended in 
Hypoxanthine-Aminopterine-in-Thymidine (HAT) (Sigma-Aldrich, 
Gillingham, UK) medium for 10 days before screening the supernatant 
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 Table 2.2 The antibodies used in the pilot IHC TMA study 
An automated staining system was used to stain the TMA slides   
(Optimax, Biogenix, California, U.S.). 
 
Antibody Type Manufacturer Clone 
Code 
Optimal 
Dilution 
References 
      
CK 7 Mouse 
Monoclonal 
IgG1 
Bond, Peloris 
& Novocastra 
Reagents, 
Newcastle, 
U.K 
OV-TL-
12/30 
 
NCL-L-
CK7-
OVTL 
1:20 (van Niekerk, 
Jap et al. 1991) 
      
CK 20 Mouse 
Monoclonal 
IgG2a 
Bond, Peloris 
& Novocastra 
Reagents, 
Newcastle, 
U.K 
Ks20.8 
 
NCL-L-
CK20 
1:50 (Moll, Lowe et 
al. 1992) 
      
CEA Mouse 
Monoclonal 
IgG1 
Bond, Peloris 
& Novocastra 
Reagents, 
Newcastle, 
U.K 
II-7 1:60 (Nap, 
Hammarstrom 
et al. 1992) 
      
CA 125 Mouse 
Monoclonal 
IgG1 
Bond, Peloris 
& Novocastra 
Reagents, 
Newcastle, 
U.K 
OV185:1 
 
NCL-L-
CA125 
1:20 (Keen, Szakacs 
et al. 1999) 
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Table 2.3 Immunohistochemical details of the individual marker studies (1 of 2) 
 
Antigen Antibody 
Type 
Company 
 
Clone 
 
Code 
Dilution Antigen 
Retrieval 
Solution 
Positive 
Control 
Tissue 
Negative control 
antibody 
TMA 
copies 
stained 
Scoring Data 
Collected 
 
Positive cut-off 
Reference 
 
CK7 
IgG1 
Monoclonal 
Mouse 
Dako, Ely, 
UK 
OV-TL 
12/30 
 
M7018 
0.505mg/ml 
 
 
1:200 
Citrate  
 
 
pH 6.0 
OVCA 
 
 
ANO 10 
Non-immune murine 
IgG1 100mg/L 1:40 
MCA928,Serotec, 
Oxford, UK 
1,2,3,4 % Cells 
 
 
>5%  
(Poels, Jap et 
al. 1989) 
 
CD66ce 
(CEA) 
IgG1 
Monoclonal 
Mouse 
Serotec, 
Oxford, 
UK 
198 
 
 
MCA1839 
1mg/ml 
 
 
1:400 
Citrate  
 
 
pH 6.0 
OVCA 
 
 
ANO 18 
Non-immune murine 
IgG1 100mg/L 1:40 
MCA928,Serotec, 
Oxford, UK 
1,2,3,4 % Cells 
 
 
>5% 
(Nap, 
Hammarstrom 
et al. 1992) 
 
p53 IgG2a 
Monoclonal 
Mouse 
Dako, Ely, 
UK 
DO-7 
 
M7001 
390ml/L 
 
1:30 
Citrate 
  
pH 6.0 
OVCA 
 
ANO 139 
Non-immune murine 
IgG2b 100mg/L 1:8 
X0944,Dako, Ely, UK 
1,2 % Cells 
 
>10 % 
(Lassus, 
Leminen et al. 
2003) 
 
Bcl-2 
IgG1 
Monoclonal 
Mouse 
Dako, Ely, 
UK 
124 
 
 
M0887 
280ml/L 
 
 
1:50 
EDTA  
 
 
pH 8.0 
Tonsil 
Non-immune murine 
IgG1 100mg/L 1:18 
MCA928,Serotec, 
Oxford, UK 
1,2 % Cells 
 
 
>10% 
(Delia, Aiello 
et al. 1992) 
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Table 2.3 Immunohistochemical details of the individual marker studies (2 of 2) 
 
Antigen Antibody 
Type 
Company 
 
Clone 
 
Code 
Dilution Antigen 
Retrieval 
Solution 
Positive 
Control 
Tissue 
Negative control 
antibody 
TMA 
copies 
stained 
Scoring Data 
Collected 
 
Positive cut-off 
Reference 
HLA 
Class I 
IgG2a 
Monoclonal 
Mouse 
Gift: Prof. 
Ploegh 
Harvard 
Medical 
School, US 
HC-10 
 
 
 
 
 
 
1:10 
Citrate  
 
 
 
 
pH 6.0 
Tonsil 
Omission of primary 
antibody 
Normal swine serum 
1,4 % Cell 
membrane 
intensity 
 
 
>10% cells 
 +1 intensity 
(Stam, Spits et 
al. 1986) 
 
ȕ2-m 
Polyclonal 
Rabbit 
 
Dako, Ely, 
UK 
 
 
A0072 
 
 
1:3000 
None Tonsil 
Omission of primary 
antibody 
Normal swine serum 
1,3 >10% cells 
 +1 intensity 
(Madjd, 
Spendlove et 
al. 2005) 
 
CD59 
IgG2a 
Monoclonal 
Mouse 
Serotec, 
Oxford, UK 
MEM-43 
 
MCA1054 
1 mg/ml 
 
 
1:7 
Citrate  
 
 
pH 6.0 
Tonsil 
Non-immune murine 
IgG2a 100mg/L 1:1 
MCA929 Serotec, 
Oxford, UK 
1,2 % Cells 
 
 
 50% 
(Madjd, Pinder 
et al. 2003) 
           
CD55 
IgG2b 
Monoclonal 
Mouse 
In-house RM1 
1mg/ml 
 
1:16 
Citrate 
  
pH 6.0 
Tonsil 
Non-immune murine 
IgG2b 100mg/L 1:8 
X0944,Dako, Ely, UK 
3,4 Intensity Score 
 
 225 
(Madjd, 
Durrant et al. 
2004) 
 
CD 46 
IgG1 
Monoclonal 
Mouse 
In-house MZ1 
1mg/ml 
 
Undiluted 
Citrate 
  
 
pH 6.0 
Tonsil 
Non-immune murine 
IgG1 100mg/L 1:1 
MCA928,Serotec, 
Oxford, UK 
3,4 Intensity Score 
 
 
 65 
(Madjd 2005) 
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Figure 2.5 ELISA showing titration of MZ1 antiserum against purified CD46
 ELISA plates were coated with 5 ȝ l/ml of purified CD46 overnight at 
4°. Protein was detected with mouse antiserum and then rabbit anti- 
mouse HRP conjugate and OD measured at 405 nM. 
 
 

 

Figure 2.6 Western blot of protein samples from 791T cells 
 The cells were separated by SDS- (10%) and Western blotted. Lanes 1 
and 2 represent non-reduced samples probed with rabbit polyclonal anti 
CD46 (lane 1) and MZ1 (lane 2). Lanes 3 and 4 represent reduced 
samples probed with MZ1 in the presence or absence of blocking 
peptide respectively. M represents 10KDa molecular weight markers. 
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against peptide-BSA conjugate. Positive wells were cloned at 3, 1 and 
0.3 cells/well and re-screened for antibody producing clones. Second 
and third clonal expansions followed. Supernatant showing reactivity to 
the immunised peptide on ELISA was tested using a mouse isotyping 
kit (Serotec, Oxford, UK). IgG1 positive supernatant was discovered 
and purified to produce the MZ1 monoclonal antibody, the 
concentration of which was 1mg/ml. 
Western blotting 
The MZ1 monoclonal antibody was tested against the CD46 expressing 
cell line (791T) by reducing and non-reducing Sodium Dodecyl Sulfate 
PolyAcrylamide Gel Electrophoresis (SDS-PAGE) and Western blotting. 
Samples were separated by standard 10% SDS-PAGE and Western 
blotted before probing with the anti-CD46 antibodies. The antibodies 
were either anti-CD46 monoclonal antibody (MZ1, 1/5) or the rabbit 
anti-human CD46 polyclonal antibody (1/200) (Gift: N Rushmere, 
University of Wales College of Medicine) (Singhrao, Neal et al. 1999; 
Madjd, Durrant et al. 2005). The Western blot was developed with 
1/4000 rabbit anti Mouse or 1/2000 goat anti rabbit-HRP conjugated 
secondary antibodies (Dako, Denmark) and developed with ECL+ 
reagent (Amersham, UK). Polyclonal rabbit anti-CD46 was shown to 
detect a strong band by non-reducing SDS-PAGE while MZ1 was 
unable to identify any protein bands under these conditions. Under 
reducing conditions a band of approximately 65KDa was identified (lane 
4) which could be blocked by the pre-incubation of MZ1 with peptide-
BSA conjugate (lane 3), demonstrating specificity of the antibody for the 
65KDa protein band (Fig. 2.6). 
Peptide blocking of anti-CD46 monoclonal antibody on tissue 
sections 
The specificity of MZ1 was demonstrated on a series of formalin fixed, 
paraffin embedded breast cancer sections using standard IHC 
protocols, the MZ1 antibody having been pre-incubated with varying 
concentrations of the Z154-BSA peptide conjugate to which it had been 
raised. A strong staining pattern to the MZ1 antibody was seen in 
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breast tumours (Fig 2.7a) which was completely inhibited when the 
monoclonal antibody was pre-incubated in the presence of the peptide 
conjugate (Fig. 2.7b). 
Immunohistochemical staining of the ovarian TMA with MZ1 
Having created the monoclonal MZ1 antibody, Dr Madjd also proved 
that it was specific for CD46 and that it could be used to study CD46 
expression in FFPE tissues. The details of its use in this study are 
contained in Table 2.3. 
2.3. Statistical tests 
Following scoring, the expression data were statistically analysed. The 
majority of the statistical analyses were performed using the computer 
package SPSS version 11.0 & 13.0 (SPSS Inc, Chicago, Illinois, US). 
2.3.1. p values 
The null hypothesis is that no difference exists between groups. The 
alternate hypothesis is that a difference does exist between groups. 
Rejecting the null hypothesis means accepting the alternate hypothesis. 
When the null hypothesis is rejected when a true difference does not 
exist, this is a false positive and is type I error. The p value is the 
statistical chance of a false positive occurring. If a p value = 0.05, this 
means that the chance of a difference being a false positive is 1 in 20. If 
the p value is close to 1 there is a high probability that a result 
represents a false positive and if it is very small there is a low 
probability that accepting the result will represent a type I error. The 
level of chance of a false positive below which one will reject the null 
hypothesis is the alpha value and by convention is 0.05; therefore, a p 
value of <0.05 is considered to represent statistical significance. This is 
not the same as the difference between groups being large; it simply 
means that the probability of the difference having occurred by chance 
alone is relatively low. If 20 independent hypotheses are tested on the 
same data, with an alpha value of 0.05, one false positive association 
will occur. For this reason, where (n) number of hypotheses are being 
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Figure 2.7 Peptide blocking of MZ1
 
Immunohistochemical staining of serial breast sections stained with 
anti-CD46 monoclonal antibody. 
 
 
Figure 2.7a    
 
Without pre-incubation with specific CD46 peptide. 
 
 
Figure 2.7b    
 
 
 
Following pre-incubation with specific CD46 peptide 
 

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tested, the alpha value should be adjusted to (0.05/n)  this is the 
Bonferroni correction (Swinscow, Campbell et al. 2002). 
2.3.2. Univariate analysis of associations with clinicopathological 
criteria  Persons Chi squared (Ȥ2) test 
The data for molecular marker expression and that representing the 
clinicopathological characteristics of the individual cases with which 
they would be compared were divided into categories.  
The Ȥ2 test measures the probability that categorical variables have an 
effect on one another; for instance, that the positive expression of a 
marker would be associated with grade of disease. The categories are 
cross tabulated against each other forming tables the size of which 
range from 2 x 2 upwards, depending on the subdivision of the 
categories; positive and negative expression of a marker being 
compared with grade 1, 2 or 3 of disease would form a 2 x 3 table 
containing 6 individual cells. If there were no association between 
expression of a marker and grade, the proportions of cases with grade 
1, 2 and 3 disease would be equal in both positive and negative marker 
groups. The Ȥ2 test measures the numerical difference between this 
expected scenario (E) and what is actually observed experimentally (O) 
in each cell. The sum of ([O-E]2/E) is inputted into an Ȥ2 distribution 
which returns a p value.  
The clinicopathological categories comprised age, FIGO stage, degree 
of cytoreduction, grade of disease, the use of chemotherapy and the 
histological subtype of the disease  6 categories. The alpha value was 
therefore corrected to (0.05/6 = 0.012).  
Some tables were considerably bigger than 2 x 2 and this was reflected 
in the degrees of freedom assigned to the calculations. The degrees of 
freedom = (number of columns - 1) x (number of rows - 1)  and in the 
example of grade this = (2-1) x (3-1) = 3. The number of degrees of 
freedom has a large effect on the p value returned. When large tables 
were generated the cases were spread more sparsely between the 
cells. The Ȥ2 test represents an approximation to the more accurate 
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though complex Fishers Exact test but for it to remain a good 
approximation each cell within the table needed to contain a minimum 
number of cases. No more than 1/5 of the cells were allowed <5 cases 
and none were allowed less than 1. In cases where the cells did not 
contain the appropriate number of cases the analysis defaulted to 
Fishers Exact test. In addition, when the numbers in a fourfold table 
were fairly small (<10 cases per cell or where the total number of cases 
was <100) Yates correction was applied. These methods are 
automatically appropriately applied by the statistical package SPSS vs 
11 & 13 (Chicago, Illinois, US). 
The limitation of the Ȥ2 was that it could only be used for categorical 
variables and these needed to be arranged in a valid way into the 
fewest number of categories possible. However, the main assumption, 
that each case contributes data to only one cell, appeared valid 
(Swinscow, Campbell et al. 2002). 
2.3.3. Univariate analysis of associations with survival 
Kaplan-Meier plot 
Patients followed up over time from the point of treatment are at any 
given time point either alive, dead or lost to follow up. Ideally, no 
patients would be lost to follow up and the statistical analysis would 
only occur when all of the patients had died  of the disease or of other 
causes. However, this is impractical and the Kaplan-Meier method 
allows meaningful survival analysis with incomplete data. 
The cases survival times are ordered from smallest to largest in life 
tables from which the proportion of patients at risk of dying is then 
calculated at regular time points from treatment. For this method to be 
accurate, patients who are lost to follow up between intervals need to 
be removed  or censored  from subsequent analyses. The resulting 
cumulative survival is plotted against time as a Kaplan-Meier curve with 
censored cases being denoted by +. If the effect of a binary marker on 
survival is being studied, two life tables can be constructed  one for 
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each category. The resulting curves may then be compared on the 
same axes where survival differences may be visually apparent. 
This method assumes that the censoring of patients is a random event 
and that these cases would behave no differently from the other cases 
in the group they originated from. It also assumes that patients entered 
into the study early have the same long term survival prospects as 
those entered later. Lastly, it assumes that the survival data are 
continuous and not grouped to the nearest follow up point (Bland and 
Altman 1998). 
 Log rank statistic 
This test is used to determine whether there is a statistical difference in 
survival between two or more groups when the data are in continuous 
form and the Kaplan-Meier plot has been performed.  
In the same way as when a Kaplan-Meier curve is plotted, the data are 
ranked in order of shortest to longest survival and sequential 
calculations of expected and observed numbers of deaths within each 
group are made each time a death occurs. When data are censored, 
they are excluded from subsequent analyses. The end result is the 
generation of a total number of expected and observed deaths within 
each group. This is then used to generate the log rank statistic, the p 
value for which is derived from referring to an Ȥ2 distribution table. 
This method allowed differences in the survival experience over the 
whole of the study period to be investigated, rather than at arbitrary 
time points (such as 5 year survival). However, it makes the same 
assumptions regarding censored data as the Kaplan-Meier method. It 
also assumes that the relationship between the relative proportions of 
those dying within the different groups remains constant over time. If 
one groups rate of death at a point in time is twice that of another 
group, it should not increase to three times the rate of that group at a 
different time point  the ratio should be maintained through time. 
Practically speaking, if this assumption of proportional hazards is valid, 
this means that Kaplan-Meier curves would not cross. If the curves 
Chapter 2: Materials and Methods
108
cross then the log rank test cannot be performed and would in any 
event be unlikely to give a significant result (Bland and Altman 2004). 
2.3.4. Multivariate analysis of associations with survival  Coxs 
proportional hazards model 
The log rank test is a test of significance and does not compute size of 
effect or the independence of the effects of multiple factors on survival.  
In order to do this, the Coxs regression was performed. This 
multivariate analysis measures the interrelationships between multiple 
variables simultaneously.  
The model generates a baseline survival curve and calculates the 
hazard ratio (HR) for a variable by measuring the effect of removing it 
and adding it to the model. It determines the magnitude and 
independence of each variables individual influence on the overall 
hazard rate. It returns a HR for each variable reflecting the increased 
likelihood of death at any time point due to the presence of that factor 
compared to the baseline.  
Ninety-five percent confidence intervals (CI) are also generated. These 
delineate the range of values within which the true HR has a 0.95 
chance of lying. An HR of <1 means that the factor will predict and 
improved prognosis. An HR of >1 means that the factor will predict a 
worse prognosis. An HR of 1 indicates that the factor has no influence 
on survival. Ninety-five percent CI must therefore confine their range to 
either wholly above or below 1 for a variable to be considered to have 
an effect on survival independently of other factors. 
If a factor is associated with survival on univariate analysis but its HR 
95% CI straddles 1 on Cox regression then this would suggest that this 
factors effect on survival was due to an association with a more 
important, truly independent prognostic factor, such as FIGO stage. 
The Cox model assumes that the effects of a factors ability to predict 
outcome remains constant over time and that hazard rates remain 
proportionate between groups independently of time. Therefore, 
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variables which do not predict survival in a univariate analysis or factors 
with Kaplan-Meier curves that cross should not be included in this 
model, because in those situations this assumption is not valid (Cox 
1972). 
2.3.5. Power calculations 
The power calculations for this study were performed in conjunction 
with an experienced biostatistician, Dr Sarah Lewis (UoN) using the 
EGRET package (1999) (Cytel Inc, Massachusetts, US).  
The power calculations were made part way through the construction of 
the array when a full database was accessible. At this point it was 
possible to project the maximum number of cases which could be 
included in the study and to access information key to performing the 
calculations. Power calculations were undertaken in order to determine 
the importance of adding extra cases into the study and to project the 
size of effects that the future array would be able to detect. 
The database revealed a total study period of 23 years with patients 
being accrued over 15 years. Of the 296 patients within a consecutive 
series of 358 who had died by November 2005, 40% had died within 
the first 12 months of their diagnosis, 88% had died by 60 months and 
100% by 270 months. 62 were currently alive. Estimates of deaths over 
time were used as a guide to the baseline hazard function. From 
previous TMA work using other tissue types, it was estimated that a 
sample size of approximately 300 would be necessary to look for the 
relatively small effects that molecular markers exert on prognosis: HRs 
of between 1.5 and 2 being usual for molecular markers demonstrating 
independent prognostic power (Madjd, Spendlove et al. 2005; Watson, 
Spendlove et al. 2006; Rolland, Spendlove et al. 2007; Ullenhag, 
Mukherjee et al. 2007). Detailed information regarding the statistical 
variance for molecular marker expression in ovarian cancer as 
measured by TMA was not available from previous published work or 
pilot studies and so It was assumed that in most cases the molecular 
markers being studied would allocate the cases into one of two groups 
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(eg, high-low expression) and that the allocation of cases would often 
be unequal and range from 10:90 to 50:50. This range of potential 
allocation scenarios was investigated for between 300 and 360 cases. 
The alpha value was 0.05 and the power to detect an effect was set at 
0.85 (Table 2.4).  
Three hundred and thirty-nine cases would have an 85% chance of 
detecting a hazard ratio <0.67 and >1.5 with a false positive rate of 0.05 
for an allocation of 10:90. Therefore, all available cases were added to 
the array and this information was then used in interpreting the results 
of the multivariate analyses.  
The main assumptions of these calculations concern the estimations of 
HR and baseline hazard function. The limitations of using this method 
included the inelegance of the estimation of the molecular marker 
expression data (which limited the helpfulness of the calculations in 
predicting how the model would perform in situations where the data 
were not binary) and that the information could only be used to partially 
determine the optimal sample size (because the sample size was 
relatively fixed). The advantages of using power calculations were that 
it gave an idea of minimum sizes of effect that could be found in 
differing scenarios and informed a request to extend the series to 
eventually include cases up to 2002. The calculations also provided 
reassurance that the study was not overpowered, which could lead to 
the identification of very small differences unlikely to be of any clinical 
significance (Florey 1993). 
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Table 2.4 Power calculations 
 How detectable size of effect alters with increasing volume of cases and 
the proportional allocation of cases when the expression of a marker is 
binary. 
 
 
Allocation 
ratio 
 § 300+ Cases  § 300 Cases 
  No 
Cases 
Detectable HR  No  
Cases 
Detectable HR 
       
50:50  354 0.72> HR >1.38  300 0.67>HR >1.5 
40:60  364 0.73>HR>1.38  288 0.7>HR>1.43 
30:70  348 0.71>HR >1.40  300 0.71>HR>1.41 
20:80  339 0.67>HR >1.49  300 0.67>HR>1.50 
10:90  358 0.61>HR >1.65  300 0.59>HR>1.70 
     
 
  
Assuming a fixed power of 0.85 and alpha value of 0.05 
HR = Hazard Ratio 
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Chapter 3: Construction and Evaluation of the Tissue 
Microarray  
 
This chapter deals with two distinct but inter-related processes vital to 
the production of a TMA which is to be used in the study of novel 
markers; firstly the physical construction of the tissue microarray and 
secondly the assessment of preliminary staining data derived from it. 
The physical construction of the TMA involved identifying suitable 
cases, biopsying representative tissue and arraying and recording the 
position of this tissue in a systematic manner in order that the 
subsequently accrued expression data could be linked to 
clinicopathological data in order to provide meaningful analyses. The 
assessment of preliminary staining data from the array involved staining 
one copy of the array for four antigens (CK7, CK20, CEA and CA125) 
and comparing the expression data acquired with that widely available 
in the literature. Following this pilot evaluation of expression data, two 
antigens (CK7 and CEA) were studied in more detail in a full evaluation 
of the TMA. From the four copies of the array which were stained for 
these two antigens data were also generated from which the optimum 
number of copies to be used in the subsequent experimental work 
could be determined. Analysing this data also helped address potential 
concerns regarding the theoretical issue of tissue heterogeneity and 
sub-optimal tissue sampling in TMA work. 
The aim of this chapter is therefore to document how the array was 
assembled and to give specifics about inclusions, exclusions, locations 
of particular samples and the pathological representativeness of the 
final cohort. Its aim is also to demonstrate that the TMA could produce 
staining data equivalent to that found within the literature through the 
use of two copies of the array which optimally balanced tissue core loss 
with accuracy of expression data and conservation of tissue and 
reagents 
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3.1. Construction of the TMA 
 
 
3.1.1. Method
An overview of the steps involved in producing a TMA is outlined in 
Figure 3.1. Firstly potential cases for inclusion were determined through 
their identification on a prospectively maintained clinical database 
(Figure 3.2). The original pathology reports from these potential cases 
were then acquired from the patient record and subsequently 
anonymised (Figure 3.3). This allowed tissue to be located in the 
pathological archives which was then assessed contemporaneously by 
a gynaecological pathologist in order ultimately to identify 
representative tissue biopsy sites and to exclude inappropriate cases 
(Figure 3.4a-c). Tissue cores were then physically extracted from the 
appropriate block sites and inserted into the tissue array blocks in grid 
patterns (Figure 3.5a, b). A meticulous record of the positioning of the 
case tissue was produced (Figure 3.6a-d) and the final TMA blocks 
were then sectioned and H&E stained (Figure 3.7a, b) 
3.1.2. Results
The cases included were recruited from those diagnosed between 
January 1st 1982 and December 31st 1997. The cohort of cases 
considered for inclusion numbered 424 after initial exclusions had been 
made (Figure 3.2), for which it was possible to find pathology reports for 
403. Following contemporaneous review it was found that 66 of cases 
were unsuitable for inclusion and that 19 borderline cases had been 
included on the first array block. It was found that two cases had been 
physically included twice on the TMA under different study numbers 
(Figure 3.2). Ultimately tissue cores from a total of 339 surgically 
treated primary ovarian cancers were represented in four TMA blocks 
with five representative cores from each case being used to construct 
five copies of the TMA. 76 cases were represented on each of the TMA 
blocks 1-3 with 159 on the fourth block (Figure 3.6a-d).  
The 339 cases included in the study were mostly epithelial ovarian 
cancers (98.5%). Serous adenocarcinomas (52.5% of the total) were 
the most numerous and clear cell adenocarcinomas (7.4% of the total) 
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Figure 3.1 The process of constructing and utilising a TMA  
The process of constructing a TMA begins with the identification of a 
suitable cohort of patients which may include many hundreds of 
cases. Cases are identified, retrieved and histopathologically 
reviewed after which representative tissue biopsies are physically 
taken from the archived blocks and transferred into a TMA format. 
The finished TMA is sectioned, stained for the marker being 
investigated and the staining evaluated. The expression data derived 
is then compared statistically with clinicopathological parameters 
including survival in a univariate and multivariate analysis. 



Please refer to Figure 1; Rimm, D. L., R. L. Camp, et al. (2001). 
"Tissue microarray: a new technology for amplification of tissue 
resources." Cancer J 7(1): 24-31. 

  
  


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  Despite the complex logistics, 339 individual cases of primary ovarian cancer treated surgically were represented on the 4 final array blocks from 
the investigated cohort of 441 presenting between 1982 and 1997 at DCGH. 
 
Exclusions from arrayed cases  - 19 
19 Borderline cases  
2 duplicated cases 
ANO 214 (SNO 127 duplicating SNO 376) 
ANO 104 (SNO 282 duplicating SNO 71)  
5 Bowel cancer 
2 Benign disease 
1 Sarcoma 
1 Stomach cancer  
Exclusions from database cases - 66 
21 No pathology report available 
11 Borderline cases 
20 No suitable tissue 
5 Identified after arrays completed 
9 Not ovarian cancer  
424 cases of apparent ovarian 
cancer recorded on database 
358 cases represented on the 
array 
339 cases of primary surgically 
treated ovarian cancer 
360 cores on TMA 
Cases unavailable from registry - 17 
14 cases not on prospective database 
1 case representing recurrent disease 
2 cases without pre-treatment biopsy taken  
441 new cases of ovarian 
cancer diagnosed at DCGH 
between 1982 and 1997 as 
recorded by the Trent cancer 
registry 
Study numbers 1 - 464 generated 
SNOs representing non-existent cases - 38 
8 Unassigned 
30 Duplicated cases already assigned  SNOs 
Figure 3.2 
Logistics of identifying cases 
for the TMA 
Restrictions placed on access to 
the complete dataset, a need for 
anonymisation and the staggered 
manner in which the tissue became 
available introduced errors which 
were identified and tracked. The 
study numbers were allocated 
before the database had been 
audited for duplicate cases and too 
many were issued. 441 cases of 
ovarian cancer were treated at 
DCGH in the recruitment period but 
only 424 cases could be included. 
Borderline tumours were 
erroneously included on the first 
array block but subsequently 
excluded. There were other 
reasons why cases ZHUHQ¶W 
included in the final array following 
their histopathological review. Two 
cases were accidentally arrayed 
twice but this did not happen more 
frequently as cases usually had 
their suitable blocks temporarily 
removed from the archive during 
the arraying process. The most 
representative blocks were 
removed from the archive 
permanently and having punch 
holes to identify that the case had 
already been arrayed. 
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Figure 3.3 
 
Anonymised pathology report 
When a case was identified for inclusion, a copy of the original 
pathology report was acquired which contained data essential for 
locating the archived tissue and then for narrowing down the number of 
blocks which needed to be reviewed by the pathologist. This was later 
anonymised and kept in the records. The unique pathology number 
could only be linked back to the patient through the original report in the 
patient’s notes and therefore was allowed to remain by the ethics 
committee. 
 

  
  

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Figure 3.4 Identification of representative areas to include on the array 
 
Figure 3.4a Archived tissue blocks 
Each case to be included had up to 25 blocks pertaining to it within the 
archive. Blocks macroscopically appearing to contain cancer tissue 
were removed from the archive for review. 
 
 
 
Figure 3.4b H&E sections 
Section of these blocks were reviewed, typed and graded by a 
gynaecological pathologist. The most representative areas on the 
H&E slides were marked. 
 

Figure 3.4c Marking the blocks 
Using the H&E slides, the corresponding representative blocks 
identified were permanently separated from the main archive. The 
marker dots were transferred onto the blocks in preparation for the 
next stage; where the tissue was removed using the microarrayer. 
 
 

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Figure 3.5 The Beecher Instruments manual tissue microarrayer (Sun 
Prairie, WI, U.S.) 
 
 
Figure 3.5a Frontal view  
Showing the positioning of a recipient block beneath the tissue 
microarrayer turret. The tissue is first precisely sampled and then 
precisely transferred using two separate (donor and recipient) needle 
punches mounted on the same swinging turret. The turret moves 
upwards and downwards, allowing the needles manoeuvrability in the 
Z axis. Ensuring that a correct depth of sample is transferred is 
dependent on the operator. 
 
 
 
 
 
                  
                 Turret 
 
 
                 Needle mounts 
 
                 Recipient block 
 
 
 
 
 
Figure 3.5b  Seen from above 
The perpendicular orientation of the micrometers is shown. These 
alter the turret’s (and thereby the needle punches’) alignment in 
precise increments. This allows each core to be precisely spaced from 
its neighbours (in this case 1mm) in the X and Y axes in order to 
produce a navigable grid pattern.  
 
 
                     Micrometers 
 
 
 
 
 
 
 
 
                        
 
                  Donor and recipient needle  
                  punches 

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Figure 3.6 
 
The array grids mapping the location of tissue cores 
corresponding to each case from the 360 arrayed 
The 0.6mm tissue cores were extracted from donor blocks (which had 
had representative sites marked on them at histopathological review) 
using a Beecher Instruments™ (Sun Prairie, California, US) manual 
arrayer. The 339 cases were finally represented on four  individual 
TMA blocks as illustrated bellow.  For easier use, when the cases had 
all been arrayed their study number (SNO) was replaced by an array 
number (ANO), representing the case’s sequential position on the 
array. This process was performed 5 times, producing 5 copies of the 
array. The individual block is identified as X:Y, where X = the TMA 
block within a copy of the array (1-4)  and Y = the copy of the array 
being studied (1-5). 
 
Figure 3.6a Array block 1:1 
Showing the locations of the first 76 cases. The blanked out areas are 
the locations of borderline cases, arrayed but not used in this study. 
The first grid shows a case’s SNO (the letters representing the block 
within that case’s archive which arrayed) and the second grid shows 
its equivalent, final ANO. K represents a core of kidney, positioned to 
help orientation at microscopic evaluation. 

 















120
Chapter 3: Construction and Evaluation of the Tissue Microarray
Figure 3.6b Array block 2:1  
Showing the locations of the second 76 cases. The blanked out areas 
are the locations of cases arrayed wrongly. The first grid shows a 
case’s SNO (the letters representing the block within that case’s 
archive which arrayed) and the second grid shows its equivalent, final 
ANO. The boxed case, SNO 127, was found to be a duplicate of SNO 
376 and was excluded from analysis. K represents a core of kidney, 
positioned to help orientation at microscopic evaluation.  
 





 
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Figure 3.6c Array block 3:1  
Showing the locations of the third 76 cases. The first grid shows a 
case’s SNO (the letters representing the block within that case’s 
archive which arrayed) and the second grid shows its equivalent, final 
ANO. The boxed case, SNO 282C, was found to be a duplicate of 
SNO 71 and was excluded from analysis. K represents a core of 
kidney, positioned to help orientation at microscopic evaluation. 
 




 
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Figure 3.6d Array block 4:1 
Showing the locations of the fourth 159 cases. The first grid shows a 
case’s SNO (the letters representing the block within that case’s 
archive arrayed) and the second grid shows its equivalent, final ANO. 
K represents a core of kidney, positioned to help orientation at 
microscopic evaluation. 
 







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Figure 3.7 The TMA blocks 
 
Figure 3.7a A final recipient TMA block 
Once the donor cores had been precisely arrayed, the block was 
heated for 10-15 minutes at 37°C and the surface levelled using a 
clean glass slide. The block was then be sectioned using a standard 
microtome.  
 
 
 
Figure 3.7b Section from an array block  
Once the array block had been ‘faced’ sections were taken and 
mounted onto slides. One slide from each TMA block was H&E 
stained for evaluation, as shown below. 
 
 

124
Chapter 3: Construction and Evaluation of the Tissue Microarray
were the least common.  The 30 borderline tumours represented 8% of 
the cases but were not included in subsequent analyses. The cancers 
were mostly high grade (66%) (Table 3.1).
3.1.3. Discussion 
441 new diagnoses of cancer (ICD-10 C56-C57 (World Health 
Organization. 1992) + cases of uncertain malignant potential - 
borderline cases) from DCGH were registered with the Trent Cancer 
Registry (TCR) between 1982 and 1997, the time period from which 
cases were selected.  In 1991 the county of Derbyshire had a 
population of approximately 459 000 at risk of ovarian cancer and 
during these 15 years that cases presented the incidence of ovarian 
cancer increased from 15 – 19  / 100 000 (Direct Age-Standardised 
Rate) with approximately 1087-1308 new cases of ovarian cancer being 
expected to present within the county during that time frame (Great 
Britain. Office of Population Censuses and Surveys. 1991; Quinn and 
Great Britain. Office for National Statistics. 2001). Since 2001, DCGH 
has had the clear remit to treat all cases of ovarian cancer within an 
830 000 strong catchment (as cancer centre for the Derby/Burton 
cancer network) but prior to this reorganisation, following the Calman-
Hine report in 1995, the provision of cancer services was more 
fragmented (Calman and Hine 1995). It had been normal for most 
patients with ovarian cancer to be treated at their nearest hospital, 
sometimes by non-specialists. This may explain why a relatively small 
proportion of the county’s workload presented to DCGH during the 
recruitment period - which would not be the case today. From 1982-
1997 the department served an immediate population at risk of ovarian 
cancer of approximately 117 000 (Derby City) and it would be expected 
that approximately 277- 333 cases would have presented from this 
catchment to the lone gynaecologist with an interest in cancer who 
performed the majority of the operations for ovarian cancer at that time 
(Great Britain. Office of Population Censuses and Surveys. 1991; 
Kehoe, Powell et al. 1994; Botha 2007). When taking these factors into 
account, a caseload of 441 seems an appropriate one for a single 
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 Table 3.1 The distribution among the histological subtypes and grades of the 
cases within the final series 
 
Histological type Number % of series (n=339) 
 
Epithelial 334 99 
Serous (total) 178 53 
Serous (papillary) 21 6 
Endometrioid 42 12 
Mucinous 35 10 
Undifferentiated 54 16 
Clear cell 25 7 
 
Non-epithelial 5 1 
Yolk Sac 1  
Teratoma 1 
Granulosa 1 
Mixed Müllerian 2 
 
Borderline cancers* 30 / 369 8 
 
Grade 
 
Number % of series (n=339) 
Ungradable § 2 1 
G1 39 11 
G2 73 22 
G3 (High grade) 225 66 
* 30 borderline cases were excluded during the creation of the 339 sized series 
§ 1 yolk sac tumour and 1 clear cell tumour were considered ungradable 
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handed gynaecological cancer service serving a mainly local population 
but receiving some county wide referrals in a sporadic fashion  (Quinn 
and Great Britain. Office for National Statistics. 2001; Calvert 2007). 
With 424 of the 441 cases originating from DCGH on the TCR 
(notification via hospital coding department, pathology department or 
death certificate) represented on the prospectively accrued database, 
the ascertainment rate had been particularly good considering that it 
had not been formally resourced. There is the possibility that some 
cases had presented and had not been recorded by the database or 
TCR. However as TCR has a good record concerning the 
ascertainment of cases (as measured indirectly by mortality : incidence 
ratios) and produces data which consistently meets stringent quality 
checks, the systematic non-registration of significant numbers of cases 
presenting to DCGH is unlikely (Parkin, World Health Organization. et 
al. 1997; Botha 2007). 
Eurocare 4 highlighted the fact that compared to many European 
countries, U.K cancer registries have less information supplied to them 
from pathology departments, with an 83% microscopic verification rate 
of cancer cases (compared to 98% in Sweden) and a high proportion of 
cases being registered via the death of the patient (Death Certificate 
Only (DCO) cases = 6.7% :UK Association of Cancer Registries target 
= 2%) (Berrino, De Angelis et al. 2007). A recent peer review of TCR 
found that the DCO rate of 4.3% in 2002 fell to 3.2% in 2007 following 
the introduction of “live feeds” of electronic pathology data from 
individual laboratories implying that this problem has historically been 
problematic locally (Botha 2007). It was found during this study that 
difficulties in tracing pathology reports were exacerbated by the lack of 
a system in the past linking a patient’s pathology number to their unique 
identifying data and this may explain some of the problems previously 
experienced by TCR. Though this situation made anonymising the 
cases simpler, 21 cases could not be included due having no pathology 
number with which to locate archived tissue. 
As others have observed, it was found that constructing the TMA itself 
took relatively little time compared with the collection and review of the 
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material  during which a significant number of cases became unsuitable 
for inclusion (Simon, Mirlacher et al. 2004). This study concerns the 
behaviour of frankly malignant forms of ovarian cancer and cases found 
to be borderline were excluded. Because the pathological review 
lagged behind the assembly of the first TMA block it was found that 19 
borderline cases had already been arrayed and they were excluded 
from the scoring grid instead. The potential remains to study the 
expression of markers in these 6% of cases should a suitable 
hypothesis develop. Twenty of the cases on the prospective database 
had little or no tissue available for inclusion in the TMA. This was either 
because the patient had been treated privately or because surgery had 
been abandoned for technical reasons with only a small biopsy being 
obtained for diagnostic purposes. During the pathological review, full 
immunohistochemical panels were occasionally generated to aid 
accurate diagnosis in difficult cases. Of the 380 cases reviewed, 9 were 
found to have been misdiagnosed as having ovarian cancer. Though 
the numbers involved were small, each patient may have come to harm 
through the inappropriate treatment of their true condition.  The number 
of pathological misdiagnoses in the department is likely to have fallen to 
even lower levels with the routine use of complex marker panels in 
difficult cases, the sub-specialisation of pathologists and the review of 
cases by the Multi Disciplinary Team (MDT) but the importance of 
anonymisation in this studies design is emphasised by this finding 
(Hernandez, Bhagavan et al. 1984; Veenhuizen, De Wit et al. 1997). 
From a logistical point of view it would have simplest to have performed 
each step in the process for all cases before moving on to the next step 
but time constraints meant that multiple tasks had to be carried out 
concurrently for different cases. This used time efficiently and identified 
systematic problems at an early stage but the logistics were complex 
and errors did occur, the most obvious being the assignment of multiple 
study numbers to individual cases and the duplicate arraying of two 
cases. This way of working also meant that the tumours were arrayed in 
batches, leading to relatively few being located in each block. If all 339 
tumours had been available together at the same time, two blocks 
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would have been enough to contain them. By making sure that when 
errors occurred they did not go unnoticed or uncorrected, the TMA was 
ultimately found to be easy to navigate and score by individuals 
unfamiliar with the complexities of its construction. 
Of the 339 cases of ovarian cancer included, 98% of were found to be 
epithelial which is above the 90% normally seen in unselected series 
(Benedet 2000). A lower representation of non-epithelial cases 
probably reflects onward referral of this disparate group of rare cancers 
to the supra-regional centre, with only the occasional case remaining 
under the long term care of the department at DCGH.  Though the 
series may have been partially selected in this respect, the breakdown 
of histological type within the series was otherwise typical. In line with 
the published frequencies (in brackets); 52% of the cases were of the 
serous subtype (40-50%), 12% were endometrioid (12-18%), 10% were 
mucinous (9-15%), 7% were clear cell (4-6%), and 16% were 
undifferentiated (5-25%) (Scully 1977; Heintz, Odicino et al. 2001; Quirk 
and Natarajan 2005). Borderlines made up 8% of all cases reviewed 
(up to 15%) (FIGO 1987). This series was more likely to have cases 
with higher grade disease (66% G3) than generally reported (47% G3), 
(Heintz, Odicino et al. 2001). This may be a true difference but is more 
likely to reflect the well documented difficulty of objectively reproducing 
the commonly used grading systems for all histological types between 
observers (Hernandez, Bhagavan et al. 1984).  There is variation in 
how ovarian cancers are graded by individual pathologists with some 
workers altering their grading system depending on the histological type 
(Silva and Gershenson 1998), others grading all subtypes with standard 
grading systems such as the WHO (Serov, Scully et al. 1973), 
Gynaecology Oncology Group (GOG) (Benda and Zaino 1994) or FIGO 
(Benedet 2000) methods, and others still attempting to develop 
reproducible, universal systems of their own (Bichel and Jakobsen 
1989; Shimizu, Kamoi et al. 1998). For that reason conclusions 
regarding the number of highest grade cancers within our series are 
difficult to make. 
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 3.2. Evaluation of the TMA 
 
 
3.2.1. Pilot evaluation – one copy four antigens
When the first copy of the TMA had been constructed, a pilot evaluation 
of expression data generation was performed. The aim was to see if 
raw expression data for a number of markers could be acquired and 
compared to that in the literature, in order to reveal any major errors in 
the TMAs construction. As there was no useable database yet 
available, markers were selected that had no major known associations 
with clinicopathological factors and for which expression data from a 
number of sources was readily available. Though CK7, CK20, CEA and 
CA125 may not represent an ideal diagnostic ovarian panel, they met 
these criteria. 
 
3.2.1.1. Method 
Unlike the remainder of the IHC work, the four slides of the first copy of 
the TMA used in the pilot were not stained by the author but added to a 
partly automated run of routine work performed in the pathology 
department of DCGH. The materials and methods therefore differed 
from the general IHC protocol described in 2.2 and these differences 
and the method for the pilot study are recorded in detail in 2.2.10 and 
Table 2.2. 
 
3.2.1.2. Results 
Positive CK7 staining was seen mainly within the cytoplasm of the cells 
(Figure 3.8a-c). Scoring in binary fashion, approximately 64% of 
tumours were deemed positive for CK7 (Table 3.2). Loss of tissue cores 
effectively excluded 8% of cases from analysis. 
Positive CK20 staining was seen mainly within the cytoplasm of the 
cells (Figure 3.9a-c). Scoring in binary fashion, approximately 5% of 
tumours were deemed positive for CK20 (Table 3.3). 8% of cases had 
too little tissue for analysis. 
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Figure 3.8 Examples of the expression patterns seen when staining for CK7 
 
Figure 3.8a Whole sections of normal breast tissue (positive control) staining 
strongly for CK7 
Section below seen at x 100 magnification staining cytoplasmically 
with no background staining seen. 
 
 
 
Figure 3.8b 
 
An example at x100 magnification of a TMA core staining very 
positively for CK7 
As the staining was homogenous, the cores were scored by % cells to 
the nearest 5%, excluding normal tissue in the evaluation. A cut-off of 
5% represented positivity. 
 
 
 
Figure 3.8c 
 
An example of a TMA core negative for CK 7 expression see at 
x100 magnification 
 

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Table 3.2 
CK7 
 
Histological type  
 n=313 
 Overall 
Number of 
cases 
Number of analysed 
cases 
 
CK7 
Positive 
% (n) 
Cases expected  
CK7 Positive 
% 
 
Serous  178 168 71 (119) 100 
[1, 2] 
 
 
Mucinous 35 28 39 (11) 80-100 
[1, 2] 
 
 
Total 339 313 64 (199) 94-100 
[1, 3-7] 
 
 
 
 
 
 
 
 
 
 
 
The number of cases 
staining positive for CK7 
through staining a single 
copy of the TMA at DCGH 
using an automated staining 
system.  
The scoring system was 
binary. The % number of 
cases expected to stain 
positive, as discerned from the 
literature, is inset for 
comparison. 
 
1. Cathro, H.P. and M.H. Stoler, Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol, 2002. 117(6): p. 944-51. 
2. Wauters, C.C., et al., Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol, 1995. 26(8): p. 852-5. 
3. Nishizuka, S., et al., Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer 
Res, 2003. 63(17): p. 5243-50. 
4. Lagendijk, J.H., et al., Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian 
carcinomas as primary sites. Hum Pathol, 1998. 29(5): p. 491-7. 
5. Heatley, M.K., Immunohistochemical biomarkers of value in distinguishing primary ovarian carcinoma from gastric carcinoma: a systematic review with statistical 
meta-analysis. Histopathology, 2008. 52(3): p. 267-76. 
6. Chu, P., E. Wu, and L.M. Weiss, Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol, 2000. 13(9): p. 962-72. 
7. Berezowski, K., J.F. Stastny, and M.J. Kornstein, Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol, 1996. 9(4): p. 
426-9. 
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Figure 3.9 Examples of the expression patterns seen when staining for  
CK20 
 
Figure 3.9a Whole sections of bowel tissue (positive control) staining 
strongly for CK20 
Cytoplasmic staining with no background staining is observed at x100 
magnification. 
 
 
 
Figure 3.9b 
 
An example at x100 magnification of a TMA core staining very 
positively for CK20  
The scoring system was binary: positive if any tumour cells stained 
positive and negative if no cells stained positive. 
 
   
 
Figure 3.9c 
 
An example of a TMA core negative for CK20 expression seen at 
x100 magnification 
 



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Table 3.3 
CK20  
 
Histological type  
 n=313 
 Overall 
Number of 
cases 
Number of analysed 
cases 
 
CK20  
Positive 
% (n) 
Cases expected  
CK20 Positive 
% 
 
Serous  178 169  (1) 0 
[1-3] 
 
Mucinous 35 27 33 (9) 0-27 
[1-4] 
 
 
Total 339 313 5 (17) 2-36 
[1, 2, 4-8] 
 
 
 
 
 
 
 
 
 
The number of cases 
staining positive for CK20 
through staining a single 
copy of the TMA at DCGH 
using an automated staining 
system 
The scoring system was 
binary.The % number of cases 
expected to stain positive, as 
discerned from the literature, 
is inset for comparison. 
 
1. Cathro, H.P. and M.H. Stoler, Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol, 2002. 117(6): p. 944-51. 
2. Berezowski, K., J.F. Stastny, and M.J. Kornstein, Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol, 1996. 9(4): p. 
426-9. 
3. Wauters, C.C., et al., Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol, 1995. 26(8): p. 852-5. 
4. Moll, R., et al., Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol, 1992. 140(2): p. 427-47. 
5. Chu, P., E. Wu, and L.M. Weiss, Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol, 2000. 13(9): p. 962-72. 
6. Nishizuka, S., et al., Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer 
Res, 2003. 63(17): p. 5243-50. 
7. Lagendijk, J.H., et al., Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian 
carcinomas as primary sites. Hum Pathol, 1998. 29(5): p. 491-7. 
8. Heatley, M.K., Immunohistochemical biomarkers of value in distinguishing primary ovarian carcinoma from gastric carcinoma: a systematic review with statistical 
meta-analysis. Histopathology, 2008. 52(3): p. 267-76. 
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Positive CEA staining was seen in the membrane and cytoplasm of 
those tumour cells which stained (Figure 3.10a-c). 36% of tumours 
stained positively for CEA when a binary scoring system was used 
(Table 3.4). Loss of tissue cores occurred in 8% of cases. 
Positive CA125 staining was seen in the cell membrane and cytoplasm 
of strongly staining tumour cells (Figure 3.11a-c). 57% of tumours 
stained positively for CA125 when employing a binary scoring system 
(Table 3.5) 9% of cases had too little tissue to analyse. 
3.2.1.3. Discussion 
Overall the expression of CEA, CA125 and CK20 reflected that which 
would have been predicted by a body of published literature largely 
based on whole section staining. The results of the pilot staining for 
CK7 were however dissonant, with a low rate of expression (64%) for a 
marker which is usually more universally expressed (80-100%) 
(Wauters, Smedts et al. 1995; Cathro and Stoler 2002; Nishizuka, Chen 
et al. 2003; Heatley 2008). There were several possible reasons for 
this; a problem with the methodology of staining (wrong antibody, poor 
antigen retrieval etc), a genuine result and a new finding or a problem 
with tissue heterogeneity within the TMA.  
The most concerning situation would be if tissue heterogeneity in the 
TMA had resulted in a very high rate of false negatives for this 
ubiquitously expressed marker, though on reviewing the literature this 
would seem unlikely. When TMAs were introduced, initially workers 
were concerned that analysing an extremely small percentage of the 
tumours (approximately 0.3%) might mean that false negatives were 
introduced if the expression of a marker was unevenly distributed 
throughout the tumour – tissue heterogeneity (Torhorst, Bucher et al. 
2001). Work by Goethals and co-workers seemed to support this 
concern. This group studied 5 colorectal cancers and took 50 random 
TMA cores from each, staining them with a heterogeneously staining 
marker -carbonic anhydrase IX. On analysing  the standard errors of 
the expression data they concluded that significant heterogeneity 
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Figure 3.10 Examples of the expression patterns seen when staining for 
CEA 
 
Figure 3.10a Whole sections of bowel tumours (positive control) 
Seen to stain cell membrane and cytoplasm strongly with no 
background staining seen at x 100 magnification. 
 
 
 
Figure 3.10b An example at x200 magnification of a TMA core staining 
positively for CEA   
As the staining was homogenous, the cores were scored by % cells 
to the nearest 5%, excluding normal tissue in the evaluation. A cut-
off of 5% represented positivity.  
 
 
 
Figure 3.10c 
 
 
An example of a TMA core negative for CEA expression seen at 
x100 magnification 
  
136
Chapter 3: Construction and Evaluation of the Tissue Microarray
Table 3.4 CEA 
 
Histological type  
 n=312 
 Overall 
Number of 
cases 
Number of 
analysed cases 
 
CEA  
positive 
% (n) 
Cases 
expected  CEA 
positive 
% 
 
Serous  178 166 26 (43) 31-100 
[1-3] 
 
Mucinous 35 30 43 (13) 13-67 
[1, 3-5] 
Total 339 312 36 (113) 21-42 
[1, 3, 4, 6-10] 
 
 
 
 
 
 
 
 
 
1. Multhaupt, H.A., C.P. Arenas-Elliott, and M.J. Warhol, Comparison of glycoprotein expression between ovarian and colon adenocarcinomas. Arch Pathol Lab Med, 1999. 123(10): p. 909-
16. 
2. Kabawat, S.E., et al., Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear 
cell types. Am J Clin Pathol, 1983. 79(1): p. 98-104. 
3. Macdonald, F., et al., Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours. J Clin Pathol, 1988. 41(3): p. 260-4. 
4. Lagendijk, J.H., et al., Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary 
sites. Hum Pathol, 1998. 29(5): p. 491-7. 
5. Keen, C.E., et al., CA125 and thyroglobulin staining in papillary carcinomas of thyroid and ovarian origin is not completely specific for site of origin. Histopathology, 1999. 34(2): p. 113-7. 
6. Heatley, M.K., Immunohistochemical biomarkers of value in distinguishing primary ovarian carcinoma from gastric carcinoma: a systematic review with statistical meta-analysis. 
Histopathology, 2008. 52(3): p. 267-76. 
7. Berezowski, K., J.F. Stastny, and M.J. Kornstein, Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol, 1996. 9(4): p. 426-9. 
8. Breitenecker, G., et al., Comparison between tissue and serum content of CA 125, CA 19-9, and carcinoembryonic antigen in ovarian tumors. Int J Gynecol Pathol, 1989. 8(2): p. 97-102. 
9. Torenbeek, R., et al., Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology, 1998. 32(1): 
p. 20-7. 
10. Lagendijk, J.H., et al., Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. 
Comparison between a statistical and an intuitive approach. J Clin Pathol, 1999. 52(4): p. 283-90. 
 
The number of cases staining 
positive for CEA through 
staining a single copy of the 
TMA at DCGH using an 
automated staining system 
The scoring system was binary. 
The % number of cases 
expected to stain positive, as 
discerned from the literature, is 
inset for comparison. 
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Figure 3.11 Examples of the expression patterns seen when staining for  
CA125 
 
Figure 3.11a Whole sections of ovarian cancer tissue (positive control) 
staining appropriately 
Cell membrane staining was seen with no background staining 
observed at x100 magnification. 
 
 
 
Figure 3.11b 
 
An example at x200 magnification of a TMA core staining 
positively for CA125 
As the staining was homogenous, the cores were scored by % cells 
to the nearest 5%, excluding normal tissue in the evaluation. A cut-off 
of 5% represented positivity. 
 
 
 
Figure 3.11c 
 
An example of a TMA core negative for CA125 expression seen 
at x100 magnification 
 
 

138
Chapter 3: Construction and Evaluation of the Tissue Microarray
Table 3.5 
CA125 
 
Histological type  
 n=307 
 Overall 
Number of 
cases 
Number of analysed 
cases 
 
CA125  
Positive 
% (n) 
Cases expected  
CA125 Positive  
% 
 
Serous  178 162 76 (123) 68-93 
[1-6] 
Mucinous 35 28 14 (4) 25-43 
[2, 3, 6] 
Total 339 307 57 (174) 54-78 
[1-3, 6-10] 
 
 
 
 
 
 
 
 
The number of cases staining 
positive for CA125 through 
staining a single copy of the 
TMA at DCGH using an 
automated staining system 
The scoring system was binary. 
The % number of cases 
expected to stain positive, as 
discerned from the literature, is 
inset for comparison. 
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existed, which could only be reduced to acceptable limits if five 
separate cores were used in assessing cases (Goethals, Perneel et al. 
2006). Conversely, most other workers have found high correlations 
between whole section data (considered the gold standard) and that 
produced by TMAs when tissue cores are purposefully selected from 
non-random, representative tumour sites: most usually there has been 
a 91% concordance with single core evaluation, 95-96% on evaluating 
two cores, 98% on evaluating three cores and diminishing returns 
thereafter (Camp, Charette et al. 2000; Hoos and Cordon-Cardo 2001; 
Rosen, Huang et al. 2004). It has always been realised that TMAs could 
have a theoretically higher false negative rate than full sections which 
might have great clinical impact if an attempt was made to use them 
diagnostically but false negatives aside, it was also felt that the data 
obtained from staining of hundreds of tumours would give a more 
accurate assessment of the true expression of a marker within the 
general population of cancers than the very accurate assessment of 
just a few cases by whole section. TMAs have been shown to generate 
accurate expression data across populations due to this power, while 
they may not have the resolution to provide accurate information about 
individual cases (Kononen, Bubendorf et al. 1998; Mucci, Akdas et al. 
2000; Rubin, Dunn et al. 2002). Concerns about tissue heterogeneity in 
TMA work have therefore receded with increasing experience and the 
assessment of five cores per case as suggested by Goethals et al is 
uncommon. Some workers do however continue to examine three 
cores (Fernebro, Dictor et al. 2002; Rubin, Dunn et al. 2002; Rosen, 
Huang et al. 2004) though many argue for less cores to be used per 
case, as long as there are enough tumour cells present within each 
sample and enough cases within the series (Nocito, Bubendorf et al. 
2001; Hedvat, Hegde et al. 2002). It is interesting to note that the group 
who validated TMAs in ovarian cancer using triplicate cores moved to 
using two cores in their subsequent work (Rosen, Yang et al. 2006) and 
of the five most recent TMA publications (PubMed search “Tissue Micro 
Array” 24 April 2008),  three evaluated a single core, one examined two 
cores and a single study investigated triplicate cores (Prentice, Klausen 
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et al. 2007; Cohen, Prus et al. 2008; Harris, La Cerda et al. 2008; 
Preusser, Janzer et al. 2008; Yang, Hung et al. 2008).In addition, the 
use of larger tissue cores has been mathematically discredited (Nocito, 
Kononen et al. 2001).  
3.2.2. Full evaluation – four copies two antigens 
The results of the CK7 pilot staining were therefore unlikely to be due to 
tissue heterogeneity and more likely to be due to experimenter error 
(incorrect antibody, mixing up of slides etc) and/or methodological 
variances such as the use of a different manufacturer of primary 
antibody or the use of an automated system at DCGH to perform the 
amplification step. In order to investigate this further, four copies (not 
five as the fifth copy had been constructed in error and ethical approval 
for its use at that point had not been obtained) of the TMA were 
manually re-stained for CK7, along with CEA for comparison. 
Importantly this additionally allowed the effect of staining multiple 
copies of the array on overall case loss and accuracy of data to be 
assessed. 
 
3.2.2.1. Method 
As described in detail in 2.2 and table 2.2 
 
3.2.2.2. Results 
CK7 (Table 3.6) 
When evaluating a single copy of the TMA, 85-88% of cases were 
positive for CK7 when using a cut off of 5% to allocate cases to the 
positive group. Depending on the TMA studied, between 16 and 33% of 
cases could not be assessed due to tissue core loss. The pattern of 
distribution among the quartiles followed a general pattern - 
approximately 1/5 of the cases in the first quartile, 1/8 in the second 
quartile, 1/4 in the third quartile and 2/5 in the highest centile. The 
distribution of expression data when arranged in to quartiles varied 
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Table 3.6 A complete breakdown of the expression data for CK7 on staining 
four copies of the TMA 
Quartiles, % positive cases and the number of cores available to form 
average expression data are shown. The data were generated for each 
possible combination of the arrays (1-4) to observe the effects of staining 
more than a single copy on power, accuracy and reproducibility. 
 
 Quartile 
% cells CK Positive 
 Number of cores 
contributing to 
average 
0- 
25 
26-
50 
51-
75 
76- 
100 
> 5%  = 
Positive
N º 
Cases 
with 
data 
0 1 2 3 4 
Single 
core 
 
1 23 13 14 51 86 245 94 245 X X X 
2 24 11 10 56 85 228 111 228 X X X 
3 21 14 16 48 87 286 53 286 X X X 
4 21 20 13 45 88 271 68 271 X X X 
 
Two 
cores 
 
1+2 21 13 19 47 86 290 49 89 201 X X 
1+3 21 14 21 44 87 312 27 93 219 X X 
1+4 20 15 24 41 87 310 29 104 206 X X 
2+3 22 16 20 43 86 307 32 100 207 X X 
2+4 22 15 21 43 87 297 42 95 202 X X 
3+4 20 16 24 40 90 317 22 50 267 X X 
 
Three 
cores 
 
1+2+3 20 16 20 44 86 321 18 54 96 171 X 
1+2+4 19 17 20 44 88 319 20 60 93 166 X 
1+3+4 17 15 27 40 88 328 11 44 94 190 X 
2+3+4 21 15 24 40 88 320 19 38 99 183 X 
 
Four 
cores 
 
1+2+3+4 19 16 27 39 88 328 11 27 56 90 155 
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most between TMA copies within the middle two centiles but largely 
followed this same pattern.  
When evaluating two copies of the TMA and averaging the data, five of 
the possible six combinations resulted in 86-87% of the cases being 
categorised positive. A sixth combination (copy 3+4) classified a higher 
proportion, 90%, of cases positive. The majority of cases had an 
average derived from two tissue cores (60-79%). Data from a single 
core was available for many of the remaining cases (14-30%) while 
cases with no data available represented between 6-14% of the whole. 
The distribution of the expression data amongst the quartiles followed 
the same pattern irrespective of the combinations analysed. 
When evaluating three copies of the TMA and averaging the expression 
data, three of the four combinations resulted in 88% of the cases being 
categorised positive. The fourth combination classified 86% of tumours 
positive. Depending on combination 3-6% of cases could not be 
evaluated due to core loss. However 49-56% had all three cores 
available for averaging, 27-29% had two and 1-18% of cases were 
evaluated on the basis of a single core. The distribution of expression 
data among the quartiles, while still remaining within the general pattern 
was less uniform than when two cores had been evaluated. 
When evaluating all four copies of the TMA and averaging the 
expression data, 88% of the cases were classified positive. 3% of cases 
had no expression data available.  46% had all four cores available for 
averaging, 27% had three, 17% two and 8% of cases were evaluated 
on the basis of a single core. The distribution of expression data among 
the quartiles remained within the general pattern. 
CEA (Table 3.7) 
When evaluating a single copy of the TMA, three of the four copies 
classified 19% of the cases as positive for CEA on the basis of a 5% 
cut-off. The fourth copy classified 17% of cases positive.  Depending on 
which TMA was evaluated 10-19% of cases had insufficient material to 
be assessed following processing of the TMA. The distribution of 
expression data amongst the quartiles followed a general pattern of 8-9 
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Table 3.7 A complete breakdown of the expression data for CEA on staining four 
copies of the TMA 
Quartiles, % positive cases and the number of cores available to form 
average expression data are shown. The data were generated for each 
possible combination of the arrays (1-4) to compare the effects of staining 
more than a single copy on power, accuracy and reproducibility. 
 
 Quartile 
% cells CEA Positive 
 Number of cores 
contributing to average 
0- 
25 
26-
50 
51-
75 
76- 
100 
> 5%  = 
Positive
N º 
Cases 
with 
data 
0 1 2 3 4 
Single 
Array 
 
1 87 5 2 7 19 274 65 274 X X X 
2 89 2 2 8 17 255 84 255 X X X 
3 88 3 2 8 19 304 35 304 X X X 
4 88 2 2 9 19 289 50 289 X X X 
 
Two 
Arrays 
 
1+2 88 4 2 7 21 311 28 93 218 X X 
1+3 87 5 2 6 21 321 18 64 257 X X 
1+4 87 4 2 7 20 322 17 81 241 X X 
2+3 87 4 2 7 20 321 18 83 238 X X 
2+4 88 3 2 7 20 306 33 68 238 X X 
3+4 87 4 3 6 20 324 15 55 269 X X 
 
Three 
Arrays 
 
1+2+3 87 4 3 6 21 327 12 28 92 207 X 
1+2+4 87 3 3 7 21 326 13 39 82 205 X 
1+3+4 86 5 3 6 22 329 10 20 80 229 X 
2+3+4 87 4 3 6 22 326 13 27 76 223 X 
 
Four 
Arrays 
 
1+2+3+4 87 4 4 5 22 331 8 16 33 88 194 
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/ 10 of cases within the first quartile, up to 1/10 within the last quartile - 
the few remaining of cases being distributed amongst to the middle 
quartiles with proportionately more in the second quartile. 
When evaluating two copies of the TMA the percentage of tumours 
staining positive was distributed from 20-21% and altering the precise 
combination of data analysed had little effect on this. Insufficient 
material was available for analysis in 4-9% of cases. Similarly the 
distribution of the expression data amongst the quartiles followed the 
general pattern previously described. The majority of cases (64-79%) 
had data from two cores available for averaging with evaluation on the 
basis of a single core necessary in 16-27% of cases, depending on the 
combination of TMAs assessed. 
When evaluating three copies of the TMA, 21-22% of tumours were 
determined positive for CEA on the basis of their averaged expression 
data. 3-4% of cases could not be assessed due to a lack of a single 
core to evaluate. The majority of cases (61-68%) had all three cores 
available for averaging, 22-27% had two and 5-11% of tumours were 
evaluated on the basis of a single core. The distribution of expression 
data between the quartiles followed the general pattern described 
previously. 
When four copies of the TMA were evaluated, 22% of the tumours were 
found to be positive for CEA on the basis of their averaged expression 
data with only 2.3% of cases having no tissue available for evaluation. 
The majority of cases (57%) had all four cores available when 
calculating averaged data, 26% had three, 10% had two and 5% were 
assessed on the basis of a single core.
3.2.2.3. Discussion 
The cores were scored by percentage to allow averaging of data. 
Irrespective of how many or which copies of the TMA were analysed, 
the expression data for CK7 was the same and agreed with the 
published literature, normally being positive in around 88% of cases 
(range 85-90%). A similar result was seen with CEA, with the 
145
Chapter 3: Construction and Evaluation of the Tissue Microarray
expression data varying little between combinations of copies of the 
TMA and agreeing although with the published literature.  It is therefore 
a possibility that the low expression of CK7 determined in the pilot study 
was due to methodological errors, supporting the use of manual 
staining by a single investigator in the subsequent work. 
In line with other studies, it was found that tissue was frequently lost 
during the processing of the TMA slides and that occasionally, 
unusable or insufficient tissue had been transferred. In the literature this 
occurs in 2-25% of cases and in the pilot study it occurred in 8% 
(Mucci, Akdas et al. 2000; Hoos and Cordon-Cardo 2001; Rosen, Yang 
et al. 2006). By staining more than one copy of the TMA it was 
discovered that over 300 cases consistently had tissue available for 
analysis, the optimal number determined by previous power 
calculations. Therefore it was concluded that staining two copies of the 
TMA in further experiments would strike a good balance between 
limiting tissue wastage, maximising data quality and maintaining the 
power of the study.  It was also discovered that tissue loss was 
exacerbated if EDTA was used as the antigen retrieval solution and so 
its use was avoided where possible in subsequent work (Figure 3.12).   
 
During this chapter it has been shown that a typical series of 339 
surgically treated primary ovarian cancers was assembled into a TMA. 
It has been shown that the staining of two copies could accurately 
reproduce appropriate raw expression data for a series of well studied 
markers whilst also ensuring that sufficient cases were included in the 
study. The next chapter will describe the results of the evaluation and 
transformation of the prospective database into a form which could be 
used in conjunction with the TMA to study marker associations with 
clinicopathological characteristics.  
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Figure 3.12 Loss of tissue cores 
Loss of tissue cores occurred with greater frequency at the beginning 
and, as shown below, near the end of the array block. The type of 
antigen retrieval solution also affected tissue loss. The slides bellow 
show consecutive TMA sections which underwent citrate and EDTA 
antigen retrieval respectively.  
 
 
 
 
 
Tissue loss worse            
towards the base              
of the TMA block  
 
  
Tissue loss                       
compounded by                
EDTA  based                    
antigen retrieval 
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Chapter 4: Development and Evaluation of the Database  
 
This chapter covers the management and testing of the electronic data 
available for the cases in the study cohort concerning events during a 
23 year period that extended from 1st January 1982 up to the study 
database being frozen on 31st November 2005. The aim of this section 
is to substantiate the steps involved in transforming the raw clinical 
database into its leaner form - the analysis database - which could be 
used to analyse expression data in a valid way. The administration of 
the database, evidence for the datas consistency and the 
clinicopathological characteristics of the series are described. 
4.1. Database management 
The database was originally populated using Case Record Forms 
(CRFs) in 1992 with data being retrospectively extracted from the 
clinical record (Figure 4.1). The stimulus to collect the data in this way 
was a need to perform a departmental audit and the rapid expansion in 
the availability of sophisticated data management programs to the 
average user that was occurring (Crockett, Scott et al. 1992). 
Prospective data were added from 1992 onwards (new cases and 
follow up data) with the currently preferred electronic format being 
Microsoft Access 2003.  A copy of this database became the original 
study database which was kept at DCGH. This underwent multiple 
transformations through multiple formats before single validated SPPS 
vs.11.0 file containing anonymous clinicopathological data was 
produced that could be used to analyse expression data and then 
compare it to published work; the analysis database. Multiple copies 
and back-ups were generated during this process and when the 
analysis database had been validated they were collected to together 
onto two identical CD-ROMs (one held securely at each site) with the 
original files being overwritten and deleted from their primary sources. 
The timelines involved in managing the data are illustrated in figure 4.2.  
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Figure 4.1 The Case Record Form (CRF) 
The form below was used to extract data from the clinical record and to 
transcribe it onto the electronic database in 1992. These data are 
prospectively maintained and new cases added. 
      
Data  Values 
First name  
 
Surname  
 
Hospital 
number 
 
Year of 
diagnosis 
(1982-1997) 
Date of 
surgery 
(1st January 1982 -  31st December 1997) 
Age at 
diagnosis 
> 0 
 
Consultant Gynae-oncologist 
 
Gynaecologist Other Surgeon Missing 
Pre-op 
CA125 
                Units / ml Missing 
FIGO 
Stage 
Ia-Ib-Ic   IIa-IIb-IIc IIIa-IIIb-IIIc  IV Missing 
Residual 
disease 
None  <2cm > 2cm Missing 
Grade Undifferentiated 
 
Poor Moderate Well Missing 
Histological 
type 
Serous  Mucinous Endometrioid Other Missing 
Treatment Nothing 
 
Platinum Carboplatin Other Missing 
Date of 
last follow 
up 
(1st January 1982 – 31st November 2005) Missing 
Date of 
death  
(1st January 1982 – 31st November 2005) Missing 

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Figure 4.2 Timeline illustrating the processes involved in producing an anonymised and unlinked database of clinicopathological parameters 
 
 1 January 1982 Present day 
  
 Recruitment 31 December 1997 Completion of follow up  
 Initial cohort 1992  
   
DCGH Case Record Forms (CRFs) are used to transcribe patient data onto an electronic database which is kept on the departmental computer. All cases presenting to DCGH 
from 1st January 1982 onwards are included with 290 individual case records of confirmed ovarian cancer being transcribed
 
    
 
 
1992 Continual accrual of cases  
 
 
 
New Cases of ovarian cancer are added to the database as they present. The database is continuously prospectively maintained with respect to survival and follow up data 
    
  April 2004  
 The database is transferred to the trust server and a copy is made for the study. Study numbers are allocated to 424 individual cases. The 
database is audited. The pathology fields are populated. The array coordinate fields are populated. The missing data fields are populated. 
The patient identifying data is removed 
 
    
  31st November 2005  
UoN The patient identifying data is removed. The database is exported to the department at UoN. The database attributes are transformed. Data quality 
checks are performed. Validation expression data are analysed. The study number field is removed and the UoN database unlinked. The survival 
data is censored on this date. Physical back-up master copies are made for each site. All other database versions are permanently erased. The 
database is transferred to a single secured computer. 
 
    
  June 2006  
DCGH A back-up copy of the final transformed and validated database is transferred back to DCGH and held securely. The study number is deleted 
from the study database on the trust server and the DCGH database is permanently unlinked. 358 case records of confirmed ovarian cancer 
are held (including 19 borderlines cases). The original database continues to be updated. 
 
 
UoN 
 
 
Novel marker expression data are added to anonymised and unlinked database held at UoN 
1
5
0
The consistency of the data was checked in a number of ways.  Within 
the data columns (attributes) containing continuous values; the range, 
mean, median and outlying values were checked. Data were frequently 
categorised or re-categorised en route to the production of a final 
analysis database and the distribution of data within final categorical 
datasets was compared to that documented in published series. The 
completeness of data was assessed by observing the number of cells 
(fields) with missing values. The validity of the clinical data was 
checked by assessing its ability to reproduce known clinicopathological 
and survival associations. The correctness of data was assessed during 
formal audits where clean data obtained contemporaneously from the 
medical record were compared to that in the database.  A continuous 
process of testing the logic of each case entry into the database was 
manually undertaken.  
4.2. Database attributes 
 
Each individual attribute was assessed for its consistency and this 
occurred simultaneously for multiple variables, as demonstrating the 
inter-relationships between the clinicopathological data was essential in 
validating it.  For this reason the results reported bellow occasionally 
references associations with data the consistency of which is 
documented later in the chapter. A complete record of the data 
attributes held on the analysis database can be found in appendix 3. 
4.2.1. Patient characteristics
4.2.1.1. Results 
Age 
The age at diagnosis data were recorded on the original clinical 
database, included unchanged on the analysis database and were in 
the range 24  90 years with one missing field present. The data were 
plotted on a scatterplot (Figure 4.3). Outlying results were checked and 
found to be correct with the logic of these entries assessed and found 
to be in order. The median age of presentation was 62.0 years (mean = 
61.9). The distribution of data amongst the age categories used by 
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Figure 4.3 A scatterplot illustrating the distribution of age data within the 
analysis database. 
The data is separated out by year of presentation in order to 
distinguish outliers more clearly. The data highlighted were assessed 
for correctness and the logic of their case entries and were found to 
be consistent. 
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FIGO (Figure 4.4a) (Table 4.1a) (Heintz, Odicino et al. 2001), the ONS 
(Figure 4.4b) (Table 4.1b) (Quinn and Great Britain. Office for National 
Statistics. 2001)  and the Surveillance, Epidemiology and End Results 
programme (SEER) (Table 4.1c) (Quirk and Natarajan 2005) was 
similar when comparing the analysis database to these large 
epidemiological studies. On testing the data in SEER categories, 
increasing age was seen to be associated with reduced survival though 
in this form age was not an independent prognostic factor (Figure 4.5) 
(Table 4.2). However assessing the data in its continuous form, age did 
exert independent prognostic power (Table 4.3). 
4.2.1.2. Discussion 
The age related data on the database were similar to each of the series 
it was compared with and most similar to the U.K. data (Quinn and 
Great Britain. Office for National Statistics. 2001) (Holschneider and 
Berek 2000; Heintz, Odicino et al. 2001). This series was slightly older 
than that seen in the more international studies and this may reflect the 
effect of race, differing birth cohort characteristics and a later stage at 
presentation in the U.K.(Berrino, De Angelis et al. 2007). The data were 
transformed into SEER categories in order to investigate if age was 
associated with survival in a univariate analysis as this categorisation 
has been used to describe the age distribution in the largest number of 
ovarian cancer patients and separates the data into a small number of 
clinically sensible categories. In this form increasing age was seen to 
be a non-independent prognostic factor which is consistent with other 
groups findings (DiSilvestro, Peipert et al. 1997; Heintz, Odicino et al. 
2001) though on using the data in its continuous form age did have 
independent prognostic power (Figure 4.3). This in turn agrees with 
other workers findings and further supports the validity of the dataset 
(Thigpen, Brady et al. 1993; Crijns, Boezen et al. 2003). As the HR was 
small and as a comparable univariate analysis of the continuous data 
was not technically possible, the result of this multivariate analysis 
should be treated with caution but the result was intuitively correct. 
Therefore the continuous data were included in the multivariate model 
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Figure 4.4a Bar graph showing the distribution of cases within FIGO age 
categories 
Data re-categorised and compared to the evidence provided to FIGO: 
a similar distribution is observed (Heintz, Odicino et al. 2001). 
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Figure 4.4b Bar graph showing the distribution of cases within ONS 
categories 
Data re-categorised and compared to the ONS data for 1997: similar 
trends are seen (Quinn and Great Britain. Office for National 
Statistics. 2001). 
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Table 4.1a The distribution of age data on the analysis database when re-
categorised to allow comparison with the evidence supplied to 
FIGO by Heinz and co-workers (Heintz, Odicino et al. 2001) 
 
 
 
 
Age 
categories 
 
 
Number of 
cases in the 
evidence 
provided to 
FIGO 
 
Distribution 
by % in each 
category 
Number of 
cases on the 
analysis 
database 
Distribution by % 
in each category 
15-29 127 4 1 
30-39 270 8 8 2
40-49 731 21 44 13
50-59 896 26 83 25
60-69 823 24 103 31
70-79 453 13 80 24
80 109 3 19 6
Totals 3409 338 
 
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Table 4.1b The distribution of the age data amongst the cases on the 
analysis database when re-categorised to allow comparison 
with the ONS data in Cancer Trends 1997 (Quinn and Great 
Britain. Office for National Statistics. 2001) 
 
Age 
categories 
Number of 
cases in the 
UK - 1997 
Distribution 
by % in 
each 
category 
Number of 
cases on 
the 
analysis 
database 
Distribution by 
% in each 
category 
<1 0 0 0 0 
1-4 0 0 0 0 
5-9 10 0 0 
10-14 10 0 0 
15-19 10 0 0 
20-24 30 1 1 
25-29 70 1 0 0 
30-34 90 2 1 
35-39 130 2 7 2 
40-44 190 3 14 4 
45-49 400 7 28 8 
50-54 530 9 34 10 
55-59 630 10 57 17 
60-64 680 11 63 19 
65-69 800 13 38 11 
70-74 860 14 53 16 
75-79 750 12 25 7 
80-84 560 9 12 4 
85 390 6 5 2 
Total 6140 338 
 
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Table 4.1c The distribution of age data on the analysis database when 
re-categorised to allow comparison to the data recorded by 
the Surveillance, Epidemiology and End Results (SEER) 
programme of the National Cancer Institute in the U.S 
(epithelial ovarian cancer) 
 
 
 
Age 
categories 
Number of 
cases in 
SEER series 
Distribution 
by % in each 
category 
Number of 
cases on the 
analysis 
database 
 
Distribution 
by % in each 
category 
< 30 783 4 1 
 
30-59 9690 43 135 40
 
 60 11905 53 202 60
22 378 338 Totals 
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Figure 4.5 A Kaplan-Meier plot of age within the analysis database when 
reclassified into the categories used in reporting the SEER data 
A statistically significant worsening of survival with advancing age is 
shown. 
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Table 4.2 Cox’s multivariate analysis of independent prognostic factors 
and age data in SEER categories 
Within the analysis database age was not an independent prognostic 
factor when re-categorised this way 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
 
FIGO Stage   
1 0.001 
2 2.424 (1.426  4.121) <0.001 
3 4.621 (2.864  7.456) <0.001 
4 5.901 (3.394  10.261) <0.001 
 
Residual macroscopic 
disease 
2.238 (1.600  3.131) <0.001 
 
Patient received 
chemotherapy 
0.441 (0.315-0.617) <0.001 
 
Age at diagnosis  (years) 
SEER categories 
  
< 30 0.001 
30 -59 2.070 (0.286  14.992) 0.471 
 60 3.242 (0.449  23.417) 0.244 
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Table 4.3 Cox’s multivariate analysis of independently prognostic factors 
showing age data within the analysis database in its continuous 
form to be an independent prognostic factor 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
 
FIGO Stage   
1 0.001 

2 2.567  (1.503 - 4.383) <0.001 
3 4.719  (2.914 – 7.643) <0.001 
4 6.562 (3.737 – 11.523) <0.001 
 
Residual macroscopic 
disease 
2.131 (1.519 – 2.991) <0.001 
 
Patient received 
chemotherapy 
0.437(0.312 – 0.613) <0.001 
 
Age at diagnosis (years) 
 
Continuous data 
 
 
1.024 (1.014-1.035) 
 
 
<0.001 
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as it was important not to disregard a possible independent prognostic 
factor when assessing new markers. Overall, the data for age within the 
analysis database were complete, within an expected distribution, 
behaved in a valid manner and were appeared consistent.   
4.2.2. Pathology 
4.2.2.1. Results 
Histological type 
The data were generated by the contemporaneous histological review 
of the cases and there were no missing fields. The distribution of cases 
amongst the histological types is as detailed in 3.1.1 and Table 3.1. The 
logic of individual entries was checked by ensuring that non-epithelial 
types were presenting in appropriate age groups and that types usually 
associated poorly differentiated disease (clear cell and undifferentiated) 
were appropriately graded. Inconsistencies in logic were checked 
against the clinical record and with further pathological review on a 
number of occasions with no inaccuracies being detected. A univariate 
analysis showed that histological type predicted survival and ranked the 
subtypes; the order of increasing lethalness was clear cell, mucinous, 
endometrioid, serous and undifferentiated (Figure 4.6). In a multivariate 
analysis including known independent prognostic factors, the 
prognostic effect of histological type did not persist (Table 4.4). 
Histological grade  
The data were generated by the contemporaneous histological review 
of the cases and there were no missing fields though there were two 
instances where tumours were deemed ungradeable. The distribution 
of grades amongst the cases is as described in 3.1.1 and Table 3.1. 
When analysed in its three original categories (G1, G2, G3) and in a 
high/ low grouping (G3 = high grade; G1+G2 = low grade); more poorly 
differentiated disease was associated with poorer outcome in a 
statistically significant manner (Figure. 4.7 a, b). In a multivariate model 
including recognised independent prognostic factors, grade did not 
retain this prognostic power (Table 4.5 a, b).   
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Figure 4.6 Kaplan-Meier plot showing the differing survival characteristics 
between the histological types  
Clear cell, mucinous and endometrioid types have a relatively good 
prognosis whereas serous, undifferentiated and non-epithelial types 
have a poorer prognosis. Histological type predicts prognosis with 
statistical significance in a univariate analysis. 
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Table 4.4 Cox’s multivariate analysis of independent prognostic factors 
including histological type in order of worsening prognosis 
There is a loss of predictive power on multivariate analysis and it is 
not an independent prognostic factor. 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
Age (Continuous) 1.026 (1.015-1.037) <0.001 
FIGO Stage   
1  <0.001 
2 2.345 (1.316 -4.176) 0.004 
3 4.494 (2.657 – 7.599) <0.001 
4 6.472 (3.567 – 11.743) <0.001 
 
Residual macroscopic 
disease 
1.957 (1.380 – 2.776) <0.001 
 
Patient received 
chemotherapy 
0.445 (0.315 – 0.630) <0.001 
 
Histological type 
 
  
Clear cell  0.479 
Mucinous 0.957 (0.604 – 1.518) 0.853 
Endometrioid 1.022 (0.617 – 1.693) 0.934 
Serous 1.081 (0.773 – 1.512) 0.648 
Undifferentiated 0.600 (0.327 – 1.103) 0.100 
Other 1.696 (0.624 – 4.611) 0.301 
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Figure 4.7a Kaplan-Meier plot showing the difference in survival 
between the three grades of disease 
G1+G2 disease behave almost identically to each other whereas 
G3 predicts a worse survival in univariate analysis. 
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Figure 4.7b 
 
A Kaplan-Meier plot showing the difference in survival 
between high and low grade disease 
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 
Table 4.5a Cox’s multivariate analysis of independent prognostic factors 
including grade of disease in its three traditional categories  
Grade does not have prognostic power independently  of other factors 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
Age (Continuous) 1.027 (1.016-1.039) <0.001 
FIGO Stage   
1  <0.001 
2 2.471 (1.428-4.276) 0.001 
3 4.686 (2.866 – 7.661) <0.001 
4 6.220 (3.510 – 11.023) <0.001 
 
Residual macroscopic 
disease 
2.024 (1.436 – 2.853) <0.001 
 
Patient received 
chemotherapy 
0.441 (0.314 – 0.620) <0.001 
 
Histological grade 
 
  
G1  0.244 
G2 1.309 (0.807 – 2.123) 0.275 
G3 1.431 (0.937 – 2.186) 0.097 
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Table 4.5b Cox’s multivariate analysis of independent prognostic factors 
including high/low grade disease  
This factor loses the prognostic power it has on univariate analysis 
and is not an independent prognostic factor. 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
Age (Continuous) 1.027 (1.016-1.038) <0.001 
FIGO Stage   
1  <0.001 
2 2.447 (1.416-4.230) 0.001 
3 4.688 (2.866 – 7.667) <0.001 
4 6.235 (3.517 – 11.051) <0.001 
 
Residual macroscopic 
disease 
2.005 (1.423 – 2.825) <0.001 
 
Patient received 
chemotherapy 
0.436 (0.310 – 0.614) <0.001 
 
High / Low grade disease 1.205 (0.916 – 1.584) 0.128 
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Stage 
The data was detailed to a sub-stage level in the study database and in 
the analysis database was additionally extrapolated to generate a 
category of the major FIGO groupings I-IV. The more detailed sub-
stage data were incomplete in 76 cases but there only 9 cases with 
data missing to a FIGO Stage level. A quarter of cases were stage I, 
half were stage III with the remaining cases equally divided among the 
stage II and stage IV categories (Figure 4.8a,b)(Table 4.6). Assessing 
the association of stage with other clinicopathological variables using 
the Ȥ2 test revealed no association of stage or sub-stage with age (in 
SEER categories) though worsening  stage was associated with worse 
histological grade (13.56; p=0.035) and worse stage or sub-stage was 
significantly statistically associated with poorer prognosis histological 
subtype (Stage  87.5; p<0.01: Sub-stage  141.8; p<0.01). Increasing 
stage and sub-stage were statistically significantly associated with 
worse overall survival in univariate analysis, though the relationship 
was not linear on a sub-stage level and the survival plots crossed 
frequently (Figure 4.9 a, b). A multivariate analysis showed FIGO stage 
was an independent prognostic factor (Table 4.7)  
Specimen type 
A note was kept of the tissue source from which the arrayed cancer 
specimens were removed; 7% originated from omental metastases, 5% 
from pelvic metastases and 88% from ovarian tissue.  
4.2.2.2. Discussion 
The histological subtype had been recorded on the study database 
following its prior extraction from the original pathology reports. As all of 
the cases were reviewed contemporaneously by a specialist 
gynaepathologist, rather than general pathologists of the type who had 
produced the original reports, this original data were not assessed and 
were removed from the database. Though interesting, comparing 
historic and modern findings was unnecessary, especially as conflicts 
would be resolved in favour of the specialist gynaepathologist. The 
rankings of the tumour types in order of lethalness may appear counter-
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Figure 4.8a Histogram showing the relative distribution of cases within the FIGO 
stage groupings 
Stage III was the most common and stage II the least common. 


Figure 4.8b Histogram showing the distribution of cases within the FIGO sub-
stage groupings 
Stage IIIa was the most common and Ib the least common. 
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Table 4.6 The distribution of cases by stage 
There were less data available concerning the more detailed sub-
stage categorisation of the cases.  
 
 n (%) 
cases 
Mean 
survival 
(months) 
Median 
survival 
(months) 
Approximate 
5-year 
overall survival
FIGO Stage  
Missing data 9 / 339 (3)  
 
n=330  
 
I 85 (26) 129.4 137.6 60% 
II 37 (11) 79.3 40.7 38% 
III 168 (51) 26.3 13 10% 
IV 40 (12) 15.4 7.3 5% 
 
FIGO Sub-stage  
Missing data 76 (22)  
n = 263 
Ia 33 (13) 136.8 187.2 63% 
Ib 5 (2) 140.8  60% 
Ic 35 (13) 114.8 94.2 56% 
 
Stage but no sub-
stage data 
12  
  
  IIa 11 (4) 63.9 16.7 40% 
IIb 5 (2) 67.5 50.6 30% 
IIc 16 (6) 76.8 28.4 30% 
 
Stage but no sub-
stage data 
5  
 
IIIa 53 (20) 30.3 17.3 10% 
IIIb 24 (9) 36.6 19.4 20% 
IIIc 41 (16) 14.1 8.4 2% 
 
Stage but no sub-
stage data 
50  
 
IV 40 (15.2) 12.2 5 5% 

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Figure 4.9a Kaplan-Meier plot showing the statistically significant 
association between increasing FIGO stage and worsening 
survival 

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Figure 4.9b Kaplan-Meier plot showing the statistically significant 
association between FIGO sub-stage 
In general, survival becomes worse with increasing sub-stage but as 
there are multiple curve crossing points an assumption of 
proportional hazards may not be valid.  
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Table 4.7 Cox’s multivariate analysis of independent prognostic factors 
including FIGO stage 
When other independent factors are included into a multivariate 
model, FIGO stage retains its prognostic power and is an 
independent prognostic factor in ovarian cancer. 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
Age (Continuous) 1.025 (1.014 - 1.037) <0.001 
 
Residual macroscopic 
disease 
1.990 (1.414 – 2.801) <0.001 
 
Patient received 
chemotherapy 
0.439 (0.312 – 0.618) <0.001 
 
 
FIGO Stage 
  
1  <0.001 
2 2.506 (1.449 - 4.333) 0.001 
3 4.902 (2.992 – 8.031) <0.001 
4 6.624 (3.743 – 11.723) <0.001 
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intuitive, as clear cell and mucinous cancers are anecdotally associated 
with a poor prognosis.  However they often present at an early stage 
and overall are associated with a relatively good prognosis, unlike 
undifferentiated and serous types which are often present later leading 
to a poor prognosis  The final ranking of tumours and the observation 
that this prognostic affect disappeared on a multivariate analysis 
substantiates this and validates the dataset through its agreement with 
the wider literature (Silva, Tornos et al. 1991; Makar, Baekelandt et al. 
1995; Gospodarowicz 2001; Heintz, Odicino et al. 2001; Harrison, 
Jameson et al. 2008; Itamochi, Kigawa et al. 2008). Overall the data for 
histological type were consistent and the data were subsequently used 
in univariate (but not multivariate) analyses when investigating 
molecular marker expression. Further discussion concerning 
histological type is found in 3.2.  
The grading data in the original database was also removed with 
contemporaneous data being substituted. Histological grading has 
important prognostic power but this is inseparable from other aspects of 
disease biology such as stage and response to chemotherapy. 
Therefore it was appropriate that grade was a prognostic indicator in a 
univariate but not multivariate analysis in this dataset, supporting its 
validity (Gospodarowicz 2001). A larger than expected number of cases 
were high grade (G3) in this series but the fact that this category was of 
prognostic importance in univariate analysis when compared to G1 and 
G2 makes investigator inaccuracy an unlikely cause of this. Though a 
series with above average numbers of poorly differentiated cancers 
may have occurred by chance there is another explanation. It is 
possible that the higher number of G3 cases was at the expense of G2 
cancers with truly moderately differentiated cancers being 
unconsciously allocated to the G3 category; explaining why G2 cancers 
behaved indistinguishably from G1 cancers regarding survival. This 
would be understandable as objectifying the grading of ovarian cancer 
has proved elusive and would reflect a sensibly  cautious approach to 
reporting disease as low grade (Hernandez, Bhagavan et al. 1984). 
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Overall the data for histological grade were not inconsistent and were 
included in univariate but not multivariate analyses when assessing 
new markers. Further discussion regarding grade is found in 3.2. 
The level of missing data within the major categories of FIGO stage 
was small but the more detailed description of the disease in the form of 
sub-stage classification was often incomplete, possibly due to 
difficulties in extracting this data the clinical record. Another explanation 
is that the disease may not have been assessed clinically in some 
cases on a sub-stage level by some surgeons with the required 
pathological elements of cytology and lymph nodes not being sent. 
Despite the absence of some details, the distribution of cases amongst 
the FIGO stages in their major groupings was similar to that of 
contemporaneous cohorts (Hand, Fremgen et al. 1993; Yancik 1993; 
Ilekis, Gariti et al. 1997; Wolfe, Tilling et al. 1997; Brun, Feyler et al. 
2000; Holschneider and Berek 2000; Heintz, Odicino et al. 2001; Quirk 
and Natarajan 2005). The assumption of proportional hazards was not 
valid for the sub-stage categorisation as the survival curves crossed 
and so FIGO stage was assessed in the multivariate model in only its 
major groupings, where it predicted prognosis independently of other 
factors. As stage is  a de facto independent prognostic factor, this 
finding validates both the stage and survival data (Gospodarowicz 
2001; Heintz, Odicino et al. 2001). Overall the data were deemed 
consistent. 
As the source of tissue available for contemporaneous review 
depended upon the extent of the original surgery, some minimally 
debulked cases had only metastatic material available within the 
archive. Differential expression of molecular markers between primary 
and metastatic samples within an individual case may theoretically 
occur; as previously noted CK20 expression varies between anatomical 
sites whereas there is much better correlation concerning CK7 
expression (Tot 2002). This could perhaps most intuitively be the case 
with regards to molecules implicated biologically in metastasis such as 
cell adhesion molecules, growth factor receptors and those involved in 
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angiogenesis. There is evidence that E-cadherin is expressed more 
frequently in metastatic deposits than in paired primary samples (Elloul, 
Silins et al. 2006) and a discrepancy between vascular endothelial 
growth factor (VEGF) expression in 8 out of 30 cases where paired 
samples were compared has also been observed (Fujimoto, Sakaguchi 
et al. 2001), though other workers have found no significant differences 
in E-cadherin, ȕ-catenin, EGF and ERB2 expression between different 
anatomical sites (Davidson, Gotlieb et al. 2000). A relative lack of 
studies examining the immunohistochemical expression of markers in 
paired samples means that it is hard to be certain of the  impact of  
using metastatic samples in this experimental work but it is likely to vary 
according to the individual marker (Davidson 2007). Having a small 
proportion of metastatic samples in the series did however keep any 
theoretical impact to a minimum and it was possible to investigate any 
significant difficulties ascribable to sample related false negative or 
false positives in detail with full sections if this became necessary. 
4.2.3. Surgery 
4.2.3.1. Results 
Surgical debulking 
13 cases had data missing concerning the level of cytoreduction. The 
logic of the entries were checked by reviewing the early stage cases, 
where no instances of residual disease were expected and the stage IV 
cancers where a majority of cases were expected to have residual 
disease; these checks revealing no inconsistent results.130 (40%) of 
cases had no macroscopic disease remaining after surgery (optimally 
debulked), 89 cases (27%) had macroscopic disease with lesions of a 
maximal size of <2cm and 107 cases (33%) had bulky residual disease 
with lesions of  2cm. Regarding overall survival, optimally debulked 
disease had the best prognosis, cases with 2cm sized deposits of 
tumour had the worst survival and those cases having deposits <2cm 
residual had an intermediate prognosis (Figure 4.10a). Optimally 
debulked disease used singly also predicted a better prognosis (Figure 
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4.10b) and both ways of sub-categorising residual disease were 
prognostic for survival independently of other prognostic factors (Table 
4.8a, b). 
Pre-operative serum CA125 
217 cases had pre-operative serum CA125 values recorded with 36% 
having this data absent and no cases having serial measurements 
available for analysis. The values ranged from 0  14200. 42% of cases 
had an elevated serum CA125 above 35 U /ml; 2 % had a value 
between 35 - 60 U / ml, 7% a value between 60-150 U /ml, 12% a value 
between 150-500 U /ml and 21% a value above 500 U /ml.  Using these 
cut-off points to investigate its prognostic effect on overall survival in a 
univariate analysis revealed that a worse prognosis was predicted by a 
serum CA125 > 500 U /ml (Figure 4.11a, b). Using the Ȥ2 test to look for 
associations with other clinicopathological factors revealed statistically 
significant associations between this definition of high CA125 and 
increasing FIGO stage (17.34; p=0.01), sub-optimally debulked disease 
(9.15; p=0.002) and more lethal histological type (15.58; p=0.008). In a 
multivariate analysis including other known independently prognostic 
factors, pre-operative high pre-operative serum CA125 level did not 
retain independent prognostic power (Table 4.9). 
Surgical sub-specialisation 
Of the 339 operations performed, data concerning the degree of 
specialisation of the operating surgeon were available for 321 cases 
(missing data = 5%). Of these cases, 42% were performed by a gynae-
oncologist, 54% were performed by an unspecified gynaecologist and 
4% were treated by a general surgeon. There were no statistically 
significant variations between the surgeons concerning FIGO stage of 
disease (14.19; p=0.12), the presence of visible residual disease at the 
end of surgery (7.26; p=0.06) or the subsequent use of adjuvant 
chemotherapy (5.71; p=0.13). The survival of patients treated by the 
general surgeons was worse than that seen when a general 
gynaecologists or gynae-oncologist operated (Figure 4.12a) though this 
was not an independent prognostic factor on multivariate analysis 
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Figure 4.10a Kaplan-Meier plot showing the statistically significant univariate 
association between the increasing amount of residual disease left at 
the end of surgery and worsening survival. The groups are 
categorised >2cm,  <2cm (>0) and no macroscopic residual 
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Log rank = 130.40; 
p<0.001 
 
 
 
 
 
 
Figure 4.10b Kaplan-Meier plot with residual disease re-categorised into two 
broad categories (any macroscopic residual vs. no macroscopic 
residual) showing the strong statistical association between the 
presence of residual disease and poorer outcome in a univariate 
analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log rank = 107.89; 
P<0.001 
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Table 4.8b Cox’s multivariate analysis including the absence of any 
macroscopic residual disease 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
Age (Continuous) 
 
1.025 (1.014 - 1.037) <0.001 
FIGO Stage   
1  <0.001 
2 2.506 (1.449  4.333) 0.001 
3 4.902 (2.992   8.031) <0.001 
4 6.624 (3.743  11.723) <0.001 
 
Patient received 
chemotherapy 
 
0.439 (0.312 - 0.618) <0.001 
 
Residual disease   
 <0.001 
Macroscopic disease 
remaining 
1.990 (1.414  2.801) <0.001 
Table 4.8a Cox’s multivariate analysis of independent prognostic factors 
amount of residual disease using a threshold of 2cm sized 
deposits 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
Age (Continuous) 
 
1.024 (1.013 - 1.035) <0.001 
FIGO Stage   
1  <0.001 
2 2.624 (1.512  4.554) 0.001 
3 4.830 (2.928   7.968) <0.001 
4 6.284 (3.516  11.23) <0.001 
   
Patient received 
chemotherapy 
0.452 (0.319 - 0.642) <0.001 
 
Residual disease   
No residual  <0.001 
<2cm residual 1.673 (1.151  2.430) 0.007 
2cm residual 2.542 (1.733  3.728) <0.001 
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Figure 4.11a Kaplan-Meier graph showing the predicting of survival by pre-
operative CA125 
 Cut offs of 35, 60 and 150 U/ml (bellow) were not associated with 
statistically significant differences in survival in a univariate analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log rank = 1.003; 
p=0.316 
Figure 4.11b Kaplan-Meier graph showing the predicting of survival by pre-
operative CA125 using a cut-off of 500 U/ml 
The two groups had a statistically significant difference in survival – a 
high CA125 predicting a poorer overall survival in a univariate 
analysis. 
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
Table 4.9 Cox’s multivariate analysis including high pre-operative CA125 
CA125 >500 U/ ml did not retain the prognostic power it exhibited in 
univariate analysis. 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
Age (Continuous) 1.028 (1.013-1.043) <0.001 
FIGO Stage   
1  <0.001 
2 2.807 (1.383 – 5.697) 0.004 
3 4.613 (2.484 – 8.565) <0.001 
4 8.360 (4.059– 17.221) <0.001 
 
Residual macroscopic 
disease 
2.119 (1.354 – 3.316) <0.001 
 
Patient received 
chemotherapy 
0.457 (0.301 – 0.695) <0.001 
 
CA125 
 
  
CA125 > 500 U / ml 1.320 (0.925 – 1.884) 0.126 
Table 4.10 Cox’s multivariate analysis including degree of specialisation of 
the surgeon operating  
This was not an independent prognostic factor in this series. 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
Age (Continuous) 
 
1.026 (1.015-1.037) <0.001 
FIGO Stage   
1  <0.001 
2 2.384 (1.379 – 4.120) 0.002 
3 4.890 (2.963 – 8.072) <0.001 
4 6.953 (3.891 – 12.422) <0.001 
 
Residual macroscopic 
disease 
1.902 (1.348 – 2.684) <0.001 
 
Patient received 
chemotherapy 
0.452 (0.319 - 0.642) <0.001 
 
Specialty of surgeon 
Gynae-oncologist  0.241 
General gynaecologist 1.186 (0.917 – 1.533) 0.194 
General surgeon 1.505 (0.837 – 2.705) 0.172 
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Figure 4.12a Kaplan-Meier plot showing the effect of degree of surgical 
specialisation on survival 
Cases managed by general surgeons had the worst outcome and the 
difference was statistically significant. 
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Log rank = 7.057; 
p=0.029 
 
 
 
 
 
Figure 4.12b Kaplan-Meier plot showing the association of gynae-oncologist 
performing the surgery with survival  
As only 13 cases were managed by general surgeons, these were 
combined with the cases managed by general gynaecologists to 
investigate the influence of the gynae-oncologist’s practice on overall 
survival. There was no association found. 
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(Table 4.10). There was no difference in overall survival seen between 
the cases attended by the general gynaecologist or specialist 
gynaecologist (Figure 4.12b). 
Operation performed 
On reviewing the pathology reports a note was made of the specimens 
examined by the pathologist. There were no missing data. 17% had 
only biopsy material removed, 14% had a single ovary removed, 20% 
had both ovaries removed, 13% had ovaries and uterus removed with 
35% of cases having uterus, ovaries and omentum removed.   
4.2.3.2. Discussion 
The proportion of cases debulked to <2cm in the literature range from 
36- to 87% (Venesmaa 1994; Makar, Baekelandt et al. 1995; Kehoe 
1996; Heintz, Odicino et al. 2001) and to the point of no visible 
macroscopic disease from 15  85% (Venesmaa 1994; Eisenkop, 
Friedman et al. 1998; Bristow, Montz et al. 1999; Brun, Feyler et al. 
2000; Heintz, Odicino et al. 2001). This series data were well within 
these ranges, supporting its consistency. Optimal debulking by either 
standard is an accepted independent prognostic factor , which was 
found to be the case in this series, validating the dataset 
(Gospodarowicz 2001). Overall the data were deemed consistent and 
as the simpler classification of optimal debulking (no macroscopic 
disease) is now the widely accepted standard, the data were 
categorised in this way for the subsequent multivariate analyses. 
The data for pre-operative serum CA125 were to a large degree 
incomplete. The majority of cases missing data were from the early 
1980s when the routine use of serum CA125 was not established. 
None of the values were out of the range expected for cases of ovarian 
cancer but only 42% of cases exhibited a raised CA125 despite it 
usually being elevated in 80-90% of epithelial ovarian cancers (Hogdall, 
Christensen et al. 2007). Potential explanations include bias introduced 
through the missing data, an unusual case series or the incorrect 
extraction of data from the clinical record. If all of the missing cases had 
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a raised serum CA125 then this would elevate the proportion to 77% for 
the whole series but this seems the least plausible explanation. A 
raised serum CA125 is found less frequently in mucinous epithelial 
ovarian cancers and in only 50% of stage I cancers but there was no 
evidence that such cases were disproportionately represented in the 
group with CA125 data available (Jacobs and Bast 1989; Einhorn, 
Sjovall et al. 1992). The most likely possibility is that post- and not pre- 
operative CA125 levels were inadvertently recorded. In order to 
compare the data with other clinicopathological factors and overall 
survival, previously published cut-off points were empirically analysed 
at 35, 60, 150 and 500 U / ml Jacobs, Oram et al. 1990; Einhorn, 
Sjovall et al. 1992; Hogdall, Christensen et al. 2007). Using a cut-off of 
500 U/ ml cut-off for this series reproduced the findings of Cooper et al 
except for an association with histological grade and the independent 
effect of its prognostic power (Cooper, Sood et al. 2002) while also 
reproducing an association with optimally debulked disease found by 
other groups (Chi, Venkatraman et al. 2000; Gemer, Segal et al. 2001). 
The lack of association with grade in this series is in keeping with other 
publications though might also have been influenced by the high 
number of G3 cases in this series (Rossi, Di Vagno et al. 2004). The 
survival data were congruent to the findings of Makar et al who found 
pre-operative CA125 to be associated with poorer survival in univariate 
but not multivariate analysis (Makar, Baekelandt et al. 1995). In general 
the data reproduced known associations but it was incomplete and 
some fundamental inconsistencies were present. It may have been 
possible to more completely and accurately re-extract the data from the 
clinical record but the relative unimportance of pre-operative serum 
CA125 meant that resources were prioritised elsewhere and the 
existing data were not used further (Hunter, Daly et al. 1990; 
Gospodarowicz 2001) (Meier, Stieber et al. 1997).  
42% of cases had their operations performed by a gynae-oncologist 
and though this is a higher figure than has been seen in other series 
(21% of cases within a U.S series of over 12 000 cases presenting 
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during a similar time period that were treated by a sub-specialist) it is at 
dissonance with the perception that the majority of cases had been 
treated by a single sub-specialist (Nguyen, Averette et al. 1993). There 
is some evidence suggesting that outcomes should be better when 
cases are treated by gynae-oncologists and not general gynaecologists 
and this might support the theory that a large body of cases in this 
series had been inaccurately allocated; leading to homogeneity of 
outcomes and the observed dissonance between the anecdotal and 
objective evidence (Junor, Hole et al. 1999). Inaccurate allocation may 
have occurred in cases where the gynae-oncologist was the assistant 
(but in effect senior operator) or where the denomination of the surgeon 
was unknown. However it is just as likely that inaccurate recall was the 
explanation as other groups have  found no difference in outcomes 
between gynae-oncologist and general gynaecologist (Nguyen, 
Averette et al. 1993; Kehoe, Powell et al. 1994; Earle, Schrag et al. 
2006). However all groups agree that cases treated by general 
surgeons do worst of all and despite the small numbers involved, this 
was also the case in this series. Though inconsistent with the anecdotal 
evidence concerning the lead surgeon the data are valid but were not 
used further. As the degree of sub-specialisation of the surgeon is not 
an accepted independent prognostic factor and it did not predict 
prognosis independently in this multivariate model (Gospodarowicz 
2001). 
Though it was intended that noting the organs inspected by the 
pathologist might give an insight into the completeness of the operation 
performed, the lack of information concerning previous surgeries for 
benign conditions made this an unreliable indirect measure. A better 
measure of radicalness of surgery is residual disease. This attribute 
might therefore be better titled specimens examined by original 
pathologist . It was decided that the usefulness of this data was limited 
and it was not used in any formal analysis. 

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4.2.4. Medical treatment 
4.2.4.1. Results 
Adjuvant treatment 
73% of patients received adjuvant treatment, no cases received neo-
adjuvant treatment and data were missing in seven instances. Outlying 
data points were found to be accurate on cross referencing with the 
medical record (Figure 4.13). 72% of patients underwent a course of 
chemotherapy, 50% of patients received platinum based chemotherapy 
and 2% of cases received combined platinum and paclitaxel 
chemotherapy.  28% of patients were treated by surgery alone.  On 
univariate analysis, age (in SEER categories) was not seen to influence 
the initiation of adjuvant therapy. The use of adjuvant therapy was 
strongly influenced by stage of the disease (Table 4.11). The univariate 
Kaplan-Meier plots inferred that a decision to initiate chemotherapy 
would be associated with a long term survival disadvantage but the log 
rank test revealed no statistical association between the use of 
adjuvant therapy, or chemotherapy in general and overall survival in the 
339 cancers of all stages, (Figure 4.14 a, b). On excluding stage I 
cancers from the univariate survival analysis it is shown that the use of 
specific adjuvant treatments and of chemotherapy in general was 
associated with statistically significant improvements in survival (Figure 
4.14 c, d). Analysing the effect on survival of both of these sub-
categorisations revealed that both were independent prognostic factors, 
though radiotherapy was of borderline statistical significance in the 
more specific multivariate analysis of adjuvant treatment (Table 4.12a, 
b).  
ICON trials 
59 patients participated in the first three ICON studies that recruited in 
the 1990s (Figure 4.15). A single case was diagnosed several years 
before ICON2 commenced and is seen as an outlier on the scatterplot.  
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Figure 4.13 A scatterplot illustrating the distribution of adjuvant therapy 
received by cases within the series  
The consistency of the outlying data was checked. A move toward the 
use of carboplatin and then carboplatin and paclitaxel in combination 
in the late nineties is seen. Radiotherapy was used rarely and 
discontinued in the 1990s. 
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Table 4.11 
 
The proportion of patients undergoing specific forms of post-
operative medical treatment 
For the purposes of subsequent analyses the raw data were regrouped 
into logical categories prior to their prognostic properties being 
assessed. While the age of the patient did not influence the decision to 
start medical therapy, the stage of the disease did. 
 
 Frequency Univariate associations 
Type of treatment n= (%) Age (SEER) Stage (FIGO) 
 
Missing data 7 (2) 7 (2) 9 (3) 
 
Original categories 
( n= 332) 
Ȥ2 
(p=) 
Ȥ2 
(p=) 
  
Non-platinum treatment 72 (22)  
 
 
 
Platinum (unspecified) 74 (22) 
Carboplatin 84 (25) 
Carboplatin+ Paclitaxel 8 (2) 
Single agent Paclitaxel 1 
Radiotherapy 4 (1) 
Surgery only 89 (27) 
 
Re-categorised -  Platinum 
(n=332) 
22.4  
(0.001) 
56.4  
(<0.001) 
Platinum based chemotherapy 166 (50) 
Non-platinum based chemotherapy 73 (22) 
No chemotherapy given 93 (28) 
    
Re-categorised - Any chemotherapy 
(n=332) 
3.13 (0.209) 45.83 
(<0.001) 
Any chemotherapy given 239 (72) 
93 (28) No chemotherapy given 

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Figure 4.14a A Kaplan-Meier plot showing the association between 
adjuvant treatment and survival 
Within the series of 339 cases that included all stages of 
disease a statistically significant difference in survival is not 
present and the survival lines cross at multiple points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log rank = 11.59; 
p= 0.09 
 
 
 
 
 
Figure 4.14b A Kaplan-Meier plot seems to show the association of use of 
chemotherapy with overall survival rates for all stage disease 
As this dataset was not designed to study differences between 
particular modalities of adjuvant treatment the decision to initiate 
chemotherapy in general was instead assessed. No statistically 
significant differences were seen when all stages were included. 
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Figure 4.14c A Kaplan-Meier plot bellow showing the effect of adjuvant 
treatment on survival for stage II-IV cancers 
In these cases, the decision not to give therapy would have been 
made only if the patient was deemed too unfit to receive it. Adjuvant 
treatment is statistically associated with a survival benefit for this 
group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log rank =123.86; 
p<0.01 


Figure 4.14d A Kaplan-Meier plot showing the association of the decision 
to initiate chemotherapy with improved prognosis in stage II-
IV cancers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log rank = 57.2;  
p=<0.001 
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Table 4.12a Cox’s proportional hazards model including type of adjuvant 
therapy 
This was differentially associated with improved survival 
independently of other factors. 
 
 Hazard Ratios
(95% Confidence intervals) 
Significance (p)
 
Age at diagnosis (years) 1.019 (1.007-1.030) 0.001 
 
FIGO Stage   
1 <0.001 
2 3.505 (1.994 – 6.162) 0.001 
3 6.321 (4.566 -14.795) <0.001 
4 8.220 (4.566-14.795) <0.001 
 
Residual macroscopic disease 1.945  (1.360 – 2.782) <0.001 
 
Adjuvant treatment  
None  <0.001 
Non-Platinum chemotherapy 0.292 (0.201-0.424) <0.01 
Platinum based chemotherapy 0.494 (333-0.733) <0.01 
Radiotherapy 0.115 (0.026 – 0.516) 0.05 


Table 4.12b Cox’s proportional hazard model including  the decision to 
initiate chemotherapy  
This was associated with improved survival independently of other 
independent prognostic factors. 
 
 Hazard Ratios
(95% Confidence intervals) 
Significance (p)
 
Age at diagnosis (years) 1.025 (1.014-1.037) <0.001 
 
FIGO Stage   
1  <0.001 
2 2.506 (1.449 – 4.333) 0.001 
3 4.901 (2.992 -8.031) <0.001 
4 6.624 (3.743-11.723) <0.001 
 
Residual macroscopic disease 1.990  (1.414 – 2.801) <0.001 
 
Any chemotherapy given 0.439 (0.312 – 0.618) <0.01 

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Figure 4.15 Cases recruited to the ICON trials 
Of the 239 patients in the series who received chemotherapy, 59 
were randomised within ICON trials. Cases were recruited to ICON 
I (1991 – 2000; The use of adjuvant chemotherapy in early stage 
disease), ICON II (1991 – 1996; Carboplatin compared with CAP 
regimen) and ICON III (1995 - Combined carboplatin and paclitaxel 
versus other conventional regimens). The recruitment of cases is 
shown in the scatterplot below. 
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4.2.4.2. Discussion 
As the study cohort was selected from the years where significant 
alterations in best practice had occurred, the patients experienced a full 
spectrum of chemotherapeutic regimens ranging from single agent 
cyclophosphamide through to the current standard of 5-6 cycles of 
carboplatin (cycles AUC 6 over 60 minutes 3 weeks apart) combined 
with Paclitaxel (175mg/m2 over 3 hours) (Benedet 2000). The regimens 
used were however all acceptable practices for the day and were 
initiated whenever physically practicable to do so (Appendix 4). Despite 
this, approximately 30% of cases did not receive chemotherapy and 
comparing the sub-stage distribution of cases not receiving 
chemotherapy with the limited data available in the literature regarding 
this; 57% of stage I cases in our series (48% literature), 16% of stage II 
(10%), 17% stage III (10%) and 27% (14%) received no chemotherapy 
(Heintz, Odicino et al. 2001). This suggests a general tendency toward 
under-treatment rather than any over representation of stage I cancers 
in this series (low risk stage Ia and Ib cancers routinely being treated by 
surgery alone). As the database did not contain detailed information 
concerning the medical management of these cases it is not possible to 
know precisely why they did not receive treatment, though institutional 
issues and concerns surrounding performance status would be possible 
explanations. Conversely, as the comparison data is multi-centred, 
international and from a slightly later time period an apparent under-
treatment could also be artifactual. It is regrettable that an objective 
prospective record of medical treatment had not been assembled as 
this information would have allowed more detailed marker associations 
to be studied.  An attempt was made to retrieve this data for the 
patients that had been enrolled into the ICON studies but the MRC 
steering committee could not release this data. Consideration was 
given to the retrospective collection of this data but the resources to 
locate and extract the data accurately were unavailable. 
Ovarian cancer treatment has evolved so as to preclude the study of 
the non-use of chemotherapy in advanced disease, though evidence 
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from observational work  and studies on early epithelial ovarian cancer 
support the axiom that chemotherapy slows disease progression, 
prolongs survival and palliates symptoms and that it is not curative on 
its own and may not reduce overall mortality (Heintz, Odicino et al. 
2001) (Trimbos, Parmar et al. 2003). A univariate association between 
the use of adjuvant treatment and improved overall survival would 
therefore be expected, as has been seen by other workers (Lassus, 
Leminen et al. 2003; Rosen, Yang et al. 2006), some of who have 
found the use of chemotherapy to have independent prognostic power 
(Heintz, Odicino et al. 2001; Psyrri, Kountourakis et al. 2007). Counter-
intuitively, the use of chemotherapy initially seemed to predict a poor 
prognosis in this series. However, this is likely to be due to the inclusion 
of stage I cases in the first univariate analysis, as most of these cases 
did not receive adjuvant treatment because they already had an 
excellent prognosis - in variance to more advanced cases who have a 
better prognosis because they receive it. The subsequent analysis of 
stage II-IV cases supports this assertion as the use of adjuvant 
treatment improved overall survival in a statistically significant way, in 
this group which was expected to benefit most from it.  A multivariate 
analysis was performed, including other independent factors, using 
broad groupings (received chemotherapy or did not receive 
chemotherapy) and a more specific adjuvant therapy category. Both 
groupings showed the use of adjuvant therapy to independently predict 
a better survival. Though intuitively this would be ascribed to the effect 
of the drugs themselves, a lack of large randomised controlled trials 
comparing surgery alone with combined medical and surgical treatment 
in advanced ovarian cancer raises the possibility that it was the 
decision to initiate chemotherapy that was independently prognostic 
rather than any biological actions. The lack of objective data concerning 
performance status in this series makes it impossible to know whether 
such selection bias into the group receiving adjuvant therapy on the 
basis of fitness was occurring. However whatever the mechanism, from 
a practical point of view it was important  to include the use of adjuvant 
treatment as a factor in subsequent multivariate analyses and it was 
Chapter 4: Development and Evaluation of the Database
192
used in the same grouping that has been shown to be independently 
prognostic in observational studies  received chemotherapy / did not 
receive chemotherapy (Heintz, Odicino et al. 2001; Psyrri, 
Kountourakis et al. 2007). Overall, the data within the database 
concerning adjuvant treatment appeared consistent, almost 100% 
complete but limited in terms of objectively documented response to 
treatment.  
The fact that a case has been included in an ICON trial was an indicator 
of randomised treatment allocation and acceptable performance status 
but was otherwise of limited use as it was not possible to link the 
database to MRC held outcome data. The case which was randomised 
in to ICON I but diagnosed many years before the start of this trial was 
an early stage cancer incidentally discovered after following an 
oophrectomy where subsequent full pelvic clearance was not 
undertaken and where the initial decision to not give chemotherapy was 
subsequently reversed. Though this is unusual, interestingly it did not 
contravene the study protocol.  
4.2.5. Survival 
4.2.5.1. Results 
Date of operation 
Dates of operation ranged appropriately within the recruitment phase 
from *.2.82 - *.10.97.  This data equated to the date of initiation of 
treatment and as the follow up period spanned two millennia, they were 
transformed manually into DD/MM/YYYY format in order to facilitate the 
accurate electronic calculation of OS. Concurrently, the entries were 
checked to ensure that the dates of surgery were logical; correlating 
with year of diagnosis and being earlier than the latest survival data. 
Data were 100% complete. 
Year of diagnosis 
Year of diagnosis data were contemporaneously extracted from the 
pathology reports in order to act as an external check for the operation 
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date. The Inaccuracies which occasionally occurred were largely due to 
keying errors but all discrepancies were explored and then satisfactorily 
resolved. The number of cases treated varied from year to year within 
an acceptable range with a trend toward treating more cases 
developing over time (Figure 4.16). Data were 100% complete. 
Date of last follow up 
Patients were followed up according to a local protocol, three monthly 
for two years, 6 monthly for 5 years and thereafter annually and 
indefinitely with the patient seeing the consultant or nurse specialist at 
alternating visits and with an USS being performed every six months for 
the first 5 years and a serum CA125 and CEA being sent at every visit. 
The date of latest follow up was recorded in the database and ranged 
from *.05.82 - *.08. 05; which included clinic visits and in-patient deaths. 
The data were recoded into DD/MM/YYYY format to facilitate 
calculation of latest known survival data. The data were manually 
checked to ensure that no dates in this attribute preceded the year and 
date of diagnosis, the few errors discovered being attributable to keying 
errors introduced during the manual transformation of the date format. 
Data were available for 336 cases (99% complete).  
Date of death 
Data concerning date of death were also available for 99% of cases 
and ranged from *.05.1982 - *.04.2004.  The data were transformed 
into a DD/MM/YYYY format to facilitate subsequent calculations.  Using 
this data, patient survival status was coded 0 (alive) or 1 (dead). When 
the database was locked on 31st November 2005, 57 (17%) of patients 
were still alive.  The precise cause of death was not specifically 
recorded but anecdotally the majority died of related causes with only 
four women known to have died from causes not attributable to ovarian 
cancer. The dates of death were checked to ensue that they were later 
than the dates of diagnosis, with only keying errors discovered.  
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Figure 4.16 Histogram showing the number of cases presenting in each 
year of the recruitment phase of the study 
The year to year variation in workload is shown. 


Figure 4.17 A Kaplan-Meier curve showing raw survival data for the 
series 
Overall survival at 1-year (65%) and at 5-years (25%) is indicated. 
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Survival 
The data concerning date of diagnosis, latest follow-up, date of death 
and survival status were used to generate crude OS data up to the time 
of locking the database along with 1-year survival and 5-year survival 
rates. There were three instances of missing data (99% complete). 24 
patients (7%) died peri-operatively within a 30 day period following 
surgery. OS ranged from 0  271 months with a mean OS of 60.5 
months (95% CI 50.6  70.44; S.E 5.1) and median OS of 19.5 months 
(95% CI 15.5  23.5; S.E 2.1). The crude one year overall survival was 
63.7% and the corresponding five year measurement 25% (Figure 
4.17). Though graphically later year of diagnosis appeared to be 
associated with improved peri-operative (Figure 4.18a), 1- year (Figure 
4.18b) and 5-year OS (Figure 4.18c), no statistically significant 
differences were seen.  Mean, median and crude  five-year OS 
decreased  in a stepwise manner within the FIGO stage categorisation 
with stage I cancer having a median OS of 137.6 months and a five 
year OS of 60% whereas stage IV cancers had a median OS of 7.3 
months and a five year OS of 5% (Table 4.6). 
4.2.5.2. Discussion 
The intensity of follow up was similar to that recommended by FIGO 
and NIH and its indefinite nature on an annual basis was 
understandable in a time when changes to first line treatment were 
occurring regularly. 68% of all recurrences in cases of advanced 
ovarian cancer documented within the 24th annual report compiled by 
FIGO occurred within the first 2 years of treatment with the relative 
survival at the 4th and 5th year of follow up being almost the same for 
most stages (Heintz, Odicino et al. 2001).This data lends support to 
decreasing the intensity of review following the first 2 years and to the 
argument that risk of death from ovarian cancer returns to background 
after 5 years. However, few clinicians would discharge patients with 
treated advanced ovarian cancer this soon after treatment and as FIGO 
is not prescriptive on this point the schedule is often individualised. The 
routine use of USS in an asymptomatic follow up population without 
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Figure 4.18a Scatterplot showing the variation of deaths within 30 days of 
surgery by year of surgery 
There was no statistical association between the two (17.7; p=0.28). 
 
 
 
Figure 4.18b Scatterplot showing the variation of 1 year survival by year of 
surgery   
There was no statistical association between the two (11.47;p=0.72). 
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Figure 4.18c Scatterplot showing the variation in five year survival by year of 
diagnosis 
There was no statistical association between the two (13.57; p=0.56) 
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other evidence of recurrence is controversial and would not 
recommended by most authorities, though it may have a  specific role in 
the follow up of early and  borderline cases where fertility sparing 
surgery has been performed (1995; Benedet 2000; Zanetta, Rota et al. 
2001; Scottish Intercollegiate Guidelines Network. 2003). However, with 
an indefinite time span to the long term follow up, clinical examination 
by a consultant specialist would not have been possible for all patients 
in this series at all visits and the use of this highly sensitive (though 
likely less specific) modality may have been used as a catch all.  
The data concerning date of death were complete but the occasional 
inaccuracies reinforce the advantages of double keying entries ; which 
has been shown to reduce the number of transcription errors from 
approximately 50 / 10 000 keystrokes to 15 / 10 000 (Reynolds-Haertle 
and McBride 1992; Blumenstein 1993; Horbar and Leahy 1995). 
During the follow up period, which ranged up to 270 months, 83% of 
women died. The majority of these women are likely to have died from 
ovarian cancer, which was the anecdotal observation, but the case 
fatality rate appears higher than expected given the oft quoted fatality 
rate of approximately 2/3 (Jolles 1985; Nagle, Bain et al. 2006). Large 
long term studies reporting fatality rates at time periods in excess of 5 
years within this studys time frame are few but one American study 
estimates the fatality rate for the 38 012 patients diagnosed between 
1973 and 1997 to be 56%; even lower than 2/3, and reflecting the 
historically lower mortality of the disease in the U.S (Nagle, Bain et al. 
2006). One explanation for this series high fatality rate might be if it was 
untypical in terms of its clinicopathological make up, though there was 
no evidence that it differed significantly from other series in terms of the 
distribution of age, stage and residual disease (independently 
prognostic factors). However, the tendency toward under-treatment with 
chemotherapy could have resulted in a failure to prevent more deaths 
during this period; although such under treatment might have been 
expected to influence length of survival rather than mortality itself. A 
further explanation might be that a larger proportion of cases were 
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dying from non-cancer related causes than appreciated. Checking this 
could only be done by scrutinizing death certificates. This would have 
presented ethical, financial and (as TCR could not provide the data) 
logistical obstacles which would have been surmountable only if the 
accuracy of the data acquired offset them and if the data were crucial. It 
was permissible for the cohort to have a high fatality rate and still be 
valid and consistent for use in assessing novel expression, as long as 
the overall survival data behaved normally, reproducing known 
associations with clinicopathological factors with accepted independent 
prognostic factors being consistently identified.  As has been shown 
earlier in this chapter, such associations were frequently reproduced  
validating both the clinicopathological and survival data. Therefore it 
was decided to accept that this series had a relatively high fatality rate 
compared to other series and the complex attempt to correct for 
potential non-cause specific deaths, which were likely to be few in 
number, was not undertaken. 
The OS data were complete with only positive figures being generated, 
confirming that no systematic errors had been incurred. In addition they 
consistently produced valid associations with other clinicopathological 
factors, identifying the anticipated independent prognostic factors 
correctly. However, the proportion of deaths within 30 days of operation 
is slightly higher, though of the same order of magnitude, as seen in the 
few other studies which have reported this (Jalêuvka 1980; Elit, Bondy 
et al. 2002; Ben-Ami, Vaknin et al. 2006). This variation could 
theoretically have been caused by inferior peri-operative care though if 
this was the cause then improvement peri-operative death rates would 
have been expected over time as medical care advanced, which was 
not seen within this series. This variation may therefore be more 
convincingly explained by heterogeneity between the studies cohorts. 
As there were no instances encountered in the literature where peri-
operative deaths had been corrected for in the marker expression 
survival analyses, the OS data were used unadjusted. As expected, OS 
decreased with increasing stage but the overall all stage 5- year OS of 
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25% was poor despite a typical distribution of cases among the stages. 
Reviewing contemporaneous data from Eurocare 3, the observed 
European average 5- year survival around this time period was 34%. 
The 1- year OS statistics, which are often taken as a measure of 
diagnosis-treatment delay, are similar at 63% for this series against the 
European average of 65% and this suggests that superior treatments in 
continental Europe account for the difference at 5-years. Reviewing 
survival on a stage level;  5- year survival for Stage I cancers is 
reported in the literature as  90% but in this series only 60% survived to 
this point along with 38% of stage II cases (42-70% in the literature), 
10% for stage III (21  59% in the literature) and 5% for stage IV 
cancers (6-25% in the literature) (Hand, Fremgen et al. 1993; Yancik 
1993; Ilekis, Gariti et al. 1997; Wolfe, Tilling et al. 1997; Brun, Feyler et 
al. 2000; Holschneider and Berek 2000; Heintz, Odicino et al. 2001; 
Quirk and Natarajan 2005).  The width of these ranges is in part 
because they are a mixture of relative and crude five year OS, with 
crude OS data usually returning a lower value than its relative 
equivalent (as deaths from other causes are not included).  However, 
this series' crude figures are even lower than the bottom of these 
ranges; as was seen with the fatality data. Reasons for this worse 
survival might include patient factors (older age group, worse 
performance status), tumour factors (above average number of high 
grade cases) and treatment factors (inadequate staging procedure, 
inadequate treatment, delay in diagnosis). Intriguingly, these five year 
OS data are similar to those collated for the 19th FIGO Annual Report 
on the Results of Treatment in Gynecologic Cancer for the decade 
preceding the one from which these patients were recruited (1973-
1975) (Heintz, Odicino et al. 2001). This again suggests that the cancer 
service needed to be improved; which was recognised nationally at the 
time. 
4.3. Auditing of data 
The accuracy of the data kept on the database was assessed through 
three audit processes, the details of which are outlined in (Figure 4.19).   
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4.3.1. Results 
Study database - audit 1 
Once the irregularities had been explained (Figure 4.19), clean data 
were collected from medical records of the non-excluded cases.  The 
original audit tool (Figure 4.20) allowed the most crucial data to be 
collected as it appeared in the study database for comparison to this 
clean data. Of the 168 fields assessed for the 21 cases, 23 were not 
reliably verifiable through inspecting the medical record.  Missing data 
within the study database for this sample was found in 7 individual 
instances (96% complete. Of the 138 fields that could be assessed for 
correctness (168 minus the data fields that were missing or for which 
clean data were unavailable), 2 were found to be incorrect. One 
concerned the degree of extent of cytoreduction, one concerned the 
adjuvant treatment and both were significant inaccuracies. Assuming 
the data in the database which could not be verified from the clinical 
record was also incorrect, 81% of data were definitely correct in 96% of 
the entries.  The outcome data, survival and death, were 100% 
accurate (Table 4.13). 
Analysis database – audit 2 
A new audit tool was required to assess the data within the analysis 
database as it had been extensively modified and this was created by 
refining the original version (Figure 4.21).  Six of the cases had medical 
records which were inaccessible. Of the 98 fields assessed within the 
remaining 14 cases, 6 were not reliably verifiable from clean data. No 
instances of missing data occurred within the analysis database for 
these cases (100% complete). 5 of the assessable 92 fields were 
incorrect and assuming data which was non-verifiable was also 
incorrect, the cases assessed were 89% correct overall in a dataset 
which was 100% complete. The outcome data was 100% correct in the 
13 cases with verifiable data equating to a rate of correctness of 93% if 
unverifiable data is considered inaccurate (Table 4.13). There was no 
evidence that the database columns had become misaligned.  
Chapter 4: Development and Evaluation of the Database
202
Figure 4.19 Auditing of the database Three assessments of the accuracy of the database were performed at various stages during its evolution.  During 
the first assessment, 21 of the 54 cases selected from the original study database for audit had their important fields analysed using an audit 
tool appropriate for that database. 33 of the 54 took no part in this audit (many cases selected for this review were those likely to be unsuitable 
for inclusion into the study).  Following the production of the analysis database containing restructured clinicopathological data, a second audit 
was performed using an appropriately refined version of the original audit tool.  The clean data from the first audit was then re-categorised 
following the same principals used to generate the analysis database from the study database and the original 21 cases were re-audited using 
the refined audit tool. A third audit combined the data from both sample sets  to increase the numbers analysed while simultaneously 
screening for systematic errors that may have occurred during the various database manipulations that had occurred. 
 
Original Study Database
54 / 441 cases were selected from TCR for chart review and clean data was collected 
by R+D DCGH using the original audit tool 
Exclusions 
33 cases were not on the analysis 
database excluded from audit 
14 cases were not present on TCR but not 
on Database 
10 cases were not ovarian cancer on 
review 
2 cases of non-surgically treated ovarian 
cancer were not on database 
1 case of recurrent ovarian cancer was not 
on database 
6 cases were borderline  
Analysis database - combined audit
35 / 358 (10%) of cases on TMA had the accuracy of their 
entries on analysis database audited using the refined 
audit tool 
Analysis database
20/ 358 cases were randomly selected for chart review using a refined audit tool 
reflecting the new domains and attributes of the analysis database 
Exclusions
6 cases had notes inaccessible 
due to their being held by an off 
site storage facility 
Inclusions
14 / 358 cases on TMA had the accuracy of 
their database entries audited using audit tool 
The clean data from the original audit 
was re-categorised to allow 
comparison with the analysis database 
Inclusions
21 / 358 cases on the TMA had the 
accuracy of the original study 
database entries audited using the 
original audit tool 
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Figure 4.20 The original audit tool 
This was used extract clean data from the clinical records (medical 
record and PAS) which was compared to the study database record. 
The database was compared to the Trent Cancer Registry (TCR) 
and the case notes of ovarian cancer cases not on the database 
reviewed. Cases on the database that did not appear to be ovarian 
cancer were also reviewed. A randomly selected sample of other 
cases was identified and in total 54 of a possible 441 sets of notes 
was inspected. This audit was performed by an R+D officer 
independently of the investigative team.  
   
 
 
 
 
Study 
Number 
 
  
 
Agreement 
with 
information 
on database 
 
Date of 
surgery 
Date Missing  Y / N  
Age at 
surgery 
Years Missing  Y / N  
 
Type of 
tumour 
Serous Mucinous Endometrioid other Missing Y / N  
Grade Well Moderate Poorly Undifferentiated Missing Y / N 
Stage of 
tumour 
Stage 1 Stage 2 Stage 3 Stage 4 Missing Y / N 
Sub-stage of 
tumour 
a b c a b c a b c Missing Y / N 
Residual None < 2cm > 2cm Missing Y / N  
Treatment None Platinum Carboplatin Non-platinum Missing Y / N  
Follow up Deceased Date of 
Death 
Missing  Y / N  
 
Alive Date Last 
Seen 
Missing Y / N  
 

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Table 4.13 The audit results  
Noted are the instances where clean data could not be clearly found 
within the clinical record, data was missing from the database or where 
data was frankly inaccurate. The final column represents a worst case 
scenario where data in the database for which clean data could not be 
extracted is assumed inaccurate. There were no changes in the data 
extracted from the database for the 21 cases examined pre-and post- 
restructuring from study to analysis database.   
 
 Number of 
fields 
 
 
n= 
Clean data 
unavailable 
 
 
n= (%) 
Missing 
database 
data 
 
n= (%) 
Inaccurate 
data 
 
 
n= (%) 
Definitely 
complete and 
correct data 
 
n= (%) 
 
Audit 1 
Date of 
surgery 
21 0 0 0 21 (100) 
Age at 
surgery 
21 0 0 0 21 (100) 
Stage of 
tumour 
21 7 2 0 12 (57) 
Sub-stage of 
tumour 
21 8 5 0 8 (38) 
Residual 21 7 0 1 13 (62) 
Adjuvant 
Treatment 
21 1 0 1 19 (90) 
Date last 
seen 
21 0 0 0 21 (100) 
Date of 
death 
21 0 0 0 21 (100) 
Total 168 23 / 168 (6) 7 /168 (4) 2 / 138 (2) 136 / 168 (81)
 
Audit 2 
Date of 
diagnosis 
14 0 0 0 14 (100) 
Age at 
diagnosis 
14 0 0 2 12 (86) 
Stage of 
tumour 
14 3 0 0 11 (79) 
Residual  14 3 0 0 11 (79) 
Adjuvant 
treatment 
14 0 0 1 13 (93) 
Date last 
seen 
14 0 0 1 13 (93) 
Date of  
death 
14 0 0 1 13 (93) 
Total 98 6 0 5 / 92 (5) 92 / 98 (89)
 
Audit 3 
Date of 
diagnosis 
35 0 0 0 35 (100) 
Age at 
diagnosis 
35 0 0 2 33 (94) 
Stage of 
tumour 
35 10 2 0 23 (66) 
Residual  35 10 0 1 24 (69) 
Adjuvant 
treatment 
35 1 0 2 32 (91) 
Date last 
seen 
35 0 0 1 34 (97) 
Date of  
death 
35 0 0 1 34 (97) 
Total 245 21 2 7 / 222 (3) 218 / 245 (89)
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Figure 4.21 The refined audit tool 
In response to the initial audit of the study database at DCGH, it was 
updated; missing fields were populated and data were rearranged 
into analytically useful categories - producing the analysis database. 
Subsequently a further audit of 20 randomly selected cases from the 
358 cases on the TMA was performed by P.R using the audit tool 
bellow. The clean data collected were then used to assess the 
levels of correctness and completeness and thereby the accuracy of 
the analysis database. 
   
 
 
 
 
Array 
Number 
  
Agreement 
with 
information 
on database 
 
Date of 
Diagnosis 
Date Missing  Y / N  
Age at 
Diagnosis 
Years Missing  Y / N  
 
Stage of 
tumour 
Stage 1 Stage 2 Stage 3 Stage 4 Missing Y / N  
Residual No 
macroscopic 
disease 
Macroscopic 
disease 
present 
Missing  Y / N   
Treatment No adjuvant 
chemotherapy 
Adjuvant 
chemotherapy 
given 
Missing Y / N  
Follow up Deceased Date of Death Missing Y / N  
 
Alive Date Last 
Seen 
Missing Y / N  
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Analysis database – audit 3 
Pooling the data, 35 cases and 245 individual items of data were 
assessed using this refined audit tool.  21 pieces of individual data 
could not be verified due to a lack of clean data. 2 items of data (<1%) 
were missing.  7 items of data were definitely incorrect, with an overall 
rate of incorrectness of 89% if non-verifiable data are assumed to be 
inaccurate in a 99% complete sample of the analysis database.  
Applying the same standard, the outcome data were 97% correct. 
There was no evidence that the database columns had become 
misaligned. 
4.3.2. Discussion 
Though little specific evidence exists in the literature concerning the 
assessment of a retrospective database, guidelines have been 
suggested by one group. They suggest that data be extracted from the 
clinical records using a CRF by independent, specifically trained 
paramedical staff. They suggest that 20% of the cases are checked for 
100% of the most important data and that 100% of cases have 20% of 
their data checked. They arbitrarily suggest that with regards to 
clinicopathological data  >80% should be correctly recorded and that 
95% of clinical outcomes should be correct (Jansen, van Aalst-Cohen 
et al. 2005). In terms of accuracy of the records it is also important to 
set the correctness of entries in context by knowing the level of 
completeness of the database; an empty database being 100% correct 
(Hogan and Wagner 1997). Hogan and co-workers also suggest that 
data accuracy should be over 80% and that unbiased sample should be 
assessed by blinded auditors. 
At the point that the initial audit of the study database was performed, 
the main investigators were not allowed access to the clinical records or 
the database. Therefore the audit was performed by the R+D team and 
was designed to meet the studys governance requirements. It had dual 
aims  to investigate apparent irregularities in the database (e.g. where 
the type of tumour entered was not ovarian cancer) and to assess the 
accuracy of a random sample of notes relating to genuine primary 
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ovarian cancer cases. The strength of this first audit was that it was 
performed by a sufficiently qualified paramedical person who was 
independent of the investigative team, who had received some training 
as to how to interpret the medical notes from an ovarian cancer point of 
view. However, the original audit cases selected cannot be said to be 
an unbiased sample of the whole as many were investigated because 
of a suspicion that they should not be on the database at all. As a 
result, many of these cases became irrelevant and were excluded; 
leaving a small sample of 21 cases for assessment. Ideally the audit 
would have been performed on a larger (20%) random sample of cases 
more likely to be included in the study.  23 items of data on the 
database could not be verified from the medical record and this may 
have been due to the relative unfamiliarity of the worker with ovarian 
cancer cases, illegibility of the notes, loss of parts of the paper record, 
accurate information having been obtained from an unknown source or 
inappropriate entries in database. Assuming that unverifiable entries 
were the same as frankly inaccurate entries, the data were over 80% 
correct in a highly complete sample.  The data collected concerning 
histology and grade were not analysed as the wholesale review and 
updating of these attributes was being undertaken. The outcome data 
were above the 95% recommended, being 100% accurate. As these 
results reflect a worst case scenario (with some of the unverifiable 
entries likely to be correct), it provided initial reassurance about the 
accuracy of the database, albeit in a small sample.  In addition, the 
inconsistencies between the database and TCR had been explained by 
the end of the process. 
The second assessment also had dual aims  to assess the accuracy 
of a random set of cases from the newly generated analysis database 
and to screen for any systematic errors whereby columns of data had 
become misaligned during their rearrangement. This audit used a 
randomly selected sample of cases, revealing a problem with the 
logistics of auditing the database using the clinical notes as a gold 
standard. As the time span of the study was so long, many of the 
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patients original notes had been sent to off-site storage if they were 
alive or disposed of if the patient had died. The limited accessibility of 
notes therefore introduced bias, limited sample size and increased the 
resources required to perform the audit. A sample size of 20 had been 
selected to complement the 21 cases already audited but 6 of these 
cases had to be subsequently excluded due to lack of the original 
clinical record. Of these 14 cases 6 fields could not be verified which 
was the same proportion seen in the first audit and suggested that this 
was not particular to the operator.  There were no missing fields in this 
audit, which suggests that the general update of the missing data that 
had occurred during the production of the analysis data base had been 
a success. Overall the clinicopathological data met a >80% standard of 
accuracy though the outcome data were slightly bellow a 95% standard 
(93%) due to one entrys data being unverifiable. However, overall this 
audit provided reassurance concerning the integrity of the data 
following the considerable transformations that had occurred between 
versions. 
The main aim of the third audit was to use the clean data from audit 1 to 
re-audit the analysis database and to pool this data with that from audit 
2 to assess an increased sample size. A second aim was to screen 
once more for major errors introduced by erroneous sorting of the data. 
The final audits sample size was smaller than the 20% hoped for and 
approximately 10% of cases from the whole series were assessed. The 
level of inaccuracy seen in the third audit within the clean data from the 
first audit (all inaccuracies discovered during these audits being 
corrected as a final step before locking the analysis database) fell, 
reflecting a reduction in the contribution of inaccuracies from retired 
data attributes such as sub-stage. This audit confirmed a level of 
correctness for clinicopathological and outcome data above the 80% 
and 95% standards. Reassuringly the multiple rearrangements of the 
data were achieved without introducing any errors within the alignment 
of the database columns. Though individually a patients electronic 
record should be as close to 100% accurate as possible, for a study 
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designed to survey large populations of tumours this level of accuracy 
was a strong supporter of the consistency of the data. 
4.4. General discussion 
The final analysis database contained both prospective and 
retrospectively collected data. Though the prospective collection of data 
is widely felt to be superior to its retrospective collection in terms of 
quality the latter technique is increasing, as new techniques such as 
TMAs seek to make use of archived biological material. Reassuringly, 
results as accurate as prospectively executed work may be obtained if 
sufficient quality controls are in place (Concato, Shah et al. 2000). The 
database anonymisation protocol aimed to unlink the data so that 
subsequent attempts to re-identify patients using reasonable methods 
would be unsuccessful. Though obvious patient identifying fields such 
as surname were removed from the database, combinations of 
seemingly anonymous data could conceivably still be used by 
knowledgeable or malicious users to re-identify patients. If the data was 
to be anonymised to the standard required for general access, it would 
require encrypting, transforming into a query only database and 
protecting by mathematical techniques that prevent queries being run 
that can return patient identifiable combinations of data (Chiang, Hsu et 
al. 2003; Malin 2007).  As this was not feasible, the decision was made 
to physically restrict access to the database and the final SPSS 
database master copy was transferred to Professor Durants personal 
computer for day to day use in the laboratory.  It is unlikely that anyone 
could re-identify patients without a combination of malicious intent, 
particular clinical knowledge and multi-site privileges. In addition, the 
chances of harm resulting from the unauthorised re-linking of these 
data are slight, as many of the patients are deceased and much of the 
newly generated data is not be useful on the individual patient level as 
it is derived from TMA studies.  
The main aim of this chapter has been to report how the data were 
handled and to provide evidence for its consistency and substantiate 
the final analysis database and multivariate model that would be used 
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to investigate the prognostic effect of novel markers. The data crucial to 
these analyses are shown in Table 4.14. The data were over 98% 
complete and met the required standards of correctness at audit. The 
data were re-categorised in valid ways and used in that form 
reproduced known associations. Age, FIGO stage, residual disease 
and the use of chemotherapy were all independent prognostic factors; 
as predicted by the literature. Grade and histological subtype were 
important prognostic factors but without independence of effects, again 
as expected from the literature. Compared with other series, this cohort 
had a slightly higher median age, a higher number of G3 cases, was 
probably under treated with platinum based chemotherapy had a poor 
overall survival and was limited by having no objective response to 
chemotherapy data included. However the data was consistent, being 
correct, complete and valid, and suited to the investigation of the 
prognostic effect of molecular markers. 
In the previous chapter it was shown that the TMA would produce valid 
expression data and in this chapter it has been shown that the 
database was valid. In the following chapter the integration of the two to 
produce meaningful associations will be evaluated. 
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 Table 4.14 
 
The essential data in the final analysis database 
This data were used for analysing the prognostic power of novel markers 
in univariate (UV) and multivariate (MV) analysis. The factors used in the 
multivariate model were all independent prognostic factors. The 
statistically essential data are emboldened. From a total possible number 
of fields of 1356 within these four factors, 33 pieces of data were 
missing. The essential data in the analysis database was 98% complete. 
 
 
Data Column Data type Categories Missing
Data
Identifier ANO  Continuous 1-360 0
Age AGEDIAGNOSED 
(MV) 
Continuous 24 - 90 1
age - 
recode-SEER 
(UV) 
Ordinal 1:< 30 years  
2: 30-59  
3:  60 years  
1
Stage FIGO Stage 
(UV) (MV) 
Ordinal 1 :Stage I 
2: Stage  II 
3: Stage  III 
4: Stage  IV 
9 
Residual residual- 
recode-MACRO 
(UV) (MV) 
Ordinal 0: Residual disease  
1: Residual disease  
13 
Adjuvant 
treatment 
adjuvant- 
recode-ANYCHEMO 
 
(UV) (MV) 
Ordinal 0: No chemotherapy  
1: Chemotherapy  
7 
Outcome SURVIVALMONTHS Continuous 0-271 3 
DEAD Categorical 0: Alive 
1: Dead 
3 
Grade TUMOURGRADE 
(UV) 
Ordinal 0: Ungradeable 
1: Grade 1  
2: Grade 2  
3: Grade 3 
0 
Histological 
Type 
tumourtype- 
recode-BESTWORST 
(UV) 
Ordinal 1: Clear cell 
2: Mucinous 
3: Endometrioid 
4: Serous 
5: Undifferentiated 
6: other 
0 
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Chapter 5: Evaluating the Integrated Tissue Microarray 
 
In the two preceding chapters the ability of the TMA to generate reliable 
expression data and the consistency of the data in the analysis 
database were confirmed. In this chapter the integration of these two 
elements is assessed.  
The successful integration of TMA and database and the validity of 
using this as a tool to investigate the prognostic power of novel markers 
would be confirmed if it were able to reproduce the prognostic 
associations between molecular markers and outcome that other high 
quality research has identified. The ideal single molecular marker to 
validate the TMA in this way would be an accepted independently 
prognostic marker that has been confirmed as such by separate groups 
and which is prognostic in a multivariate model including all accepted 
independently prognostic clinicopathological factors. Though a plethora 
of individual studies has reported the independent prognostic power of 
immunohistochemically detected molecular markers, including CD24, 
kallikrein 9 and Actinin 4, none has yet met the criteria for being 
accepted into clinical or research practice, though CycloOXygenase2 
(COX2) and oestrogen/progesterone receptors have recently begun to 
emerge as promising candidates (Yousef, Kyriakopoulou et al. 2001; 
Kristiansen, Denkert et al. 2002; Hogdall, Christensen et al. 2007; 
Steffensen, Waldstrom et al. 2007; Yamamoto, Tsuda et al. 2007). This 
lack of translation into the clinic setting has generally been due to a 
difficulty in consistently replicating results and the use of multivariate 
models by researchers subsequently considered too incomplete to 
determine the independence of effects (Agarwal and Kaye 2005). As a 
single gold-standard molecular marker could not be identified against 
which to validate the TMA, the prognostic properties of two biomarkers, 
which have at least been widely studied and about which much is 
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known both within and without ovarian cancer, were investigated 
instead: p53 and Bcl-2. 
5.1. Introduction 
 5.1.1. Immunohistochemical staining for p53
p53 is the 53KDa gene product of the gene of the same name located 
on the short arm of chromosome 17 (17p.13) which was first discovered 
and described over 30 years ago (Linzer and Levine 1979; Lane 1992). 
With the discovery that loss of heterozygosity within chromosome 17 
was associated with the development of lung (Takahashi, Nau et al. 
1989), colonic (Baker, Fearon et al. 1989), breast (Cropp, Lidereau et 
al. 1990) and ovarian cancer (Russell, Hickey et al. 1990; Sato, Saito et 
al. 1991), researchers began to investigate a tumour suppressor role for 
the p53 gene and its product. This was subsequently confirmed by a 
massive body of work which followed. It is now known that mutations 
within the p53 tumour suppressor oncogene are present in the majority 
of cancers and mostly lie within a highly conserved region between 
exons 5 and 8 and are mainly of a missense type (Greenblatt, Bennett 
et al. 1994).  
The normal, wild type p53 (WTp53) exists in relatively small amounts 
within the cell and degrades rapidly under the control of the murine 
double minute 2 gene (MDM2) (Jones, Roe et al. 1995). Under 
circumstances of cellular stress, such as hypoxia or exposure to 
cytotoxic drugs like cisplatin, levels of p53 increase, leading to cell cycle 
arrest and subsequent DNA repair or apoptosis via a variety of 
downstream mechanisms designed to maintain the overall stability of 
the genome (Ferreira, Tolis et al. 1999). However, missense mutations 
in the p53 gene lead to the production of a mutant form of p53 which, 
as well as being functionally inactive, is stable enough to accumulate 
within the nucleus where it can be visualised using standard 
immunohistochemical techniques (Iggo, Gatter et al. 1990). The most 
commonly employed monoclonal anti-p53 antibody is the DO-7 clone, 
which stains both mutant and WTp53. Though tumours staining positive 
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with DO-7 may be expressing either form of p53, strong nuclear 
staining is widely regarded as indicating the presence of the inactive 
mutant form, as WTp53 is so rapidly degraded that its expression is 
unlikely to be reliably observed using immunohistochemistry (Pillai, 
Roberts et al. 2003). Tumour kinetics are dependent on the balance 
between cell proliferation and cell death  which within cancer systems 
may largely be due to apoptosis; a mechanism distinct from necrosis 
which is the final common pathway of action of many cytotoxic drugs 
(White 1996). As mutant p53 cannot trigger apoptosis, tumours 
expressing strong nuclear staining for p53 on immunohistochemistry 
should theoretically be more aggressive. This reasoning is supported by 
considering mutant p53s other functions which include the induction of 
vascular endothelial growth factor (Kieser, Weich et al. 1994) and 
macrophage colony stimulating factor (Asschert, Vellenga et al. 1997)  
both of which are implicated in carcinogenesis. 
The mutant pattern of immunohistochemical expression of p53 has 
subsequently been shown to be associated with poorer outcome in a 
variety of cancers, including ovarian cancer, where it has been shown 
to display both prognostic (regarding OS) (Hartmann, Podratz et al. 
1994; Henriksen, Wilander et al. 1995; Klemi, Pylkkanen et al. 1995; 
Eltabbakh, Belinson et al. 1997; Geisler, Geisler et al. 1997; Anttila, Ji 
et al. 1999; Crijns, Duiker et al. 2006) and predictive (regarding 
response to chemotherapy) power (Anttila, Ji et al. 1999; Ferrandina, 
Fagotti et al. 1999; Levesque, Katsaros et al. 2000; Reles, Wen et al. 
2001). Furthermore, occasional studies have shown this prognostic 
power to be retained following multivariate analysis (Klemi, Pylkkanen 
et al. 1995; Geisler, Geisler et al. 1997). However, these associations 
have not invariably been established and some studies have failed to 
discover such prognostic (Marks, Davidoff et al. 1991; Sheridan, 
Silcocks et al. 1994; Allan, Campbell et al. 1996; Rhei, Bogomolniy et 
al. 1998; Levesque, Katsaros et al. 2000) and predictive powers 
(Silvestrini, Daidone et al. 1998; Fallows, Price et al. 2001; 
Kupryjanczyk, Szymanska et al. 2003).  
Chapter 5: Evaluating the Integrated Tissue Microarray
215
Almost all immunohistochemical studies on mutant p53 in ovarian 
cancer have been performed on whole sections, though at least two 
have now been performed using tissue microarrays. The earlier study, 
by Lassus et al, included 500 sequential cases of serous ovarian 
cancer arranged on a tissue microarray and stained for p53 using the 
most commonly employed techniques and the DO-7 antibody. The 
authors felt that there were three distinct types of staining. There was 
weak diffuse staining similar to that seen in normal tissue, strong 
nuclear staining and tumours which were entirely negative for p53. 
They concluded that tumours staining completely negative for p53 and 
those staining strongly for p53 represented an abnormally functioning 
p53 gene and they grouped them together in a category termed 
aberrant p53. Tumours with >20% of cells or <50%of cells staining 
positive for p53 were considered to be expressing WTp53 and were 
considered a separate, normal entity. Using these criteria, aberrant p53 
expression was found to be associated with reduced OS following 
multivariate analysis (Lassus, Leminen et al. 2003). The second study 
by the van der Zee group combined populations from two centres and 
stained 5 copies of an array containing 476 patients using the DO-7 
antibody at a low concentration, 1:2000. This team set their cut-off at 
50%, due to the presence of weak background staining in their control 
tissues (presumed to indicate WTp53). They found no associations with 
OS and were unable to replicate the Lassus studys findings (de Graeff, 
Hall et al. 2006).  
In the current study the TMA was stained with the most commonly 
employed technique. The DO-7 antibody was selected and nuclear 
staining in  10% of cells within a core defined positivity for mutant p53 
with other staining assumed to indicate the presence of WTp53 (Kerns, 
Jordan et al. 1992; Baas, Mulder et al. 1994; Kmet, Cook et al. 2003). 
After the staining data had been acquired, the serous tumours were 
considered separately and the staining data were re-categorised using 
the cut-offs suggested by Lassus and co-workers to define aberrant 
p53 expression. 
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The hypothesis was that the expression data from this TMA would 
reproduce the clinicopathological associations published by other 
groups.  
5.1.2. Immunohistochemical staining for Bcl-2 
Bcl-2 is an oncoprotein encoded by the gene of the same name which 
is located on chromosome 18 and which was first described in the 
context of B-Cell Lymphoid tumours over 20 years ago (Cleary, Smith 
et al. 1986). The gene encodes not one but a family of proteins, within 
the so-called Bcl-2 family, which regulate apoptosis. Some are pro-
apoptotic (Bax, Bak, BAD) (Oltvai, Milliman et al. 1993; Farrow, White 
et al. 1995) while others are anti-apoptotic (Bcl-2, Bcl-x) (Hockenbery, 
Nunez et al. 1990) (Vaux, Cory et al. 1988; Boise, Gonzalez-Garcia et 
al. 1993). Bcl-2 itself prevents apoptotic stimuli from orchestrating the 
release of cytochrome c from mitochondria and thereafter the 
downstream activation of capsases  the irreversible final common 
pathway of apoptosis which leads to the demolition of the cell (Reed 
1997; Youle and Strasser 2008). In non-lymphoid tissues, the 
expression of Bcl-2 is generally restricted to tissues such as neurones 
(post-mitotic long lived cells), skin (long lived stem cells) or breast 
(glandular tissue under hormonal control regarding involution) with 
Bcl-2 not generally being seen within normal ovarian tissue 
(Hockenbery, Zutter et al. 1991).  
Bcl-2 expression has, however, been widely studied in ovarian cancer 
with respect to its prognostic and predictive properties and may be 
visualised immunohistochemically in between 20% and 50% of ovarian 
cancers, depending on the antibody employed and the specific 
methods employed to stain and evaluate tissue sections (Baekelandt, 
Kristensen et al. 1999; Mano, Kikuchi et al. 1999; Kupryjanczyk, 
Szymanska et al. 2003; Eltabbakh, Mount et al. 2004; Lee, Park et al. 
2005). Being a protein involved in antagonising apoptosis, Bcl-2 
expression might be expected to be associated with ovarian cancers 
that proliferate aggressively, poorer survival and greater resistance to 
chemotherapy. While this has occasionally been shown to be the case 
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(Mano, Kikuchi et al. 1999), Bcl-2 expression has more often been 
shown to either have no effect on response to chemotherapy and 
survival (Marone, Scambia et al. 1998; Silvestrini, Daidone et al. 1998; 
Geisler, Geisler et al. 2000; Kupryjanczyk, Szymanska et al. 2003) or 
have a counterintuitively positive effect on them (Henriksen, Wilander et 
al. 1995; Herod, Eliopoulos et al. 1996; Marx, Binder et al. 1997; 
Baekelandt, Kristensen et al. 1999; Diebold 2003; Ferlini, Raspaglio et 
al. 2003) 
In the current study the TMA was stained for Bcl-2 using standard 
techniques and reagents to investigate whether it would produce 
associations between clinicopathological and expression data which 
were concordant with those in the literature. Cases with an average of 
>10% of cells staining positive for Bcl-2 in the cytoplasm were 
considered positive for Bcl-2 expression, a cut-off used by other 
workers (Nezhat, Cohen et al. 2002; Lee, Park et al. 2005).  
5.1.3. Analysis of the combined p53/Bcl-2 immunophenotype 
In breast and colorectal cancer it has been shown that co-expression of 
markers may reveal independently prognostic information that is not 
apparent on examination of the individual markers themselves. In 
breast cancer, the p53 (+) Bcl-2 (-) immunophenotype represents a 
state independently prognostic of poor prognosis (Rolland, Spendlove 
et al. 2007). In colorectal cancer, the p53(-) Bcl-2(+) immunophenotype 
was found to be independently prognostic of good prognosis (Watson, 
Madjd et al. 2005). Therefore, in this study the data generated in 
5.2 and 5.3 are combined and the prognostic power of the four possible 
p53 (+/-) Bcl-2 (+/-) immunophenotypes is investigated with respect to 
the hypothesis that a p53 (+) Bcl-2 (-) immunophenotype would be 
associated with an aggressive phenotype. 
The expression data were combined to generate immunophenotypes 
and Kaplan-Meier plots were produced for each. The 
immunophenotypes were subsequently regrouped into two groups on 
the basis of their prognostic behaviour  relatively good or relatively 
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poor  and these groups were then used to investigate univariate 
associations with clinicopathological factors and survival and to test for 
independence of effects. 
5.2. Results 
 5.2.1. Immunohistochemical staining of p53
The location of staining was as expected, within the nucleus (Figure 
5.1a, b) with negative controls not staining (Figure 5.1c) (Kerns, Jordan 
et al. 1992). Concordance approached 100%. The median percentage 
of cells expressed was <5% (Figure 5.1d). Of the 339 cases of ovarian 
cancer included in the study, 306 had p53 expression data available for 
analysis, indicating a rate of core loss of 10% (Figure 5.2). Of the cases 
analysed, 44% were p53 positive as defined by >10% of cells staining 
positive per case (Table 5.1). There were no obvious major differences 
between the clinicopathological characteristics of the whole series of 
395 cases and the analysed group of 306 (Table 5.2). On univariate 
analysis using the Ȥ2 method p53 positive status was found to be 
associated with advancing FIGO stage, sub-optimally debulked cases, 
higher grade cancers and those cases having a worse histological 
subtype (Table 5.2). The Kaplan-Meier plot (Figure 5.3) illustrates that 
p53 positive tumours had a poorer survival. This association with 
survival was not independent of other clinicopathological parameters on 
Coxs regression (Table 5.3); though as expected patient age, FIGO 
stage, degree of cytoreduction and the use of chemotherapy were 
independently prognostic of OS. 
Concerning the sub-analysis of the serous ovarian cancers to facilitate 
comparison with the results of the Lassus group, 164 cases were 
available for analysis of which 138 (84%) expressed the aberrant form 
of p53 (Figure 5.4) (Table 5.4). The Kaplan-Meier plot (Figure 5.5) 
showed a relationship between aberrant p53 expression and improved 
survival. This prognostic power was not independent of other 
clinicopathological factors (Table 5.5) (Lassus, Leminen et al. 2003). 
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Figure 5.1 p53 expression  
 
 
Figure 5.1a Example of nuclear p53 staining seen at x 200 magnification on 
the positive control tissue 
 
 
 
 
 
 
Figure 5.1b Example of nuclear p53 staining seen at x 400 magnification on 
the positive control tissue 
 
 
 
  
Chapter 5: Evaluating the Integrated Tissue Microarray
220
Figure 5.1c The negative control in the p53 staining arm showed no staining 
– seen at x 200 magnification  
 
 
 
 
 
 
 
Figure 5.1d Histogram showing the degree of p53 expression within the 
series 
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Figure 5.2 Flow diagram showing how a group of 298 tumours with data 
available concerning p53 and Bcl-2 expression was generated   
 
 
 
 
Figure 5.3 Kaplan – Meier curve showing the negative effect of positive p53 
expression status on survival 
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Table 5.1 The distribution of the immunohistochemical expression of p53,  
Bcl-2 and their combined phenotypes 
 
 n
o
 cases % of cases 
 
 
p53 % cells staining n=306  
0-25 190 62 
26-50 37 12 
51-75 59 19 
76-100 20 7 
p53 Positive (>10% cells staining) 136 44 
 
Bcl-2 % cells staining n=323  
0-25 257 80 
26-50 37 12 
51-75 16 5 
76-100 13 4 
Bcl-2 Positive (>10% cells positive) 142 44 
 
 
p53 Bcl-2 Phenotypes 
 
n=298  
Improved prognosis phenotype   
p53(-) Bcl-2 (+) 77 26 
  
Other phenotypes   
p53(-) Bcl-2 (-) 87 29 
p53(+) Bcl-2 (+) 82 27 
p53(+)  Bcl-2 (-) 52 18 
Combined other phenotypes 221 74 
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Table 5.2 The main clinicopathological characteristics of the entire series and 
those of the tumours expressing p53 
 A univariate analysis by Ȥ2 of p53 status vs. clinicopathological criteria is 
also shown. 
 Whole series
 
Analysed cases
 
p53 (+) 
 
p53 (-) 
 
Ȥ2 
(p=) 
 
 n
o
 cases 
(%) 
n
o
 cases 
(%) 
n
o
 cases
(%) 
n
o
 cases 
(%) 
 
 
FIGO Stage n=375 n=297 n=131 n=166 
 
 
1 99 (26) 75 (25) 18 (14) 57 (34)  
2 46 (12) 35 (12) 12 (9) 23 (14)  
3 188 (50) 152 (51) 79 (60) 73 (44) 22.48 
4 42 (11) 35 (12) 22 (17) 13 (8) (<0.001)
 
Optimally   
Debulked 
n=376 n=294 n=130 n=164  
Yes 157 (42) 119 (41) 32 (25) 87 (53) 24.33 
No 219 (58) 175 (60) 98 (75) 77 (47) (<0.001)
 
Grade n=376 n=304 n=135 n=169 
 
 
1 50(13) 34 (10) 10 (7) 24 (14)  
2 93 (25) 66 (22) 25 (19) 41 (24) 5.99 
3 233 (62) 204 (67) 100 (74) 104 (62) (<0.001)
 
Histological  
Type 
n=395 n=306 n=136 n=170  
Serous 203 (51) 164 (54) 81 (60) 83 (49)  
Endometrioid 46 (12) 38 (12) 11 (8) 27 (16)  
Mucinous 50 (13) 30 (10) 11 (8) 19 (11)  
Undifferentiated 65 (17) 47 (15) 26 (19) 21 (12)  
Clear cell 26 (7) 23 (8) 4 (3) 19 (11) 16.64 
Other 5 (1) 4 (1) 3 (2) 1  (0.001) 
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Table 5.3 Multivariate analysis of p53 expression by Cox’s regression 
p53 status does not predict prognosis independently of other 
clinicopathological parameters. 
 
 Hazard Ratios
(95% Confidence intervals) 
Significance (p)
 
Age at diagnosis (years) 1.028 (1.017-1.040) <0.001 
   
FIGO Stage   
1  <0.001 
2 2.754 (1.565 – 4.845) 0.001 
3 5.250 (3.149 -8.751) <0.001 
4 6.623 (3.637-12.062) <0.001 
 
Residual macroscopic disease 2.167  (1.522 – 3.085) <0.001 
 
Patient received 
chemotherapy 
0.494 (0.342 – 0.713) <0.001 
 
p53 Positive 0.949 (0.73-1.233) 0.695 
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Figure 5.4 Flow diagram illustrating how a group of 164 serous ovarian 
cancers became available for analysis and the distribution of 
aberrant p53 staining within that group 
 
 
 
 
 
Figure 5.5 Kaplan-Meier curve showing the positive effect of aberrant p53 
expression status on survival  
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Table 5.4 The distribution of cases into aberrant and normal p53 expression 
within the serous ovarian cancer subset using the criteria of Lassus 
et al (Lassus, Leminen et al. 2003) 
 
 n
o
 cases % of cases 
 
p53 % cells staining 164  
 20 (Negative) 89 54 
> 20  50 (Normal) 26 16 
>  50 49 30 
 20 or > 50 (Aberrant p53 expression) 138 84 
Table 5.5 Multivariate analysis by Cox’s regression of aberrant p53 
expression described by Lassus et al (Lassus, Leminen et al. 2003) 
This classification does not retain independent prognostic significance 
when analysed in conjunction with other clinicopathological factors in our 
model. 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
 
Age at diagnosis (years) 1.026 (1.009-1.044) 0.002 
 
FIGO Stage   
1  0.004 
2 2.008 (0.864  4.664) 0.105 
3 2.973 (1.439  6.142) 0.003 
4 5.102  (2.090  12.454) <0.001 
 
Residual macroscopic 
disease 
2.313 (1.441  3.714) 0.002 
 
Patient received 
chemotherapy 
0.321 (0.195  0.531) <0.001 
 
p53 – Aberrant Expression 
 
0.791 (0.500  1.252) 0.317 
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5.2.2. Immunohistochemical staining of Bcl-2 
 
The staining was located as expected, within the endoplasmic reticulum 
and mitochondrial membrane (Figure 5.6a) (Hockenbery, Nunez et al. 
1990). The negative controls did not stain (Figure 5.6b). Concordance 
was evaluated and found to be in excess of 90%. The median 
percentage cell staining within tumours was 5% (Figure 5.6c). 323 
cases had Bcl-2 expression data available for analysis, indicating a 
core loss of 5% (Figure 5.2). Of the cases analysed 142 (44%) were 
Bcl-2 positive (Table 5.1). There were no obvious major differences 
between the clinicopathological characteristics of the whole series of 
394 and the analysed group of 323 (Table 5.6). On univariate analysis, 
Bcl-2 positive status had no statistically significant associations with 
clinicopathological parameters (Table 5.6). Though the Kaplan-Meier 
plot (Figure 5.7) initially appeared to indicate that Bcl-2 status stratified 
the cases into separate prognostic groups, there was no statistically 
significant difference found and so a multivariate analysis was not 
performed. 
5.2.3. Analysis of the combined p53/Bcl-2 immunophenotype
298 cases possessed the data concerning p53 and Bcl-2 expression 
required to be included in the co-analysis (Figure 5.2). There were no 
concerns that this was an unrepresentative sample of the entire series 
on comparing clinicopathological data (Table 5.7). There was no 
association between the expression of p53 and the expression of Bcl-2 
(1.93; P=0.159). The cases were numerically evenly distributed 
between the four possible immunophenotypes (Table 5.1) and the 
Kaplan-Meier curves (Figure 5.8) demonstrated that these groupings 
were prognostic, with three of the immunophenotypes performing 
similarly with respect to prognosis while a fourth (the p53 (-) Bcl-2 (+) 
phenotype) behaved differently and predicted a better prognosis 
(Figure 5.9). On univariate analysis the possession of this better 
prognostic phenotype was not associated with patient age, FIGO stage, 
histological subtype or the use of chemotherapy. However, it was 
associated with a lower grade of disease and an increased likelihood of 
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Figure 5.6 The expression of Bcl-2 
 
 
Figure 5.6a Example of a tissue microarray core staining positive for Bcl-2 
seen at x 200 magnification 
 
 
 
 
Figure 5.6b The tonsillar tissue used as a negative control in the Bcl-2 arm 
did not stain – seen at x 200 magnification 
 


 
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Figure 5.6c Histogram showing the range of percentage of cells staining with 
the Bcl-2 antibody within the cases and the median value 
 


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Table 5.6 The main clinicopathological characteristics of the entire series 
and those of the tumours expressing Bcl-2  
Univariate analysis by Ȥ2 of Bcl-2 status vs. clinicopathological 
criteria is also shown. 
 
 Whole 
series 
 
Analysed cases
 
Bcl-2 
Positive 
 
Bcl-2 
Negative 
 
Ȥ2
(p=) 
 
 n
o
 cases (%) 
 
n
o
 cases (%) n
o
 cases (%) n
o
 cases (%)  
 
Age n=394 
 
n=322 n=142 n=180  
< 30  1 1 1 0 
30  59  167 (42) 130 (40) 54 (38) 76 (42) 1.78 
>60  226 (57) 191(59) 87 (61) 104 (58) (0.41) 
 
FIGO Stage n=375 n=314 n=140 n=174  
1 99 (26) 81 (26) 38 (27) 43 (25) 
2 46 (12) 34 (11) 17 (12) 17 (10) 
3 188 (50) 162 (52) 71 (51) 91 (52) 1.30 
4 42 (11) 37 (12) 14 (10) 23 (13) (0.73) 
 
Optimally  
Debulked 
n=376 n=311 n=136 n=175  
Yes 157 (42) 125 (40) 59 (43) 66 (38) 1.02 
No 219 (58) 186 (60) 77 (57) 109 (62) (0.31) 
 
Chemotherapy n=388 n=316 n=140 n=176 
 
 
Yes 283 (73) 228 (72) 99 (71) 129 (73) 
No 104 (27) 88 (28) 41 (29) 47 (27) 0.26 
Platinum 195 (50) 160 (51) 70 (50) 90 (51) (0.61) 
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Figure 5.7 Kaplan-Meier curve showing the lack of association between Bcl-2 
expression and survival 
 

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Table 5.7 The main clinicopathological characteristics of the entire series 
and those of the tumours expressing the p53(-) Bcl-2 (+) 
phenotype  
A univariate analysis by Ȥ2 of this phenotype status vs. 
clinicopathological criteria is also shown. 
 
 Whole 
series 
 
Analysed 
cases 
 
Other 
Phenotypes 
 
p53 (-) 
Bcl-2 (+) 
 
Ȥ2 
(p=) 
 
 n
o
 cases 
(%) 
n
o
 cases 
(%) 
n
o
 cases 
(%) 
n
o
 cases 
(%) 
 
 
` 
FIGO Stage n=375 
 
n=289 n=213 n=76  
1 99 (26) 74 (26) 47 (22) 27 (36) 
2 46 (12) 34 (12) 24 (11) 10 (13) 
3 188 (50) 148 (51) 114 (54) 34 (45) 7.09 
4 42 (11) 33 (11) 28 (13) 5 (7) (0.07) 
 
Optimally  
Debulked 
 
n=376 n=286 n=212 n=74  
Yes 157 (42) 117 (41) 77 (36) 40 (54) 7.14 
No 219 (58) 169 (59) 135 (64) 34 (46) (0.008) 
 
Grade n=376 n=296 n=219 n=77 
 
 
1 50(13) 34 (12) 19 (9) 15 (20) 
2 93 (25) 64 (22) 45 (21) 19 (25) 8.138 
3 233 (62) 198 (67) 155 (71) 43 (56) (0.002) 
 
Chemotherapy n=386 n=291 n=215 n=76 
 
 
Yes 276 (72) 214 (74) 163 (76) 51 (67)  
No 110 (29) 77 (26) 52 (24) 25 (33) 2.19 
Platinum 195 (50) 149 (51) 114 (50) 35 (46) (0.14) 
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Figure 5.8 Kaplan-Meier curve showing the differential effect on survival of 
the four different p53 (+/-) Bcl-2 (+/-) immunophenotypes  
The p53 (-) Bcl-2 (+) phenotype was associated with an  improved 
prognosis.  
 

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Figure 5.9 Kaplan-Meier curve showing the association of a  p53 (-) Bcl-2 (+) 
immunophenotype with  improved survival  


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optimal cytoreduction at operation (Table 5.7). The association with 
improved survival found on univariate analysis was not maintained 
when looking for the independence of effects using Coxs proportional 
hazards model (Table 5.8).
5.3. Discussion 
p53 
In this study we found that 44% of cases stained positive for p53, which 
compares well to what has been found in other studies (43-47%) (Kmet, 
Cook et al. 2003)[Reviewed]. p53 positive tumours were associated 
with the clinicopathological features of aggressive disease, which has 
been found by most studies investigating the prognostic significance of 
the immunohistochemical expression of p53 in ovarian cancer (Marks, 
Davidoff et al. 1991; Klemi, Pylkkanen et al. 1995; Allan, Campbell et al. 
1996; Diebold, Baretton et al. 1996; Eltabbakh, Belinson et al. 1997; 
Anttila, Ji et al. 1999). p53 was associated with reduced survival in a 
univariate analysis which agrees with many studies (Hartmann, Podratz 
et al. 1994; Henriksen, Wilander et al. 1995; Klemi, Pylkkanen et al. 
1995; Eltabbakh, Belinson et al. 1997; Geisler, Geisler et al. 1997; 
Anttila, Ji et al. 1999; Crijns, Duiker et al. 2006) but is at dissonance 
with others (Marks, Davidoff et al. 1991; Sheridan, Silcocks et al. 1994; 
Allan, Campbell et al. 1996; Rhei, Bogomolniy et al. 1998; Levesque, 
Katsaros et al. 2000). p53 did not have independent prognostic power 
in this series, though this has been found in other work (Klemi, 
Pylkkanen et al. 1995; Geisler, Geisler et al. 1997). In this multivariate 
model, chemotherapy was found to be an independent prognostic 
factor. Though no data were available concerning response to 
chemotherapy in this series, other workers have found p53 
abnormalities to be associated with a poorer response to 
chemotherapy, as would be biologically plausible (Anttila, Ji et al. 1999; 
Ferrandina, Fagotti et al. 1999; Levesque, Katsaros et al. 2000; Reles, 
Wen et al. 2001). An intrinsic link between p53 expression, response to 
chemotherapy and survival might explain why p53 expression lost its 
prognostic power on multivariate analysis in this series, though it must 
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Table 5.8 Multivariate analysis by Cox’s regression  
The p53 (-) Bcl-2 (+) phenotype, which predicts good prognosis, does not 
retain independent prognostic power when analysed together with other 
clinicopathological parameters. 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance (p) 
 
Age at diagnosis (years) 1.028 (1.016-1.041) <0.001 
 
FIGO Stage   
1  <0.001 
2 2.042 (1.150 – 3.628) 0.015 
3 3.773 (2.253 – 6.317) <0.001 
4 5.010 (2.700 – 9.297) <0.001 
 
Residual macroscopic 
disease 
1.886  (1.321 – 2.693) <0.001 
 
Patient received 
chemotherapy 
0.836 (0.543 – 1.288) 0.836 
 
Good prognosis phenotype 
 
p53(-) Bcl-2 (+) 
 
 
0.746 (0.538 – 1.033) 
 
 
0.695 
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be noted that the ability of p53 to predict response to chemotherapy 
has not been universally found (Silvestrini, Daidone et al. 1998; 
Fallows, Price et al. 2001; Kupryjanczyk, Szymanska et al. 2003). 
Within the subset of 164 serous ovarian cancers, employing the criteria 
of Lassus et al, 54% of tumours were defined negative for p53 and 84% 
expressed aberrant p53. There was a statistically significant association 
between this aberrant form and survival but it was the reverse of what 
was found by the Lassus group, as it predicted improved survival and 
did not persist following multivariate analysis. The effect of dividing our 
group by Lassus criteria was to transfer many tumours that were 
considered p53 positive on the basis of standard criteria, 10% of 
nuclei staining strongly (which were associated with a poorer prognosis 
in this series), into a normal category. This may explain why the 
polarity of our findings in this analysis is the reverse of the Lassus 
group. Lassus et al describe a system that may account for the 
expression of WTp53 detected by DO-7 and, though this makes 
biological sense, it could be that their criteria for allocating cases were 
more subtle than a numerical cut-off could describe. Though the 
findings of the Lassus group could not be reproduced, this is in keeping 
with the van der Zee group (Crijns, Duiker et al. 2006). This second 
studys findings were replicated by this work regarding the univariate 
associations between p53 expression and higher FIGO stage, grade 
and chance of suboptimal surgery. While they did not demonstrate a 
similar association with survival, this could explained by their setting of 
the cut-off for abnormal p53 expression at 50%, which is a high level 
compared to most previously published studies.  
The lack of consistency between the findings of published work might 
be explained by methodological differences such as the type of tissue 
used, the antibodies employed, the scoring systems employed, 
differences between the studied groups and the factors included in the 
multivariate model (Shahin, Hughes et al. 2000). Another explanation 
remains: the use of immunohistochemistry as a tool for investigating 
disruption of p53 function. Although immunohistochemistry has been 
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shown to have a high correlation with gene sequencing for detecting 
missense mutations in the p53 gene (Sheridan, Silcocks et al. 1994) 
the immunohistochemically determined rate of non-functional p53 is 
lower than the actual rate that would be detected on full sequencing of 
the gene from exon 2 through 11 looking for null mutations not 
associated with the production of a stable mutant p53 gene product 
(Skilling, Sood et al. 1996). While missense mutations make up the 
majority of p53 mutations amongst ovarian cancers, 
immunohistochemistry has been shown to have superior prognostic 
power when sequencing data concerning null mutations are combined 
with it (Shahin, Hughes et al. 2000). However, with 
immunohistochemical detection of p53 having quite a high negative 
predictive value for p53 mutations (81%) (Wang, Helland et al. 2004) 
researchers have been undeterred and there are currently over 150 
citations including (p53; Ovarian cancer; Prognosis) (PubMed 2008), 40 
of which were of sufficient quality to be included in a meta-analysis 
(Crijns, Boezen et al. 2003).  
In summary, the TMA was able to reproduce the findings of a significant 
body of work into the immunohistochemical expression of p53 in 
ovarian cancer though, due to inconsistency in the literature, doing this 
inherently contradicted the findings of other work. The state of the 
current literature highlights the importance of attempting to adhere to as 
standardised a method as possible when investigating p53 
immunohistochemically and following the ReMARK guidelines is to be 
recommended (McShane, Altman et al. 2006). 
Bcl-2 
In this study, 44% of tumours stained positively for Bcl-2 which lies 
within the expected range of 20-50% suggested by other groups work 
(Baekelandt, Kristensen et al. 1999; Mano, Kikuchi et al. 1999; 
Kupryjanczyk, Szymanska et al. 2003; Eltabbakh, Mount et al. 2004; 
Lee, Park et al. 2005). In line with other studies it was found that Bcl-2 
was not associated with any clinicopathological factors. Although this 
made it more likely that any prognostic power would be independent in 
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nature, as in these other studies a statistically significant difference in 
OS was not found (Mano, Kikuchi et al. 1999; Schuyer, van der Burg et 
al. 2001; Kupryjanczyk, Szymanska et al. 2003). It was, therefore, 
inappropriate to include Bcl-2 expression into the multivariate model as 
this may have led to a type I error.  
Considering the biology of Bcl-2 in more depth can help explain why no 
associations were found by this work and that of other groups and can 
also help explain why when associations between Bcl-2 expression and 
survival have been found they have indicated a counterintuitive link with 
better outcome (Henriksen, Wilander et al. 1995; Herod, Eliopoulos et 
al. 1996; Marx, Binder et al. 1997; Baekelandt, Kristensen et al. 1999; 
Diebold 2003; Ferlini, Raspaglio et al. 2003). Firstly, Bcl-2 has been 
shown not only to block apoptosis but to have a function independent of 
this whereby it can slow the cell cycle at various points, thereby 
inhibiting proliferation which leads to tumour survival but in an indolent 
form (Mazel, Burtrum et al. 1996; Vairo, Innes et al. 1996; Lind, Wayne 
et al. 1999; Vairo, Soos et al. 2000; Belanger, Cote et al. 2005). 
Secondly, given their ability to form hetero- and homo-dimmers, it is 
now thought that a more complicated story explains the Bcl-2 family 
proteins control over apoptosis whereby the relative levels of their 
members determine which of their individual functions predominate 
(Youle and Strasser 2008). The ratio of Bcl-2 to Bax is important and it 
has been shown that Bax triggers cell death more effectively in tumours 
where Bcl-2 is expressed more highly and that outcome may be 
improved in these circumstances (Oltvai, Milliman et al. 1993; Marx, 
Binder et al. 1997; Schuyer, van der Burg et al. 2001). Therefore, 
considering the co-staining of Bax and Bcl-2 in our series may have 
yielded more prognostically useful information. Finally, it has been 
noted that cleavage of a regulatory loop domain of Bcl-2 by capsases 
can convert it into a Bax-like death effector initiating a self potentiating 
cascade toward apoptosis. This would occur more readily in 
environments of relative Bcl-2 abundance (Cheng, Kirsch et al. 1997).  
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While the findings of the TMA staining with Bcl-2 were unremarkable 
they were, however, consistent with a large body of 
immunohistochemical work performed in this area and further support 
the validity of the findings produced using the integrated TMA. 
p53 / Bcl-2 immunophenotypes 
The loss of tissue cores in tissue microarray work can be problematic 
when co-expression data for cases are being analysed. In this study, 
10% of cores were lost in the p53 experiment and 5% were lost in the 
Bcl-2 arm, which were individually within acceptable limits for TMA work 
(Hoos and Cordon-Cardo 2001; Henshall 2003). However, though a 
maximum loss of cases of 15% through studying these two markers 
together did not occur, 12% of cases had incomplete co-expression 
data which was still at the high end of an acceptable range. Fortunately, 
despite this loss of data, the power of the study was unaffected 
(approximately 300 cases were still available) and this tissue loss 
appeared random in nature with no skewing of the clinicopathological 
data detected. 
The results show that one immunophenotype has a different prognosis 
to the others. The p53 (-) Bcl-2 (+) expressing tumours have the best 
prognosis with a 5-year survival, almost double that of the other 
phenotypes combined (39.5% vs. 21.5%). In this work, no relationship 
between the expression of p53 and Bcl-2 was found, which is at 
variance to work in breast and colorectal cancer and one study 
involving small numbers of ovarian cancers where inverse relationships 
have been described (Rolland, Spendlove et al. 2006; Watson, Durrant 
et al. 2006) (Henriksen, Wilander et al. 1995). However, it is in keeping 
with the majority of work in ovarian cancer where this association has 
been investigated (Herod, Eliopoulos et al. 1996; Baekelandt, 
Kristensen et al. 1999; Geisler, Geisler et al. 2000; Schuyer, van der 
Burg et al. 2001; Kupryjanczyk, Szymanska et al. 2003; Lee, Park et al. 
2005). This studys hypothesis, that the p53 (+) Bcl-2 (-) phenotype 
would lead to particularly aggressive behaviour as seen in breast 
cancer, remained unsubstantiated. Ovarian cancer appears to have 
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more in common with colorectal cancer, where the Bcl-2 positive 
tumours within the p53 negative group also had the best prognosis. 
This may be understandable, given the occasional clinical mimicry of 
the two diseases which can sometimes be impossible to resolve. 
Though the prognostic information provided by co-expression data 
does not reach independent significance, its univariate association is 
less likely to have occurred when compared to the prognostic capability 
of p53 alone (p=0.01 vs. p=0.02). An additional advantage of 
considering Bcl-2 expression in combination with p53 data is that this 
identifies cases with a prognosis better than normal, whereas p53 
status alone stratifies cases into two groups of differently poor 
prognoses. Considering the multivariate analysis, it is interesting to note 
that the independent prognostic power of chemotherapy use becomes 
non-independent on the addition of this new prognostic group, implying 
that their influences on outcome are mechanistically interrelated. This 
connection is not predicted by a univariate association and so it may be 
that this immunophenotype has the power to predict response to 
chemotherapy rather than whether a patient would receive it. However, 
a lack of data concerning response to chemotherapy in this series 
makes it impossible to investigate this hypothesis further. These 
findings concerning the co-expression of p53 and Bcl-2 support 
previous work in stage III ovarian cancers (Baekelandt, Kristensen et al. 
1999). This group also found that p53 expression (but not Bcl-2 
expression) was predictive of OS and, in addition, they concluded that 
the co-expression of these factors was a better predictor of prognosis 
than the individual markers themselves. They found that 21% of their 
cases expressed a p53 (-) Bcl-2 (+) phenotype and that this predicted 
better prognosis independently of other clinicopathological factors. The 
slightly lower frequency of this immunophenotype compared to that 
found in the current study (26%) may be due to the addition of all 
stages (including better prognostic stage I and II cases), which would 
also explain why this immunophenotype was not independently 
prognostic in this work. Importantly, the Baekelandt group did not 
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discover any predictive capabilities for these markers when used alone 
or in combination with regard to response to chemotherapy.  
It is biologically plausible that a combination of differential p53/Bcl-2 
expression data should prove synergistic: p53 negative tumours may 
retain a functional apoptotic pathway and tumours expressing Bcl-2 
have a protein present which slows their proliferation, which are both 
potentially potent anti-tumour processes. However, in addition, WT p53 
may trigger apoptosis by upregulating the expression of Bax more 
effectively in the presence of higher levels of Bcl-2 (Oltvai, Milliman et 
al. 1993; Miyashita, Kitada et al. 1995; Miyashita and Reed 1995; 
Jones, Turner et al. 1998) and this functional interdependence due to 
cross-talk between p53, Bax and Bcl-2 has been established for some 
time (Eliopoulos, Kerr et al. 1995).  
It is, therefore, logical that p53 (-) Bcl-2 (+) tumours should have the 
best prognosis and, while their response to chemotherapy is also likely 
to be better, this may be better established by suitably designed 
prospective work. 
5.4. General discussion 
The principal aim of this section was to evaluate whether this TMA and 
database were linked in such a way as to be able to effectively 
reproduce prognostic information generated in other studies. From this 
point of view, it is interesting to note that the co-staining data, 
generated principally to facilitate comparison with published work in 
breast and colon cancer, produced an unexpected finding which, on 
subsequent review of the literature, had incidentally almost completely 
successfully replicated a previous high quality study in ovarian cancer 
(Baekelandt, Kristensen et al. 1999). 
Given the volume of published data concerning these two markers in 
ovarian cancer and the irresolvable methodological differences 
between studies, it is only possible to decide what should have been 
found in this large series of ovarian cancers by observing what has 
been found by a majority of workers. In this context it is not 
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controversial to state that p53 is usually associated with aggressive 
disease and worse survival and is not an independent marker for 
prognosis in ovarian cancer while Bcl-2 expression is probably not a 
prognostic marker on its own, though it might have some prognostic 
influence for improved outcome in p53 negative tumours. Our findings 
are, therefore, in line with the main body of work in this area. One of the 
major conclusions of this section is the importance of adopting a 
consistent approach to the investigation of molecular markers. For that 
reason, this study has sought to follow practice which would allow its 
data to be replicated or incorporated into a future meta-analysis 
(McShane, Altman et al. 2006).  
As there was no gold-standard marker that could be employed in order 
to incontrovertibly prove the effectiveness of the integration of the TMA, 
this section aimed instead to replicate meaningful data for two 
commonly studied molecular markers in order to support the use of the 
TMA in studying novel markers about which little is known. While this 
has been successful it has also identified interesting avenues for further 
investigation, particularly regarding the predictive power of p53 (+/-) 
Bcl-2 (+/-) phenotypes within the clinical setting.  
Having confirmed the validity of the TMA in producing expression data, 
the consistency of the database and the validity of using the two 
together, the following chapters will describe the expression and 
prognostic significance of novel immunological molecular markers. 
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Chapter 6: HLA Class I Antigen Expression is an 
Independent Prognostic Factor in Ovarian Cancer 
 
6.1. Introduction  
 
Ovarian cancer is the most common gynaecological cancer in the UK 
and represents the fourth most common cancer site in women. Its low 
5-year survival of 29% has altered little over the last 40 years despite 
advances in treatment (Quinn 2001). Improving our understanding of 
the molecular events which underlie the divergent outcomes of 
apparently identical cases through the search for biomarkers which 
predict prognosis independently of traditional criteria is fundamental to 
the development and subsequent targeting of novel treatments.  
Downregulation of Human Leucocyte Antigen (HLA) class I antigen 
expression has been documented in a variety of tumours, including 
ovarian cancer, and is often, though not exclusively, associated with 
features of aggressive disease and a poorer prognosis (Kabawat, Bast 
et al. 1983; Stein, Momburg et al. 1988; Concha, Esteban et al. 1991; 
Levin, Klein et al. 1991; Hicklin, Marincola et al. 1999; Vitale, Pelusi et 
al. 2005; Norell, Carlsten et al. 2006). HLA class I antigen 
downregulation as a biomarker has also been shown to have prognostic 
powers in breast and colon cancer independent of the traditional 
prognostic markers for these diseases (Madjd, Spendlove et al. 2005; 
Watson, Ramage et al. 2006). In ovarian cancer the presence of tumour 
specific cytotoxic T-cells (CTL) within the tumour infiltrating lymphocytes 
of advanced ovarian cancer suggest an important role for HLA class I 
antigens (Santin, Bellone et al. 2004). However, while HLA class I 
antigen downregulation has been shown to predict poor prognosis in 
aneuploid types (Moore, Fowler et al. 1990), the independence of this 
prognostic power is as yet unreported in unselected ovarian neoplasms.  
The aim of this study was thus to investigate whether HLA class I 
antigen downregulation predicts prognosis in unselected ovarian 
cancer, the hypothesis being that this would be associated with poorer 
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survival. We used established tissue microarray (TMA) techniques and 
immuno-histochemistry to study 339 sequential cases of ovarian cancer 
(Kononen, Bubendorf et al. 1998; Hoos, Urist et al. 2001; Rosen, Huang 
et al. 2004).  
The mouse anti-human monoclonal antibody to HLA class I heavy chain 
(HC-10Gift: Prof. H Ploegh, Harvard Medical School, USA) has been 
raised to denatured HLA class I heavy chains freed from the ȕ2 
Microglobulin light chain (ȕ2-m) element of denatured native HLA class I 
antigen and preferentially recognises HLA-B and HLA-C on formalin 
fixed paraffin embedded tissue (Stam, Spits et al. 1986). HC-10 is the 
single antibody with the widest sensitivity for HLA class I heavy chain 
types. HLA class I antigens require the presence of ȕ2-m in order to 
function and co-staining tumours for ȕ2-m using a commercial 
polyclonal rabbit anti-human antibody allows the generation of HC-
10/ȕ2-m phenotypes.  
 
6.2. Results 
The HC-10 positive tumours were scored (0-3) regarding the intensity of 
their cell membrane staining and the ȕ2-m positive tumours were scored 
regarding the percentage of cell membranes staining (Figure 6.1 a, b, 
c, d).  
Average values for intensity of membranes staining HC-10 positive 
were determined over zero fields (28/339; 8.3% cases), one field 
(82/339; 24.2% cases) and two fields (229/339; 67.6% cases). Average 
values for percentage of cells ȕ2-m positive were determined over zero 
fields (24/339; 7.1% cases), one field (102/339; 37.2% cases) and two 
fields (213/339; 62.8% cases). In defining positivity (to allow for co-
expression analysis of both markers), any degree of positive staining 
was considered to indicate positive expression  thereby minimising 
false negatives while also adopting a reproducible system. This equated 
to a cut off of t10% for ȕ2-m staining (cores scored to within the nearest 
10%) and t1 intensity for HC-10. t10% of cell membranes staining with 
t1 intensity effectively defined positivity for both markers. 
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Figure 6.1 HC-10 and ȕ2 Microglobulin expression patterns  
 
 
 
Figure 6.1a   Ovarian cancer tissue core staining weakly (+1) with HC-10 in 
the cell membrane 
 
 




Figure 6.1b   Ovarian cancer tissue core staining moderately (+2) with  
HC-10 in the cell membrane 
 


 
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Figure 6.1c   

Ovarian cancer tissue core staining strongly (+3) with HC-10 in 
the cell membrane 
 

 
 
 
Figure 6.1d   
 
Ovarian cancer tissue core staining positive for ȕ2 Microglobulin 
in the cell membrane of 100% of the cells 
 
 
 

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Neither the degree of HC-10 nor the degree of ȕ2-m expression showed 
any correlation with clinicopathological characteristics (data not shown) 
or prognosis [Log rank = 1.18; p=0.28 and Log rank = 1.89; p=0.17 
respectively] and, as intended, subsequent analyses focused on their 
combined phenotypes. Of the series of 395 patients, 298 had 
expression data complete enough to allow for co-analysis (Figure.6.2). 
Any variation from an expected HC-10(+)ȕ2-m(+) phenotype was 
considered a downregulation of the HLA class I antigen. An 
HC-10(+)ȕ2-m(-) phenotype is likely to represent a state of genuinely 
free, non-functional HLA Class I heavy chain and an HC-10(-)ȕ2-m(-) 
phenotype complete loss of HLA class I antigen. An HC-10(-)ȕ2-m(+) 
phenotype may represent downregulation of HLA class I antigen and/or 
the presence of other HLA class I heavy chain locus products not 
identified by HC-10. 32.8% (102/298) of cases were negative for HC-10 
and 55.6% (175/298) of cases were negative for ȕ2-m. With only 34.6% 
(103/298) of cases HC-10(+)ȕ2-m(+), 65.4% (195/298) of cases had 
phenotypes suggestive of HLA class I antigen downregulation, 
revealing this to be a common event in this series (Table 6.1).  
There were no striking differences between the clinicopathological 
characteristics of the entire series and this apparently randomly 
selected 298-strong subgroup of cases (Table 6.2). The median age of 
diagnosis for these cases was 62 years, the median follow up for this 
group was 21.7 months (Range = 0-271 months) and the 5-year 
survival was 27.1%. This groups characteristics are similar to those of 
large scale reports (Yancik 1993; 1998; Brun, Feyler et al. 2000; Quinn 
2001; Quirk and Natarajan 2005). On univariate analysis using the Ȥ2 
method, the HC-10(+)ȕ2-m(+) phenotype was not found to be 
associated with age (using the Surveillance, Epidemiology, and End 
Results programme of the National Cancer Institute subdivisions (Quirk 
and Natarajan 2005)]), FIGO stage, degree of cytoreduction, grade, 
histological type or the use of chemotherapy (Table 6.3). However, as 
seen in the Kaplan-Meier plot (Figure 6.3), those patients without this 
phenotype did have a worse prognosis [Log Rank = 5.69 (p=0.017)]. 
These cases with phenotypes indicating downregulation of HLA class I 
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Figure 6.2 Flow diagram illustrating the derivation of the study cohort 
298 cases from the original series of ovarian cancers were analysed 
immunohistochemically for functional HLA class I antigen expression. 


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 Table 6.1 The immunohistochemical expression of HC-10, ȕ2-m and their 
combined phenotypes 
 
 N
o
 Cases % of Cases 
HLA class I heavy chain (HC-10) intensity n=311 
<1 102 32.8 
1-2 85 27.3 
2-3 124 39.9 
HLA class I heavy chain (HC-10) 
positive (t1 intensity) 209 67.2 
 
ȕ2 microglobulin light chain % cells 
positive 
n=315 
0-25 242 76.8 
26-50 42 13.3 
51-75 19 6 
76-100 12 3.8 
ȕ2 microglobulin light chain  positive (>10% 
cells) 
140 44.4 
 
HLA Class I antigen expression 
phenotypes 
 
n=298 
HC-10 (+) ȕ2-m (+) 103 34.6 
   
Downregulated 195 65.4 
   
HC-10 (+) ȕ2-m  (-) 98 32.9 
HC-10 (-) ȕ2-m (+) 68 23.8 
HC-10 (-)  ȕ2-m (-) 29 9.7 
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 Table 6.2 Association of the HC-10(+)ȕ2-m(+) phenotype with clinicopathological 
features in a univariate analysis  
 
Whole 
series 
 
n = 395 
Analysed 
cases 
n = 298 
HC-10(+) 
ȕ2-m (+) 
 
n=103 
Downregulated 
Phenotypes 
n=195 
 
 
 
N
o
 cases 
(%) 
N
o
 cases 
(%) 
N
o
 cases 
(%) 
N
o
 cases 
(%) 
Ȥ2 
(p=)
      
Age 
 
n=394 
 
n=297 n=103 n=194  
< 30 1 (0.3) 1 (0.3) 0 1 (0.5)  
30 – 59 167 (42.4) 119 (40.1) 42 (40.8) 77 (39.7) 0.554 
>60 226 (57.4) 177 (59.6) 61 (59.2) 116 (59.8) (0.758)
 
FIGO Stage 
 
n=375 
 
n=290 n=99 n=191  
1 99 (26.4) 77 (26.6) 27 (27.3) 50 (26.2)  
2 46 (12.3) 33 (11.4) 9 (9.1) 24 (12.6)  
3 188 (50.1) 144 (49.7) 51 (51.5) 93 (48.7) 0.836 
4 42 (11.2) 36 (12.4) 12 (12.1) 24 (12.6) (0.841)
 
Optimally  
Debulked 
n=376 n=287 n=99 n=188 0.057 
Yes 157 (41.8) 119 (41.5) 42 (42.4) 77 (41.0) (0.811)
 
Grade 
 
n=376 
 
n=296 n=99 n=195  
1 50(13.3) 32 (10.8) 11 (10.9) 21 (10.8)  
2 93 (24.7) 66 (22.3) 19 (18.8) 47 (24.1) 1.102 
3 233 (62) 198 (66.9) 71 (70.3) 127 (65.1) (0.576)
 
Histological 
Type 
n=395 n=298 n=103 n=195  
Serous 203 (51.4) 162 (54.4) 52 (50.5) 110 (56.4)  
Endometrioid 46 (11.7) 37 (12.4) 11 (10.7) 26 (13.3)  
Mucinous 50 (12.7) 26 (8.7) 12 (11.7) 14 (7.2)  
Undifferentiated 65 (16.5) 45 (15.1) 17 (16.5) 28 (14.4)  
Clear cell 26 (6.6) 24 (8.1) 10 (9.7) 14 (7.2) 3.264 
Other 5 (1.3) 4 (1.4) 1 (1) 3 (1.5) (0.659)
      
Chemotherapy 
 
n=388 
 
n=292 n=100 n=192 0.228 
Yes 283 (73.2) 214 (73.3) 75 (75) 140 (72.9) (0.633)
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Figure 6.3 HC-10 (+) ȕ2-m (+) phenotype and overall survival 
 
Kaplan-Meier plot showing the improved overall survival for patients with 
HC-10 (+) ȕ2-m (+) ovarian cancers. 
 


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antigen had a 5-year survival of 23.2% compared with 34.7% when both 
HC-10 and ȕ2-m were expressed. Factors in this series found to predict 
prognosis independently of each other were age (as a continuous 
variable), FIGO stage, the absence of residual macroscopic disease 
following primary surgery and whether the patient received 
chemotherapy of any form. These factors were included in the Coxs 
model along with the HLA class I antigen expression phenotype. The 
presence of the HC-10(+)ȕ2-m(+) phenotype was found to retain its 
power to predict an improved prognosis independently of the other 
factors [Hazard Ratio 0.587 (p<0.001; 95% Confidence intervals 0.442-
0.781)] (Table 6.3). When the other phenotypes were analysed in a 
similar fashion, no correlations were found in either univariate or 
multivariate analysis (data not shown), indicating that it is the lack of an 
expected HC-10(+)ȕ2-m(+) phenotype that is deleterious in ovarian 
cancer. 
6.3. Discussion 
As with all TMA work, the final group analysed (298) is smaller than the 
original series identified (395) due to incomplete data and missing 
tissue. Studying the co-expression of two markers exacerbated this. 
Significant selection bias within the final analysed group could 
potentially have been introduced by non-random loss of tissue but, as 
the final group varies little from the original series regarding its 
clinicopathological characteristics, this is unlikely to have occurred. With 
298 cases available the power of the study was retained. 
In this study we show, along with other work, that downregulation of 
HLA class I antigen is a common event in ovarian cancer (Vitale, Pelusi 
et al. 2005; Norell, Carlsten et al. 2006). The 34.6% of tumours which 
retained a complete HC-10(+)ȕ2-m(+) phenotype had a better prognosis 
than other cases and, furthermore, the expression/loss of this 
phenotype is an independent prognostic factor in ovarian cancer of a 
similar magnitude to the presence/absence of residual macroscopic 
disease (Table 6.3). The absence of complete HLA class I antigen 
expression leading to a worse prognosis supports work by Vitale et al 
(Vitale, Pelusi et al. 2005) which concluded that downregulation of HLA 
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Table 6.3 Multivariate analysis by Coxs regression using the HC-10(+) ȕ2-m (+) 
phenotype as a factor  
The analysis shows that a retained HC-10(+) ȕ2-m (+) phenotype is an 
independent prognostic factor for good prognosis 
 
 Hazard Ratios 
(95% Confidence intervals) 
Significance 
(p) 
 
Age at diagnosis 
(years) 
1.027 (1.015-1.038) <0.001 
 
FIGO Stage   
1  <0.001 
2 2.934 (1.591  5.414) 0.001 
3 5.796 (3.311-10.146) <0.001 
4 8.071(4.247-15.338) <0.001 
 
Residual macroscopic 
disease 
2.026 (1.405-2.921) <0.001 
 
Patient received 
chemotherapy 0.430 (0.287  0.644) <0.001 
 
HC-10 (+)   ȕ2-m  (+) 
phenotype 0.587 (0.442-0.781) <0.001 
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type I loss was associated with worse disease  in this case stage III 
cancers. Differences in our methodologies (regarding powering, 
biomarker co-analysis and the use of UICC independent prognostic 
factors (Gospodarowicz 2001) in statistical analyses) meant that, while 
we should not duplicate this specific finding, we were better positioned 
to demonstrate a novel and important independent association with 
prognosis. 
Cancer cells may be eliminated by, be in equilibrium with or escape 
innate or adaptive immunological control mechanisms via immunediting 
(Ochsenbein, Klenerman et al. 1999; Dunn, Bruce et al. 2002) and an 
important mechanism by which the immune system eliminates cancer 
cells is via a CTL based response to abnormal peptide presented in 
conjunction with HLA class I antigen on tumour cells (Seliger, Maeurer 
et al. 2000). Given the genetic instability of cancer, such a selective 
pressure might result in the evolution and ultimate protection of tumours 
from this process via downregulation of HLA class I antigen expression, 
as either an early or multi-step process (Klein and Klein 1985). This is 
likely to be important in the clinical course of ovarian cancer (Algarra, 
Cabrera et al. 2000) and evidence for such tumour sculpting comes 
from the observation that highly tumour specific CTL exist within the 
tumour infiltrating lymphocyte population of advanced disease whose 
function can be inhibited by anti-HLA class I monoclonal antibodies but 
which fail to elicit a clinically adequate immune response (Santin, 
Hermonat et al. 2000; Santin, Bellone et al. 2004). That downregulation 
of HLA class I antigen should associate with worse survival, as we 
found, is therefore logical.  
When HLA class I antigen expression is lost, killer-cell inhibitory 
receptors on the surface of natural killer (NK) cells (which produce an 
inhibitory signal when bound to HLA class I antigen) no longer function. 
The missing self hypothesis concludes that a resultant increase in NK 
cell killing activity will compensate for diminished T-cell killing in these 
circumstances (Ljunggren and Karre 1990). This may occur clinically in 
breast and colorectal cancer and explain the improvement in prognosis 
of those tumours with total loss of HLA class I antigen expression 
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(Madjd, Spendlove et al. 2005; Watson, Ramage et al. 2006). However, 
our data suggest that this mechanism must be less effective in ovarian 
cancers. This may be due to a concurrent acquired resistance to NK 
cell killing (Garrido, Ruiz-Cabello et al. 1997), a lack of NK cell 
presence within the tumour infiltrating lymphocytes (Kabawat, Bast et 
al. 1983; Ferguson, Moore et al. 1985) or the rapid exhaustion of this 
mechanism by the large volume nature of ovarian disease (Ochsenbein, 
Klenerman et al. 1999). 
There are 7 reported mechanisms by which a state of downregulated 
HLA class I antigen might occur: total HLA class I antigen loss due to 
the disrupted synthesis of antigen-processing machinery components 
such as ȕ2-m and transporter associated with antigen processing; 
haplotypic loss of either one or two haplotypes due to chromosomal 
events; HLA A, B or C locus downregulation due to altered HLA class I 
antigen gene transcription; individual HLA allelic loss due to gene point 
mutations or deletions; a compound state of two or more of these 
events; an unresponsiveness to interferons due to downregulation of 
the interferon response sequence element and subsequent pathway 
disruption; and, finally, downregulation of HLA A-B-C molecules with a 
concurrent upregulation of HLA-E. The most frequent event observed in 
this series was loss of ȕ2-m. This contributed to over 55% of the loss of 
HLA class I antigen. The mechanisms for ȕ2-m loss in cancer are, like 
those for heavy chain, varied but commonly include loss of mRNA 
stability (Hicklin, Wang et al. 1998) and mutational silencing (Bicknell, 
Kaklamanis et al. 1996). However, genomic loss due to chromosomal 
defects, particularly in chromosome 15, are not frequently observed in 
ovarian cancer. In melanoma, ȕ2-m mutations are primarily related to 
extensive loss of chromosome 15 material (Paschen, Arens et al. 2006) 
but, though alterations in chromosome 15 in ovarian cancer have been 
well documented, there are no reports of frequent alterations in the ȕ2-
m locus (15q21). These mechanisms may relate to ovarian cancer 
where we have demonstrated a significant loss and clear clinical 
correlation with poor outcome. However, other reports suggest that HLA 
class I antigen downregulation in ovarian cancer is a post translational 
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event that can be restored upon interferon-ܵ treatment (Boyer, Dawson 
et al. 1989; Mobus, Asphal et al. 1993; Santin, Rose et al. 1996; 
Freedman, Kudelka et al. 2000). The exact mechanism of HLA-class I 
antigen loss in ovarian cancer warrants further investigation and would 
be most successfully achieved on freshly isolated tumour samples.  
Our work shows that ovarian cancers not expressing the 
HC-10(+)ȕ2-m(+) phenotype have a poorer prognosis irrespective of 
their gross appearance. Future work could also test whether 
foreknowledge of this phenotype might predict those cases which will 
respond best to CTL or interferon-ܵ based immunotherapies. 
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Chapter 7: The Prognostic Significance of Membrane 
Bound Complement Regulatory Protein Expression in 
Ovarian Cancer  
 
7.1. Introduction 
Ovarian cancer is the most common gynaecological cancer in the UK 
and represents the fourth most common cancer site for women. Its low 
5-year survival of 29% has altered little over the last 40 years (Quinn 
2001). Novel immunotherapies will demand an improved understanding 
of the tumour-host immunological interface if they are to reach their 
potential to improve prognosis in this disease. 
The complement cascade is an important effector mechanism of the 
innate immune system which, via the classical, lectin or alternative 
pathways, can lead to cell lysis and Complement Dependent 
Cytotoxicity (CDC) via the deposition of membrane attack complex 
(MAC) (Muller-Eberhard 1986; Walport 2001; Walport 2001). Most 
normal tissues protect themselves from non-specific bystander effects 
through the expression of membrane bound complement regulatory 
proteins (mCRP) (Morgan 1989; Morgan and Meri 1994). These include 
CD46 (membrane co-factor protein) which inhibits the cascade by 
acting as a cofactor for factor I in the cleavage of C3b and C4b in the 
alternate pathway (Cole, Housley et al. 1985; Seya, Ballard et al. 1988; 
Devaux, Christiansen et al. 1999); CD55 (Decay Accelerating Factor) 
which accelerates the decay of the C3 and C5 convertases (Medof, 
Lublin et al. 1987; Nicholson-Weller and Wang 1994); and CD59 
(Protectin) which interferes with the assembly of MAC by binding to C8 
and C9 (Meri, Morgan et al. 1990; Rollins and Sims 1990). 
The distribution of mCRP in cancers often differs to that in analogous 
normal tissues which may alter their susceptibility to CDC (McConnell, 
Klein et al. 1978; Magyarlaki, Mosolits et al. 1996; Bjorge, Hakulinen et 
al. 2005). CD46 is upregulated in breast cancer (Hofman, Hsi et al. 
1994) and colorectal cancer but downregulated in renal cancers 
(Niehans, Cherwitz et al. 1996; Blok, Daha et al. 2000). CD55 is 
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upregulated in colorectal and renal cancers but expressed at lower 
levels in breast cancers (Niehans, Cherwitz et al. 1996; Li, Spendlove 
et al. 2001). CD59 expression is upregulated in poorly differentiated 
colorectal and renal cancers (Koretz, Bruderlein et al. 1993; Niehans, 
Cherwitz et al. 1996) but lost in gastric cancers (Kiso, Mizuno et al. 
2002). Additionally, same-site heterogeneity of CD55 and CD59 
expression predicts survival in breast cancer (Madjd, Pinder et al. 2003; 
Madjd, Durrant et al. 2004) and colorectal cancer cases (Durrant, 
Chapman et al. 2003; Watson, Durrant et al. 2006). 
In ovarian cancer cell lines and a small series of tumours, CD46 and 
CD59 showed wide expression in vitro and in vivo in both benign and 
malignant neoplasms, while CD55 was variably expressed. 
Furthermore, the presence of high levels of mCRP represents a method 
of immune protection from complement activating antibodies to tumour 
associated antigens (Bjorge, Hakulinen et al. 1997; Bjorge, Hakulinen 
et al. 2005). We therefore investigated the hypothesis that ovarian 
tumours with differentially high expression of mCRP expression would 
be the most protected from complement mediated lysis and would 
display the worst prognosis and most aggressive behaviour. 
7.2. Results 
 
7.2.1. Immunohistochemistry  
The expression of CD46 varied in intensity and in the percentage of 
expression within the cell membranes of different tumours but 95% of 
the 316 tumours examined expressed CD46 to some degree (Figure 
7.1a). The distribution of expression of CD55 was similar to CD46 and 
all of the 318 tumours examined expressed this marker to some extent 
(Figure 7.1b). The intensity of staining for CD59 was of homogenous 
intensity but varied regarding the percentage number of cells staining 
with 86% of the 293 tumours examined expressing some CD59 (Figure 
7.1c). With such ubiquitous positive expression evident, relative high 
versus low expression states were determined as described previously 
to stratify tumours further (Table 7.1). As tissue was lost during 
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Figure 7 CD46, CD55 and CD59 expression patterns 
  
Figure 7.1a 

A core from an ovarian tumour staining positive for CD46 at x 100 
magnification with an insert at x 200 magnification 
There was diffuse cytoplasmic staining, granular cell membrane 
staining and no nuclear staining. Both intensity and % cells staining 
varied between tumours and so each was recorded 

. 
 
 

Figure 7.1b 

A core from an ovarian tumour staining positive for CD55 at x 100 
magnification with an insert at x 200 magnification 
The staining pattern seen was similar to that of CD46 and expression 
data were collected in the same way 




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 

Figure 7.1c 

A core from an ovarian tumour staining positive for CD59 at x 100 
magnification with an insert at x 200 magnification 
The staining was granular, in the cell membrane and with some 
distribution cytoplasmically. There was no nuclear staining. There was 
no variation in the intensity of the staining between positive tumours 
and so only percentage of cells staining was recorded for this marker 



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 Table 7.1 Summary of the immunohistochemical expression data for CD46, 
CD55 and CD59 
 
 CD46 CD55 CD59 
  
no cases (%) 
 
no cases (%) 
 
no cases (%) 
 
 n=316  n=318 n=293 
Average % Cells   
0 16 (5) 0 41 (14) 
1-5 5 (2) 0 34 (12) 
6-25 19 (6) 2 (1) 82 (28) 
26-50 91 (29) 3 (1) 74 (25) 
51-75 104 (33) 22 (7) 44 (15) 
76-100 81 (26) 291 (92) 18 (6) 
 
Average Intensity 
Score 
 
 
0-100 268 (85) 8 (3)  
101-200 44 (14) 147 (46) 
201 – 300 4 (1) 163 (51) 
 
Positive expression 300 (95) 318 (100) 252 (86) 
 
High expression 156 (49) 143 (45) 82 (28) 
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processing, average values for CD46 expression were calculated using 
zero cores in 7%, one core in 23% and two cores in 70% of cases; for 
CD55 expression, zero cores in 6%, one core in 25% and two cores in 
69% of cases; and for CD59, zero cores in 14%, one core in 30% and 
two cores in 56% of cases. 276 (81%) of cases had relative high-low 
expression data for all three markers available. 11% of these cases 
displayed universally high mCRP expression and 29% had universally 
low expression (Figure 7.2). There were no striking differences between 
the clinicopathological characteristics of the entire series and the sets of 
expression data generated (Table 7.2). 
7.2.2. Comparison of differential mCRP expression with 
clinicopathological factors  univariate analysis using the 
Ȥ2 method  
Relatively high CD59 expression was associated with a more advanced 
FIGO stage, the presence of post-surgical macroscopic disease, worse 
histological type and less chance that the patient would have received 
chemotherapy. Relatively high CD55 expression was associated with 
advanced FIGO stage, the presence of post-surgical macroscopic 
disease and worse histological type (Table 7.3). There were no 
associations discovered between differential CD46 expression and 
clinicopathological factors and this was also the case for tumours 
expressing relatively low levels of all three mCRP. However, low 
expression of CD55 and low expression of CD59 were associated with 
one another (16.16; p<0.001) and CD59 [-] CD55 [-] cases (low co-
expression tumours, 45% of the whole) were associated with earlier 
FIGO stage, a higher chance of optimal debulking and better 
histological type (Table 7.4). 
7.2.3. Association of differential mCRP expression with overall
survival 
 
Individually, relatively high expression states of CD59 or CD55 were 
associated with worse prognosis in a univariate analysis (Figure 
7.3a, b). Low co-expression of CD59 and CD55 was associated with 
the best prognosis (Figure 7.3c). There was no association between 
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Figure 7.2 The distribution of tumours between the eight 
i
C
 
 
mmunophenotypes that combined high [+] and low [-]  
D46- CD55-CD59 expression data generates 

n = 31 (11%) 
n = 53 (19%) 
n = 8   (3%) 
n = 44 (16%) 
n = 19 (7%) 
n = 21 (8%) 
n = 20 (7%) 
n = 80 (29%) 
CD 46 
+ 
- 
CD 55
CD 55
+
+
- 
+ CD 59
- CD 59
CD 59
CD 59
- 
+ 
- 
+ 
- 
+ 
- 
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 Table 7.2
  
The major clinicopathological features of each of the analysed 
groups 
 
 Whole 
series 
 
CD46 
cases 
analysed 
CD55 
cases 
analysed 
CD59 
cases 
analysed 
Cases with 
complete 
mCRP data 
 
 
no
 
cases
 
(%) no
 
cases
 
(%) no
 
cases
 
(%) no
 
cases
 
(%) no
 
cases
 
(%) 
 
 n = 395 n=316 n=318 n=293 n=276 
 
Age 
 
n=394 n=315 n=317 n=292 n=275 
< 30  1 1 1 1 1 
30 – 59  167 (42) 124 (39) 124 (39) 116 (40) 106 (39) 
>60  226 (57) 190 (60) 192 (61) 175 (60) 168 (61) 
 
FIGO 
 Stage 
 
n=375 n=308 n=311 n=284 n=269 
1 99 (26) 81 (26) 79 (25) 74 (26) 69 (26) 
2 46 (12) 33 (11) 34 (11) 34 (12) 31 (12) 
3 188 (50) 159 (52) 162 (52) 144 (51) 141 (52) 
4 42 (11) 35 (11) 36 (12) 32 (11) 28 (10) 
 
Optimally   
Debulked 
 
n=376 
 
n=304 
 
n=307 
 
n=281 
 
n=266 
 
157 (42) 
 
123 (41) 
 
122 (40) 
 
116 (41) 
 
110 (41) 
      
 
Received 
Chemotherapy 
n=388 n=310 n=313 n=286 n=271 
 283 (73) 224  (72) 228 (73) 208 (73) 200 (74) 
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 Table 7.3 
 
A univariate analysis showing statistical associations between the 
major clinicopathological characteristics and differential CD59 and 
CD55 expression 
 
 CD59 
low 
CD59 
high 
Ȥ2 
(p=) 
CD55 
low 
CD55 
high 
Ȥ2 
(p=) 
 
 no
 
cases
 
(%) 
 
no
 
cases
 
(%) 
 
 no
 
cases
 
(%) 
no
 
cases 
(%) 
 
 
FIGO  
Stage 
 
 
n=284 
   
n=311 
 
  
1 60 (30) 14 (17)  50 (29) 29 (21)  
2 28 (14) 6 (7)  23 (14) 11 (8)  
3 92 (45) 52 (64) 9.39 75 (44) 87 (62) 9.87 
4 23 (11) 9 (11) (0.03) 22 (13) 14 (10) (0.02) 
 
Optimally   
Debulked 
 
 
n=281 
   
n=307 
 
  
Yes 91 (45) 25 (32) 4.21 76 (45) 46 (33) 4.30 
No 111 (55) 54 (68) (0.04) 93 (55) 92 (67) (0.04) 
 
Histological  
Type 
 
 
n=293 
   
n=318 
 
  
Serous 103 (49) 55 (67)  88 (50) 81 (57)  
Endometrioid 27 (13) 9 (11)  22 (13) 18 (13)  
Mucinous 26 (12) 4 (5)  17 (10) 12 (8)  
Undifferentiated 32 (15) 12 (15)  24 (14) 27 (19)  
Clear cell 19 (9) 2 (2) 12.12 22 (13) 3 (2) 13.08 
Other 4 (2) 0 (0.03) 2 (1) 2 (1) (0.02) 
 
Chemotherapy n=286   n=313 
 
  
Yes 142 (70) 66 (82) 4.34 129 (75) 99 (70)  
No 63  (31) 15 (19) (0.04) 43 (25) 42 (30) (0.34) 
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 Table 7.4 Association of clinicopathological factors in a univariate analysis 
with the CD59 [+/-] CD55 [+/-] immunophenotypes 
 CD59 [-] CD55 [-]  
 
Other  
Immunophenotypes 
Ȥ2 
(p=) 
 
 
no cases (%)
 
no cases (%)
 
 
FIGO Stage 
 
n=273   
1 39 (32) 30 (20) 
2 19 (16) 13 (9) 
3 46 (38) 97 (64) 
4 17( 6) 12 (8) 18.06 
(<0.001) 
 
Optimally  
Debulked 
 
n=270 
 
Yes 58 (48) 52 (35) 4.7 
(0.03) No 63 (52) 97 (65) 
 
Histological 
Type 
 
n=280 
 
Serous 57 (45) 95 (62) 
 
Endometrioid 19 (15) 16 (10) 
Mucinous 12 (10) 13 (8) 
Undifferentiated 19 (15) 25 (16) 
Clear cell 17 (14) 4 (3) 16.36 
(0.01) Other 2 (2) 1 
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Figure 7.3c A Kaplan-Meier plot showing that tumours expressing relatively 
low levels of both CD59 and CD55 have the best prognosis
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Figure 7.3 Univariate associations between the expression of mCRP and 
overall survival 
 
 
 
Figure 7.3a A Kaplan-Meier showing that high CD55 expression is associated 
with a reduction in overall survival   
 
 
 
 
 
 
Figure 7.3b A Kaplan-Meier plot showing that high CD59 expression is 
associated with a reduction in overall survival 
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CD46 expression or low expression of all three mCRP and survival. 
Factors in this series found to predict prognosis independently of each 
other were age (as a continuous variable), FIGO stage, the absence of 
post-surgical residual macroscopic disease and whether the patient 
received chemotherapy. The survival associations found on univariate 
analysis did not persist following Cox’s multivariate analysis when these 
independent prognostic factors were included in the model (CD59 
p=0.262; CD55 p=0.364; CD59 [-] CD55 [-] p=0.386). 
7.3. Discussion  
In this work a novel anti-CD46 antibody was employed in order to study 
the co-expression of three mCRP in Formalin Fixed Paraffin Embedded 
(FFPE) tissue. For the first time, this allowed a large historical series to 
be fully surveyed and the biologically plausible hypothesis that 
differential expression of mCRP stratifies prognosis to be tested.  
The immunohistochemical expression of these three mCRP in frozen 
normal ovarian tissue and adenomas has previously been described by 
two groups. Though the numbers studied have been small, CD59 and 
CD46 seem to be universally expressed, with CD55 being present more 
variably (Bjorge, Hakulinen et al. 1997). Within the Müllerian elements 
of the female genital tract, mCRP upregulation and overexpression has 
been shown to be associated with the development of cervical and 
endometrial cancers (Simpson, Jones et al. 1997) (Murray, Mathure et 
al. 2000). This agrees with observations at other cancer sites but, 
though the suspicion is that similar changes occur during ovarian 
carcinogenesis, direct evidence that upregulation of mCRP is part of its 
natural history is currently lacking (Cheung, Walter et al. 1988). The 
limited indirect evidence available suggests that CD59 is equally 
universally and highly expressed in both carcinomas and normal tissue, 
that CD55 is only expressed in 75% of ovarian cancers and that CD46 
expression is unchanged following malignant transformation (Bjorge, 
Hakulinen et al. 1997; Macor, Mezzanzanica et al. 2006). In this study 
CD59 was widely and strongly expressed and CD46 was moderately 
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expressed, which is in keeping with other work. However, in this series 
tumours were universally CD55 positive and, while this finding is at 
variance to the work of Bjorge et al, it is supported by other data 
(Symonds, Perkins et al. 1985). Methodological variations make it 
impossible to say whether CD55 expression in this series represented 
overexpression and upregulation relative to other studies and normal 
tissue, though a methodological variation in itself could explain the 
discrepancy as the definition of positive expression in this series was 
very sensitive and included cases displaying even weak staining. 
Despite this, CD55 may be more widely expressed in the ovarian 
cancer population than previously appreciated. 
Given that deposition of complement is associated with tumour cell 
killing (Perlmann, Perlmann et al. 1981; Bara and Lint 1987; Fishelson, 
Donin et al. 2003) and that resistance to this can be overcome when 
CD55 and CD59 are blocked (Gorter, Blok et al. 1996; Bjorge, 
Hakulinen et al. 1997; Donin, Jurianz et al. 2003), the almost ubiquitous 
expression of mCRP we observed may indicate an immunological 
evasion tactic, particularly if carcinogenesis and upregulation are 
intertwined. In such circumstances tumours expressing relatively low 
levels of mCRP might be expected to be associated with an improved 
prognosis (Gorter and Meri 1999).  
However, in this study differential CD46 expression did not correlate 
with survival. While this may represent a limitation of factor I availability, 
a pre-requisite for its activity, this lack of clinical impact might also be 
explained by the modest contribution of the alternative pathway to 
complement activation in cancer. In this situation, CD55 and CD59 
expression would effectively become the co-determinants of 
complement inhibition and immune evasion, which is concordant with 
the suspicions of other workers (Bjorge, Hakulinen et al. 1997; Devaux, 
Christiansen et al. 1999; Madjd, Durrant et al. 2005). This hypothesis is 
supported by this work’s other findings – that relative high expression of 
CD59 and CD55 predicted an aggressive phenotype and reduced 
survival while tumours expressing neither in high levels had the best 
outcomes. 
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The modest, non-independent prognostic effect of mCRP expression in 
ovarian cancer might be explained if only very low absolute levels of 
mCRP are required to protect the developing tumour from the effects of 
complement, as data from CD55 transgenic pigs would suggest, or if 
other mechanisms of complement defence prevail (Morgan 1989; 
Carrington and dos Santos Cruz 2001; Donin, Jurianz et al. 2003). As 
mCRP are implicated in T cell regulation and the inhibition of T cell 
activation, it is also conceivable that the clinical behaviour of tumours 
would be less predictable than hypothesised, while it is additionally 
possible that these clinically apparent tumours may have passed 
through the phase where their behaviour could be predicted by their 
relationship with the immune system (Astier, Trescol-Biemont et al. 
2000; Dunn, Bruce et al. 2002; Marcenaro, Augugliaro et al. 2003; 
Capasso, Durrant et al. 2006; Spendlove, Ramage et al. 2006). 
Considering the fall in the number of cases from over 300 to 273 that 
occurred prior to the multivariate analysis of the co-expression data 
being performed, a final explanation for the non-independent prognostic 
effects observed remains a type II error associated with reduction in 
statistical power. 
Though the prognostic power of mCRP was of borderline clinical 
significance, the ubiquitous presence of mCRP in a large series of 
ovarian cancers represents important corroboratory clinical evidence. 
Ovarian cancer appears particularly suited to immunotherapy, with 
strategies employing CDC being particularly intuitive as the soluble 
components of the innate immune system have been shown to 
penetrate the disease well (Rubin 1993; Gorter and Meri 1999; 
Fishelson, Donin et al. 2003; Bjorge, Hakulinen et al. 2005). However, 
as CD55 and CD59 have important functional roles in antagonising 
CDC, such immunotherapy may need to routinely incorporate a parallel 
mCRP blocking strategy in order to achieve clinically effective cell killing 
(Bjorge, Hakulinen et al. 1997; Bjorge, Junnikkala et al. 1997; Macor, 
Mezzanzanica et al. 2006). Important future work might focus on more 
directly studying the changes in mCRP expression through 
carcinogenesis and progression in a large series and the power of 
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mCRP expression to predict response to immunotherapeutic and 
conventional medical treatments. 
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Chapter 8: General Discussion  
Ovarian cancer is the fourth most common cancer in British women, 
and accounted for over 6000 new cancer registrations in 1997 and over 
4000 deaths in 1999. Despite improvements in life-extending 
treatments, its high mortality has remained static over recent decades, 
in contrast to what has been seen in breast cancer (Quinn 2001). This 
is due to a persisting combination of late stage at diagnosis and 
tendency toward the development of resistance to conventional 
chemotherapy (Heintz, Odicino et al. 2001; Ozols, Bundy et al. 2003). 
Though making diagnoses earlier and achieving stage shift will 
theoretically do most to improve outcomes, this requires the 
establishment of a mass screening programme, the precise 
methodology and efficacy of which are yet to be defined (Jacobs, 
Mackay et al. 2006). Improvements in treatment are therefore also 
required, with the systematic investigation of molecular markers 
expressed in tissue having the potential to aid drug development and 
the targeting and tailoring of therapy through the discovery of 
independent markers of prognosis  as has been the case for Herceptin 
in breast cancer (Shepard, Jin et al. 2008). The impact of Herceptin 
was assessed in recurrent ovarian cancer and, though little clinical 
impact was seen for this mAb (Bookman, Darcy et al. 2003), 
immunotherapy remains particularly theoretically suited for use in 
ovarian cancer as it circumvents traditional mechanisms of 
chemoresistance and targets microscopic residual disease which may 
be outside the cell cycle (Bjorge, Stoiber et al. 2006). There is 
evidence, however, that the immune system edits ovarian cancer which 
may make it less susceptible to de novo and artificial immune attack, 
with escape mechanisms likely to be directed against both the cell 
mediated and humoural modalities (Schuster, Nechansky et al. 2006). 
Two potential mechanisms of escaping immune attack might include 
the downregulation of HLA class I and the expression of mCRPs (Dunn, 
Old et al. 2004), the expression of which have both been shown to have 
independent prognostic power in colorectal cancer (Watson, Durrant et 
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al. 2006; Watson, Ramage et al. 2006). It was therefore logical in this 
thesis to study the biomarker potential of HLA class I and mCRP 
expression in ovarian cancer tissue. Interestingly, the role of the 
immune system was overlooked by the landmark paper by Hanahan et 
al which reviewed the fundamental steps in carcinogenesis (Hanahan 
and Weinberg 2000) and this probably reflects the fact that the theory 
of immunosurveillance had historically been discredited while its 
resurgence, in the form of immunoediting, was yet to be widely 
appreciated (Dunn, Bruce et al. 2002). The importance of the immune 
system in both the development of cancer and its treatment has 
subsequently led to the suggestion that immunoediting be termed the 
seventh hallmark of cancer (Smyth, Dunn et al. 2006). 
Despite the surfeit of studies examining tissue biomarkers in ovarian 
cancer, no immunohistochemical marker has yet been translated into 
clinical practice (Agarwal and Kaye 2006). Part of the reason for this is 
that many single, small studies are often unrepeatable or examine 
markers of limited clinical relevance (Gospodarowicz 2001). Difficulties 
in externally validating research often stem from inconsistencies in 
approach, a point which has been emphasised each time the literature 
surrounding a marker has been reviewed in this thesis. Attempts to 
standardise the reporting of research by developing consensus 
statements have been made for randomised trials (CONSORT - 
Consolidated Standards of Reporting Trials) (Moher, Schulz et al. 
2001), diagnostic tests (STARD - Standards for Reporting of Diagnostic 
Accuracy) (Bossuyt, Reitsma et al. 2003) and, latterly, molecular 
markers of prognosis (REMARK - Reporting recommendations for 
tumour marker prognostic studies) (McShane, Altman et al. 2006). This 
thesis attempted to follow these guidelines closely so that the results 
would have greater reproducibility and so that the data would be 
useable in potential future meta-analyses. To this end, the cohort that 
was gathered for this study has been described in detail with 
explanations being given as to which cases were excluded and why, 
along with a description of how treatments were allocated. The samples 
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used, their processing, their storage and their histological review have 
been described and the assays used, which have been accurately 
recorded, sought to replicate the most common practices found within 
the literature. The assessment of the staining was consistent, blinded 
and concordant. The study design has been described in some depth 
as have the endpoints (OS  no data on PFS), the candidate variables 
in the multivariate model and the rationale for the sample size (related 
to power calculations and convenience). All statistical methods have 
been described along with any limitations, assumptions and missing 
data issues. A detailed description of how the data were re-categorised 
along with the logic behind the creation of cut-off points has been given. 
The data have been thoroughly assessed and a diagram of flow 
through the study produced showing the numbers of cases dropping 
out at each stage, along with the clinicopathological and demographic 
characteristics of each subgroup. The relation of the markers to 
standard prognostic variables has been recorded and an estimation of 
sizes of effect using HR has been reported along with Kaplan Meier 
plots checking the assumption of proportional hazards. All confidence 
intervals have been reported for all variables in the final multivariate 
model. Importantly, an attempt has been made at all points to 
emphasise the limitations of the work and to set it in its clinical context. 
Studying a large population and addressing best practice in this way 
supports the main findings of the thesis. 
TMAs have become established as a valid high throughput platform for 
the study of biomarkers in tissue and may be used in researching 
genomics, transcriptomics and proteomics (Kononen, Bubendorf et al. 
1998). The cohort available for this thesis numbered in excess of 400 
cases and this technique represented an attractive method of reducing 
the amount of antibody which would be required whilst also allowing all 
tumours to be stained in single standardised runs (Kononen, Bubendorf 
et al. 1998). The physical construction of the TMA, as has been found 
by others, represented a small amount of work compared to that 
involved in assembling the appropriate data and tissue for this work 
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(Simon, Mirlacher et al. 2004). Logistical, ethical and bureaucratic 
considerations occasionally introduced errors and delays, though these 
were often anticipated and managed, with the study finally being 
completed to time and with no major systematic errors detected. By 
fostering a productive relationship with the R&D department at DCGH, 
this thesis was also able to adhere to best practice regarding research 
governance issues. Since the inception of TMAs, concerns regarding 
tissue heterogeneity and the ability of a tissue core to be representative 
of a whole tumour have been recorded (Kononen, Bubendorf et al. 
1998; Goethals, Perneel et al. 2006). This concern was thoroughly 
addressed during an extensive validation process for TMAs and has 
mostly been shown to be unfounded where large populations have 
been surveyed (Kononen, Bubendorf et al. 1998; Mucci, Akdas et al. 
2000; Fernebro, Dictor et al. 2002; Hedvat, Hegde et al. 2002). 
However, there is variation between researchers regarding the optimal 
number of cores to use per case, with between one and 5 being 
variously employed. In this thesis the use of two cores was shown to be 
optimal in balancing the loss of cases and statistical power due to loss 
of tissue, the need to conserve resources and the improved accuracy 
seen when using higher numbers of cores. An accurate and complete 
database of the main clinical prognostic factors and outcome measures 
was essential in providing reassurance that this series was typical 
whilst also fundamental to the investigation of associations between 
markers and outcome. The dataset was found to be consistent and the 
multivariate model developed included the factors which may have 
been anticipated a priori: stage, residual disease, the use of 
chemotherapy and age. Though the data were consistent, they were 
limited inasmuch as no objective response to chemotherapy had been 
recorded. Showing that an independent prognostic marker mediates its 
effect through response to treatment provides important biological 
insights and can prove useful in the design of clinical trials and 
potentially in the tailoring of treatments. Though this was not 
correctable in this thesis, the impact of its absence may perhaps at 
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least be attenuated by the fact that no replacement first-line treatments 
for ovarian cancer are yet being considered (Agarwal and Kaye 2005). 
As no tissue biomarker for ovarian cancer has yet been introduced into 
clinical practice, this could not be used to validate the integration of the 
TMA and clinicopathological data (Agarwal and Kaye 2006). 
Notwithstanding this, several individual studies have been published 
which show particular markers as having independent prognostic 
factors in ovarian cancer (Kristiansen, Denkert et al. 2002; Yamamoto, 
Tsuda et al. 2007). The known difficulty in replicating the findings of 
single studies in biomarker research meant that attempting this for 
validation of the integrated TMA was an unattractive strategy with a 
high chance of failure. It therefore appeared more logical to study the 
expression of p53 and Bcl-2 for this purpose, as they have been 
exhaustively examined in cancer research at all sites. As the literature 
is hopelessly divided on the clinical relevance of the expression of 
these markers in ovarian cancer, this strategy had the disadvantage of 
being inherently unable to provide 100% assurance as to the validity of 
the TMA. However, the advantage of using these markers was that the 
large amount of data available made it possible to develop a broad 
perspective concerning which associations should be found most 
commonly. Duplicating these associations was likely to provide more 
accurate validation than duplicating single studies, where the false 
positive and negative correlation rates would be high. The integrated 
TMA ultimately produced data supportive of its validity by reproducing 
the most common findings within the body of literature reviewed 
concerning p53 and Bcl-2. 
On examining the prognostic effect of immunological molecular 
markers, deviation from the co-expression of HC-10 and ȕ2m was found 
to occur in 65% of cases and correlated independently with reduced 
survival. The conclusion is that loss of a phenotype compatible with 
successful antigen presentation is an immune escape mechanism 
correlated with poor prognosis. This novel finding agrees with data 
collected at other cancer sites and preliminary work in ovarian cancer, 
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is intuitive and provides evidence that immunoediting occurs in ovarian 
cancer (Vitale, Pelusi et al. 2005; Watson, Ramage et al. 2006). It also 
has implications for the targeting and development of immunotherapies 
heavily reliant on CD8+ cells for their clinical effect, such as vaccines. 
However, such conclusions must be interpreted in the light of certain 
caveats. Firstly, as HC-10 does not identify all HLA class I haplotypes 
or allelic variations and, as the patients individual tissue types were not 
known, it is conceivable that there was a pool of cases within the 
Downregulated HLA class I group which continued to express a 
phenotype compatible with successful antigen presentation. 
Unfortunately, a satisfactory panel of antibodies with the required 
specificities does not exist with which to exhaustively test this theory 
immunohistochemically on FFPE tissue (Cabrera, Lopez-Nevot et al. 
2003) and it remains plausible that the identification of such cases may 
have resulted in either an augmentation or attenuation of the prognostic 
effects revealed by this work. Secondly, though the HC-10 (+) ȕ2m (+) 
phenotype represented the immunohistochemical expression of a 
phenotype compatible with intact Antigen Processing Machinery (APM), 
it did not confirm that antigen presentation was actually occurring, for 
which functional studies would be required. Despite these 
methodological constraints, the independent association of the 
HC-10 (+) ȕ2m (+) phenotype with improved prognosis supports other 
work on immunoediting in ovarian cancer while implying that this 
phenotype approximates the identification of functional/non-functional 
HLA class I well (Vitale, Pelusi et al. 2005). Han and co-workers 
recently reported the results of studying several APM elements using 
immunohistochemistry, including HC-10, ȕ2m, TAP1, TAP2 and tapsin, 
within a cohort of 150 epithelial ovarian cancers. Though the co-
expression immunophenotypes were not studied, the individual 
expression data were concordant with that presented in this thesis. The 
loss of individual APM elements correlated with each other, with a state 
of loss of all APM elements being shown to be an independent 
prognostic factor. Though these findings validate the observations in 
this thesis, this group also discovered that a loss of APM elements 
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correlated with a reduction in TILs, with the presence of TILs being 
found to be a positive independent prognostic factor, as in other studies 
(Han, Fletcher et al. 2008). The use of the TMA constructed in this 
thesis to study the prognostic effect of TILs would therefore represent 
an interesting future application, as TILs have not yet been surveyed in 
detail in a large population of ovarian cancers using this technique. As 
proof of principle, this platform has been used to study TILs in breast 
and colorectal cancer, (Pages, Berger et al. 2005; Theurillat, Ingold et 
al. 2007). As the absence of intra-tumoral T cells is related to higher 
levels of serum VEGF, acquiring these data would also allow cross 
comparison with recent data generated by other workers using this 
TMA which shows that high VEGFR expression is a negative 
independent prognostic factor in ovarian cancer (Cooper, Ritchie et al. 
2002; Duncan, Al-Attar et al. 2008).  
IFNܵ has been shown to upregulate HLA class I and improve CD8+ 
recognition (Raffaghello, Prigione et al. 2005) and though it also has 
the effect of lowering NK cell cytotoxicity, it is interesting to note that 
recent work on the TMA constructed during this thesis by other workers 
has shown that loss of the IFNܵ receptor is associated with a poor 
prognosis (Duncan, Rolland et al. 2007). This may indicate a limited 
role for NK cells in ovarian cancer systems, reflect the multiple anti-
tumour effects of intact IFNܵ signalling, or both. A minor role for NK cell 
killing in ovarian cancer might be explained if concurrent immune 
escape mechanisms develop in parallel with HLA class I loss which 
abrogates the NK stimulating effect of this state of missing self. One 
such mechanism might be through the inappropriate expression of non-
classical class I HLA molecules such as HLA-G. The expression of this 
molecule is normally restricted to a small number of cell types which 
includes trophoblastic cells. However, it is abnormally expressed in up 
to 70% of ovarian cancers, where it has been shown to inhibit NK cell 
lysis though not predicting prognosis independently of other factors 
(Lin, Yan et al. 2007) (Sheu and Shih Ie 2007). Investigating the 
expression of this marker in tandem with TILs and the existent HLA 
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class I data could provide interesting insights into the nature of 
immunoediting in this large population of ovarian cancers. Other non-
classical HLA markers which might contribute to improved 
understanding if studied might include the MICA and MICB. These 
markers have been little studied in ovarian cancer but may represent an 
additional way in which stressed cells can stimulate the immune system 
in the absence of HLA class I: through the binding of NK cells via the 
NKG2D receptor and the binding of ܶį T cells via their TCR (Bauer, 
Groh et al. 1999; Qi, Zhang et al. 2003). Indeed, relative over-
expression of MICA has been shown to be a positive independent 
prognostic factor in colorectal cancer, though similar observations have 
not been made in breast cancer (Madjd 2005; Watson, Spendlove et al. 
2006). Intriguingly, bacterial adhesins released by diarrhoea inducing 
Escherichia coli strains have been shown to upregulate MICA in normal 
gastrointestinal epithelium by signalling via CD55, in one of its non-
complement dependent roles, justifying its future study further in this 
series (Tieng, Le Bouguenec et al. 2002).  
The study of the co-expression of mCRPs and their prognostic effect in 
a large population of ovarian cancers was a novel undertaking and 
generated important population data. However, the prognostic effects, 
though consistent with the theory that mCRP expression represents an 
immune escape mechanism, were of borderline significance. 
Carcinogenesis is generally felt to be associated with an increase in 
mCRP expression and function, with the upregulation of one mCRP 
potentially being able to cover for loss of another (Koretz, Bruderlein et 
al. 1993; Gorter and Meri 1999). The ubiquitous expression of the 
mCRP in this series supports this assertion and may also represent a 
further mechanism of resistance to chemotherapy. Conventional 
chemotherapy is thought to effect cell death through a sterile process of 
apoptosis. During this process, apoptotic bodies are removed by 
macrophages which secrete powerful mediators in order to prevent the 
overwhelming inflammation and potential auto-immunity that might 
otherwise ensue. However, evidence is accumulating that 
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chemotherapeutic cytotoxicity is, in fact, immunogenic with both innate 
and adaptive immune systems being implicated along with the 
triggering of a systemic inflammatory response (Zitvogel, Apetoh et al. 
2008). mCRP expression may therefore attenuate the local effects of 
inflammation on cancer cells and may thereby be linked to 
responsiveness to conventional chemotherapy as well as 
immunotherapy. Unfortunately, methodological constraints prevented 
the testing of this theory in this series but it could be studied in series 
with access to PFS data. 
The TMA constructed and validated in this thesis was used to study 
molecular markers in a novel way and provides new data. Though 
these studies are individual, the use of a large number of specimens 
and an adherence to best practice provides reassurance that the 
findings are correct, while setting a standard that if repeated by other 
groups may ensure that the literature does not become a mass of 
contradictory reports. The strength of this approach is that, once the 
integrated TMA was produced, expression data could be assessed for 
multiple markers in a homogenous, high-throughput manner which was 
systematic and which used resources efficiently. Indeed, subsequently 
it has been used by other workers in the study of a variety of markers. 
Once a larger number of molecular markers have been assembled it 
may become possible to employ sophisticated bioinformatics that 
include hierarchical clustering and Artificial Neural Networks (ANNs) in 
order to identify new prognostic groups using the co-expression data 
(Gospodarowicz 2001). Ellis and co-workers employed this technique in 
a large series of breast cancers. Using expression data for 25 markers, 
this group discovered 5 new prognostic groups defined by the 
expression of 9 key antigens (Abd El-Rehim, Ball et al. 2005). The 
molecular characterisation of ovarian cancer in this and other ways is 
likely to be crucial to the aim of mapping the proteomic circuit within the 
cell and the overall aim of oncological care: the development of 
treatment specific to an individuals disease (Calvo, Liotta et al. 2005).  
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Appendices 
 
Appendix 1 
 
 
The World Health Organisation International Histological 
Classification of tumours N°9 
Histological Typing of Ovarian Tumours, World Health Organisation, 
1973 (Serov, Scully et al. 1973) – abridged. 
I. Common “Epithelial” Tumours 
A. Serous Tumours 
1. Benign 
a) Cystadenoma and papillary cystadenoma 
b) Surface papilloma 
c) Adenofibroma and cystadenofibroma 
2. Carcinomas of low malignant potential (borderline) 
a) Cystadenoma and papillary cystadenoma 
b) Surface papilloma 
c) Adenofibroma and cystadenofibroma 
3. Malignant 
a) Adenocarcinoma, papillary adenocarcinomas and 
 papillary cystadenocarcinoma 
b) Surface papillary carcinoma 
c) Malignant adenofibroma and cystadenofibroma 

B. Mucinous Tumours 
1. Benign 
a) Cystadenoma 
b) Adenofibroma and cystadenofibroma 
2. Carcinomas of low malignant potential (borderline) 
a) Cystadenoma 
b) Adenofibroma and cystadenofibroma 
3. Malignant 
a) Adenocarcinoma and cystadenocarcinoma 
b) Malignant adenofibroma and cystadenofibroma 

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C. Endometrioid Tumours 
1. Benign 
a) Adenoma and cystadenoma 
b) Adenofibroma and cystadenofibroma 
2. Carcinomas of low malignant potential (borderline) 
a) Adenoma and cystadenoma 
b) Adenofibroma and cystadenofibroma 
3. Malignant 
a) Carcinoma 
(1) Adenocarcinoma 
(2) Adenocanthoma 
(3) Malignant adenofibroma and cystadenofibroma 
b) Endometrioid stromal sarcomas 
c) Mesodermal Müllerian Mixed Tumours 
 (Homologous / Heterologous) 
D. Clear Cell Tumours 
1. Benign: Adenofibroma 
2. Carcinomas of low malignant potential (borderline) 
3. Malignant: Carcinoma and adenocarcinomas 
E. Brenner Tumours 
1. Benign 
2. Of borderline malignancy (proliferating) 
3. Malignant 
F. Mixed Epithelial Tumours 
1. Benign 
2. Of borderline malignancy 
3. Malignant 

G. Undifferentiated carcinoma 

H. Unclassified epithelial tumours 

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II.  Sex Cord Stromal Tumours 
A. Granulosa - stromal tumours 
1. Granulosa cell tumour 
2. Tumours in the thecoma - fibroma group 
a) Thecoma 
b) Fibroma 
c) Unclassified 
B. Androblastomas: Sertoli - Leydig cell tumours 
1. Well differentiated 
a) Tubular androblastoma: Sertoli cell tumour  
b) Tubular androblastoma with lipid storage: Sertoli cell 
 tumour with lipid storage 
c) Sertoli-Leydig cell tumour 
d) Leydig cell tumour: Hilus cell tumour 
2. Of intermediate differentiation 
3. Poorly differentiated (sarcomatoid) 
4. With heterologous elements 

C. Gynadoblastoma 

D. Unclassified 

III. Lipid (Lipoid) Cell Tumours 

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IV. Germ Cell Tumours 
A. Dysgerminoma 
B. Endodermal sinus tumour 
C. Embryonal Carcinoma 
D. Polyembryoma 
E. Choriocarcinoma 
F. Teratoma 
1. Immature 
2. Mature 
a) Solid 
b) Cystic 
(1) Dermoid cyst (Mature cystic teratoma) 
(2) Dermoid cyst with malignant transformation 
c) Monodermal and highly specialised 
(1) Struma Ovarii 
(2) Carcinoid 
(3) Struma Ovarii and carcinoid 
(4) Others 

G. Mixed forms 
V. Gonadoblastoma 
A. Pure 
B. Mixed with dysgerminoma or other form of germ cell tumour 
VI. Soft tissue tumours not specific to the ovary 
VII. Unclassified tumours 
VIII. Secondary (Metastatic) Tumours 

Appendices
287
IX. Tumour-Like conditions 
A. Pregnancy luteoma 
B. Hyperplasia of ovarian stroma and hyperthecosis 
C. Massive oedema 
D. Solitary follicle cyst and corpus luteum cyst 
E. Multiple follicle cyst (polycystic ovaries) 
F. Multiple luteinised follicle cysts and/or corpus lutea 
G. Endometriosis 
H. Surface-epithelial inclusion cysts (germinal inclusion cysts) 
I. Simple cysts 
J. Inflammatory lesions 
K. Parovarian cysts 
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Appendix 2  
 
Staging of ovarian cancer by the FIGO and TNM classifications 
(Benedet 2000) 
 
FIGO  TNM 
 Primary tumour cannot be assessed  TX 
0  No evidence of primary tumour  T0 
I  Tumour confined to the ovaries  T1 
IA Tumour limited to one ovary, capsule intact 
No tumour on ovarian surface 
No malignant cells in ascites or peritoneal washings 
T1a
IIB Tumour limited to both ovaries, capsules intact 
No tumour on ovarian surface 
No malignant cells in ascites or peritoneal washings 
T1b
IC Tumour limited to one or both ovaries 
With any of the following:- 
Capsule ruptured, tumour on ovarian surface, positive malignant 
cells in the ascites or positive peritoneal washings 
T1c 
II  Tumour involves one or both ovaries with pelvic extension  T2 
IIA Extension and/ or implants in uterus and/or tubes 
No malignant cells in the ascites or peritoneal washings 
T2a
 
IIB Extension to other pelvic organs 
No malignant cells in the ascites or peritoneal washings 
T2b
 
IIC IIA/B with positive malignant cells in the ascites or positive 
peritoneal washings 
T2c 
III  Tumour involves one or both ovaries with microscopically 
confirmed peritoneal metastasis outside the pelvis and/or 
regional lymph node metastasis 
 T3 
or 
N1 
IIIA Microscopic peritoneal metastasis beyond the pelvis  T3a
IIIB Macroscopic peritoneal metastasis beyond the pelvis 2cm or less in 
dimension 
T3b
IIIC Peritoneal metastases beyond the pelvis more than 2cm in greatest 
dimension and/or regional lymph node metastasis 
T3c 
or 
N1 
IV  Distant metastasis beyond the peritoneal cavity 
( including parenchymal  liver metastasis and pleural effusion with 
positive cytology) 
M1
   
Regional Nodes   
Regional lymph nodes cannot be assessed 
No regional lymph node metastasis 
Regional lymph node metastasis 
Nx
N0
N1
 
Distant Metastasis Mx
M0
M1
 Distant metastasis cannot be assessed 
No distant metastasis 
Distant metastasis (excluding peritoneal metastasis) 
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A record of all the data attributes contained within the final analysis database. A total of 339 frank ovarian cancer cases and 19 borderline 
cases were represented. Emboldened data columns represent data extracted from the original study database. Attributes used in the 
statistical analyses are also highlighted. 
 
Data Column Data type Categories Missing Used in 
final 
analyses 
Notes 
Identifying  
numbers 
ANO (Array  number) Continuous  1-360 0 Yes  
PATHNUMBER Ordinal 6*****82  H97****7 0  
 
 
No 
 
 
From the pathology form 
ARRAY COORDINATES Ordinal 1:A1  4:N3 0 Derived from and present on 
the scoring grids 
Date treatment 
initiated 
DATEOFOP (operation) Ordinal */02/1982  */10/1997 0 Used to in determining 
overall survival but could be 
removed 
YEAROFOP Continuous 1992 - 1997 0 Derived from DATEOFOP 
YEARDIAGNOSED Continuous 1992 - 1997 0 Derived from pathology form 
Age diagnosis 
made 
AGEDIAGNOSED Continuous 24 - 90 1 Yes  
ageORIGINAL Ordinal 1:  < 54 years at diagnosis 
2:  54-70 years at diagnosis 
3:   70 years at diagnosis 
1 No First empirical subdivision of 
age into groupings 
agerecodeSEER Ordinal 1:< 30 years at diagnosis 
2: 30-59 years at diagnosis 
3:  60 years at diagnosis 
1 Yes Age regrouped into 
categories used by SEER 
agerecodeICON Ordinal 1: < 55 years at diagnosis 
2: 55-65 years at diagnosis 
3:  65 years at diagnosis 
1  
 
 
No 
 
Age re-categorised into 
categories used in the ICON 
trials 
agerecodeEUROPE Ordinal 1: <40 years at diagnosis 
2: 40-60 years at diagnosis 
3:  60 years at diagnosis 
1 Groupings used by a small 
European series (Brun, 
Feyler et al. 2000) 
A
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Continued  
Data Column Data type Categories Missing Used in 
final 
analyses 
Notes 
Operating 
consultants  
specialty 
SPECIALISTSURGEON Nominal General surgeon 
General gynaecologist 
Gynae-oncologist 
39 No 
 
The importance of operator is 
that they have an interest 
specifically in gynaecological 
cancer specialistsurgeonrecode Categorical 0: Non-Gynae-oncologist 
1:Gynaeoncologist 
39 
Stage of 
disease 
STAGE Ordinal 1 :Stage I 
2: Stage  II 
3: Stage  III 
4: Stage  IV 
9 Yes Staged according to FIGO 
classification 
SUBSTAGE Nominal Stage Ia, Ib, Ic 
Stage IIa, IIb, IIc 
Stage IIIa, IIIb, IIIc 
Stage IV 
116  
 
 
 
 
 
 
No 
 
The sub-stage category was 
incomplete and of uncertain 
accuracy. 
Operation 
performed 
OPERATION 
oprecode 
Categorical 1: Biopsy 
2: Single oophrectomy 
3: Bilateral oophrectomy (BSO) 
4: Total hysterectomy (TH) + BSO 
5: TH + BSO + Omentectomy 
0 Data derived from the 
original pathology report and 
reflective of this more than 
radicalness of surgery 
Residual 
disease 
RESIDUAL DISEASE Nominal > 2cm 
< 2cm 
Nothing 
13 Residual disease was re-
categorised on a more 
stringent criteria whereby any 
visible remaining disease is 
considered sub-optimally 
debulked 
residualrecodeMACRO Ordinal 0: Macroscopic disease present 
1: No macroscopic disease 
present 
13 Yes 
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Continued  
Data Column Data type Categories Missing Used in 
final 
analyses 
Notes 
Tissue 
reviewed by 
pathologist 
tissuesourcerecodeRAW Nominal 1: Omental metastasis 
2: Pelvic Metastasis 
3: Ovary 
1  
 
 
 
 
 
 
 
 
No 
 
Collected at the time of 
contemporaneous review of 
the tumours to help explain 
any unusual results should 
they occur due to the 
potential differential 
expression of markers 
between primary and 
secondary sources of tissue 
Tumour cell 
type 
TUMOURTYPE Nominal Serous 
Serous papillary 
Endometrioid 
Mucinous 
Undifferentiated 
Clear cell 
Granulosa cell 
Mixed Müllerian cell 
Teratoma 
Yolk sac 
0  
The nominal data in the 
study database were 
replaced with that from the 
contemporaneous review 
and were logically re-
categorised, following which 
a survival analysis 
performed. The categories 
were then ranked in order of 
increasingly poor prognosis 
with borderline cases 
excluded (which had the best 
prognosis of all) from the 
final analysis database 
tumourtype- 
recodeBESTWORST 
Ordinal 1: Clear cell 
2: Mucinous 
3: Endometrioid 
4: Serous 
5: Undifferentiated 
6: other 
0 Yes 
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Continued  
Data Column Data type Categories Missing Used in 
final 
analyses 
Notes 
Tumour grade TUMOURGRADE Ordinal 0:Ungradeable 
1: Grade 1  
2: Grade 2  
3: Grade 3 
0 Yes The study database data 
were replaced by the data 
from the contemporaneous 
review 
Post-operative 
medical therapy 
ADJUVANTTHERAPY Nominal CARBO&TAXOL (Carboplatin and 
paclitaxel) 
CARBOPLATIN 
NON-PLATINUM (Chemotherapy) 
RADIOTHERAPY 
TAXOL (Paclitaxel) 
 
7  
 
 
 
 
No 
 
As explained formally in 
chapter 2, the optimal re-
categorisation of data 
concerning adjuvant 
treatment in this series was 
whether the case had 
received chemotherapy or 
not adjuvantrecodePLAT Categorical 1: No chemotherapy 
2: Platinum based chemotherapy 
3: Other chemotherapy 
4: Other adjuvant treatment 
7 
adjuvantrecodeANYCHEMO Ordinal 0: No chemotherapy received 
1: Chemotherapy received 
7 Yes 
Participation in 
trials 
ICONTRIAL Categorical 1: ICON I 
2: ICON II 
3: ICON III 
0 No Information concerning the 
ICON trial participation was 
obtained from the MRC 
before the database was 
unlinked 
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Continued  
Data Column Data type Categories Missing Essential 
for final 
analysis 
Notes 
Outcome data LASTFOLLOWUP Ordinal */03/1992  */08/2005 N/A  
 
 
 
 
 
No 
 
LASTFOLLOWUP and 
DATEOFDEATH data each 
concerned those cases either 
alive or dead and so missing 
data in the latestsurvival 
column better reflects the 
completeness of these 
attributes in the database. 
 DATEOFDEATH Ordinal */05/1982  */04/2004 N/A 
 LATESTSURVIVAL Ordinal */05/1982 - */08/2005 3 Using the data above, the 
latest confirmed survival for 
each patient could be 
determined 
 SURVIVALMONTHS Continuous 0-271  3 Yes Using DATEOFOP and 
LATESTSURVIVAL allowed 
survival data to be generated 
 DEAD Categorical 0: Alive 
1: Dead 
3 Yes Knowing the survival status 
of the patient allowed data to 
be censored in the survival 
analyses 
 survivalrecode5YEAR Categorical 0: Died within 5 years of diagnosis 
1: Survived 5 years after diagnosis 
3 No Data generated to aid 
comparison with other series 
 survivalrecodePERIOP Categorical 0: Survived  beyond 30 days 
    post  op     
1: Died within days 30 post- op  
     
3 No Some authorities use 28 
days 

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